Causes and consequences of microvascular dysfunction

Citation for published version (APA):

Rensma, S. P. (2020). *Causes and consequences of microvascular dysfunction: focus on the brain*. [Doctoral Thesis, Maastricht University]. ProefschriftMaken. <https://doi.org/10.26481/dis.20201029sr>

Document status and date:

Published: 01/01/2020

DOI:

[10.26481/dis.20201029sr](https://doi.org/10.26481/dis.20201029sr)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Causes and consequences of microvascular dysfunction:

Focus on the brain

Sytze Rensma

DE
MAASTRICHT
STUDIE

Causes and consequences of microvascular dysfunction:
focus on the brain

door Sytze Pieter Rensma

© copyright Sytze Pieter Rensma, 2020

Printing: ProefschriftMaken || www.proefschriftmaken.nl

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission of the author or the copyright-owning journals for previous published chapters.

Causes and consequences of microvascular dysfunction: Focus on the brain

PROEFSCHRIFT

ter verkrijging van de graad van doctor aan de Universiteit Maastricht,

op gezag van de Rector Magnificus, Prof.dr. Rianne M. Letschert

volgens het besluit van het College van Decanen,

in het openbaar te verdedigen

op Donderdag 29 oktober 2020 om 16.00 uur

door Sytze Pieter Rensma

Promotor

Prof. Dr. C.D.A. Stehouwer

Copromotor

Dr. T.T. van Sloten

Beoordelingscommissie

Dr. V.P.M. van Empel (voorzitter)

Prof. dr. H.J.G.M. Crijns

Prof. dr. D.E.J. Linden

Prof. dr. F.E. de Leeuw (Radboud Universitair Medisch Centrum, Nijmegen)

Prof. dr. M. Muller (VU Medisch Centrum, Amsterdam)

Prof. dr. P.W. de Leeuw

Contents

CHAPTER 1	General introduction	7
CHAPTER 2	Cerebral small vessel disease and risk of incident stroke, dementia and depression, and all-cause mortality: a systematic review and meta-analysis	19
CHAPTER 3	Type 2 diabetes, change in depressive symptoms over time, and cerebral small vessel disease – Longitudinal data of the AGES-Reykjavik Study	109
CHAPTER 4	Microvascular dysfunction is associated with worse cognitive performance: The Maastricht Study	131
CHAPTER 5	Associations of arterial stiffness with cognitive performance, and the role of microvascular dysfunction: The Maastricht Study	167
CHAPTER 6	Blood Pressure Variability And Microvascular Dysfunction: The Maastricht Study	199
CHAPTER 7	General discussion	243
	Nederlandse samenvatting	259
	Valorisation addendum	267
	Dankwoord	269
	Curriculum Vitae	273

CHAPTER 1

General introduction

General introduction

Ageing is frequently characterized by age-related adverse cerebral outcomes such as dementia, late-life depression and stroke.¹ The burden of these diseases is high and is likely to increase in future decades as a result of the ageing of the general population.¹ Identifying possible factors contributing to these diseases is needed for future prevention and treatment. One important factor may be the functional and structural deterioration of the microvasculature (i.e., microvascular dysfunction).

The microvasculature facilitates, among other things, oxygen and nutrient delivery to the brain,² and microvascular dysfunction may thus be implicated in the development of adverse cerebral outcome. Microvascular dysfunction has been associated with various cardiovascular risk factors,³ and emerging evidence indicates that it may be implicated in the pathways between these risk factors and adverse cerebral outcome.²⁻⁵ To elucidate the role of microvascular dysfunction in adverse cerebral outcome, this thesis aims to identify possible causes of microvascular dysfunction and to investigate whether microvascular dysfunction is associated with dementia, late-life depression and stroke. In addition, this thesis aims to evaluate whether microvascular dysfunction mediates the pathways between several cardiovascular risk factors and dementia, late-life depression and stroke.

Microvasculature – structure and function

The microvasculature is, in terms of surface area, the largest component of the vascular system (98%) and includes all blood vessels with a diameter below 150-200 μm .² This network of blood vessels facilitates local blood perfusion, blood-tissue diffusion and haemostatic balance,⁶ which is needed for nutrient distribution and waste product collection in tissues. In addition, the microvasculature regulates blood pressure via vascular resistance.⁷ The microvasculature consists of three types of small vessels: arterioles, capillaries and venules. Arterioles regulate blood flow according to local metabolic demand using vasomotion. The capillaries consist of only a single endothelial layer, which helps facilitate exchange of substances with the interstitium, both via passive diffusion and active transcellular transport. The latter is especially important in brain tissue, because the uninterrupted endothelial lining making up the blood-brain barrier allows passive diffusion of only small molecules such as water and ions, as well as lipid-soluble molecules, whereas exchange of molecules such as glucose relies on active transcellular transport.^{8,9} Small venules collect capillary blood, regulate capillary pressure, and support recruitment of inflammatory cells (e.g., leukocytes) from blood into tissue.^{2,10}

Microvascular dysfunction – potential causes

Microvascular dysfunction has been associated with cardiovascular risk factors such as arterial stiffening¹¹ and type 2 diabetes.^{12,13} Arterial elasticity dampens cardiac pulsatile energy, which protects the microvasculature from high pulsatile damage. Arterial stiffening increases the pulsatile intensity flowing into the microvasculature, which induces a microvascular remodelling response and may cause microvascular damage directly. The remodelling response initially serves to limit the penetration of the pulsatile load into the microvasculature by raising vascular resistance, but may ultimately lead to maladaptive proliferation of the arteriolar wall.¹⁴ Type 2 diabetes may also induce

microvascular dysfunction via various mechanisms, including hyperglycaemia, arterial stiffening, impaired insulin-dependent dilation, production of advanced glycation end products, increased oxidative stress and epigenetic changes.¹³ In addition to arterial stiffness and type 2 diabetes, other determinants of microvascular dysfunction, such as inflammatory processes, oxidative stress, hypertension, ageing and obesity, have been identified and may share these pathophysiological mechanisms.²

Microvascular dysfunction – consequences: focus on the brain

Prolonged injury to the microvasculature may result in structural and functional microvascular changes, including capillary rarefaction, glycocalyx degeneration, impaired capillary flow regulation, impaired arteriolar and venular dilation response, blood-brain barrier dysfunction, increased inflammatory response and procoagulant activation.^{5, 6, 15} These changes may lead to inefficient nutrient and oxygen extraction from the microcirculation⁶ and may thus threaten tissue function by lack of nutrients and hypoxia. The effects of microvascular dysfunction could be particularly detrimental to cerebral tissue due to its high microvascular blood flow and metabolic needs. The cerebral microvasculature is involved in the regulation of many processes that are important for cognitive function and mood regulation (i.e., cerebral perfusion, neurogenesis, neurovascular coupling, blood-brain barrier permeability and cerebral autoregulation).¹⁵ Impairment of these processes may lead to neuronal dysfunction and ischaemia, which could ultimately lead to lower cognitive performance and depression.^{11, 15-18} In addition, acute and prolonged cerebral hypoperfusion and impaired haemostatic regulation may predispose to stroke.

Microvascular dysfunction - markers

Only a few organs can be used to measure microvascular function noninvasively. These measures include brain measures (magnetic resonance imaging features of cerebral small vessel disease);⁴ eye measures (flicker light-induced retinal arteriolar and venular dilation response);¹⁹ kidney measures (albuminuria);²⁰ plasma biomarkers of microvascular dysfunction²¹ and skin measures (heat-induced skin hyperaemia).¹⁹ Cerebral small vessel disease features are closely linked to brain microvascular structure and evidence indicates that these features originate from cerebral microvascular dysfunction.^{3, 4, 6} To the extent that microvascular dysfunction is a generalised phenomenon, measures of microvascular dysfunction in other vascular beds such as the retina, kidney and skin, or plasma biomarkers of microvascular dysfunction may also reflect brain microvascular dysfunction.^{5, 12}

Contribution of this thesis to current knowledge

It has been hypothesised that cerebral small vessel disease is an important contributor to adverse cerebral outcome (i.e., dementia, depression and stroke) and increased mortality risk.³ However, systematic research on these possible consequences of cerebral small vessel disease is limited. Seven meta-analyses²²⁻²⁸ have examined the association of certain features of cerebral small vessel disease (i.e., white matter hyperintensities and cerebral microbleeds) and these outcomes. However, no meta-analysis on incident dementia, depression or stroke, or all-cause mortality has thus far been conducted for other features of cerebral small vessel disease (i.e., lacunes, perivascular spaces and total cerebral atrophy). Furthermore, no meta-analysis has evaluated the prognostic value of

the presence of combined cerebral small vessel disease features. It is, however, important to investigate the effects of individual and combined cerebral small vessel disease features on incident dementia, depression and stroke, and all-cause mortality, because cerebral small vessel disease is highly prevalent in the general population,²⁹ and timely intervention may help prevent or reduce progression of cerebral small vessel disease and these clinical outcomes.

In addition, cerebral small vessel disease is thought to mediate the association between type 2 diabetes and incident depression.¹⁷ In view of the increased risk of depression in type 2 diabetes, identifying factors that mediate this relation might help to prevent or treat type 2 diabetes-related depression.^{13,30} However, no previous study has investigated whether the association between type 2 diabetes and depressive symptoms is mediated by cerebral small vessel disease.

It has been hypothesised that cerebral small vessel disease reflects microvascular dysfunction, and that microvascular dysfunction contributes to cognitive decline and dementia.³ However, it is unknown whether other measures of microvascular dysfunction in various vascular beds, such as the retina, kidney and skin, or plasma biomarkers of microvascular dysfunction, contribute similarly.^{5, 12} Multiple measures of generalised microvascular dysfunction may, however, better determine cognitive function than a microvascular dysfunction measure in a single vascular bed, such as cerebral small vessel disease.

In this respect, generalised microvascular dysfunction may also mediate the association between greater arterial stiffness and worse cognitive function. Previous studies have shown an association between arterial stiffness and cognitive function.^{11, 16, 31-44} However, whether any association between aortic or carotid stiffness and worse cognitive performance is explained, or mediated, by microvascular dysfunction is unknown.

Finally, it has been hypothesised that greater blood pressure variability (i.e., greater fluctuations of blood pressure over time) may lead to microvascular dysfunction^{45, 46} via increases in pulsatile pressure⁴⁵ and sudden falls in blood pressure.⁴⁶ Vascular beds of organs with low vascular impedance (i.e., the microvasculature of the brain, eyes and kidneys) may be particularly vulnerable, because pulsatile energy may penetrate deeply into these microvascular beds.⁴⁵ However, no studies have investigated the association between blood pressure variability and measures of microvascular dysfunction in multiple vascular beds.⁴⁷⁻⁴⁹

Cohort studies used in this thesis

In this thesis, data of two cohort studies are used: The Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study and The Maastricht Study. The AGES-Reykjavik Study is an observational population-based cohort study originating from the Reykjavik Study.⁵⁰ The present thesis includes longitudinal data from 3,316 participants of the AGES-Reykjavik Study, who were examined from 2002 to 2006 and re-examined five years later, from 2007 to 2011. The Maastricht Study is an ongoing observational population-based cohort study that focuses on the aetiology, pathophysiology, complications and comorbidities

of type 2 diabetes and is characterized by an extensive phenotyping approach.⁵¹ The present thesis includes cross-sectional data from the 3,451 participants who completed the baseline survey between November 2010 and September 2013.

Outline of this thesis

Figure 1.1 summarizes the investigated associations in this thesis (see below).

In *chapter two*, we conducted a systematic review and meta-analysis on the association between various cerebral small vessel disease features and incident stroke, dementia and depression, and all-cause mortality. Additionally, we investigated the effect of presence of two or more individual cerebral small vessel disease features on these outcomes.

In *chapter three*, we investigated, in the AGES-Reykjavik study, the longitudinal association between baseline type 2 diabetes and change in depressive symptoms over time. In addition, we investigated whether any such association was mediated by cerebral small vessel disease.

In *chapter four*, we investigated, in The Maastricht Study, whether a composite score of various microvascular dysfunction measures was associated with worse cognitive performance.

In *chapter five*, we investigated, in The Maastricht Study, the associations between arterial stiffness and worse cognitive performance. In addition we investigated whether any such association is mediated by a composite score of various microvascular dysfunction measures.

In *chapter six*, we investigated, in The Maastricht Study, whether very short- to mid-term blood pressure variability was associated with various microvascular dysfunction measures.

Finally, in *chapter seven*, we discussed the key findings of this thesis, their clinical implications and recommendations for future research. In addition, we addressed relevant methodological considerations.

Figure 1.1. Schematic representation of the investigated associations in the present thesis. Numbers indicate corresponding chapters.

1. Feigin VL, Lawes CM, Bennett DA and Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. *Lancet Neurol.* 2003;2:43-53.
2. Houben A, Martens RJH and Stehouwer CDA. Assessing Microvascular Function in Humans from a Chronic Disease Perspective. *J Am Soc Nephrol.* 2017;28:3461-3472.
3. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. *Lancet Neurol.* 2010;9:689-701.
4. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge R, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M and nEuroimaging STfRVco. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol.* 2013;12:822-38.
5. Muris DM, Houben AJ, Schram MT and Stehouwer CD. Microvascular dysfunction: an emerging pathway in the pathogenesis of obesity-related insulin resistance. *Rev Endocr Metab Disord.* 2013;14:29-38.
6. Ostergaard L, Engedal TS, Moreton F, Hansen MB, Wardlaw JM, Dalkara T, Markus HS and Muir KW. Cerebral small vessel disease: Capillary pathways to stroke and cognitive decline. *J Cereb Blood Flow Metab.* 2016;36:302-25.
7. Pries AR, Secomb TW and Gaehtgens P. Structural autoregulation of terminal vascular beds: vascular adaptation and development of hypertension. *Hypertension.* 1999;33:153-61.
8. Stamatovic SM, Johnson AM, Keep RF and Andjelkovic AV. Junctional proteins of the blood-brain barrier: New insights into function and dysfunction. *Tissue Barriers.* 2016;4:e1154641.
9. Wilhelm I, Nyul-Toth A, Suciu M, Hermenean A and Krizbai IA. Heterogeneity of the blood-brain barrier. *Tissue Barriers.* 2016;4:e1143544.
10. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. *Circ Res.* 2007;100:158-73.
11. van Sloten TT, Protogerou AD, Henry RM, Schram MT, Launer LJ and Stehouwer CD. Association between arterial stiffness, cerebral small vessel disease and cognitive impairment: A systematic review and meta-analysis. *Neurosci Biobehav Rev.* 2015;53:121-30.
12. Umemura T, Kawamura T and Hotta N. Pathogenesis and neuroimaging of cerebral large and small vessel disease in type 2 diabetes: A possible link between cerebral and retinal microvascular abnormalities. *J Diabetes Investig.* 2017;8:134-148.
13. Stehouwer CDA. Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle With Widespread Consequences. *Diabetes.* 2018;67:1729-1741.
14. van Sloten TT, Mitchell GF, Sigurdsson S, van Buchem MA, Jonsson PV, Garcia ME, Harris TB, Henry RM, Levey AS, Stehouwer CD, Gudnason V and Launer LJ. Associations between arterial stiffness, depressive symptoms and cerebral small vessel disease: cross-sectional findings from the AGES-Reykjavik Study. *J Psychiatry Neurosci.* 2016;41:162-8.
15. De Silva TM and Faraci FM. Microvascular Dysfunction and Cognitive Impairment. *Cell Mol Neurobiol.* 2016;36:241-58.
16. Cooper LL, Woodard T, Sigurdsson S, van Buchem MA, Torjesen AA, Inker LA, Aspelund T, Eiriksdottir G, Harris TB, Gudnason V, Launer LJ and Mitchell GF. Cerebrovascular Damage Mediates Relations Between Aortic Stiffness and Memory. *Hypertension.* 2016;67:176-82.

17. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D and Charlson M. 'Vascular depression' hypothesis. *Arch Gen Psychiatry*. 1997;54:915-22.
18. van Sloten TT, Sigurdsson S, van Buchem MA, Phillips CL, Jonsson PV, Ding J, Schram MT, Harris TB, Gudnason V and Launer LJ. Cerebral Small Vessel Disease and Association With Higher Incidence of Depressive Symptoms in a General Elderly Population: The AGES-Reykjavik Study. *Am J Psychiatry*. 2015;172:570-8.
19. Sorensen BM, Houben AJ, Berendschot TT, Schouten JS, Kroon AA, van der Kallen CJ, Henry RM, Koster A, Sep SJ, Dagnelie PC, Schaper NC, Schram MT and Stehouwer CD. Prediabetes and Type 2 Diabetes Are Associated With Generalized Microvascular Dysfunction: The Maastricht Study. *Circulation*. 2016;134:1339-1352.
20. Martens RJ, Henry RM, Houben AJ, van der Kallen CJ, Kroon AA, Schalkwijk CG, Schram MT, Sep SJ, Schaper NC, Dagnelie PC, Muris DM, Gronenschild EH, van der Sande FM, Leunissen KM, Kooman JP and Stehouwer CD. Capillary Rarefaction Associates with Albuminuria: The Maastricht Study. *J Am Soc Nephrol*. 2016;27:3748-3757.
21. van Sloten TT, Schram MT, Adriaanse MC, Dekker JM, Nijpels G, Teerlink T, Scheffer PG, Pouwer F, Schalkwijk CG, Stehouwer CD and Henry RM. Endothelial dysfunction is associated with a greater depressive symptom score in a general elderly population: the Hoorn Study. *Psychol Med*. 2014;44:1403-16.
22. DeBette S and Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ*. 2010;341:c3666.
23. Charidimou A, Shams S, Romero JR, Ding J, Veltkamp R, Horstmann S, Eiriksdottir G, van Buchem MA, Gudnason V, Himali JJ, Gurol ME, Viswanathan A, Imaizumi T, Vernooij MW, Seshadri S, Greenberg SM, Benavente OR, Launer LJ, Shoamanesh A and International M-MI. Clinical significance of cerebral microbleeds on MRI: A comprehensive meta-analysis of risk of intracerebral hemorrhage, ischemic stroke, mortality, and dementia in cohort studies (v1). *Int J Stroke*. 2018;1747493017751931.
24. Wang L, Leonards CO, Sterzer P and Ebinger M. White matter lesions and depression: a systematic review and meta-analysis. *J Psychiatr Res*. 2014;56:56-64.
25. van Agtmaal MJM, Houben A, Pouwer F, Stehouwer CDA and Schram MT. Association of Microvascular Dysfunction With Late-Life Depression: A Systematic Review and Meta-analysis. *JAMA Psychiatry*. 2017.
26. Wang DN, Hou XW, Yang BW, Lin Y, Shi JP and Wang N. Quantity of Cerebral Microbleeds, Antiplatelet Therapy, and Intracerebral Hemorrhage Outcomes: A Systematic Review and Meta-analysis. *J Stroke Cerebrovasc Dis*. 2015;24:2728-37.
27. Charidimou A, Kakar P, Fox Z and Werring DJ. Cerebral microbleeds and recurrent stroke risk: systematic review and meta-analysis of prospective ischemic stroke and transient ischemic attack cohorts. *Stroke*. 2013;44:995-1001.
28. Charidimou A, Imaizumi T, Moulin S, Biffi A, Samarasekera N, Yakushiji Y, Peeters A, Vandermeeren Y, Laloux P, Baron JC, Hernandez-Guillamon M, Montaner J, Casolla B, Gregoire SM, Kang DW, Kim JS, Naka H, Smith EE, Viswanathan A, Jager HR, Al-Shahi Salman R, Greenberg SM, Cordonnier C and Werring DJ. Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds: A meta-analysis. *Neurology*. 2017;89:820-829.

29. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge R, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB and Dichgans M. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol.* 2013;12:822-38.
30. Lustman PJ and Clouse RE. Depression in diabetic patients: the relationship between mood and glycemic control. *J Diabetes Complications.* 2005;19:113-22.
31. Taniguchi Y, Fujiwara Y, Nofuji Y, Nishi M, Murayama H, Seino S, Tajima R, Matsuyama Y and Shinkai S. Prospective Study of Arterial Stiffness and Subsequent Cognitive Decline Among Community-Dwelling Older Japanese. *J Epidemiol.* 2015;25:592-9.
32. Hajjar I, Goldstein FC, Martin GS and Quyyumi AA. Roles of Arterial Stiffness and Blood Pressure in Hypertension-Associated Cognitive Decline in Healthy Adults. *Hypertension.* 2016;67:171-5.
33. Tsao CW, Himali JJ, Beiser AS, Larson MG, DeCarli C, Vasan RS, Mitchell GF and Seshadri S. Association of arterial stiffness with progression of subclinical brain and cognitive disease. *Neurology.* 2016;86:619-26.
34. Meyer ML, Palta P, Tanaka H, Deal JA, Wright J, Knopman DS, Griswold ME, Mosley TH and Heiss G. Association of Central Arterial Stiffness and Pressure Pulsatility with Mild Cognitive Impairment and Dementia: The Atherosclerosis Risk in Communities Study-Neurocognitive Study (ARIC-NCS). *J Alzheimers Dis.* 2017;57:195-204.
35. Muela HCS, Costa-Hong VA, Yassuda MS, Moraes NC, Memoria CM, Machado MF, Bor-Seng-Shu E, Nogueira RC, Mansur AJ, Massaro AR, Nitrini R, Macedo TA and Bortolotto LA. Higher arterial stiffness is associated with lower cognitive performance in patients with hypertension. *J Clin Hypertens (Greenwich).* 2018;20:22-30.
36. Rouch L, Cestac P, Sallerin B, Andrieu S, Bailly H, Beunardeau M, Cohen A, Dubail D, Hernandorena I, Seux ML, Vidal JS and Hanon O. Pulse Wave Velocity Is Associated With Greater Risk of Dementia in Mild Cognitive Impairment Patients. *Hypertension.* 2018;72:1109-1116.
37. Palta P, Sharrett AR, Wei J, Meyer ML, Kucharska-Newton A, Power MC, Deal JA, Jack CR, Knopman D, Wright J, Griswold M, Tanaka H, Mosley TH and Heiss G. Central Arterial Stiffness Is Associated With Structural Brain Damage and Poorer Cognitive Performance: The ARIC Study. *J Am Heart Assoc.* 2019;8:e011045.
38. Pase MP, Beiser A, Himali JJ, Tsao C, Satizabal CL, Vasan RS, Seshadri S and Mitchell GF. Aortic Stiffness and the Risk of Incident Mild Cognitive Impairment and Dementia. *Stroke.* 2016;47:2256-61.
39. Huck DM, Hanna DB, Rubin LH, Maki P, Valcour V, Springer G, Xue X, Lazar J, Hodis HN, Anastos K, Kaplan RC and Kizer JR. Carotid Artery Stiffness and Cognitive Decline Among Women With or at Risk for HIV Infection. *J Acquir Immune Defic Syndr.* 2018;78:338-347.
40. DuBose LE, Voss MW, Weng TB, Kent JD, Dubishar KM, Lane-Cordova A, Sigurdsson G, Schmid P, Barlow PB and Pierce GL. Carotid beta-stiffness index is associated with slower processing speed but not working memory or white matter integrity in healthy middle-aged/older adults. *J Appl Physiol (1985).* 2017;122:868-876.
41. Lim SL, Gao Q, Nyunt MS, Gong L, Lunaria JB, Lim ML, Ling A, Lam CS, Richards AM, Ling LH and Ng TP. Vascular Health Indices and Cognitive Domain Function: Singapore Longitudinal Ageing Studies. *J Alzheimers Dis.* 2016;50:27-40.

42. Poels MM, van Oijen M, Mattace-Raso FU, Hofman A, Koudstaal PJ, Witteman JC and Breteler MM. Arterial stiffness, cognitive decline, and risk of dementia: the Rotterdam study. *Stroke*. 2007;38:888-92.
43. Tarumi T, Gonzales MM, Fallow B, Nualnim N, Pyron M, Tanaka H and Haley AP. Central artery stiffness, neuropsychological function, and cerebral perfusion in sedentary and endurance-trained middle-aged adults. *J Hypertens*. 2013;31:2400-9.
44. Geijselaers SL, Sep SJ, Schram MT, van Boxtel MP, van Sloten TT, Henry RM, Reesink KD, Kroon AA, Koster A, Schaper NC, Dagnelie PC, van der Kallen CJ, Biessels GJ and Stehouwer CD. Carotid stiffness is associated with impairment of cognitive performance in individuals with and without type 2 diabetes. The Maastricht Study. *Atherosclerosis*. 2016;253:186-193.
45. Mitchell GF. Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. *J Appl Physiol (1985)*. 2008;105:1652-60.
46. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. *Lancet*. 2010;375:938-48.
47. Goldstein IB, Bartzokis G, Guthrie D and Shapiro D. Ambulatory blood pressure and the brain: a 5-year follow-up. *Neurology*. 2005;64:1846-52.
48. Gunstad J, Cohen RA, Tate DF, Paul RH, Poppas A, Hoth K, Macgregor KL and Jefferson AL. Blood pressure variability and white matter hyperintensities in older adults with cardiovascular disease. *Blood Press*. 2005;14:353-8.
49. Madden JM, O'Flynn AM, Dolan E, Fitzgerald AP and Kearney PM. Short-term blood pressure variability over 24 h and target organ damage in middle-aged men and women. *J Hum Hypertens*. 2015;29:719-25.
50. Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, Sigurdsson G, Thorgeirsson G, Aspelund T, Garcia ME, Cotch MF, Hoffman HJ and Gudnason V. Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. *Am J Epidemiol*. 2007;165:1076-87.
51. Schram MT, Sep SJ, van der Kallen CJ, Dagnelie PC, Koster A, Schaper N, Henry RM and Stehouwer CD. The Maastricht Study: an extensive phenotyping study on determinants of type 2 diabetes, its complications and its comorbidities. *Eur J Epidemiol*. 2014;29:439-51.

CHAPTER 2

Cerebral small vessel disease and risk of incident stroke, dementia and depression, and all-cause mortality: a systematic review and meta-analysis

SP Rensma,* TT van Sloten,* LJ Launer, CDA Stehouwer

*These authors contributed equally to the manuscript

Abstract

MRI features of cerebral small vessel disease, i.e. white matter hyperintensities, lacunes, microbleeds, perivascular spaces, and cerebral atrophy, may be associated with clinical events, but the strength of these associations remains unclear. We conducted a systematic review and meta-analysis on the association between these features and incident ischaemic and haemorrhagic stroke, all-cause dementia and depression, and all-cause mortality. For the association with stroke, 36 studies were identified (number of individuals/events [n]=38,432/4,136), for dementia 28 (n=16,458/1,709), for depression nine (n=9,538/1,746), and for mortality 28 (n=23,031/2,558). Only two studies evaluated perivascular spaces; these results were not pooled. Pooled analyses showed that all other features were associated with all outcomes (hazard ratios ranged 1.22-2.72). Combinations of two features were more strongly associated with stroke than any individual feature. Individual features and combinations of CSVD features are strongly associated with incident ischaemic and haemorrhagic stroke, all-cause dementia and depression, and all-cause mortality. If these associations are causal, the strength of these associations suggests that a substantial burden of disease is attributable to CSVD.

Introduction

Cerebral small vessel disease (CSVD) features include white matter hyperintensities (WMHs) and lacunes of presumed vascular origin, cerebral microbleeds (CMBs), perivascular spaces, and total cerebral atrophy.¹ These features are related to ageing and vascular risk factors,² and are highly prevalent.¹ CSVD has been suggested to be an important source of morbidity associated with ischaemic and haemorrhagic stroke, dementia, and depression,² and CSVD may increase mortality risk.²

However, systematic evidence for the importance of MRI CSVD features is limited. For instance, no meta-analysis for incident stroke, dementia, depression, or mortality has been conducted for lacunes, perivascular spaces, or total cerebral atrophy. Two meta-analyses^{3, 4} have examined the association of only WMHs³ or microbleeds⁴ and incident stroke and dementia, and mortality. Of two meta-analyses^{5, 6} on WMHs and incident depression, only one⁶ found an association. Three other meta-analyses⁷⁻⁹ have examined the association between CMBs and incident stroke. However, these studies included only individuals with prior stroke,⁷⁻⁹ and evaluated only haemorrhagic stroke.^{7, 9} Finally, no meta-analysis has evaluated the predictive value of presence of combined CSVD features.

We did a systematic review and meta-analysis on the association between CSVD features, including WMHs, lacunes, CMBs, perivascular spaces, and total cerebral atrophy, and incident ischaemic and haemorrhagic stroke, all-cause dementia and depression, and all-cause mortality. Additionally, we investigated the effect of two or more individual CSVD features combined on any of these outcomes.

Methods

This review was prepared according to the meta-analyses of observational studies in epidemiology (MOOSE) checklist (Appendix A).¹⁰ This protocol was published in PROSPERO (CRD42016038521) (Appendix B).¹¹

Evaluation procedure

Two independent investigators (SR and TVS) selected all relevant studies based on title and abstract, retrieved selected full texts, performed eligibility assessments, extracted data, and assessed risk of bias. Disagreement between the reviewers was resolved by consensus. A third independent reviewer (CS) solved any persisting disagreements.

Information sources and search

We identified relevant studies through a search of MEDLINE and Embase, from inception to March 2017 (for search terms see Tables S1.1-S1.4). We applied no language restrictions. We hand-searched reference lists of eligible studies and related meta-analyses to identify further relevant studies.

Eligibility criteria and study selection

We included prospective cohort studies in adults (with and without a history of stroke or depression) that evaluated the association between baseline MRI features of CSVD and incident ischaemic or haemorrhagic stroke, dementia or depression, or all-cause mortality. For CSVD, we included WMHs and lacunes of presumed vascular origin, CMBs, perivascular spaces, and total cerebral atrophy.¹ Studies were also included when they did not specifically assess lacunes but did assess subcortical infarcts (infarcts in the deep brain region not extending into the cortex) and silent infarcts (infarcts detected in individuals without prior stroke), which include lacunes.¹ We excluded studies with a sample size ≤ 50 , a mean follow-up < 12 months, or including only CSVD occurring in long-term inflammatory or neurodegenerative conditions (e.g. multiple sclerosis or Parkinson's disease). In the case of multiple publications from the same cohort, we included the most up-to-date or comprehensive information.

Data collection process

We used a predesigned extraction form to collect information on the following items: study size; follow-up duration; age; sex; prior stroke; baseline cognitive performance; prior depression; MRI characteristics; definitions of CSVD features; outcome definitions; number of events; statistical analysis used; reported risk estimates; and variables adjusted for in the analyses. Any relevant missing information was requested from corresponding authors.

Risk of bias assessment

We evaluated risk of bias with the Newcastle-Ottawa scale (NOS) (Appendix C).

Variable definition

We used definitions of CSVD features and outcomes as reported in the original published papers. Incident stroke included fatal and non-fatal cerebral infarction and intracerebral haemorrhage. Incident dementia included Alzheimer's disease, presumed vascular

dementia and dementia not further specified. Incident depression subtype was not specified by any of the included studies. For stroke and depression, we included both first and recurrent events.

Statistical analysis

We pooled results for each CSVD feature when $\geq$ three studies were available with the same outcome. We pooled hazard ratios (HRs) using the random effects inverse variance method. We included the fully adjusted HR (but without adjustments for other CSVD features) (if available). HRs were reported by 49 studies, whereas fifteen studies reported results as odds ratios or relative risks (Table S3); these were treated as HRs.

For WMHs, we separately pooled dichotomous and continuous measures. For dichotomous measures, we compared the HR for a higher vs. a lower category. When $\geq$ two categories for WMHs were present, we selected the two categories with the highest number of participants and events. For total cerebral atrophy, we pooled only studies using a continuous scale (as percentage total intracranial volume or raw volume), as there were few data with atrophy measured dichotomously. We standardized continuous measures per standard deviation. For studies that reported only deep or periventricular WMHs instead of total WMHs, we included the results for periventricular WMHs in the main analysis, because periventricular WMHs more closely represent total WMHs.¹² Similarly, for studies that reported only deep or lobar CMBs instead of total CMBs, we included the results for deep CMBs in the main analysis, because deep CMBs more closely represent total CMBs⁸ and are more strongly related to hypertension.¹ For analyses with combined presence of $\geq$ two individual CSVD features as the determinant, we pooled HRs for any combination of individual features.

We evaluated the level of statistical heterogeneity across pooled studies per CSVD feature using the I^2 test.¹³ High statistical heterogeneity was defined as $I^2 > 60\%$. We assessed potential publication bias using funnel plots and, when $\geq$ ten studies were included in the analysis, by Egger's test. We corrected for the potential effect of significant funnel plot asymmetry using the trim and fill approach.¹⁴

We did several pre-specified sensitivity analyses. We repeated analyses by subtype of disease (ischaemic or haemorrhagic stroke, and Alzheimer's disease or presumed vascular dementia); using only population-based cohort studies; using only studies with high-risk populations (e.g. individuals with prior stroke or other cardiovascular disease, mild cognitive impairment, prior depression, or chronic kidney disease); including only high-quality studies (defined as NOS score $>$ four); using only studies that measured WMHs on an observer-rated semi-quantitative scale; using only studies that measured WMHs on an automated quantitative scale; replacing the results for periventricular WMHs with those for deep WMHs; replacing the risk estimates for deep CMBs with those for lobar CMBs; and replacing adjusted risk estimates with unadjusted risk estimates. In addition, we did several post hoc analyses, including repeating the analyses using only studies that included individuals with prior stroke. Other post hoc analyses are described in the supplemental material (Table S2).

Analyses were done with Review Manager 5.3 and R 3.2.3.

Results

Selection process and study characteristics

Figure 1 shows the selection process of included studies. In the systematic review, we included 36 studies for ischaemic or haemorrhagic stroke ($n=38,432/4,136$ individuals/events), 28 for all-cause dementia ($n=16,458/1,709$), nine for depression ($n=9,538/1,746$), and 28 for all-cause mortality ($n=23,031/2,558$). Table S3 shows the number of included studies in the pooled analyses and per CSVD feature. Only two studies evaluated perivascular spaces; these results were not pooled (Table S3). Full study characteristics and NOS scores are provided as supplemental material (Tables S4.1–S4.4 and S5.1–S5.4, respectively).

Stroke

All CSVD features were statistically significantly associated with incident ischaemic or haemorrhagic stroke, with moderate to substantial heterogeneity across studies pooled per CSVD feature (Figure 2, Figures S1.1a–S1.1e). Of all included studies, 95% found a positive association between any feature and stroke (Figures S1.1a–S1.1e). One study in the systematic review could not be included in the pooled analysis because no risk estimates were presented (Table S3). This study reported a statistically significant association between WMHs and stroke.

For analyses with stroke subtype as the outcome (ischaemic or haemorrhagic), sufficient studies were available for WMHs on a dichotomous scale (14 studies) and CMBs (10 studies) (Table S3). For WMHs, the HRs were qualitatively similar for the risk of ischaemic and haemorrhagic stroke (Figure S2.1). For CMBs, the risk of haemorrhagic stroke was higher than that of ischaemic stroke (Figure S2.4).

Dementia

All features, except CMBs, were statistically significantly associated with incident all-cause dementia, with moderate to substantial heterogeneity across studies pooled per CSVD feature (Figure 2, Figures S1.2a–S1.2e). Of all included studies, 80% found a positive association between any feature and dementia (Figures S1.2a–S1.2e). 12 studies were excluded from the pooled analysis (Table S3), of which six (four on WMHs, one on perivascular spaces and one on total cerebral atrophy) found a statistically significant association with dementia.

For analyses with dementia subtype as the outcome (Alzheimer's disease or presumed vascular dementia), sufficient studies were available for WMHs on a dichotomous scale (9 studies) (Table S3). For WMHs, the risk of presumed vascular dementia was higher than that of Alzheimer's disease (Figure S2.1).

Depression

WMHs on a dichotomous scale and total cerebral atrophy were statistically significantly associated with incident depression, with low to substantial heterogeneity across studies pooled per CSVD feature (Figure 2, Figures S1.3a–S1.3c). Of all included studies, 94% found a positive association between any feature and depression (Figures S1.3a–S1.3c). Four studies were excluded from the pooled analysis (Table S3), of which one, on lacunes, found a statistically significant association with depression.

Figure 1. A & B

All-cause mortality

WMHs, lacunes and CMBs were statistically significantly associated with all-cause mortality, with low to moderate heterogeneity across studies pooled per CSVD feature (Figure 2, Figures S1.4a-S1.4d). Of all included studies, 94% found a positive association between any feature and all-cause mortality (Figures S1.4a-S1.4d). All four studies that were excluded from the pooled analysis (Table S3) showed a statistically significant association with all-cause mortality.

Figure 1. C & D

Combinations of CSVD features

For incident stroke, two studies examined the combined effect of WMHs and lacunes and one of WMHs and CMBs (Table S3). No study examined the combined effect of $\geq$ three individual features, or examined the association between multiple individual features combined and any of the other outcomes. The combination of two CSVD features was statistically significantly associated with incident ischaemic and haemorrhagic stroke (Figure 2, Figure S1.1f). This risk was higher than the risk of any individual CSVD feature (Figure 2).

Sources of heterogeneity

Substantial heterogeneity ($I^2 > 60\%$) was present in four of the 17 main analyses (Figure 2). Exploration of heterogeneity showed that more concordance was present in analyses with only high-quality studies and with only studies that measured WMHs on an automated quantitative scale (Tables S6.1-S6.4). Results of these analyses were qualitatively similar to the results of the main analyses.

Potential publication bias

Significant funnel plot asymmetry was found for analyses with stroke (for WMHs on a dichotomous scale, lacunes and CMBs) and all-cause mortality (for WMHs on a dichotomous scale) (Table S7, Figure S3). We used the trim and fill approach to adjust the estimates for funnel plot asymmetry. The adjusted estimates were qualitatively similar to those in the main analyses (Table S8).

Sensitivity analyses

Results were quantitatively similar when analyses were repeated using only population-based cohort studies; using only high-quality studies; replacing the risk estimates for periventricular WMHs with those for deep WMHs; replacing the risk estimates for deep CMBs with those for lobar CMBs; and replacing adjusted risk estimates with unadjusted risk estimates (Figures S2.1-S2.5). In high-risk populations, the associations between WMHs and lacunes and all-cause dementia were weaker and not statistically significant (Figures S2.1, S2.3). For all studied outcomes, except for depression, the strength of the association was higher for WMHs measured on an automated quantitative scale than for WMHs measured on an observer rated semi-quantitative scale (Figure S2.1). Finally, in the post hoc analyses of studies with only stroke cases, WMHs, lacunes and microbleeds were associated with incident recurrent stroke, and WMHs and microbleeds, but not lacunes, were associated with higher mortality (Figure S2.1-2.5). The results of the other post hoc analyses are provided in the supplemental material (Figures S2.1-S2.5).

Figure 2. Pooled hazard ratios (95% confidence intervals) for the association between MRI features of cerebral small vessel disease (CSVD) and incident ischaemic and haemorrhagic stroke, all-cause dementia and depression, and all-cause mortality. *Higher vs. lower as defined by the individual studies. [†]Heterogeneity, $I^2 < 30\%$, [‡] $I^2 = 30-60\%$, ^{††} $I^2 > 60\%$. For the forest plots of each pooled analysis, see supplemental material, Figures S1.1-S1.4. Abbreviations: WMHs = white matter hyperintensities; SD = standard deviation

Discussion

Main findings

This systematic review and meta-analysis shows that various individual CSVD features are consistently and strongly associated with a higher incidence of ischaemic and haemorrhagic stroke, all-cause dementia and depression, and all-cause mortality. In addition, the combination of two CSVD features is more strongly associated with incident stroke than individual features alone. The combined effect of multiple CSVD features could not be investigated for all-cause dementia or depression, or all-cause mortality. This indicates that, if these associations are causal, the strength of these associations suggests that a substantial burden of disease is attributable to CSVD.

Our findings agree with and extend previous meta-analyses³⁻⁹ on CSVD. These studies evaluated only WMHs,^{3,5,6} or only CMBs,^{4,7-9} and found an association with incident stroke, dementia, depression or mortality. The present meta-analysis is the first to evaluate the effect of various CSVD features in different study populations on multiple clinical outcomes.

Methodologic considerations

Some methodological issues warrant consideration. First, the associations with all outcomes were consistent across the different MRI features. Our analyses suggest individual MRI features of CSVD may not carry a differential risk for a specific clinical event, but may reflect disease severity, consistent with the hypothesis that these features are manifestations of the same disease.¹ For instance, cerebral microbleeds were associated not only with incident intracerebral haemorrhage, but also with ischaemic stroke. In accordance, a recent study among individuals with CADASIL¹⁵ found that presence of cerebral microbleeds was associated with ischaemic stroke. Second, there was substantial quantitative heterogeneity in four of the 17 main analyses. More concordance was present among high-quality studies and among studies that measured WMHs on an automated quantitative scale. Third, potential publication bias was present in four of the 17 main analyses. However, additional analyses suggested that this bias may have led to only a slight overestimation of true effect estimates (adjusted estimates calculated using the trim and fill approach were qualitatively similar to the results of the main analysis). Fourth, only two studies evaluated perivascular spaces, and only three studies evaluated the effect of combinations of CSVD features. Evidence for associations between perivascular spaces or combined CSVD features and the outcomes studied is, therefore, weak, and this requires further study. Fifth, effect estimates for stroke were higher than for dementia and depression, and mortality. The assessment of dementia and depression may have a larger measurement error than the assessment of stroke or death. Furthermore, other non-vascular factors may lead to dementia, depression, or greater mortality. Sixth, the association between CMBs and incident dementia was not statistically significant. This needs to be interpreted cautiously, because only four studies with relatively small samples were included in this analysis. Finally, results of most sensitivity analyses were consistent with our main analyses, with few exceptions. For CMBs, risk of haemorrhagic stroke was higher than for ischaemic stroke, which is in accordance with a previous meta-analysis.⁸ This may be due to direct enlargement of CMBs transforming to intracranial haemorrhage.¹⁶ In addition, in high-risk populations, the associations between WMHs and lacunes and all-cause dementia were weaker than those in the population based studies. Similarly, in stroke populations, the associations between MWHs, lacunes and microbleeds and (recurrent) stroke and mortality were weaker. This may be due to the lower quality and smaller sample size of studies done in high-risk populations (only three of these 12 studies had a NOS score >four and their mean sample size was 209) and stroke populations (four of these 21 studies had a NOS score >four and their mean sample size was 861) as compared to population-based studies (11 of these 12 studies had a NOS score >four and their mean sample size was 1,484).

Underlying mechanisms

CSVD may lead to stroke, dementia, depression, and mortality through multiple mechanisms. First, CSVD may be a direct cause of stroke, dementia, and depression. Notably, MRI features of CSVD may reflect poor cerebral blood flow regulation, predisposing to ischemia (e.g. due to chronic cerebral hypoperfusion), which may lead to stroke.¹⁷ Furthermore, interruption of prefrontal subcortical structures or loops involved in cognitive function or mood regulation may directly lead to cognitive decline and depression.^{1, 18} Second, CSVD may indirectly lead to cognitive decline and depression

through incident stroke. Similarly, CSVD may increase mortality risk through incident stroke, dementia, and depression. Third, CSVD has been suggested¹⁹ to lead to cognitive decline through interaction with Alzheimer's disease pathology. In accordance, the present study showed that CSVD increased the risk not only of presumed vascular dementia, but also of Alzheimer's disease. Fourth, CSVD reflecting an individual's poor health or social economic status might also explain our findings, particularly the association between CSVD and all-cause mortality. Although studies that adjusted for measures of frailty (e.g. walking speed) or education found similar results, we cannot exclude the possibility of residual confounding.

Implications

This review has several clinical and research implications. It shows that individuals with CSVD features are at high risk of ischaemic and haemorrhagic stroke, all-cause dementia, depression and mortality; a risk similar to that of individuals with diabetes²⁰⁻²³ or hypertension.²⁴⁻²⁸ An incidental finding of CSVD should be recognized as implying a substantial risk of stroke, dementia, depression, and mortality, and should prompt work-up and treatment of relevant risk factors. Prevention of CSVD itself could be an important therapeutic goal, although evidence for effective interventions is lacking. Trials are therefore needed that target suspected mechanisms of CSVD, including blood-brain barrier dysfunction, capillary flow pattern dysregulation, and blood pressure variability.¹⁷ In addition, CSVD may be a surrogate marker of risk of stroke, dementia and depression. CSVD features can be quantified reliably²⁹ and their change over time may be more sensitive than change of cognition.³⁰ However, only one previous study³¹ found that reduction of progression of CSVD correlated with reduced occurrence of clinical endpoints, while others^{32, 33} did not. This requires further study. Finally, the present study showed that the combination of two CSVD features is most strongly associated with incident stroke. This suggests that imaging scales that integrate many CSVD features, such as the scale recently developed by Huijts et al.,³⁴ are most suitable to assess CSVD and most likely to enable improved risk prediction of clinical outcomes beyond established risk factors.

Limitations

This review has some limitations. We only evaluated baseline measurements of CSVD. Baseline measurements may, however, not accurately reflect the exposure to new lesions during follow-up. We also did not evaluate the location of CSVD features, although their clinical consequences may depend upon location, so our estimates are an average over possibly different associations per region. In addition, the pooled estimates for WMHs on a dichotomous scale should be interpreted with caution. Different definitions of this measure were used across studies which hampers its interpretation.

Conclusion

The present systematic review and meta-analysis shows that various CSVD features are strongly and consistently associated with a higher incidence of ischaemic and haemorrhagic stroke, all-cause dementia and depression, and greater all-cause mortality.

References

1. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge R, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB and Dichgans M. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol.* 2013;12:822-38.
2. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. *Lancet Neurol.* 2010;9:689-701.
3. DeBette S and Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ.* 2010;341:c3666.
4. Charidimou A, Shams S, Romero JR, Ding J, Veltkamp R, Horstmann S, Eiriksdottir G, van Buchem MA, Gudnason V, Himali JJ, Gurol ME, Viswanathan A, Imaizumi T, Vernooij MW, Seshadri S, Greenberg SM, Benavente OR, Launer LJ, Shoamanesh A and International M-MI. Clinical significance of cerebral microbleeds on MRI: A comprehensive meta-analysis of risk of intracerebral hemorrhage, ischemic stroke, mortality, and dementia in cohort studies (v1). *Int J Stroke.* 2018;1747493017751931.
5. Wang L, Leonards CO, Sterzer P and Ebinger M. White matter lesions and depression: a systematic review and meta-analysis. *J Psychiatr Res.* 2014;56:56-64.
6. van Agtmaal MJM, Houben A, Pouwer F, Stehouwer CDA and Schram MT. Association of Microvascular Dysfunction With Late-Life Depression: A Systematic Review and Meta-analysis. *JAMA Psychiatry.* 2017.
7. Wang DN, Hou XW, Yang BW, Lin Y, Shi JP and Wang N. Quantity of Cerebral Microbleeds, Antiplatelet Therapy, and Intracerebral Hemorrhage Outcomes: A Systematic Review and Meta-analysis. *J Stroke Cerebrovasc Dis.* 2015;24:2728-37.
8. Charidimou A, Kakar P, Fox Z and Werring DJ. Cerebral microbleeds and recurrent stroke risk: systematic review and meta-analysis of prospective ischemic stroke and transient ischemic attack cohorts. *Stroke.* 2013;44:995-1001.
9. Charidimou A, Imaizumi T, Moulin S, Biffi A, Samarasekera N, Yakushiji Y, Peeters A, Vandermeeren Y, Laloux P, Baron JC, Hernandez-Guillamon M, Montaner J, Casolla B, Gregoire SM, Kang DW, Kim JS, Naka H, Smith EE, Viswanathan A, Jager HR, Al-Shahi Salman R, Greenberg SM, Cordonnier C and Werring DJ. Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds: A meta-analysis. *Neurology.* 2017;89:820-829.
10. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA and Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA.* 2000;283:2008-12.
11. Booth A, Clarke M, Ghersi D, Moher D, Petticrew M and Stewart L. An international registry of systematic-review protocols. *Lancet.* 2011;377:108-9.
12. Prasad K, Wiryasaputra L, Ng A and Kandiah N. White matter disease independently predicts progression from mild cognitive impairment to Alzheimer's disease in a clinic cohort. *Dement Geriatr Cogn Disord.* 2011;31:431-4.
13. Higgins JP and Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med.* 2002;21:1539-58.

14. Duval S and Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics*. 2000;56:455-63.
15. Puy L, De Guio F, Godin O, Duering M, Dichgans M, Chabriat H and Jouvent E. Cerebral Microbleeds and the Risk of Incident Ischemic Stroke in CADASIL (Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy). *Stroke*. 2017;48:2699-2703.
16. Akoudad S, Portegies MLP, Koudstaal PJ, Hofman A, Van Der Lugt A, Ikram MA and Vernooij MW. Cerebral Microbleeds Are Associated with an Increased Risk of Stroke: The Rotterdam Study. *Circulation*. 2015;132:509-516.
17. Ostergaard L, Engedal TS, Moreton F, Hansen MB, Wardlaw JM, Dalkara T, Markus HS and Muir KW. Cerebral small vessel disease: Capillary pathways to stroke and cognitive decline. *J Cereb Blood Flow Metab*. 2016;36:302-25.
18. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D and Charlson M. 'Vascular depression' hypothesis. *Arch Gen Psychiatry*. 1997;54:915-22.
19. de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. *Stroke*. 2002;33:1152-62.
20. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams DE and Geiss L. Changes in diabetes-related complications in the United States, 1990-2010. *N Engl J Med*. 2014;370:1514-23.
21. Xu WL, Qiu CX, Wahlin A, Winblad B and Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. *Neurology*. 2004;63:1181-6.
22. Yu M, Zhang X, Lu F and Fang L. Depression and Risk for Diabetes: A Meta-Analysis. *Can J Diabetes*. 2015;39:266-72.
23. Gregg EW, Cheng YJ, Saydah S, Cowie C, Garfield S, Geiss L and Barker L. Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey. *Diabetes Care*. 2012;35:1252-7.
24. Imano H, Kitamura A, Sato S, Kiyama M, Ohira T, Yamagishi K, Noda H, Tanigawa T, Iso H and Shimamoto T. Trends for blood pressure and its contribution to stroke incidence in the middle-aged Japanese population: the Circulatory Risk in Communities Study (CIRCS). *Stroke*. 2009;40:1571-7.
25. Verdecchia P, Reboldi GP, Angeli F, Schillaci G, Schwartz JE, Pickering TG, Imai Y, Ohkubo T and Kario K. Short- and long-term incidence of stroke in white-coat hypertension. *Hypertension*. 2005;45:203-208.
26. Li G, Rhew IC, Shofer JB, Kukull WA, Breitner JC, Peskind E, Bowen JD, McCormick W, Teri L, Crane PK and Larson EB. Age-varying association between blood pressure and risk of dementia in those aged 65 and older: a community-based prospective cohort study. *J Am Geriatr Soc*. 2007;55:1161-7.
27. Sharp SJ, Aarsland D, Day S, Sonnesyn H, Ballard C and Syst AsSVD. Hypertension is a potential risk factor for vascular dementia: systematic review. *Int J Geriatr Psychiatry*. 2011;26:661-669.
28. Barengo NC, Antikainen R, Kastarinen M, Laatikainen T and Tuomilehto J. The effects of control of systolic and diastolic hypertension on cardiovascular and all-cause mortality in a community-based population cohort. *J Hum Hypertens*. 2013;27:693-7.

29. De Guio F, Jouvent E, Biessels GJ, Black SE, Brayne C, Chen C, Cordonnier C, De Leeuw FE, Dichgans M, Doubal F, Duering M, Dufouil C, Duzel E, Fazekas F, Hachinski V, Ikram MA, Linn J, Matthews PM, Mazoyer B, Mok V, Norrving B, O'Brien JT, Pantoni L, Ropele S, Sachdev P, Schmidt R, Seshadri S, Smith EE, Sposato LA, Stephan B, Swartz RH, Tzourio C, van Buchem M, van der Lugt A, van Oostenbrugge R, Vernooij MW, Viswanathan A, Werring D, Wollenweber F, Wardlaw JM and Chabriat H. Reproducibility and variability of quantitative magnetic resonance imaging markers in cerebral small vessel disease. *J Cereb Blood Flow Metab.* 2016;36:1319-37.
30. Benjamin P, Zeestraten E, Lambert C, Ster IC, Williams OA, Lawrence AJ, Patel B, MacKinnon AD, Barrick TR and Markus HS. Progression of MRI markers in cerebral small vessel disease: Sample size considerations for clinical trials. *J Cereb Blood Flow Metab.* 2016;36:228-40.
31. Dufouil C, Chalmers J, Coskun O, Besancon V, Bousser MG, Guillon P, MacMahon S, Mazoyer B, Neal B, Woodward M, Tzourio-Mazoyer N, Tzourio C and Investigators PMS. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. *Circulation.* 2005;112:1644-50.
32. Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, Sullivan M, Horowitz KR, Ding J, Marcovina S, Lovato LC, Lovato J, Margolis KL, O'Connor P, Lipkin EW, Hirsch J, Coker L, Maldjian J, Sunshine JL, Truwit C, Davatzikos C, Bryan RN and investigators AM. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. *Lancet Neurol.* 2011;10:969-77.
33. Williamson JD, Launer LJ, Bryan RN, Coker LH, Lazar RM, Gerstein HC, Murray AM, Sullivan MD, Horowitz KR, Ding J, Marcovina S, Lovato L, Lovato J, Margolis KL, Davatzikos C, Barzilay J, Ginsberg HN, Linz PE, Miller ME and Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes I. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. *JAMA Intern Med.* 2014;174:324-33.
34. Huijts M, Duits A, van Oostenbrugge RJ, Kroon AA, de Leeuw PW and Staals J. Accumulation of MRI Markers of Cerebral Small Vessel Disease is Associated with Decreased Cognitive Function. A Study in First-Ever Lacunar Stroke and Hypertensive Patients. *Front Aging Neurosci.* 2013;5:72.

Supplemental material

Supplemental methods section

Appendix A. MOOSE Statement - Reporting Checklist for Authors, Editors, and Reviewers of Meta-analyses of Observational Studies

Reporting Criteria	Reported (Yes/No)
Reporting of Background	
Problem definition	Yes
Hypothesis statement	Yes
Description of Study Outcome(s)	Yes
Type of exposure or intervention used	Yes
Type of study design used	Yes
Study population	Yes
Reporting of Search Strategy	
Qualifications of searchers (e.g. librarians and investigators)	Yes
Search strategy, including time period included in the synthesis and keywords	Yes (Supplemental material, Tables S1.1 to S1.4)
Effort to include all available studies, including contact with authors	Yes
Databases and registries searched	Yes
Search software used, name and version, including special features used (eg, explosion)	Yes
Use of hand searching (eg, reference lists of obtained articles)	Yes
List of citations located and those excluded, including justification	Yes (Figure 1, Table S3)
Method for addressing articles published in languages other than English	Yes
Method of handling abstracts and unpublished studies	Yes
Description of any contact with authors	Yes
Reporting of Methods	
Description of relevance or appropriateness of studies assembled for assessing the hypothesis to be tested	Yes
Rationale for the selection and coding of data (e.g. sound clinical principles or convenience)	Yes
Documentation of how data were classified and coded (e.g. multiple raters, blinding, and interrater reliability)	Yes
Assessment of confounding (e.g. comparability of cases and controls in studies where appropriate)	Yes
Assessment of study quality, including blinding of quality assessors; stratification or regression on possible predictors of study results	Yes (Supplemental material, Appendix C)
Assessment of heterogeneity	Yes (Supplemental material, Table S2)

Reporting Criteria	Reported (Yes/No)
Description of statistical methods (e.g. complete description of fixed or random effects models, justification of whether the chosen models account for predictors of study results, dose-response models, or cumulative meta-analysis) in sufficient detail to be replicated	Yes
Provision of appropriate tables and graphics	Yes (Figure 1, Supplemental material)
Reporting of Results	
Table giving descriptive information for each study included	Yes (Supplemental material, Tables S4.1 to S4.4, Tables S5.1 to S5.4)
Results of sensitivity testing (e.g. subgroup analysis)	Yes (Supplemental material, Figures S2.1 to S2.4, Tables S6.1 to S6.4)
Indication of statistical uncertainty of findings	Yes
Reporting of Discussion	
Quantitative assessment of bias (e.g. publication bias)	Yes (Supplemental material, Figure S3, Table S7 and S8)
Justification for exclusion (e.g. exclusion of non-English-language citations)	No
Assessment of quality of included studies	Yes (Supplemental material, Tables S5.1 to S5.4)
Reporting of Conclusions	
Consideration of alternative explanations for observed results	Yes
Generalization of the conclusions (i.e. appropriate for the data presented and within the domain of the literature review)	Yes
Guidelines for future research	Yes
Disclosure of funding source	Yes

Appendix B. PROSPERO protocol

UNIVERSITY of York
Centre for Reviews and Dissemination

NHS
National Institute for
Health Research

PROSPERO International prospective register of systematic reviews

Cerebral small vessel disease and risk of stroke, dementia, depression, and all-cause mortality: a systematic review and meta-analysis

Sytze Rensma, Thomas Van Sloten, Lenore Launer, Coen Stehouwer

Citation

Sytze Rensma, Thomas Van Sloten, Lenore Launer, Coen Stehouwer. Cerebral small vessel disease and risk of stroke, dementia, depression, and all-cause mortality: a systematic review and meta-analysis. PROSPERO 2016:CRD42016038521 Available from http://www.crd.york.ac.uk/PROSPERO_REBRANDING/display_record.asp?ID=CRD42016038521

Review question(s)

Are different magnetic resonance imaging (MRI) defined manifestations of cerebral small vessel disease (i.e. higher white matter hyperintensity volume, presence of lacunes, cerebral microbleeds and perivascular spaces, and brain atrophy) associated with a higher risk of incident stroke, dementia, depression and/or all-cause mortality?

Searches

We will identify relevant studies through a search of MEDLINE and EMBASE, from July 1977 (first recorded use of brain MRI) to present, using predefined search terms. In addition, we will identify papers by reviewing the reference list of all relevant articles identified.

There are no language restrictions.

Types of study to be included

Prospective studies will be included that evaluate the association between manifestations of cerebral small vessel disease and incident stroke, dementia, depression and/or all-cause mortality.

Specific inclusion criteria are:

1. MRI defined manifestations of cerebral small vessel disease (as defined by the STandards for Reporting Vascular changes on nEuroimaging [STRIVE] [1]) determined at baseline:
 - a. Volume of white matter hyperintensities of presumed vascular origin
 - b. Lacunes of presumed vascular origin, subcortical infarcts and silent brain infarcts. Subcortical infarcts and silent brain infarcts will be included, because most of these infarcts are lacunes of presumed vascular origin [1].
 - c. Cerebral microbleeds
 - d. Perivascular spaces
 - e. Brain atrophy
2. Any of the following outcomes (as defined by the individual studies):
 - a. Incident clinical stroke (first or recurrent) (not silent stroke)
 - b. Incident dementia
 - c. Incident depression (first or recurrent episode)
 - d. All-cause mortality

3. Study population of at least 50 subjects
4. Mean/median follow-up duration = 12 months after brain MRI
5. Studying adults (individuals aged 18 years or older)
6. Full-text article available (no congress abstracts)

Specific exclusion criterion is:

1. Studies only including individuals with cerebral inflammatory or neurodegenerative diseases (e.g. multiple sclerosis, lupus erythematosus, Huntington's disease and Parkinson's disease) or monogenetic cerebrovascular disease (e.g. CADASIL)

Condition or domain being studied

Manifestations of cerebral small vessel disease detected by MRI include white matter hyperintensities, lacunes of presumed vascular origin, cerebral microbleeds, perivascular spaces and cerebral atrophy. Several studies have evaluated the association between these manifestations and various outcomes, including incident stroke, dementia, depression and mortality. However, the results of these studies have not been consistent. Thus far, no study has systematically evaluated the association between different manifestations of cerebral small vessel disease and incident stroke, dementia, depression and/or all-cause mortality.

Participants/ population

All adults in whom the association between manifestations of cerebral small vessel disease and incident stroke, dementia, depression and/or all-cause mortality is evaluated as specified above (please see "types of study to be included"), both in the general population and in a hospital-based setting.

Intervention(s), exposure(s)

The exposure variable is the presence of MRI defined manifestations of cerebral small vessel disease.

Comparator(s)/ control

The control is the group of participants without or with a lower burden of MRI defined manifestations of cerebral small vessel disease.

Outcome(s)

Primary outcomes

1. Incident clinical stroke (first or recurrent)
2. Incident dementia
3. Incident depression (first or recurrent episode)
4. All-cause mortality

Secondary outcomes

1. Specific subtypes of stroke (ischaemic vs. haemorrhagic stroke)
2. Specific subtypes of dementia (vascular dementia vs. Alzheimer's disease)

Data extraction, (selection and coding)

Two independent reviewers (SR and TVS) will select all relevant studies based on title and abstract. Full texts will then be retrieved and assessed for eligibility. In the case of multiple publications from the same cohort, we will include the most up-to-date or comprehensive information. Two independent reviewers (SR, TVS) will extract data with use of a pre-designed data extraction form. Any disagreements between the reviewers will be resolved by consensus. A third independent reviewer is available to solve any persisting disagreements. We will collect information on the following items: study size; follow-up duration; age; sex; diabetes mellitus, prior stroke; other

prior cardiovascular diseases; hypertension; atrial fibrillation; baseline cognitive performance; prior depression; baseline depression scale score; MRI characteristics; definitions of CSVD features; outcome definitions; number of events; statistical analysis used; reported risk estimates; and other variables adjusted for in the analyses.

Risk of bias (quality) assessment

Two reviewers (SR and TVS) will independently assess the risk of bias with the Newcastle-Ottawa Scale. Any disagreements between the reviewers will be resolved by consensus. A third independent reviewer (CS) is available to resolve any persisting disagreements.

Strategy for data synthesis

All analyses will be done with Cochrane Review manager (version 5.3) and R statistical software (version 3.2.3). We will pool results for each manifestation of cerebral small vessel disease when at least three studies are available with the same outcome. For white matter hyperintensity volume and brain atrophy, we will pool results separately for dichotomous and continuous measures. For analysis with combined presence of two or more individual features of CSVD as the determinant, we will pool HRs for any accumulating combination of individual features of CSVD. Continuous measures will be included as per one higher standard deviation (SD). Weighted subgroup SDs will be used when no overall SD is provided. For studies that measure deep and periventricular white matter hyperintensity volumes separately and do not provide a measure of total white matter hyperintensity volume, we will include the results for periventricular white matter hyperintensity volume in the main analysis only, because periventricular white matter hyperintensity volume is more closely related to total white matter hyperintensity volume. For lacunes, cerebral microbleeds and perivascular spaces, we will pool results for dichotomous measures. For studies that measure deep and lobar microbleeds separately and do not provide a total microbleed count, we will include the results for deep microbleeds in the main analysis only, because deep microbleeds are more closely related to the total cerebral microbleed count [1, 4]. Pooled hazard ratios (HRs) will be calculated using the random effects inverse variance method. Most studies will report HRs. Odds ratios and relative risks will be treated as HRs. For each study, we will include the fully adjusted HR (but without adjustments for other manifestations of cerebral small vessel disease). The level of statistical heterogeneity will be evaluated using the I-squared test. High statistical heterogeneity was defined as I-squared >60%. Potential publication bias will be assessed with Egger's test and by construction of funnel plots.

Analysis of subgroups or subsets

The following sensitivity analyses will be done:

1. Analyses will be repeated separately for studies with high risk populations (i.e. individuals with previous stroke or mild cognitive impairment) and population based studies
2. Analyses will be repeated after excluding studies with a relatively high risk of bias (defined as Newcastle-Ottawa scale score <4)
3. Analyses will be repeated including only those studies that defined a lacuna of presumed vascular origin according to STRIVE, i.e. a round or ovoid, subcortical, fluid-filled (cerebrospinal fluid-like) cavity between 3-15 mm on T1 and/or T2 weighted MRI images
4. Analyses will be repeated separately for studies that measured white matter hyperintensity volume on a quantitative scale and those that measured white matter hyperintensity volume on a visual semi-quantitative scale (e.g. Fazekas and Wahlund scale).
5. Analyses will be repeated replacing the results for periventricular white matter hyperintensity volume with those for deep white matter hyperintensity volume
6. Analyses will be repeated replacing the results for deep cerebral microbleeds with those for lobar cerebral microbleeds
7. Analyses will be repeated with unadjusted (or minimally adjusted) risk estimates
8. For white matter hyperintensity volume and brain atrophy, results will be pooled per ten millilitre volume instead

of per SD.

Contact details for further information

Mr Rensma

s.rensma@maastrichtuniversity.nl

Organisational affiliation of the review

Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands

Review team

Mr Sytze Rensma, Maastricht University Medical Centre

Dr Thomas Van Sloten, Maastricht University Medical Centre

Dr Lenore Launer, Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health

Professor Coen Stehouwer, Maastricht University Medical Centre

Anticipated or actual start date

01 November 2015

Anticipated completion date

01 April 2017

Funding sources/sponsors

Sytze Rensma, Thomas van Sloten and Coen Stehouwer are supported by the European Regional Development Fund as part of Het Operationeel Programma Zuid-Nederland (OP-ZUID), the province of Limburg, Department of Economic Affairs of Netherlands (grant 310.041), Stichting de Weijerhorst, Pearl String Initiative Diabetes, Cardiovascular Centre Maastricht, Cardiovascular Research Institute Maastricht (CARIM), School for Nutrition, Toxicology and Metabolism (NUTRIM), Stichting Annadal, and Health Foundation Limburg.

Conflicts of interest

None known

Language

English

Country

Netherlands

Subject index terms status

Subject indexing assigned by CRD

Subject index terms

Cerebral Small Vessel Diseases; Dementia; Depression; Depressive Disorder; Humans; Stroke

Any other information

References 1. Wardlaw, J.M., et al., Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol*, 2013. 12(8): p. 822-38. 2. Wells GA SB, S.B., O'Connell D, Peterson J et al., The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. p. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. 3. Prasad, K., et al., White matter disease independently predicts progression from mild cognitive impairment to Alzheimer's disease in a clinic cohort. *Dement Geriatr Cogn Disord*, 2011. 31(6): p. 431-4. 4. Charidimou, A., et al., Cerebral microbleeds and recurrent stroke risk: systematic review and meta-analysis of prospective ischemic stroke and transient ischemic attack cohorts. *Stroke*, 2013. 44(4): p. 995-1001.

Stage of review

Completed but not published

Date of registration in PROSPERO

04 May 2016

Date of publication of this revision

04 May 2017

Stage of review at time of this submission	Started	Completed
Preliminary searches	Yes	Yes
Piloting of the study selection process	Yes	Yes
Formal screening of search results against eligibility criteria	Yes	Yes
Data extraction	Yes	Yes
Risk of bias (quality) assessment	Yes	Yes
Data analysis	Yes	Yes

PROSPERO

International prospective register of systematic reviews

The information in this record has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites.

Appendix C. Adjusted Newcastle-Ottawa Scale

For the present study, items 2 and 3 (selection category) of the original Newcastle-Ottawa Scale (NOS) for cohort studies were combined (for the individual items, see below). The original items evaluated the quality of the assessment of the exposed and non-exposed cohorts, respectively. In the present study, however, the total study was “exposed” to the risk factor under study (i.e. cerebral small vessel disease). A study can be awarded a maximum of one star for each numbered item within the selection and outcome categories. A maximum of two stars can be given for comparability.

The individual items of the scale are described below.

Selection

1) Representativeness of the cohort

- a) truly representative of the general population *
- b) somewhat representative of the general population *
- c) high risk populations (e.g. individuals with: prior stroke, mild cognitive impairment, cardiovascular disease, prior depression (for the association with incident depression), or individuals receiving dialysis)
- d) no description or other cohorts

2) Ascertainment of determinant (cerebral small vessel disease)

- a) use of an MRI scanner with a field strength of 1.5 Tesla or higher and the following (minimal) sequences: for white matter hyperintensities: T2-weighted and fluid-attenuated inversion recovery (FLAIR); for lacunes: T1- and/or T2-weighted; for cerebral microbleeds: T2*-weighted gradient echo sequence; for perivascular spaces: T2-weighted; and for total cerebral atrophy: T1/FLAIR *
- b) not a method described above
- c) no description

3) Demonstration that outcome of interest was not present at start of study

- a) yes *
- b) no

Comparability

1) Comparability of cohorts based on of the design or analysis

- a) study controls for cardiovascular risk factors; smoking habits, type 2 diabetes, and systolic blood pressure, and/or use of antihypertensive medication. *
- b) study controls for age, sex, and (for studies evaluating incident dementia) education *
- c) other

Outcome

1) Assessment of outcome

- a) objective measurements and/or record linkage and/or expert opinion *

For depression: validated criteria, ICD codes

For dementia: validated cognitive tests, ICD codes

For stroke: clinical diagnosis

For mortality: population or hospital register

- b) self- and/or peer-report

- c) no description/other

2) Was follow-up long enough for outcomes to occur

- a) yes (median/mean follow-up duration >4 year) *

- b) no

3) Adequacy of follow-up of cohorts

- a) complete follow-up and/or all subjects accounted for *

- b) subjects lost to follow-up unlikely to introduce bias, small number lost (>80 % follow-up), or description provided of those lost *

- c) follow up rate <80% and no description of those lost to follow-up

- d) no statement

Supplemental results section

Table S1.1 –Search strategy for incident ischaemic and haemorrhagic stroke

PubMed
<p>((("White matter" AND (hyperintens* OR lesion* OR disease* OR change*)) OR ("leukoaraiosis" OR "Leukoaraiosis"[Mesh] OR "Leukoaraiosis/pathology"[Mesh]) OR (("cerebral small vessel" OR "cerebral small-vessel") AND disease*) OR "Cerebral Small Vessel Diseases"[Mesh]) OR (((("lacunar" OR "deep" OR "subcortical" OR "silent" OR "small vessel") AND (infarc* OR Stroke*)) OR "Stroke, Lacunar"[Mesh]) OR ((microinfarct* OR microscopic infarct*) AND ("brain" OR cerebral* OR cerebrum*)) OR ((("brain" OR cerebral* OR cerebrum*) AND ((microhemorrhag* OR microbleed* OR microhaemorrhag*) OR ("dot-like" AND (suscept* OR hemosid*)))) OR ((("brain" OR cerebral* OR cerebrum*) AND (Virchow-Robin* OR Virchow Robin* OR "etat crible" OR (perivascular space*))) OR ((("brain" OR cerebral* OR cerebrum*) AND ("Atrophy" OR volum* OR "volume loss")) AND ("Magnetic Resonance Imaging"[Mesh] OR "MRI" OR "magnetic resonance imaging") AND ((("Stroke" OR ("brain" OR cerebral* OR cerebrum*)) AND (Infarction* OR hemorrhag* OR haemorrhag*)) or "Stroke"[Mesh] or "Stroke/epidemiology"[Mesh] or "Cerebral Hemorrhage"[Mesh] OR "Cerebral Infarction"[Mesh])) AND ("Longitudinal study" OR "Cohort study" OR "Prospective study" OR "Longitudinal Studies"[Mesh] or "Cohort Studies"[Mesh] OR "Prospective Studies"[Mesh])</p>
Embase
<p>((exp white matter/ AND (hyperintensity.mp. OR lesion.mp. OR disease.mp. OR exp diseases/)) OR exp white matter lesion/ OR leukoaraiosis.mp. OR cerebral small vessel disease.mp. OR exp cerebrovascular disease/ OR (exp lacunar stroke/ OR ((lacunar.mp. OR deep.mp. OR subcortical.mp. OR silent.mp. OR small vessel.mp.) AND (exp infarction/ OR exp stroke/)) OR ((microinfarct.mp. OR microscopic infarct.mp.) AND (cerebral.mp. OR exp brain/ OR cerebrum.mp.))) OR (((cerebral.mp. OR exp brain/ OR cerebrum.mp.) AND (microhaemorrhage.mp. OR microhemorrhage.mp. OR microbleed.mp.)) OR (dot-like.mp. AND (susceptible.mp. OR hemosiderin.mp.))) OR ((cerebral.mp. OR exp brain/ OR cerebrum.mp.) AND (virchow-robin.mp. OR Virchow robin.mp. OR etat crible.mp. OR perivascular space.mp.)) OR (((cerebral.mp. OR exp brain/ OR cerebrum.mp. OR exp brain size/) AND (exp atrophy/ OR volume loss.mp.)) OR exp brain atrophy/) AND (((cerebral.mp. OR exp brain/ OR cerebrum.mp.) AND (exp infarction/ OR exp stroke/ OR exp bleeding/ OR microhaemorrhage.mp. OR microhemorrhage.mp.)) OR Exp brain infarction/ OR exp cerebrovascular accident/) AND (MRI.mp. OR magnetic resonance imaging.mp. OR exp nuclear magnetic resonance imaging/) AND (exp longitudinal study/ OR exp cohort analysis/ OR exp prospective study/)</p>

Table S1.2 –Search strategy for incident all-cause dementia

PubMed
<p>(((((("White matter" AND (hyperintens* OR lesion* OR disease* OR change*)) OR ("leukoaraiosis" OR "Leukoaraiosis"[Mesh] OR "Leukoaraiosis/pathology"[Mesh]) OR ((("cerebral small vessel" OR "cerebral small-vessel") AND disease*) OR "Cerebral Small Vessel Diseases"[Mesh]) OR (((("lacunar" OR "deep" OR "subcortical" OR "silent" OR "small vessel") AND (infarc* OR Stroke*)) OR "Stroke, Lacunar"[Mesh] OR ((microinfarct* OR microscopic infarct*) AND ("brain" OR cerebral* OR cerebrum*))) OR ((("brain" OR cerebral* OR cerebrum*) AND ((microhemorrhag* OR microbleed* OR microhaemorrhag*) OR ("dot-like" AND (suscept* OR hemosid*)))) OR ((("brain" OR cerebral* OR cerebrum*) AND (Virchow-Robin* OR Virchow Robin* OR "etat crible" OR (perivascular space*))) OR ((("brain" OR cerebral* OR cerebrum*) AND ("Atrophy" OR volum* OR "volume loss")) AND ("Magnetic Resonance Imaging"[Mesh] OR "MRI" OR "magnetic resonance imaging")) AND ((("Dementia" OR "Alzheimer disease" OR "Vascular dementia" OR "Dementia"[Mesh] OR "Dementia/epidemiology"[Mesh] OR "Alzheimer Disease"[Mesh] OR "Dementia, Multi-Infarct"[Mesh] OR "Dementia, Vascular"[Mesh] OR "Mild Cognitive Impairment"[Mesh] OR "cognitive impairment")) AND ((("Longitudinal study" OR "Cohort study" OR "Prospective study" OR "Longitudinal Studies"[Mesh] OR "Cohort Studies"[Mesh] OR "Prospective Studies"[Mesh]))</p>
Embase
<p>((exp white matter/ AND (hyperintensity.mp. OR lesion.mp. OR disease.mp. OR exp diseases/)) OR exp white matter lesion/ OR leukoaraiosis.mp. OR cerebral small vessel disease.mp. OR exp cerebrovascular disease/ OR (exp lacunar stroke/ OR ((lacunar.mp. OR deep.mp. OR subcortical.mp. OR silent.mp. OR small vessel.mp.) AND (exp infarction/ OR exp stroke/)) OR ((microinfarct.mp. OR microscopic infarct.mp.) AND (cerebral.mp. OR exp brain/ OR cerebrum.mp.))) OR (((cerebral.mp. OR exp brain/ OR cerebrum.mp.) AND (microhaemorrhage.mp. OR microhemorrhage.mp. OR microbleed.mp.)) OR (dot-like.mp. AND (susceptible.mp. OR hemosiderin.mp.))) OR ((cerebral.mp. OR exp brain/ OR cerebrum.mp.) AND (virchow-robin.mp. OR Virchow robin.mp. OR etat crible.mp. OR perivascular space.mp.)) OR (((cerebral.mp. OR exp brain/ OR cerebrum.mp. OR exp brain size/ AND (exp atrophy/ OR volume loss.mp.)) OR exp brain atrophy/)) AND (exp dementia/ OR exp Alzheimer disease/ OR exp multifarct dementia/ OR vascular dementia.mp. OR exp cognitive defect/ OR cognitive impairment.mp.) AND (MRI.mp. OR magnetic resonance imaging.mp. OR exp nuclear magnetic resonance imaging/ AND (exp longitudinal study/ OR exp cohort analysis/ OR exp prospective study/))</p>

Table S1.3 –Search strategy for incident depression

PubMed
<p>((("White matter" AND (hyperintens* OR lesion* OR disease* OR change*)) OR ("leukoaraiosis" OR "Leukoaraiosis"[Mesh] OR "Leukoaraiosis/pathology"[Mesh]) OR ((("cerebral small vessel" OR "cerebral small-vessel") AND disease*) OR "Cerebral Small Vessel Diseases"[Mesh]) OR (((("lacunar" OR "deep" OR "subcortical" OR "silent" OR "small vessel") AND (infarc* OR Stroke*)) OR "Stroke, Lacunar"[Mesh] OR ((microinfarct* OR microscopic infarct*) AND ("brain" OR cerebral* OR cerebrum*))) OR ((("brain" OR cerebral* OR cerebrum*) AND ((microhemorrhag* OR microbleed* OR microhaemorrhag*) OR ("dot-like" AND (suscept* OR hemosid*)))) OR ((("brain" OR cerebral* OR cerebrum*) AND (Virchow-Robin* OR Virchow Robin* OR "etat crible" OR (perivascular space*))) OR ((("brain" OR cerebral* OR cerebrum*) AND ("Atrophy" OR volum* OR "volume loss")) AND ("Magnetic Resonance Imaging"[Mesh] OR "MRI" OR "magnetic resonance imaging") AND ("Depression" OR "Depression"[Mesh] OR "Depressive Disorder, Major"[Mesh] OR "Suicide" OR "Suicide"[Mesh]) AND ((("Longitudinal study" OR "Cohort study" OR "Prospective study" OR "Longitudinal Studies"[Mesh] OR "Cohort Studies"[Mesh] OR "Prospective Studies"[Mesh]))</p>
Embase
<p>((exp white matter/ AND (hyperintensity.mp. OR lesion.mp. OR disease.mp. OR exp diseases/)) OR exp white matter lesion/ OR leukoaraiosis.mp. OR cerebral small vessel disease.mp. OR exp cerebrovascular disease/ OR (exp lacunar stroke/ OR ((lacunar.mp. OR deep.mp. OR subcortical.mp. OR silent.mp. OR small vessel.mp.) AND (exp infarction/ OR exp stroke/)) OR ((microinfarct.mp. OR microscopic infarct.mp.) AND (cerebral.mp. OR exp brain/ OR cerebrum.mp.))) OR (((cerebral.mp. OR exp brain/ OR cerebrum.mp.) AND (microhaemorrhage.mp. OR microhemorrhage.mp. OR microbleed.mp.)) OR (dot-like.mp. AND (susceptible.mp. OR hemosiderin.mp.))) OR ((cerebral.mp. OR exp brain/ OR cerebrum.mp.) AND (virchow-robin.mp. OR Virchow robin.mp. OR etat crible.mp. OR perivascular space.mp.)) OR (((cerebral.mp. OR exp brain/ OR cerebrum.mp. OR exp brain size/ AND (exp atrophy/ OR volume loss.mp.)) OR exp brain atrophy/)) AND (exp depression/ OR exp major depression/ OR exp suicide/ OR exp suicide attempt/ AND (MRI.mp. OR magnetic resonance imaging.mp. OR exp nuclear magnetic resonance imaging/ AND (exp longitudinal study/ OR exp cohort analysis/ OR exp prospective study/))</p>

Table S1.4 –Search strategy for all-cause mortality

PubMed
<p>((("White matter" AND (hyperintens* OR lesion* OR disease* OR change*)) OR ("leukoaraiosis" OR "Leukoaraiosis"[Mesh] OR "Leukoaraiosis/pathology"[Mesh]) OR ("cerebral small vessel" OR "cerebral small-vessel") AND disease*) OR "Cerebral Small Vessel Diseases"[Mesh]) OR (((("lacunar" OR "deep" OR "subcortical" OR "silent" OR "small vessel") AND (infarc* OR Stroke*)) OR "Stroke, Lacunar"[Mesh] OR ((microinfarct* OR microscopic infarct*) AND ("brain" OR cerebral* OR cerebrum*))) OR ((("brain" OR cerebral* OR cerebrum*) AND ((microhemorrhag* OR microbleed* OR microhaemorrhag*) OR ("dot-like" AND (suscept* OR hemosid*)))) OR ((("brain" OR cerebral* OR cerebrum*) AND (Virchow-Robin* OR Virchow Robin* OR "etat crible" OR (perivascular space*))) OR ((("brain" OR cerebral* OR cerebrum*) AND ("Atrophy" OR volum* OR "volume loss")) AND ("Magnetic Resonance Imaging"[Mesh] OR "MRI" OR "magnetic resonance imaging") AND ("Death" OR "Mortality" OR "Death"[Mesh] OR "all-cause mortality" OR "Mortality"[Mesh] OR "survival analysis"[Mesh] OR "survival analysis" AND ("Longitudinal study" OR "Cohort study" OR "Prospective study" OR "Longitudinal Studies"[Mesh] OR "Cohort Studies"[Mesh] OR "Prospective Studies"[Mesh]))</p>
Embase
<p>((exp white matter/ AND (hyperintensity.mp. OR lesion.mp. OR disease.mp. OR exp diseases/)) OR exp white matter lesion/ OR leukoaraiosis.mp. OR cerebral small vessel disease.mp. OR exp cerebrovascular disease/ OR (exp lacunar stroke/ OR ((lacunar.mp. OR deep.mp. OR subcortical.mp. OR silent.mp. OR small vessel.mp.) AND (exp infarction/ OR exp stroke/)) OR ((microinfarct.mp. OR microscopic infarct.mp.) AND (cerebral.mp. OR exp brain/ OR cerebrum.mp.))) OR (((cerebral.mp. OR exp brain/ OR cerebrum.mp.) AND (microhaemorrhage.mp. OR microhemorrhage.mp. OR microbleed.mp.)) OR (dot-like.mp. AND (susceptible.mp. OR hemosiderin.mp.))) OR ((cerebral.mp. OR exp brain/ OR cerebrum.mp.) AND (virchow-robin.mp. OR Virchow robin.mp. OR etat crible.mp. OR perivascular space.mp.)) OR (((cerebral.mp. OR exp brain/ OR cerebrum.mp. OR exp brain size/ AND (exp atrophy/ OR volume loss.mp.)) OR exp brain atrophy/)) AND (exp death/ OR exp mortality/ OR exp survival/ OR survival analysis.mp.) AND (MRI.mp. OR magnetic resonance imaging.mp. OR exp nuclear magnetic resonance imaging/ AND (exp longitudinal study/ OR exp cohort analysis/ OR exp prospective study/))</p>

Table S2 – Description of post hoc analyses

Post hoc analyses
<p>Post hoc analyses were done when at least 3 studies were available per outcome. Results were pooled using only studies with a first episode of ischaemic of haemorrhagic stroke or depression; using only studies with stroke patients; using only hazard ratios (i.e. excluding studies that reported odds ratios or relative risks); using risk estimates comparing highest vs. lowest categories of white matter hyperintensities (irrespective of the number of participants per category), instead of risk estimates comparing higher and lower categories with the highest number of participants and events; using only risk estimates for silent cerebral infarcts; excluding studies that reported risk estimates for silent cerebral infarcts only; using only studies with Newcastle-Ottawa Scale (NOS) score >3; using only studies with NOS score >5; using only risk estimates of periventricular white matter hyperintensities; using only risk estimates of deep white matter hyperintensities; using only risk estimates for deep cerebral microbleeds; and using only risk estimates for lobar cerebral microbleeds.</p>

Table S3. Number of included studies in the systematic review and pooled analyses

Outcome	White matter hyperintensities			Lacunes		Cerebral microbleeds				Perivascular spaces			Total cerebral atrophy		Combination of CSVD features	
	Systematic review	Pooled analysis*	Systematic review	Systematic review	Pooled analysis*	Systematic review	Systematic review	Pooled analysis*	Systematic review	Systematic review	Pooled analysis*	Systematic review	Systematic review	Pooled analysis*	Pooled analysis*	Pooled analysis
Scale																
Any stroke type	Any	Dichotomous	Continuous	Any	Dichotomous	Any	Dichotomous	Any	Dichotomous	Any	Dichotomous	Any	Continuous	Dichotomous		
	24	23	4	15	15	15	15	0	0	3	3	3	3	3		
Ischaemic stroke		11	0		0		9		0		0		0			
Haemorrhagic stroke		7	0		0		8				0		0			
All-cause dementia	24	15	7	11	10	4	4	1	0	8	0	4	0			
Alzheimer's disease		8	0		0		0		0		0		0			
Presumed vascular dementia		4	0		0		0		0		0		0			
Depression	9	8	6	2	11	1	0	1	0	3	0	3	0			
All-cause mortality	19	16	6			10	10	0	0	3	0	3	0			

*Studies were excluded from the pooled analysis, because no risk estimates were presented,⁽¹⁻⁸⁾ less than three studies were available per CSVD feature⁽⁹⁻¹²⁾ or white matter hyperintensities were not evaluated on a dichotomous or continuous scale.^(3, 13-19) 30 studies^(2, 9-11, 15, 19-46) evaluated multiple CSVD manifestations and 22 studies^(2-10, 19-21, 23, 31, 34, 42-44, 46, 47, 49-57) evaluated multiple outcomes. HRs were reported by 48 studies.^(4, 8, 10, 12, 13, 15-18, 20-24, 26, 28, 31-34, 36-38, 40, 41, 43-45, 47-53, 57-88) Fifteen studies^(3, 9, 14, 27, 29, 30, 42, 54-56, 89-93) reported results as odds ratios or relative risks and these were treated as HRs. Abbreviations: CSVD: cerebral small vessel disease; HRs: hazard ratios.

Table S4.1 –Characteristics for studies on the association between cerebral small vessel disease and incident ischaemic and haemorrhagic stroke

Table S4.1.a. Studies on the association between white matter hyperintensities (WMHs) and incident ischaemic and haemorrhagic stroke

Reference	Study population characteristics					MRI characteristics		WMHs assessment	Stroke type	Number of events	Outcome	Adjustments
	FU (y)	Study	N*	Study participants	Country	Age (y)	Male (%)					
49	3.3	NA	832	Stroke	Denmark	59.6	58.0	1.5-3T, T2, DWI	IS	55	HR= 1.65 (0.70-3.86) for WMHs grade 2 HR= 2.00 (1.01-3.93) for PVHs grade 2 HR= 1.93 (0.89-4.18) for DWMHs grade 2	CHA2DS2-VASc score
51	5.0	NA	81	Stroke	Sweden	66.4	63.0	T2	Any type	24	HR= 1.70 (1.20-2.70) for WMHs grade 2-3	DM
19	6.3	Shimane	2684	Community-dwelling	Japan	57.8	54.9	0.15T, 0.2T, 1.5T, T1, T2, PD, FLAIR	Any type	102	OR= 2.08 (1.04-4.17) for PVHs grade 3-4 OR= 2.73 (1.32-5.63) for DWMHs grade 0-2	Age, sex, BP, HC, DM, smoking, alcohol, family history of stroke
48	4.9	3-CS	1,232 (1,643)	Community-dwelling	France	72.3	37.4	1.5T, T1, T2, PD	Any type	11	HR= 2.70 (0.80-9.00) for 3 rd quartile WMHs HR= 3.60 (1.00-12.50) for 3 rd quartile PVHs HR= 2.60 (0.90-7.70) for 3 rd quartile DWMHs	Age, sex, BP, HC, DM, smoking, alcohol, WMV
20	5.3	SMART-MR	1,228	With cardiovascular disease(s)	Netherlands	58.6	79.6	1.5T, T1, T2, FLAIR, IR	IS	46	HR= 1.04 (1.01-1.06) per mL WMHs HR= 1.47 (1.10-1.77) per SD WMHs ² HR= 3.60 (1.90-6.90) for 5 th quintile WMHs	Age, sex, BMI, BP, HC, DM, smoking, alcohol
21	5.6	FOS	2,177	Community-dwelling	USA	62	47.1	1T, 1.5T, T1, T2	Any type	32	HR= 1.33 (0.93-1.90) per log WMHs HR= 1.33 (0.93-1.90) per SD WMHs ² HR= 2.28 (1.02-5.13) for high WMHs HR= 2.97 (1.28-6.85) for high WMHs	Age, sex, BP, DM, smoking, alcohol, CervD
55	1.9	NA	228	Stroke	China	68.3	57.0	1.5T, T1, T2, FLAIR, DWI	Any type	29	HR= 4.18 (2.04-8.56) per WMHs grade OR= 4.32 (1.58-11.79) for WMHs grade 2-3	Age, sex, BP, DM, smoking, alcohol, CVD, AF

Reference	Study population characteristics				MRI characteristics		WMHs assessment	Stroke type	Number of events	Outcome	Adjustments		
	FU (y)	Study	N ^a	Study participants	Country	Age (y)						Male (%)	
66	3.5	NA	230	With cardiovascular disease(s)	Netherlands	62	68	1.5T, T1, T2, PD	SQ (0-4 for PVHs, 0-3 for DWMHs) ¹ , dichotomised (2-4 vs. 0 for PVHs, 1-3 vs. 0 for DWMHs)	IS	21	HR= 3.60 (1.40-9.20) for PVHs grade 2-4 HR= 1.50 (0.60-3.80) for DWMHs 1-3	Age, BP, CVD, medication None
27	4.2	NA	226 (305)	Stroke	Japan	NA	45.1	1.5T, T1, T2, PD	SQ (0-3) ¹ , dichotomised (2-3 vs. 1)	Any type	52	OR= 2.97 (1.46-6.05) for WMHs grade 2-3 OR= 2.54 (1.10-5.85) for WMHs grade 2-3 ² OR= 3.22 (0.85-12.2) for WMHs grade 2-3	None
2	2.4	LADIS	639	MCI	Europe	74.1	45.1	1.5T, T2*, FLAIR, DWI	SQ (1-3) ¹ , dichotomised (3 vs. 1)	Any type	NA	P < 0.05 (p-value for Kaplan-Meier log rank test for difference in WMHs grade for stroke group vs. control)	None
47	9.6	3-CS	1677	Community-dwelling	France	72.0	39.0	1.5T, T1, T2, PD	Qt, continuous (per unit ln(WMHs/TCV, per SD), dichotomised (4 th quartile vs. rest)	Any type	68	HR= 1.72 (1.24-2.40) per lnWMH HR= 1.42 (1.15-1.76) per SD ² HR= 1.88 (1.16-3.07) for 4 th quartile WMHs	Age, sex, ASE, BP, HC, DM, smoking, CVD, APOE
94	9.6	3-CS	1731	Community-dwelling	France	72.0	39.0	1.5T, T1, T2, PD	Qt, continuous (per unit ln(WMHs/TCV), dichotomised (4 th quartile vs. rest)	IS	54	HR= 1.50 (1.03-2.20) per lnWMH HR= 1.60 (0.91-2.80) for 4 th quartile WMHs	Age, sex, ASE, BP, HC, DM, smoking, CVD, APOE
29	NA	NA	933	Community-dwelling	Japan	NA	57.4	0.15T, 0.2T, T1, T2, PD	QI, absence vs. presence	Any type	19	OR= 4.81 (1.13-20.58) for WMHs presence	None
67	7.0	CHS	1,395 (3,293)	Community-dwelling	USA	75	40.5	0.35T-3T, T1, T2, PD	SQ (0-9) ¹ , dichotomised (2 vs. 0-1 for any type stroke, 5-9 vs. 0-1 for IS)	Any type	117	HR= 1.50 (1.00-2.20) for WMHs grade 2 HR= 2.86 (1.70-4.80) for WMHs grade 5-9	Age, sex, race, BP, DM, CVD, AF, clinic None
30	5.0	ESR	9,522	Stroke	Turkey	65	56.6	T2, FLAIR	SQ (0-3) ¹ , dichotomised (3 vs. 0-2)	Any type	2181	OR= 1.53 (1.39-1.69) for WMHs grade 3 OR= 1.88 (1.32-2.66) for WMHs grade 3	None
68	5.0	HSAMC	320	Stroke	Finland	70.8	49.7	1.0T, T1, T2, PD	SQ (0-3) ¹ , dichotomised (2-3 vs. 0)	IS	76	HR = 1.80 (1.11-2.95) for WMHs grade 2-3	ASE, BP, AF, peripheral arterial disease

Reference	Study population characteristics				MRI characteristics		WMHs assessment	Stroke type	Number of events	Outcome	Adjustments
	FU (y)	Study	N ^a	Study participants	Country	Age (y)	Male (%)				
³¹	5.0	NA	75	Stroke	China	70.7	52.0	Any type	12	HR= 1.97 (1.47-2.62) per mL WMHs ² HR= 4.97 (2.49-9.77) per SD WMHs ²	Age
⁹⁵	3.4	ODC	179	Receiving haemodialysis	Japan	58.2	63.7	Any type	10	OR= 3.09 (0.82-11.60) for PVHs grade 2-3 ² OR= 5.96 (1.53-23.24) for DWMHs grade 2-3 ²	None
³²	1.5	NA	266	Stroke	Japan	67.2	62.8	IS	17	HR= 10.66 (2.60-43.68) for WMHs grade 2-3 HR= 0.02 (0.001-0.26) for WMHs grade 2-3	Age, sex, vascular risk factors, stroke type, days from stroke onset, CMBs
⁹⁶	2.5	NA	617	Stroke	Greece	71.0	38.2	Any type	351	HR non-AF group= 2.23 (1.37-3.62) for WMHs presence HR AF group= 1.83 (0.55-6.17) for WMHs presence HR total= 2.17 (1.38-3.41) for presence of WMHs ²	CHA2DS2-VASc score
³³	10.0	RSS	665 (1,007)	Community-dwelling	Netherlands	72	48.2	Any type	77	HR= 1.80 (0.90-3.70) for 3 rd tertile PVHs HR= 4.80 (2.10-7.80) for 3 rd tertile DWMHs	Age, sex, BP, DM, CVD
³⁴	8.3	NA	634 (655)	Stroke	Finland	40.0	58.8	IS	69	HR= 1.07 (0.40-2.85) for WMHs grade 2-3	Age, sex, BP, DM, stroke type, silent cerebral infarcts, prior TIA
⁶⁹	2.7	NA	82	Stroke	USA	76.3	48.9	ICH	NA	HR= 9.00 (1.20-67.20) for higher tertiles PVHs	None
³⁶	2.2	NA	908	Stroke	China	68.4	57.7	ICH	96	HR= 3.47 (0.46-26.25)	None
⁴³	7.4	FOS	1,414 (1,469)	Community-dwelling	USA	65.7	46.7	Any type	45	HR= 1.45 (1.11-1.90) per SD WMHs HR= 2.73 (1.48-5.02) for 5 th quintile WMHs	ASE, BMI, BP, DM, smoking, APOE
⁴³	5.9	FHS	224	Community-dwelling	USA	84.8	48.0	Any type	20	HR= 0.80 (0.46-1.40) per SD WMHs HR= 0.60 (0.15-2.37) for 5 th quintile WMHs	ASE, BMI, BP, DM, smoking, APOE

Reference	Study population characteristics				MRI characteristics		Stroke type	Number of events	Outcome	Adjustments
	FU (y)	Study	N ^a	Study participants	Country	Age (y)	Male (%)			
⁴⁴	14.5	ARIC	1,881	Community-dwelling	USA	62.4	40.0	157	HR= 1.30 (1.15-1.46) per WMHs grade	ASE, race, BMI, BP, HC, DM, smoking, alcohol, CVD, centre
								Any type	HR= 2.14 (1.45-3.16) for WMHs grade 3-9	
								IS	HR= 1.30 (1.14-1.47) per WMHs grade	
								ICH	HR= 2.12 (1.41-3.20) for WMHs grade 3-9	
									HR= 1.42 (0.99-2.03) per WMHs grade	
⁴⁶	4.3	NA	89	Stroke or headache	Japan	66	42.7	7	HR= 3.13 (0.93-10.54) for WMHs grade 3-9	Age, sex, BP, DM, smoking, lacunar infarcts, antiplatelet use
								Any type	HR= 1.60 (1.02-2.54) per WMHs grade	

Tables S4.1.a. Summary of study characteristics. Abbreviations: APOE: apolipoprotein E; ARIC: Atherosclerosis Risk in Communities Study; ASE: age, sex, education; BP: blood pressure; BMI: body mass index; CerVD: cerebrovascular disease; CHS: Cardiovascular Health Study; CMBs: cerebral microbleeds; CVD: cardiovascular disease; DM: diabetes mellitus; DWMHs: deep white matter hyperintensities; ESR: Ege Stroke Registry; FHS: Framingham Health Study; FLAIR: fluid attenuation inversion recovery; FOS: Framingham Offspring Study; FU: follow-up; HC: hypercholesterolemia; HR: hazard ratio; HSAMC: Helsinki Stroke Aging Memory Cohort; ICH: intracerebral haemorrhage; IR: inverse recovery; IS: ischaemic stroke; LADIS: Leukoaraiosis And Disability; mL: millilitre; MRI: magnetic resonance imaging; NA: not available; ODC: Osaka Dialysis Cohort; OR: odds ratio; PD: proton density; PVHs: periventricular hyperintensities; QI: qualitative; Qt: quantitative; RSC: Rotterdam Scan Study; SD: standard deviation; SMART-MR: Second Manifestations of ARterial disease-Magnetic Resonance; SQ: semi-quantitative; TIA: transient ischaemic attack; USA: United States of America; WMHs: white matter hyperintensities; WMV: white matter volume; 3-CS: Three-City Study. ^aParticipant number is presented as amount used in analysis, number between brackets represents total study participant number; [†] Fazekas scale; [‡]ARWMC scale; [§]Manolio scale; ^{||}Mantyla scale; [¶]Wahlund scale; [¶]ARIC study scale; [¶]Swieten scale; [¶]Rotterdam Scan Study scale; [¶]risk estimate calculated based on information in original article.

Table S4.1.b, Studies on the association between lacunes and incident ischaemic and haemorrhagic stroke

Reference	Study population characteristics					MRI characteristics		Stroke type	Number of events	Outcome	Adjustments		
	FU (y)	Study	N*	Study participants	Country	Age (y)	Male (%)						
50	2.9	NA	786	Stroke	Denmark	71.2	58.0	1T - 3T, T1, T2, T2*, FLAIR	QI, presence (>2) vs. absence	IS	46	HR= 2.52 (1.25-5.09)	Age, sex, BP, DM, CVD
59	4.2	CHS	2,647 (3,324)	Community-dwelling	USA	59.5	57.1	1.5-3.0T, T1, T2, FLAIR	QI, presence (1) vs. 1	Any type	124	HR= 1.44 (0.96-2.16)	Age, sex, BP, DM, AF, CVD, intima media thickness
19	6.3	Shimane	2,684	Community-dwelling	Japan	3.7	40.4	1.5T, T1, T2, PD	QI, presence vs. absence	Any type	102	OR= 3.66 (2.28-5.89)	Age, sex, BP, HC, DM, smoking, alcohol, family history of stroke
20	5.3	SMART-MR	1,228	With cardiovascular disease(s)	Netherlands	57.8	54.9	0.15T, 0.2T, 1.5T, T1, T2, PD, FLAIR	QI, presence vs. absence	IS	46	HR= 3.20 (1.70-5.80)	Age, sex, BMI, BP, HC, DM, smoking, alcohol
21	5.6	FOS	2,177	Community-dwelling	USA	58.6	79.6	1.5T, T1, T2, FLAIR, IR	QI, presence vs. absence	Any type	32	HR= 2.84 (1.32-6.10)	Age, sex, BP, DM, smoking, alcohol, CerVD
61	2.1	NA	170	Stroke	Canada	62	47.1	1 - 1.5T, T1, T2	QI, presence vs. absence	Any type	19	HR= 3.20 (1.20-8.70)	Age, sex, BP, HC, DM, smoking, alcohol, drug use, CerVD, migraine, CVD
62	3.4	NA	514	Hypertensive	Japan	39.4	52.4	1.5 - 3T, T2, FLAIR	QI, presence vs. absence	Any type	43	HR= 4.60 (1.91-11.03)	Age, BP, smoking, CRP level
47	9.6	3-CS	1,677	Community-dwelling	France	72.0	39.0	1.5T, T1, T2, PD	QI, presence vs. absence	Any type	68	HR= 2.69 (1.46-4.95)	Age, sex, ASE, BP, HC, DM, smoking, CVD, APOE
47	9.6	3-CS	1,731	Community-dwelling	France	72.0	39.0	1.5T, T1, T2, PD	QI, presence vs. absence	IS	54	HR= 2.12 (1.01-4.42) for 4th quartile WMHs	Age, sex, ASE, BP, HC, DM, smoking, CVD, APOE
										ICH	15	HR= 8.65 (2.49-30.05) for 4th quartile WMHs	
90	3.5	NA	585 (958)	Hypertensive	Japan	72.0	38.0	1.5T, T1, T2	QI, presence vs. absence	Any type	45	HR= 4.63 (2.04-10.5)	Age, sex, BMI, BP
29	NA	NA	933	Community-dwelling	Japan	72.3	37.2	1.5T, T1, T2	QI, presence vs. absence	Any type	19	OR= 10.48 (3.63-30.21)	None
31	5.0	NA	75	Stroke	China	NA	57.4	0.15 - 0.2T, T1, T2, PD	QI, presence vs. absence	Any type	12	HR= 9.02 (1.16-69.88)	Age
33	10.0	RSS	1,007	Community-dwelling	Netherlands	70.7	52.0	1.5T, T1, T2, DWI	QI, presence vs. absence	Any type	99	HR= 2.50 (1.70-3.90)	Age, sex, BP, DM, CVD

Reference	Study population characteristics					MRI characteristics		Lacunes assessment	Stroke type	Number of events	Outcome	Adjustments	
	FU (y)	Study	N ^a	Study participants	Country	Age (y)	Male (%)						
³⁴	8.3	NA	609 (655)	Stroke	Finland	72	48.2	1.5T, T2, 3D HASTE, PD	QI, presence (1) vs. absence	IS	64	HR= 1.47 (0.68-3.16)	Age, sex, BP, DM, stroke type, silent brain infarcts, prior TIA
⁴²	2.5	ProFESS	815 (1,014)	Stroke	Europe	66.1	63.9	T1, T2, FLAIR	QI, absence vs. presence, presence vs. absence	Any type	90	OR= 0.58 (0.36-0.94) for absence of lacunes OR= 1.72 (1.06-2.78) for presence of lacunes ¹	None
⁴⁴	14.5	ARIC	1,667 (1,799)	Community-dwelling	USA	40.0	58.8	1 - 1.5T, T1, T2, FLAIR	QI, presence vs. absence	Any type	157	HR= 2.30 (1.49-3.55)	AGE, race, BMI, BP, HC, DM, smoking, alcohol, CVD, centre
										IS	140	HR= 2.04 (1.28-3.25)	
										ICH	15	HR= 7.14 (1.63-31.34)	

Table S4.1.b. Summary of study characteristics. Abbreviations: APOE: apolipoprotein E; ARIC: Atherosclerosis Risk in Communities Study; ASE: age, sex, education; BP: blood pressure; BMI: body mass index; CerVD: cerebrovascular disease; CHS: Cardiovascular Health Study; CVD: cardiovascular disease; DM: diabetes mellitus; FLAIR: fluid attenuation inversion recovery; FOS: Framingham Offspring Study; FU: follow-up; GFR: glomerular filtration rate; HC: hypercholesterolemia; HR: hazard ratio; ICH: intracerebral haemorrhage; IR: inverse recovery; IS: ischaemic stroke; MRI: magnetic resonance imaging; NA: not available; OR: odds ratio; PD: proton density; PROFESS: Prevention Regimen for Effectively Avoiding Second Strokes trial; QI: qualitative; RSS: Rotterdam Scan Study; SMART-MR: Second Manifestations of Arterial disease-Magnetic Resonance; TIA: transient ischaemic attack; USA: United States of America; 3-CS: Three-City Study. ^aParticipant number is presented as amount used in analysis, number between brackets represents total study participant number; ¹risk estimate calculated based on information in original article.

Table S4.1.c. Studies on the association between cerebral microbleeds (CMBs) and incident ischaemic and haemorrhagic stroke

Reference		Study population characteristics			MRI characteristics		CMBs assessment		Stroke type	Number of events	Outcome	Adjustments
FU (y)	Study	N°	Study participants	Country	Age (y)	Male (%)						
58	4.9	RSS	4,759 Community-dwelling	Netherlands	63.8	44.7	1.5T, T2, 3D HASTE, PD	QI, presence vs. absence	Any type	93	HR= 1.79 (1.16-2.78)	Age, sex, BP, HC, DM, smoking, antithrombotic use, clinic
									IS	72	HR= 1.40 (0.84-2.34)	
									ICH	11	HR= 5.41 (1.58-18.46)	
52	6.0	MISTRAL	301 AD (333)	Netherlands	71.2	58.0	1T-, 3T, T1, T2, T2*, FLAIR	QI, presence vs. absence	Any type	23	HR= 3.30 (1.30-8.40)	Age, sex, MMSE, cardiovascular risk factors, WMHs, lacunes
60	3.6	Shimane	2,102 Community-dwelling	Japan	62.1	53.6	NA	QI, presence vs. absence	IS	22	HR= 4.48 (2.20-12.20)	Age, sex
									ICH	10	HR= 50.20 (16.70-150.90)	
53	1.2	Vision	236 Stroke	Canada	NA	55.1	3T, T1, T2, T2*, FLAIR	QI, presence vs. absence	Any type	24	HR= 1.50 (0.70-3.60)	Age, WMHs
54	2.3	NA	121 Stroke	China	68.0	67.8	1.5T, T1, T2, T2*	QI, presence vs. absence	Any type	16	OR 2.68 (0.92-7.82)	None
56	2.4	NA	134 Stroke	USA	79.9	53.0	1.5-3T	QI, presence vs. absence	IS	56	OR 1.53 (0.48-4.90) [†]	None
97	4.2	NA	305 Stroke	Japan			1.5T, T2* FLAIR, DWI	QI, presence vs. absence (of deep CMBs)	Lacunar infarction	62	OR 2.57 (0.93-7.08)	WMHs
30	5.0	ESR	9,522 Stroke	Turkey	65.0	56.6	T2, FLAIR	QI, presence vs. absence	Any type	2181	OR= 1.26 (1.08-1.46)	None
37	3.8	ESPRIT	397 Stroke	Netherlands	65.3	58.4	1.0 - 1.5T, T2*	QI, presence vs. absence	Any type	28	HR= 2.30 (1.00-5.30)	Age, sex
									IS	23	HR= 2.30 (0.90-5.80)	
									ICH	5	HR= 2.60 (0.30-27.00)	
31	5.0	NA	75 Stroke	China	70.7	52.0	1.5T, T1, T2, DWI	QI, presence vs. absence	Any type	12	HR= 5.95 (1.42-24.95)	None
63	5.0	ODC	179 Receiving haemodialysis	Japan	58.2	63.7	1.5T, T1, T2, T2*, FLAIR, PD	QI, presence vs. absence	IS	12	HR= 1.28 (0.25-6.53)	Age, sex, BMI, BP, HC, DM, smoking, lacunes, PVHs, DWMHs, CVD, AF, dialysis duration, haemoglobin, serum albumin, CRP, anticoagulant use
									ICH	12	HR= 21.14 (2.30-194.62)	
32	1.5	NA	266 Stroke	Japan	67.2	62.8	1T, T2, T2*	QI, presence vs. absence	IS	16	HR= 0.619 (0.17-2.13)	None
									ICH	10	HR= 85.63 (6.34-1155.65)	
64	3.5	NA	698 Community-dwelling	Japan	65.4	45.7	1.5T, T2*	QI, presence vs. absence	Any type	36	HR= 2.64 (1.34-5.19)	Age, sex, BP
									IS	10	HR= 11.77 (2.95-46.82)	
									ICH	26	HR= 1.48 (0.63-3.45)	
36	2.2	NA	908 Stroke	China	68.4	57.7	1.5T, T1, T2, T2*, FLAIR	QI, presence vs. absence	IS	96	HR= 1.35 (0.86-2.11)	None
											HR= 5.99 (1.90-18.86)	
65	2.2	NA	487 Stroke	Belgium	72.0	61.0	1-3T, T1, T2, FLAIR	QI, presence vs. absence	Any type	37	HR= 2.10 (1.10-4.20)	Age, sex, DM

Tables S4.1.c. Summary of study characteristics. Abbreviations: BP: blood pressure; BMI: body mass index; CMBs: cerebral microbleeds; CVD: cardiovascular disease; DM: diabetes mellitus; DWMHs: deep white matter hyperintensities; ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial; ESR: Ege Stroke Registry; FLAIR: fluid attenuation inversion recovery; FU: follow-up; GFR: glomerular filtration rate; HC: hypercholesterolemia; HR: hazard ratio; ICH: intracerebral haemorrhage; IS: ischaemic stroke; MISTRAL: do Microbleeds predict STroke in Alzheimer's disease Study; MRI: magnetic resonance imaging; NA: not available; ODC: Osaka Dialysis Cohort; OR: odds ratio; PD: proton density; PVHs: periventricular hyperintensities; QI: qualitative; RSS: Rotterdam Scan Study; USA: United States of America; WMHs: white matter hyperintensities. [†]Participant number is presented as amount used in analysis, number between brackets represents total study participant number; [‡]risk estimate calculated based on information in original article.

Table S4.1.d. Studies on the association between total cerebral atrophy and incident ischaemic and haemorrhagic stroke

Reference	Study population characteristics				MRI characteristics	Cerebral atrophy assessment	Stroke type	Number of events	Outcome	Adjustments			
	FU (y)	Study	N ^a	Study participants							Country	Age (y)	Male (%)
10	8.3	SMART - MR	1,215	With cardiovascular disease(s)	Netherlands	58.0	80.0	1.5T, T1, T2, FLAIR	Qt, continuous, (% ICV, per SD decrease)	IS	49	HR= 1.83 (1.33-2.51) per SD decrease in TCV	Age, sex, BMI, BP, DM, smoking, alcohol, intima media thickness
43	7.4	FOS	1,414 (1,469)	Community-dwelling	USA	65.7	46.0	1 - 1.5T, T1, T2	Qt, continuous, (% ICV, per SD decrease), dichotomised (1 st vs. 2 nd , 5 th quintile)	Any type	45	HR= 1.51 (1.13-2.01) per SD decrease in TCV HR= 1.78 (0.92-3.45) for 1 st quintile of TCV	ASE, BMI, BP, DM, smoking, APOE
43	5.9	FHS	224	Community-dwelling	USA	84.8	48.0	1 - 1.5T, T1, T2	Qt, continuous, (per % ICV, per SD decrease), dichotomised (1 st vs. 2 nd , 5 th quintile)	Any type	20	HR= 0.86 (0.49-1.53) per SD decrease in cerebral volume HR= 0.54 (0.13-2.33) for 1 st quintile of TCV	ASE, BMI, BP, DM, smoking, APOE

Tables S4.1.d Summary of study characteristics. Abbreviations: APOE: apolipoprotein E; ASE: age, sex, education; BP: blood pressure; BMI: body mass index; DM: diabetes mellitus; FHS: Framingham Health Study; FLAIR: fluid attenuation inversion recovery; FOS: Framingham Offspring Study; FU: follow-up; GFR: glomerular filtration rate; HR: hazard ratio; ICV: intracranial volume; IS: ischaemic stroke; MRI: magnetic resonance imaging; NA: not available; Qt: quantitative; SD: standard deviation; SMART-MR: Second Manifestations of ARterial disease-Magnetic Resonance; TCV: total cerebral volume; USA: United States of America. ^aParticipant number is presented as amount used in analysis, number between brackets represents total study participant number.

Table S4.1.e. Studies on the association between combinations of CSVD features and incident ischaemic and haemorrhagic stroke

Reference	Study population characteristics						MRI characteristics	Definition of combinations of CSVD features	Stroke type	Number of events	Outcome	Adjustments	
	FU (y)	Study	N ^a	Study participants	Country	Age (y)							Male (%)
98	13.0	ARIC/CHS	4,872	Community-dwelling	USA	70.8	40.2	1.5-3.0T, T1, T2, FLAIR	QI, dichotomised (WMHs grade 3-9 ^a + presence of lacunes vs. WMHs grade 0-2 + absence of lacunes)	ICH	71	HR= 4.27 (2.20-8.28) for presence of CSVD	ASE, race, BP, smoking, HC, fibrinogen, intima media thickness, carotid plaque
61	2.1	NA	170	Stroke	Canada	62	47.1	1 - 1.5T, T1, T2	QI, dichotomised (presence of WMHs + lacunes vs. absence of WMHs + lacunes)	Any type	19	HR= 7.30 (2.30-22.90) for presence of CSVD	Age, sex, BP, HC, DM, smoking, alcohol, drug use, CerVD, migraine, CVD
32	1.5	NA	266	Stroke	Japan	67.2	62.8	1T, T2, T2*	QI, dichotomised (WMHs grade 2-3 ^a + presence of CMBs presence vs. WMHs grade 0-1 + absence of CMBs)	Any type	24	OR= 2.80 (0.80-9.00) ^b for presence of CSVD	None

Tables S4.1.e. Summary of study characteristics. Abbreviations: ARIC: Atherosclerosis Risk in Communities Study; ASE: age, sex, education; BP: blood pressure; BMI: body mass index; CerVD: cerebrovascular disease; CHS: Cardiovascular Health Study; CMBs: cerebral microbleeds; CREDOS: Clinical Research Centre for Dementia of South Korea Study; CVD: cardiovascular disease; DM: diabetes mellitus; FLAIR: fluid attenuation inversion recovery; FU: follow-up; GFR: glomerular filtration rate; HC: hypercholesterolemia; HR: hazard ratio; ICH: intracerebral haemorrhage; MRI: magnetic resonance imaging; NA: not available; NS: non-significant; OR: odds ratio; QI: qualitative; USA: United States of America; WMHs: white matter hyperintensities. ^aParticipant number is presented as amount used in analysis, number between brackets represents total study participant number. ^bARIC study scale.

Table S4.2 –Characteristics for studies on the association between cerebral small vessel disease and incident all-cause dementia
Table S4.2.a, Studies on the association between white matter hyperintensities (WMHs) and incident all-cause dementia

Reference	Study population characteristics				MRI characteristics		WMHs assessment	Dementia type	Number of events	Outcome	Adjustments
	FU (y)	Study	N*	Study participants	Country	Age (y)	Male (%)				
73	3.8	NA	170	MCI	France	68.1	42.4	1.5T, T2, SE, FLAIR	Any type	67	HR= 1.01 (0.97-1.05) per unit WMHs HR= 1.32 (0.77-2.24) for WMHs grade 7-24 ³ HR= 1.14 (1.06-1.24) per unit WMHs HR= 10.00 (1.55-64.39) for WMHs grade 7-24 HR= 2.71 (1.60-4.58) per unit PVHs HR= 1.02 (0.96-1.09) per unit WMHs ³ HR= 1.67 (0.73-3.81) for WMHs grade 7-24 ³
21	5.9	FOS	2,013 (2,229)	Community-dwelling	USA	62.0	47.1	1-1.5T, T1, T2	Any type	11	HR= 2.22 (1.32-3.72) Per SD WMHs HR= 3.97 (1.10-14.30) for extensive WMHs
22	3.1	NA	52	MCI	USA	72.8	71.0	1.5T, T1, T2	Any type	17	HR= 0.83 (0.49-1.41) per SD WMHs A5E, cognition AB, GMV, HCV, lacunes
23	3.2	NA	106	Stroke	UK	79.8	53.8	1.5T, T1, FLAIR	Any type	27	HR= 1.59 (0.851-2.96) per unit WMHs MTA, thalamic infarcts, cognition AB HR= 3.05 (1.54-6.03) per SD WMHs ⁴ HR= 2.41 (1.11-5.19) for highest quartiles WMHs
89	1.3	NA	52	MCI	Italy	70.0	44.0	NA	Any type	11	HR= 2.90 (0.70-11.40) for WMHs grade 7-24 None
88	4.0	3-CS	1,139 (1,701)	Community-dwelling	France	72.3	39.3	1.5T, T1, T2	Any type	19	HR= 1.90 (0.70-5.10) for 4 th quartile WMHs A5E, cognition AB, BP, HC, DM, CVD, APOE, ICD
75	5.9	RSS	490	Community-dwelling	Netherlands	73.4	49.0	1.5T, T2, 3D HASTE, PD	Any type	46	HR= 1.57 (1.03-2.38) per SD WMHs A5E, BP, DM, smoking, BI
2	2.4	LADIS	639	MCI	Europe	74.1	45.1	1.5T, T1, T2	Any type	NA	P< 0.05 (p-value for Kaplan-Meier log rank test for difference in WMHs grade for stroke group vs. control) ⁵ None

Reference	Study population characteristics					MRI characteristics	WMHs assessment	Dementia type	Number of events	Outcome	Adjustments
	FU (y)	Study	N ^a	Study participants	Country	Age (y)	Male (%)				
⁴⁷	7.9	3-CS	1677	Community-dwelling	France	72.0	39.0	Any type	124	HR= 1.72 (1.24-2.40) per lnWMH HR= 1.73 (1.24-2.59) for 4th quartile WMHs	Age, sex, ASE, BP, HC, DM, smoking, CVD, APOE
²⁸	2.1	NA	151	MCI	USA	77.0	58.0	Any type	75	HR= 0.75 (0.42-1.35) for WMHs 1 SD above mean	ASE
⁸⁰	1.1	CREDOS	622	MCI	Korea	72.0	40.0	Any type	139	HR= 2.22 (1.43-3.43) for PVHs grade 3 HR= 0.70 (0.44-1.11) for DWMHs grade 3 HR= 16.14 (1.97-132.06) for PVHs grade 3 HR= 1.86 (1.12-3.07) for PVHs grade 3	ASE, cognition AB, BP, HC, DM, Depression score, Hachinski Ischaemic Score
¹³	2.8	NA	54	MCI	Sweden	62.9	40.0	Any type	37	HR= 1.01 (0.94-1.08) per WMH grade	None
⁷⁶	NA	CHS	2,939 (3,608)	Community-dwelling	USA	NA	NA	Any type	480	HR= 1.70 (1.36-2.10) for WMHs grade 4-9 HR= 2.10 (1.36-3.11) for WMHs grade 4-9 HR= 1.50 (1.17-1.99) for WMHs grade 4-9	ASE, cognition AB, BP, DM, CVD, race, APOE, ventricular size, large infarcts
⁹²	2.0	Gem Study	159 (183)	Community-dwelling	USA	85.5	41.5	Any type	21	HR= 3.23 (1.34-7.79) per unit WMHs/TCV HR= 2.80 (1.25-6.30) for 4 th quartile WMHs	ASE, cognition AB, PIB status, HCV
¹⁴	5/7	NA	54	MCI	Japan	NA	NA	VaD	25	OR= 4.14 (1.54-11.15) per PVHs grade ⁸	None
								AD	60	OR= 0.78 (not significant) per PVHs grade	

Reference	Study population characteristics					MRI characteristics	WMHs assessment	Dementia type	Number of events	Outcome	Adjustments
	FU (y)	Study	N ^a	Study participants	Country	Age (y)	Male (%)				
15	7.5	OFUS	524	With cardiovascular risk factor(s)	Japan	67.7	57.6	Any type	44	HR= 1.07 (1.02-1.11) per WMHs grade	ASE, APOE
								VaD	18	HR= 1.14 (1.07-1.21) per WMHs grade	
								AD	20	HR= 1.00 (0.93-1.08) per WMHs grade	
										HR= 1.00 (0.93-1.08) per WMHs grade	
3	1.5	NA	79	MCI	Singapore	61.0	59.5	Any type	23	HR= 2.38 (0.57-10.00) per PVHs grade	Age, HC, MTA
										HR= 7.69 (1.22-50.00) per DWMHs grade	
16	2.0	PAGIT	426	MCI	International	71.0	45.0	Any type	81	HR= 0.98 (0.94-1.03) per WMHs grade	Age, sex
77	5.2	RSS	810	Community-dwelling	Netherlands	72.2	48.5	Any type	34	HR= 2.00 (1.00-3.90) for PVHs 3-6	Age, sex
										HR= 0.60 (0.27-1.39) for DWMHs 3-6	
78	6.0	NA	156	MCI	USA	72.3	40.0	AD	54	HR= 1.26 (0.61-2.59) for WMHs 1 SD above mean	None
										SD below mean	
37	2.0	NA	152	MCI	Netherlands	69.9	53.0	AD	56	HR= 1.20 (0.70-2.20) for WMHs grade 6-30	Age, sex
										HR= 1.10 (0.70-2.00) for PVHs grade 3-6	
										HR= 1.30 (0.80-2.30) for DWMHs grade 4-24	
								Non-AD	16	HR= 5.80 (1.20-26.60) for WMHs 6-30	
6	5.4	NCODE	161	Depressive disorder	USA	69.2	37.9	Any type	20	HR= 6.50 (1.40-29.80) for PVHs 3-6	None
										HR= 5.70 (1.20-26.70) for DWMHs 4-24	(p=0.11) (p-value for T-test for mean difference in WMHs volume for incident dementia group vs. control)

Reference	Study population characteristics					MRI characteristics		WMHs assessment	Dementia type	Number of events	Outcome	Adjustments	
	FU (y)	Study	N ^a	Study participants	Country	Age (y)	Male (%)						
38	7.4	3-CS	1,634 (1,721)	Community-dwelling	France	72.4	39.3	1.5T, T1, T2	Qt, continuous (per ln(WMHs/TCV), per SD)	Any type	119	HR= 1.38 (1.05-1.81) per unit WMHs HR= 1.44 (1.05-1.97) per SD WMHs ⁴	ASE, cognition AB, BP, DM, CVD, digit span, smoking, alcohol, APOE, HCV, ICV, impairment of activity
17	2.8	NA	60	MCI	Finland	72.7	31.7	1.5T, T2, FLAIR, PD	SQ, (0-15) ⁴	Any type	13	HR= 1.01 (0.89-1.14) per WMHs grade	None
18	3.0	NA	152	MCI	North-America	72.5	54.2	T1, T2	SQ, (0-30) ⁴	AD	55	HR= 1.01 (0.97-1.05) per WMHs grade	Age, education, MTA, treatment arm
40	5.2	RUNDMC	500 (503)	Community-dwelling	Netherlands	65.6	56.8	1.5T, T1, T2, T2*	Qt, continuous (per log mL, per SD)	Any type	42	HR= 1.83 (0.80-4.21) per unit WMHs HR= 1.74 (0.80-3.77) per SD WMHs ⁴	ASE, cognition AB, territorial infarcts, GMV, HCV
79	3.0	LADIS	442	MCI	Europe	74.1	45.0	0.5T of 1.5T T2	SQ, (0-4) ¹ , dichotomised (2 vs. 1)	VaD	54	HR= 0.29 (0.06-1.41) for WMHs grade 2 HR= 1.69 (0.71-4.02) for WMHs grade 2	Age, PB, DM, MTA, cerVD
43	5.9	FHS	224	Community-dwelling	USA	84.8	48.0	1.5T, T1, T2	Qt, continuous (per SD), dichotomised (5 th quintile vs. rest)	AD	28	HR= 0.97 (0.65-1.45) per SD WMHs HR= 1.13 (0.43-2.95) for 5 th quintile WMHs	ASE, BP, DM, smoking, BMI, APOE
45	8.9	NA	177	Stroke	Japan	69.1	62.7	1.5T, T2	SQ, (0-3) ¹ , dichotomised (2 vs. 0-1)	Any type	26	HR= 7.13 (1.63-31.5) for DWMHs grade 2	Age, sex, cognition AB, Lacunar grade, dipper vs. Non-dipper

Tables S4.2.a. Summary of study characteristics. Abbreviations: AB: at baseline; AD: Alzheimer’s disease; APOE: apolipoprotein E; ASE: age, sex, education; BP: blood pressure; Bi: brain infarcts; BMI: body mass index; CerVD: cerebrovascular disease; CHS: Cardiovascular Health Study; CREDOS: Clinical Research Centre for Dementia of South Korea Study; CVD: cardiovascular disease; DM: diabetes mellitus; DWMHs: deep white matter hyperintensities; FHS: Framingham Health Study; FLAIR: fluid attenuation inversion recovery; FOS: Framingham Offspring Study; FU: follow-up; GMV: grey matter volume; HC: hypercholesterolemia; HCV: hippocampal volume; HR: hazard ratio; ICV: intracranial volume; LADIS: Leukoaraisosis And Disability; mL: millilitre; MRI: magnetic resonance imaging; MTA: medial temporal lobe atrophy; NA: not available; NCOD: Neurocognitive Outcomes of Depression in the Elderly study; OFUS: Osaka Follow-Up Study; OR: odds ratio; PAGIT: Placebo-Arm of Galantamine-International-1 Trial; PD: proton density; PiB: Pittsburgh compound B; PVHs: periventricular hyperintensities; Qt: quantitative; RSS: Rotterdam Scan Study; SD: standard deviation; SQ: semi-quantitative; RUNDMC: Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Cohort; TCV: total cerebral volume; UK: United Kingdom; USA: United States of America; VaD: vascular dementia; WMHs: white matter hyperintensities; 3-CS: Three-City Study. ^aParticipant number is presented as amount used in analysis, number between brackets represents total study participant number; ¹Scheltens scale; ²Manolio scale; ³modified Scheltens scale; ⁴combination of Scheltens and adjusted Fazekas scale; ⁵CREDOS scale; ⁶Rotterdam Scan Study scale; ⁷Schmidt scale; ⁸data published by ⁹⁹, ⁴risk estimate calculated based on information in original article; ⁵p-value calculated based on information in original article; ⁶unadjusted, confidence intervals calculated based on information in original article.

Table S4.2.b. Studies on the association between lacunes and incident all-cause dementia

Reference	Study population characteristics				MRI characteristics	Lacunes assessment	Dementia type	Number of events	Outcome	Adjustments
	FU (y)	Study	N ^a	Study participants	Country	Age (y)	Male (%)			
21	5.9	FOS	2,013 (2,229)	Community-dwelling	USA	62.0	47.1	1.1	HR= 6.12 (1.82-20.54)	Age, sex, BP, DM, smoking, CVD
22	3.1	NA	52	MCI	USA	72.8	71.0	17	HR= 2.88 (0.51-15.54)	ASE, cognition AB, GMV, HCV, WMHs
47	7.9	3-CS	1677	Community-dwelling	France	72.0	39.0	124	HR= 2.69 (1.46-4.95)	Age, sex, ASE, BP, HC, DM, smoking, CVD, APOE
28	2.1	NA	151	MCI	USA	77.0	58.0	75	HR= 0.82 (0.40-1.90)	ASE
72	8.0	OFUS	600	With cardiovascular risk factor(s)	Japan	67.4	57.0	57	HR= 2.64 (1.22-6.09)	ASE, cognition AB, BP, DM,
								18	HR= 1.78 (0.64-5.44)	CVD, APOE, GFR
3	1.5	NA	79	MCI	Singapore	61.0	59.5	31	HR= 5.37 (1.20-39.2)	
								23	(p = 0.309) (P-value of T-test for mean difference in number of lacunes between incident dementia and control)	None
16	2.0	PAGIT	426	MCI	International	71.0	45.0	81	HR= 1.19 (0.75-1.88)	Age, sex
100	4.3	CHS	155	Community-dwelling	USA	77.4	40.0	40	HR= 3.50 (1.10-10.90)	ASE, cognition AB, race, APOE, ICV
37	2.0	NA	152	MCI	Netherlands	69.9	53.0	56	HR= 1.10 (0.50-2.20)	Age, sex
								16	HR= 2.10 (0.70-6.40)	
40	5.2	RUNDMC	500 (503)	Community-dwelling	Netherlands	65.6	56.8	42	HR= 0.88 (0.44-1.76)	ASE, cognition AB, territorial infarct
41	3.6	RSS	1,015	Community-dwelling	Netherlands	72.1	48.0	30	HR= 2.26 (1.09-4.70)	ASE
45	8.9	NA	177	Stroke	Japan	69.1	62.7	26	HR= 2.38 (0.898-6.47)	Age, sex, PB, HC, DM, DWMHs, dipper vs. Non-dipper

Tables S4.2.b. Summary of study characteristics. Abbreviations: AB: at baseline; AD: Alzheimer's disease; APOE: apolipoprotein E; ASE: age, sex, education; BP: blood pressure; CHS: Cardiovascular Health Study; CVD: cardiovascular disease; DM: diabetes mellitus; DWMHs: deep white matter hyperintensities; FLAIR: fluid attenuation inversion recovery; FOS: Framingham Offspring Study; FU: follow-up; GFR: glomerular filtration rate; GMV: grey matter volume; HC: hypercholesterolemia; HCV: hippocampal volume; HR: hazard ratio; ICV: intracranial volume; MRI: magnetic resonance imaging; NA: not available; OFUS: Osaka Follow-Up Study; PAGIT: Placebo-Arm of Galantamine-International-11 Trial; PD: proton density; QI: qualitative; RSS: Rotterdam Scan Study; RUNDMC: Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Cohort; USA: United States of America; VaD: vascular dementia; WMHs: white matter hyperintensities; 3-CS: Three-City Study. ^aParticipant number is presented as amount used in analysis, number between brackets represents total study participant number.

Table S4.2.c. Studies on the association between cerebral microbleeds (CMBs) and incident all-cause dementia

Reference	Study population characteristics				MRI characteristics		CMBs assessment		Dementia type		Outcome		Adjustments
	FU (y)	Study	N ^a	Study participants	Country	Age (y)	Male (%)				Number of events	Outcome	
71	4.8	RSS	4,841	Community-dwelling	Netherlands	63.8	45.0	1.5T, T1, T2	QI, presence vs. absence	Any type	72	HR= 1.59 (0.88-2.89)	ASE, BP, HC, DM, APOE, smoking, antithrombotic use
15	7.5	OFUS	524	With cardiovascular risk factor(s)	Japan	67.7	57.6	1.5T, T1, T2, T2*	QI, presence vs. absence	Any type	44	HR= 1.71 (0.87-3.27)	Age sex, cognition AB, CVD, MTA, WMHs
37	2.0	NA	152	MCI	Netherlands	69.9	53.0	1.0T, T1, FLAIR, T2	QI, presence vs. absence	AD	56	HR= 0.80 (0.20-2.20)	Age sex
40	5.2	RUNDMC	500 (503)	Community-dwelling	Netherlands	65.6	56.8	1.5T, T1, T2, T2*	QI, presence vs. absence	Non-AD	16	HR= 2.60 (0.90-7.50)	ASE, cognition AB, territorial infarct

Tables S4.2.c. Summary of study characteristics. Abbreviations: AB: at baseline; AD: Alzheimer’s disease; APOE: apolipoprotein E; ASE: age, sex, education; BP: blood pressure; CMBs: cerebral microbleeds; CVD: cardiovascular disease; DM: diabetes mellitus; FLAIR: fluid attenuation inversion recovery; FU: follow-up; HC: hypercholesterolemia; HR: hazard ratio; MRI: magnetic resonance imaging; MTA: medial temporal lobe atrophy; NA: not available; OFUS: Osaka Follow-Up Study; QI: qualitative; RSS: Rotterdam Scan Study; RUNDMC: Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Cohort; VaD: vascular dementia; WMHs: white matter hyperintensities. ^aParticipant number is presented as amount used in analysis, number between brackets represents total study participant number.

Table S4.2.d. Studies on the association between perivascular spaces and incident all-cause dementia

Reference	Study population characteristics				MRI characteristics		Perivascular spaces assessment		Dementia type		Outcome		Adjustments
	FU (y)	Study	N ^a	Study participants	Country	Age (y)	Male (%)				Number of events	Outcome	
12	4.0	3-CS	505 (1,178)	Community-dwelling	France	72.5	36.4	1.5T, T1, T2	SQ (1-4), dichotomised (grade 2 vs. 1)	Any type	7	HR= 3.1 (0.7-13.9)	Age, APOE, ICV

Tables S4.2.d. Summary of study characteristics. Abbreviations: APOE: apolipoprotein E; FU: follow-up; HR: hazard ratio; ICV: intracranial volume; MRI: magnetic resonance imaging; SQ: semi-quantitative; 3-CS: Three-City Study. ^aParticipant number is presented as amount used in analysis, number between brackets represents total study participant number.

Table S4.2.e. Studies on the association between total cerebral atrophy and incident all-cause dementia

Reference	Study population characteristics				MRI characteristics		Cerebral atrophy assessment		Dementia type	Number of events	Outcome	Adjustments	
	FU (y)	Study	N*	Study participants	Country	Age (y)	Male (%)						
23	3.2	NA	106	Stroke	UK	79.8	53.8	1.5T, T1, FLAIR	Qt, continuous (per mL, per SD)	Any type	28	HR= 1.00 (0.99-1.00) per mL increase TCV HR= 1.51 (0.92-2.49) per SD decrease in TCV ⁱ	None
1	2.0	ADNI	320	MCI	USA	74.9	63.4	1.5T, NA	Qt, continuous (per mm ³)	Any type	60	p=0.04 (p-value of F-test for mean difference in baseline TCV between incident dementia and control)	None
24	3.0	NA	72	MCI	Netherlands	69.0	52.6	1.0T, T1	Qt, dichotomised (higher than median vs. lower than median)	AD	26	HR= 1.40 (0.60-3.60) for TCV lower than median	Age, sex, cognition AB
5	1.9	MHCRC	97	Depressed	USA	70.2	29.6	1.5T, T2	Qt, continuous (per mL)	Dementia	14	HR= 1.002 (1.00-1.01) per mL increase in TCV	Age, cognition AB, left hippocampal volume
38	6.7	3-CS	1,634 (1,721)	Community-dwelling	France	72.4	39.3	1.5T, T1, T2	Qt, continuous (per TCV/ICV, per SD)	Any type	119	HR= 0.94 (0.88-1.01) per unit higher TCV HR= 1.46 (0.94-2.18) per SD decrease in TCV ⁱ	ASE, cognition AB, BP, DM, CVD, digit span, smoking, alcohol, APOE, HCV, ICV, impairment of activity
7	8.5	ROS	65	MCI	USA	74.2	32.3	1.5T, T1	Qt, continuous (mm ³)	AD	15	p<0.05 (p-value for t-test for mean difference in baseline TCV between incident dementia and control)	None
43	5.9	FOS	1,288	Community-dwelling	USA	65.7	46.7	1.5T, T1, T2	Qt, continuous (per SD), dichotomised (1 st quintile vs. rest)	AD	63	HR= 1.28 (0.89-1.83) per SD decrease in TCV HR= 1.47 (0.54-4.04) for lowest 5 th quintile TCV	ASE, BP, DM, smoking, BMI, APOE
43	5.9	FHS	224	Community-dwelling	USA	84.8	48.0	1.5T, T1, T2	Qt, continuous (per SD), dichotomised (1 st quintile vs. rest)	AD	28	HR= 2.41 (1.51-3.84) per SD decrease in TCV HR= 6.69 (2.62-17.09) for lowest 1 st quintile TCV	ASE, BP, DM, smoking, BMI, APOE

Tables S4.2.e. Summary of study characteristics. Abbreviations: AB: at baseline; AD: Alzheimer’s disease; ADNI: Alzheimer’s Disease Neuroimaging Initiative; APOE: apolipoprotein E; ASE: age, sex, education; BP: blood pressure; BMI: body mass index; CVD: cardiovascular disease; DM: diabetes mellitus; FHS: Framingham Health Study; FLAIR: fluid attenuation inversion recovery; FOS: Framingham Offspring Study; FU: follow-up; HCV: hippocampal volume; HR: hazard ratio; ICV: intracranial volume; MHCRC: Mental Health Clinical Research Centre Study; mL: millilitre; MRI: magnetic resonance imaging; NA: not available; Qt: quantitative; ROS: Religious Order Study; SD: standard deviation; TCV: total cerebral volume; UK: United Kingdom; MV: white matter volume; 3-CS: Three-City Study. ^aParticipant number is presented as amount used in analysis, number between brackets represents total study participant number; ⁱrisk estimate calculated based on information in original article.

Table S4.3 –Characteristics for studies on the association between cerebral small vessel disease and incident depression

Table S4.3.a, Studies on the association between white matter hyperintensities (WMHs) and incident depression

Reference	Study population characteristics						MRI characteristics	WMHs assessment	Depression type	Number of events	Outcome	Adjustments	
	FU (y)	Study	N*	Study participants	Country	Age (y)							Male (%)
108	4.0	3-CS	956	Community-dwelling	France	NA	NA	1.5T, T1, T2, PD	Qt, continuous (per quartile, per SD), dichotomised (2 nd quartile vs. 1 st quartile)	Any type	103	OR= 2.03 (1.29-4.19) per SD ¹ OR= 1.20 (0.60-2.30) for 2 nd quartile WMHs OR= 1.30 (1.10-1.70) per quartile	Age, sex, BP, CVD, smoking, alcohol, baseline depression score, impairment of activity, WMV
25	7.5	RSS	443	Community-dwelling	Netherlands	73.4	50.0	1.5T, T1, T2	Qt, continuous (per SD)	Any type	35	HR= 0.83 (0.59-1.18) per SD WMHs	ASE
81	1.2	CREDOS	287 (590)	MCI	Korea	73.0	46.3%	1.5T, T1, T2, FLAIR, GE	SQ, (1-3) [†] , dichotomised (PVHs 3 vs. 1-2, and DWMHs 2-3 vs 1)	Any type	45	HR= 1.25 (0.63-2.48) for PVHs grade 3 HR= 2.75 (1.43-5.28) for DWMHs grade 2-3	None
93	3.0	NA	54	High risk of depression	Korea	NA	NA	3T, FLAIR	Qt, continuous (logmL, per SD) SQ, (0-4) [†] , dichotomised (2-4 vs. 0-1)	Any type	4	OR= 5.26 (1.01-26.68) per SD WMHs OR= 8.14 (1.37-48.22) for WMHs grade 2-4	ASE, MMSE, baseline depression score None
11	3.6	RSS	961 (1,047)	Community-dwelling	Netherlands	NA	NA	1.5T, T1, T2	SQ, (0-9) [†] , dichotomised (PVHs 5-9 vs. 0-4, and DWMHs ≥2mL vs. <2mL)	Any type	60	OR= 1.30 (0.60-2.60) for PVHs score 5-9 OR= 2.10 (1.10-3.90) for DWMHs (≥2mL)	ASE, MMSE
35	6.6	FOS	1212	Community-dwelling	USA	60.0	47.6	1T, T2	Qt, continuous (logmL, per SD), dichotomised (1 SD above mean vs. rest)	Any type	110	OR= 1.17 (0.93-1.48) per logmL WMHs OR= 1.16 (0.93-1.45) per SD WMHs ¹ OR= 1.60 (0.89-2.88) for WMHs 1 SD above mean	ASE, time to MRI, living alone, and CES-D at seventh examination
70	7.0	CHS	3,236	Community-dwelling	USA	NA	40.4	0.35T-1.5T, T2, PD	SQ, (0-9) [†] , dichotomised (6-9 vs. 0-5)	Any type	1033	OR= 1.21 (0.73-2.00) for WMHs score 6-9	Age, sex, race, BP, CVD, 3MSE, antidepressants, APOE

Reference	Study population characteristics				MRI characteristics		WMHs assessment		Depression type	Number of events	Outcome	Adjustments	
	FU (y)	Study	N ^a	Study participants	Country	Age (y)	Male (%)						
¹⁰²	1.0	LADIS	526	With WMHs	Europe	73.9	44.7	0.5-1.5T, FLAIR	Qt, continuous (logmL, per SD)	Any type	85	OR= 1.63 (1.20-2.20) per logmL WMHs OR= 1.60 (1.19-2.12) per SD WMHs ¹	Education, MMSE, history of depression, QoL, worsening IADL, incident stroke
¹⁰³	3.0	LADIS	399	With WMHs	Europe	73.6	45.6	0.5-1.5T, FLAIR	Qt, continuous (logmL, per SD)	Any type	82	OR= 1.36 (1.04-1.76) per logmL WMHs OR= 1.34 (1.04-1.70) per SD WMHs ¹	Education, MMSE, history of depression, QoL, worsening IADL, incident stroke
⁹	5.2	AGES-R	1,949	Community-dwelling	Iceland	74.6	43.4	1.5T, T1, T2, T2*, FLAIR	Qt, continuous (per SD), dichotomised (4 th quartile vs. rest)	Any type	197	OR= 1.02 (0.88-1.19) per SD WMHs OR= 1.12 (0.78-1.60) for 4 th quartile WMHs ²	ASE, BMI, BP DM, cognition/depression / geriatric/anxiety scores, smoking, alcohol, coronary calcium score, head coil, FU time
¹⁰⁴	2.8	PROSPER	484	With cardiovascular disease(s)	Netherlands	74.9	57.0	1.5T, FLAIR	Qt, dichotomised (2 nd - 4 th quartile vs. 1 st)	Any type	31	OR= 1.20 (0.40-3.50) for highest quartiles WMHs	Age, sex, pravastatin use

Tables S4.3.a Summary of study characteristics. Abbreviations: APOE: apolipoprotein E; AGES-R: Age, Gene/Environment Susceptibility-Reykjavik Study; ASE: age, sex, education; BP: blood pressure; BMI: body mass index; CHS: Cardiovascular Health Study; CREDOS: Clinical Research Centre for Dementia of South Korea Study; CVD: cardiovascular disease; DM: diabetes mellitus; DWMHs: deep white matter hyperintensities; FLAIR: fluid attenuation inversion recovery; FOS: Framingham Offspring Study; FU: follow-up; HR: hazard ratio; LADIS: Leukoaraiosis And Disability; mL: millilitre; MRI: magnetic resonance imaging; NA: not available; OR: odds ratio; PD: proton density; PROSPER: Prospective Study of Pravastatin in the Elderly at Risk; PVHs: periventricular hyperintensities; Qt: quantitative; RSS: Rotterdam Scan Study; SD: standard deviation; SQ: semi-quantitative; USA: United States of America; WMHs: white matter hyperintensities; WMV: white matter volume; 3-CS: Three-City Study. ^aParticipant number is presented as amount used in analysis, number between brackets represents total study participant number; ¹Fazekas scale; ²CHS scale; ³CREDOS scale; ⁴risk estimate calculated based on information in original article; ⁵unpublished data.

Table S4.3.b, Studies on the association between lacunes and incident depression

Reference		Study population characteristics			MRI characteristics		Lacunes assessment		Depression type	Number of events	Outcome	Adjustments
FU (y)	Study	N ^a	Study population	Country	Age (y)	Male (%)						
11	3.6	RSS	961 (1,047)	Netherlands	NA	NA	1.5T, T1, T2	QI, presence vs. absence	Any type	60	OR= 1.00 (0.50-1.80)	ASE, MMSE
9	5.2	AGES-R	1,949	Iceland	74.6	43.4	1.5T, T1, T2, T2*, FLAIR	QI, presence vs. absence	Any type	197	OR= 1.83 (1.10-3.05)	ASE, BMI, BP, DM, cognition/ depression /geriatric/anxiety scores, smoking, alcohol, coronary calcium score, head coil, FU time

Tables S4.3.b. Summary of study characteristics. Abbreviations; AGES-R: Age, Gene/Environment Susceptibility-Reykjavik Study; ASE: age, sex, education; BP: blood pressure; BMI: body mass index; DM: diabetes mellitus; FLAIR: fluid attenuation inversion recovery; FU: follow-up; HC: hypercholesterolemia; MRI: magnetic resonance imaging; NA: not available; OR: odds ratio; QI: qualitative; RSS: Rotterdam Scan Study. ^aParticipant number is presented as amount used in analysis, number between brackets represents total study participant number.

Table S4.3.c, Studies on the association between cerebral microbleeds (CMBs) and incident depression

Reference		Study population characteristics			MRI characteristics		CMBs assessment		Depression type	Number of events	Outcome	Adjustments
FU (y)	Study	N ^a	Study population	Country	Age (y)	Male (%)						
9	5.2	AGES-R	1,949	Iceland	74.6	43.4	1.5T, T1, T2, T2*, FLAIR	QI, presence vs. absence	Any type	197	OR= 1.10 (0.73-1.66)	ASE, BMI, BP, DM, cognition/ depression /geriatric/anxiety scores, smoking, alcohol, coronary calcium score, head coil, FU time

Tables S4.3.c. Summary of study characteristics. Abbreviations; AGES-R: Age, Gene/Environment Susceptibility-Reykjavik Study; ASE: age, sex, education; BP: blood pressure; BMI: body mass index; CMBs: cerebral microbleeds; DM: diabetes mellitus; FLAIR: fluid attenuation inversion recovery; FU: follow-up; MRI: magnetic resonance imaging; OR: odds ratio; QI: qualitative. ^aParticipant number is presented as amount used in analysis, number between brackets represents total study participant number.

Table S4.3.d. Studies on the association of perivascular spaces and incident depression

Reference	Study population characteristics				MRI characteristics	Perivascular spaces assessment	Depression type	Number of events	Outcome	Adjustments
	FU (y)	Study (y)	N ^a	Country	Age (y)	Male (%)				
9	5.2	AGES-R	1,949	Community-dwelling Iceland	74.6	43.4	1.5T, T1, T2, T2*, FLAIR	Q1, presence vs. absence	Any type	OR= 1.08 (0.70-1.66) ASE, BMI, BP, DM, cognition/depression/geriatric/anxiety scores, smoking, alcohol, coronary calcium score, head coil, FU time

Tables S4.3.d. Summary of study characteristics. Abbreviations: AGES-R: Age, Gene/Environment Susceptibility-Reykjavik Study; ASE: age, sex, education; BP: blood pressure; BMI: body mass index; DM: diabetes mellitus; FLAIR: fluid attenuation inversion recovery; FU: follow-up; MRI: magnetic resonance imaging; OR: odds ratio; Q1: qualitative. ^aParticipant number is presented as amount used in analysis, number between brackets represents total study participant number.

Table S4.3.e. Studies on the association between total cerebral atrophy and incident depression

Reference	Study population characteristics					MRI characteristics	Cerebral atrophy assessment	Depression type	Number of events	Outcome	Adjustments		
	FU (y)	Study	N ^a	Study population	Country							Age (y)	Male (%)
25	7.5	RSS	443 (479)	Community-dwelling	Netherlands	73.4	50.0	1.5T, T1, T2	Qt, continuous (per SD)	Any type	35	HR= 0.83 (0.59-1.18) per SD increase in TCV HR= 1.12 (0.70-1.82) per SD decrease in TCV ¹	ASE
35	6.6	FOS	1,212	Community-dwelling	USA	60.0	47.6	1T, T2	Qt, continuous (logmL, per SD)	Any type	110	OR= 0.80 (0.67-0.95) per logmL increase in TCV OR= 2.02 (1.18-3.53) per SD decrease in TCV ¹	ASE, time to MRI, living alone, and CES-D at seventh examination
9	5.2	AGES-R	1,949	Community-dwelling	Iceland	74.6	43.4	1.5T, T1, T2, T2*, FLAIR	Qt, continuous (per SD)	Any type	197	OR= 1.23 (1.04-1.45) per SD decrease in TCV	ASE, BMI, BP, DM, cognition/ depression /geriatric/ anxiety scores, smoking, alcohol, coronary calcium score, head coil, FU time

Tables S4.3.e. Summary of study characteristics. Abbreviations: AGES-R: Age, Gene/Environment Susceptibility-Reykjavik Study; ASE: age, sex, education; BP: blood pressure; BMI: body mass index; DM: diabetes mellitus; FLAIR: fluid attenuation inversion recovery; FOS: Framingham Offspring Study; FU: follow-up; HR: hazard ratio; mL: millilitre; MRI: magnetic resonance imaging; OR: odds ratio; RSS: Rotterdam Scan Study; SD: standard deviation; TCV: total cerebral volume; USA: United States of America. ^aParticipant number is presented as amount used in analysis, number between brackets represents total study participant number; ¹risk estimate calculated based on information in original article.

Table S4.4 –Characteristics for studies on the association between cerebral small vessel disease and all-cause mortality
Table S4.4.a. Studies on the association between white matter hyperintensities (WMHs) and all-cause mortality

Reference	Study population characteristics						MRI characteristics	WMHs assessment	Number of events	Outcome	Adjustments	
	FU (y)	Study NA	Study participants	Country	Age (y)	Male (%)						
49	3.3	NA	832	Stroke	Denmark	59.6	58.0	1.5-3T, T2, DWI	SQ (0-6) [†] , dichotomised (2 vs. 1) for WMHs, (0-3) [†] , dichotomised (2 vs. 1) for PVHs and DWMHs	80	HR= 1.45 (0.66-3.17) for WMHs grade 2 HR= 1.79 (0.98-3.25) for PVHs grade 2 HR= 1.59 (0.80-3.16) for DWMHs grade 2	CHA2DS2-VASc score
51	5.0	NA	81	Stroke	Sweden	66.4	63.0	T2	SQ (0-3) [†] , dichotomised (high vs. low)	15	HR= 1.60 (1.20-2.20) for high WMHs	None
19	6.3	Shimane	2,684	Community-dwelling	Japan	57.8	54.9	0.15- 1.5T, T1, T2	SQ (0-4 for PVHs, 0-3 for DWMHs) [‡] , dichotomised (3-4 vs. 0-2 for PVHs, 2-3 vs. 0 for DWMHs)	93	OR= 4.01 (1.91-8.45) for PVHs grade 3-4 OR= 1.03 (0.45-2.53) for DWMHs grade 2-3	Age, sex, HC, BP, DM, smoking, alcohol, family history of stroke
20	5.3	SMART-MR	1,228	With cardiovascular disease(s)	Netherlands	58.6	79.6	1.5T, T1, T2, FLAIR	Qt, continuous (per mL, per SD), dichotomised (5 th quintile vs. rest)	106	HR= 1.03 (1.01-1.05) per mL WMHs HR= 1.33 (1.10-1.61) per SD WMHs HR= 2.00 (1.30-3.00) for 5 th quintile WMHs	Age, sex, BMI, BP, HC, DM, smoking, alcohol
21	5.6	FOS	2,208 (2,229)	Community-dwelling	USA	62	47.1	1-1.5T, T1, T2	Qt, continuous (per SD), dichotomised (high vs. low)	97	HR= 1.38 (1.13-1.69) per SD WMHs HR= 2.27 (1.41-3.65) for high WMHs	Age, sex, BP, DM, smoking, alcohol, CereVD
23	3.2	NA	106	Stroke	UK	79.8	53.8	1.5T, T1, FLAIR	Qt, continuous (lnWMHs%, per SD)	60	HR= 1.18 (0.87-1.60) per lnWMHs HR= 1.23 (0.84-1.81) per SD WMHs	None
55	1.9	NA	228	Stroke	China	68.3	57.0	1.5T, T1, T2, FLAIR, DWI	SQ (0-3) [†] , dichotomised (2-3 vs. 0-1)	25	OR= 2.02 (1.03-3.96) per WMHs grade OR= 3.60 (1.30-9.98) for WMHs grade 2-3	Age, sex, BP, DM, smoking, alcohol, CVD, AF
24	2.6	NA	1,117 (1,138)	MCI	Netherlands	66	55.2	1-1.5T, T1, T2, T2*, FLAIR	SQ (0-3) [†] , dichotomised (3 vs. 0)	153	HR= 1.20 (1.00-1.40) per WMHs HR= 1.70 (1.00-2.80) for WMHs grade 3	Age, sex, HC, BP, DM, CVD
26	8.4	RSS	490	Community-dwelling	Netherlands	73.4	49.2	1.5T, T1, T2*, FLAIR, PD	Qt, continuous (per SD), dichotomised (4 th quartile vs 1 st)	191	HR= 1.38 (1.16-1.65) per SD WMHs HR= 2.05 (1.32-3.20) for 4 th quartile WMHs	Age, sex
2	2.4	LADIS	639	MCI	Europe	74.1	45.10	1.5T, T1, T2	SQ (0-4) [†]	NA	P<0.001 (p-value for Kaplan-Meier log rank test for difference in WMHs grade for mortality group vs. control)	None
84	11.8	NA	72 (108)	With imbalance, nested cohort study	USA	81.9	41.7	1.5T, T1, T2	SQ (0-2) [†] , dichotomised (2 vs. 0)	40	HR= 2.31 (1.21-4.40) for WMHs grade 2	HC, BP, DM, CVD

Reference	Study population characteristics				MRI characteristics		WMHs assessment		Number of events	Outcome	Adjustments	
	FU (y)	Study	N ^a	Study participants	Country	Age (y)	Male (%)					
45	10.0	CHS	3245	Community-dwelling	USA	74.8	40.0	0.35-3T, T1, T2, PD	SQ, (0-9) ^b , dichotomised (2 vs. 0-1)	72	HR= 1.46 (1.23-1.72) for WMHs grade 2	ASE, BP, DM, Cognition AB, smoking, CVD, APOE, renal insufficiency, walking pace, FEV1 and subclinical disease
45	5.5	NA	259	Depressed	USA	70.0	29.3	1.5T, T1, T2, PD	SQ, (0-3) ^b , dichotomised (2-3 vs. 0-1)	30	OR= 2.36 (1.07-5.21) for PVHs grade 2-3 ^c HR= 3.43 (1.29-9.08) for DWMHs grade 2-3	None Age, sex, race, CIRS score
31	5.0	NA	75	Stroke	China	70.7	52	1.5T, T1, T2, DWI	Qt, continuous (per mL, per SD)	16	HR= 1.78 (1.35-2.35) per mL WMHs HR= 3.91 (2.03-7.55) per SD WMHs	Age
47	12.0	HSAMC	396	Stroke	Finland	70.8	48.5	1.0T, T1, T2, PD	SQ, (0-3) ^b , dichotomised (3 vs. 0)	277	HR= 1.34 (1.03-1.73) for WMHs grade 3	Age, sex, HC, BP, CVD, AF, smoking, disability score
34	8.3	NA	630 (655)	Stroke	Finland	40.0	58.8	1-1.5T, T1, T2, FLAIR	SQ, (0-3) ^b , dichotomised (2-3 vs. 0)	53	HR= 3.43 (1.58-7.42) for WMHs grade 2-3	Age, sex, BP, DM, stroke type, silent brain infarcts, history of TIA
39	7.8	RUNDMC	494 (503)	Community-dwelling	Netherlands	65.7	56.5	1.5T, T1, T2 ^a , FLAIR, DTI	Qt, continuous (per SD), dichotomised (4 th quartile vs. rest)	80	HR= 1.62 (1.24-2.11) per SD WMHs OR= 1.81 (1.17-2.80) for 4 th quartile WMHs ^d	Age, sex, BP, DM, smoking None
44	14.5	ARIC	1,667 (1,799)	Community-dwelling	USA	62.4	40	1.5T, T1, T2, PD	SQ, (0-9) ^b , dichotomised (3-9 vs. 0-2)	576	HR= 1.20 (1.12-1.29) per WMHs grade 3-9 OR= 1.78 (1.42-2.23) for WMHs grade 3-9	ASE, race, BMI, BP, HC, DM, smoking, alcohol, CVD, centre
46	4.3	NA	89	Stroke	Japan	66	42.7	0.5T, T1, T2	SQ, (0-16) ^b , dichotomised (1-16 vs. 0)	4	OR= 0.28 (0.03-2.90) for WMHs grade 1-16 ^e	None

Tables S4.4.a. Summary of study characteristics. Abbreviations: AB: at baseline; APOE: apolipoprotein E; ARIC: Atherosclerosis Risk in Communities Study; ASE: age, sex, education; BP: blood pressure; BMI: body mass index; CerVD: cerebrovascular disease; CHS: Cardiovascular Health Study; CIRS: Cumulative Illness Rating Scale; CVD: cardiovascular disease; DM: diabetes mellitus; DWMHs: deep white matter hyperintensities; FLAIR: fluid attenuation inversion recovery; FOS: Framingham Offspring Study; FU: follow-up; HC: hypercholesterolemia; HR: hazard ratio; HSAMC: Helsinki Stroke Aging Memory Cohort; LADIS: Leukoaraiosis And Disability; mL: millilitre; MRI: magnetic resonance imaging; NA: not available; OR: odds ratio; PD: proton density; PVHs: periventricular hyperintensities; Qt: quantitative; RSS: Rotterdam Scan Study; SD: standard deviation; SQ: semi-quantitative; RUNDMC: Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Cohort; SMART-MR: Second Manifestations of Arterial disease-Magnetic Resonance; TIA: transient ischaemic attack; UK: United Kingdom; USA: United States of America; WMHs: white matter hyperintensities. ^aParticipant number is presented as amount used in analysis, number between brackets represents total study participant number; ^bScheltens scale; ^cFazekas scale; ^dARWMC scale; ^eARIC study scale; ^fSwieten scale; ^gCHS scale; ^hscale not specified; ⁱrisk estimate calculated based on information in original article.

Table S4.4.b, Studies on the association between lacunes and all-cause mortality

Reference		Study population characteristics				MRI characteristics		Lacunes assessment		Number of events		Outcome		Adjustments		
FU (y)	Study	N ^a	Study population	Country	Age (y)	Male (%)										
50	2.9	NA	786	Stroke	Denmark	59.5	57.1	1.5-3.0T, T1, T2, FLAIR	QI, Presence (≥2) vs. absence (0)	69	HR= 0.65 (0.33-1.50)	Age, sex, BP, DM, CVD				
19	6.3	Shimane	2,684	Community-dwelling	Japan	57.8	54.9	0.15-1.5T, T1, T2, QI, Presence vs. absence	QI, Presence vs. absence	93	OR= 1.95 (1.16-3.29)	Age, sex, HC, BP, DM, smoking, alcohol, family history of stroke				
20	5.3	SMART-MR	1,228	With cardiovascular disease(s)	Netherlands	58.6	79.6	1.5T, T1, T2, FLAIR	QI, Presence vs. absence	106	HR= 2.60 (1.70-3.90)	Age, sex, BMI, BP, HC, DM, smoking, alcohol				
21	5.6	FOS	2,208 (2,229)	Community-dwelling	USA	62.0	47.1	1-1.5T, T1, T2, QI, Presence vs. absence	QI, Presence vs. absence	97	HR= 1.53 (0.94-2.48)	Age, sex, BP, DM, smoking, alcohol, CerVD				
26	8.4	RSS	490	Community-dwelling	Netherlands	73.4	49.2	1.5T, T1, T2*, FLAIR, PD	QI, Presence vs. absence	191	HR= 1.25 (0.90-1.73)	Age, sex				
86	4.7	IVDPP	498	Dementia	USA	74.5	50.2	1.5T, T1, T2, PD	QI, Presence vs. absence	175	HR= 1.90 (1.40-2.50)	None				
31	5.0	NA	75	Stroke	China	70.7	52.0	1.5T, T1, T2, DWI	QI, Presence vs. absence	16	HR= 2.21 (0.70-6.94)	Age				
34	8.3	NA	607 (651)	Stroke	Finland	40.0	58.8	1-1.5T, T1, T2, FLAIR	QI, Presence (1) vs. absence	50	HR= 1.32 (0.51-3.38)	Age, sex, BP, DM, stroke type, WMHs, history of TIA				
39	7.8	RUNDMC	494 (503)	Community-dwelling	Netherlands	65.7	56.5	1.5T, T1, T2*, FLAIR, DTI	QI, Presence vs. absence	78	OR= 1.85 (1.21-2.83) ¹	None				
42	2.5	ProFESS	815 (1,014)	Stroke	Europe	66.1	63.9	T1, T2, FLAIR	QI, Absence vs. presence, Presence vs. absence	20	OR= 0.58 (0.36-0.94) for absence of lacunes OR= 2.22 (1.12-4.35) for presence of lacunes ¹	None				
44	14.5	ARIC	1,167 (1,799)	Community-dwelling	USA	62.4	40.0	1.5T, T1, T2, PD	QI, Presence vs. absence	576	HR= 1.69 (1.31-2.17)	ASE, race, BMI, BP, HC, DM, smoking, alcohol, CVD, centre				

Tables S4.4.b. Summary of study characteristics. Abbreviations: ARIC: Atherosclerosis Risk in Communities Study; ASE: age, sex, education; BP: blood pressure; BMI: body mass index; CereVD: cerebrovascular disease; CVD: cardiovascular disease; DM: diabetes mellitus; FLAIR: fluid attenuation inversion recovery; FOS: Framingham Offspring Study; FU: follow-up; HC: hypercholesterolemia; HR: hazard ratio; IVDPP: Ischaemic Vascular Dementia Program Project; MRI: magnetic resonance imaging; NA: not available; OR: odds ratio; PD: proton density; PROFESS: Prevention Regimen for Effectively Avoiding Second Strokes trial; QI: qualitative; RSS: Rotterdam Scan Study; RUNDMC: Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Cohort; SMART-MR: Second Manifestations of Arterial disease-Magnetic Resonance; TIA: transient ischaemic attack; USA: United States of America; WMHs: white matter hyperintensities. ^aParticipant number is presented as amount used in analysis, number between brackets represents total study participant number; ¹risk estimate calculated based on information in original article.

Table S4.4.c. Studies on the association between cerebral microbleeds (CMBs) and all-cause mortality

Reference	Study population characteristics				MRI characteristics		CMBs assessment		Number of events	Outcome	Adjustments
	FU (y)	Study	N ^a	Study population	Country	Age (y)	Male (%)				
82	5.2	RSS	3,979	Community-dwelling	Netherlands	60.3	45.6	QI, Presence vs. absence	172	HR= 1.37 (0.96-1.94)	Age, sex, BP, HC, DM, smoking, antithrombotic use, centre
83	7.0	PROSPER	381 (435)	Stroke	Netherlands	75.0	56.4	QI, Presence (≥2) vs. absence (0)	137	HR= 1.41 (0.87-2.27)	age, sex, BMI, HC, BP, DM, CVD, TIA, smoking, alcohol, statin use
52	3-6	MISTRAL	333	AD	Netherlands	72.2	58.0	QI, Presence vs. absence	147	HR= 1.70 (1.20-2.40)	Age, sex, MMSE, cardiovascular risk factors, WMHs, lacunes
53	NA	Vision	236	Stroke	Canada	NA	55.1	QI, Presence vs. absence	20	HR= 3.10 (1.20-7.80)	Age, WMHs
54	2.3	NA	121	Stroke	China	68.0	67.8	QI, Presence vs. absence	14	OR= 1.01 (0.32-3.23)	None
56	2.4	NA	134	Stroke	USA	79.9	53.0	QI, Presence vs. absence	64	OR= 1.22 (0.57-2.60)	None
24	2.6	NA	228	MCI	Netherlands	66.0	55.2	QI, categorical, presence (≥3) vs. absence (0)	153	HR= 2.00 (1.50-2.60) per microbleed HR= 2.40 (1.40-4.30) for presence of CMBs	Age, sex, HC, BP, DM, CVD
57	3.8	ESPRIT	397	Stroke	Netherlands	65.3	58.4	QI, Presence vs. absence	40	HR= 1.60 (0.80-3.30)	Age, sex
31	5.0	NA	259	Stroke	China	70.7	52.0	QI, Presence vs. absence	16	HR= 0.55 (0.17-1.83)	Age
39	7.8	RUNDMC	630 (655)	Community-dwelling	Netherlands	65.7	56.5	QI, Presence vs. absence	80	OR= 1.93 (1.17-3.17)	None

Tables S4.4.c. Summary of study characteristics. Abbreviations: AD: Alzheimer's disease; BP: blood pressure; BMI: body mass index; CMBs: cerebral microbleeds; CVD: cardiovascular disease; DM: diabetes mellitus; ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial; FLAIR: fluid attenuation inversion recovery; FU: follow-up; HC: hypercholesterolemia; HR: hazard ratio; MISTRAL: do Microbleeds predict STroke in Alzheimer's disease Study; MRI: magnetic resonance imaging; NA: not available; OR: odds ratio; PD: proton density; PROSPER: Prospective Study of Pravastatin in the Elderly at Risk; QI: qualitative; RSS: Rotterdam Scan Study; RUNDMC: Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Cohort; TIA: transient ischaemic attack; USA: United States of America; WMHs: white matter hyperintensities. ^aParticipant number is presented as amount used in analysis, number between brackets represents total study participant number; [†]risk estimate calculated based on information in original article.

Table S4.4.d. Studies on the association between total cerebral atrophy and all-cause mortality

Reference	Study population characteristics				MRI characteristics		Cerebral atrophy assessment		Number of events	Outcome	Adjustments	
	FU (y)	Study	N ^a	Study population	Country	Age (y)	Male (%)					
23	3.2	NA	106	Stroke	UK	79.8	53.8	1.5T, T1, FLAIR	Qt, continuous (per mL, per SD)	60	HR= 1.00 (0.99-1.00) per mL higher TCV HR= 1.28 (1.00-1.78) per SD decrease in TCV ⁱ	None
8	6.0	NA	98	Community-dwelling	UK	78.0	57.1	1T, T1, T2	Qt, dichotomised (1 st vs. 2 ^{nd-4th} quartile)	37	HR= 2.77 (1.05-7.31) for 1 st quartile TCV	None
10	8.3	SMART-MR	1,215	With cardiovascular disease(s)	Netherlands	58.0	80.0	1.5T, T1, T2, FLAIR	Qt, continuous (per SD)	184	HR= 1.46 (1.22-1.76) per SD decrease in TCV	Age, sex, BMI, BP, DM, smoking, alcohol, intima media thickness

Tables S4.4.d. Summary of study characteristics. Abbreviations: BP: blood pressure; BMI: body mass index; DM: diabetes mellitus; FLAIR: fluid attenuation inversion recovery; FU: follow-up; HR: hazard ratio; mL: millilitre; MRI: magnetic resonance imaging; NA: not available; Qt: quantitative; SD: standard deviation; SMART-MR: Second Manifestations of Arterial disease-Magnetic Resonance; TCV: total cerebral volume; UK: United Kingdom . ^aParticipant number is presented as amount used in analysis, number between brackets represents total study participant number 'risk estimate calculated based on information in original article.

References

1. Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P and Goldberg TE. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. *Arch Gen Psychiatry*. 2011;68:961-9.
2. Inzitari D, Pracucci G, Poggesi A, Carlucci G, Barkhof F, Chabriet H, Erkinjuntti T, Fazekas F, Ferro JM, Hennerici M, Langhorne P, O'Brien J, Scheltens P, Visser MC, Wahlund LO, Waldemar G, Wallin A and Pantoni L. Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. *BMJ*. 2009;339:b2477.
3. Prasad K, Wiryasaputra L, Ng A and Kandiah N. White matter disease independently predicts progression from mild cognitive impairment to Alzheimer's disease in a clinic cohort. *Dement Geriatr Cogn Disord*. 2011;31:431-4.
4. Sluimer JD, van der Flier WM, Karas GB, Fox NC, Scheltens P, Barkhof F and Vrenken H. Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. *Radiology*. 2008;248:590-8.
5. Steffens DC, Payne ME, Greenberg DL, Byrum CE, Welsh-Bohmer KA, Wagner HR and MacFall JR. Hippocampal volume and incident dementia in geriatric depression. *Am J Geriatr Psychiatry*. 2002;10:62-71.
6. Steffens DC, Potter GG, McQuoid DR, Macfall JR, Payne ME, Burke JR, Plassman BL and Welsh-Bohmer KA. Longitudinal magnetic resonance imaging vascular changes, apolipoprotein e genotype, and development of dementia in the neurocognitive outcomes of depression in the elderly study. *Am J Geriatr Psychiatry*. 2007;15:839-849.
7. Stoub TR, DeToledo-Morrell L and Dickerson BC. Parahippocampal white matter volume predicts Alzheimer's disease risk in cognitively normal old adults. *Neurobiol Aging*. 2014;35:1855-1861.
8. Staff RT, Murray AD, Ahearn T, Salarirad S, Mowat D, Starr JM, Deary IJ, Lemmon H and Whalley LJ. Brain volume and survival from age 78 to 85: the contribution of Alzheimer-type magnetic resonance imaging findings. *J Am Geriatr Soc*. 2010;58:688-95.
9. van Sloten TT, Sigurdsson S, van Buchem MA, Phillips CL, Jonsson PV, Ding J, Schram MT, Harris TB, Gudnason V and Launer LJ. Cerebral Small Vessel Disease and Association With Higher Incidence of Depressive Symptoms in a General Elderly Population: The AGES-Reykjavik Study. *Am J Psychiatry*. 2015;172:570-8.
10. van der Veen PH, Muller M, Vincken KL, Mali WP, van der Graaf Y and Geerlings MI. Brain volumes and risk of cardiovascular events and mortality. The SMART-MR study. *Neurobiol Aging*. 2014;35:1624-31.
11. Perez HCS. Silent brain infarcts: A cause of depression in the elderly? *Psychiatry Res*. 2013;180-182.
12. Zhu YC, Dufouil C, Soumare A, Mazoyer B, Chabriet H and Tzourio C. High degree of dilated Virchow-Robin spaces on MRI is associated with increased risk of dementia. *J Alzheimers Dis*. 2010;22:663-72.
13. Korf ES, Wahlund LO, Visser PJ and Scheltens P. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. *Neurology*. 2004;63:94-100.
14. Meguro K, Ishii H, Kasuya M, Akanuma K, Meguro M, Kasai M, Lee E, Hashimoto R, Yamaguchi S and Asada T. Incidence of dementia and associated risk factors in Japan: The Osaki-Tajiri Project. *J Neurol Sci*. 2007;260:175-82.

15. Miwa K, Tanaka M, Okazaki S, Yagita Y, Sakaguchi M, Mochizuki H and Kitagawa K. Multiple or mixed cerebral microbleeds and dementia in patients with vascular risk factors. *Neurology*. 2014;83:646-53.
16. Prins ND, van der Flier WM, Brashear HR, Knol DL, van de Pol LA, Barkhof F and Scheltens P. Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population. *J Alzheimers Dis*. 2013;36:79-85.
17. Tapiola T, Pennanen C, Tapiola M, Tervo S, Kivipelto M, Hanninen T, Pihlajamaki M, Laakso MP, Hallikainen M, Hamalainen A, Vanhanen M, Helkala EL, Vanninen R, Nissinen A, Rossi R, Frisoni GB and Soininen H. MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study. *Neurobiol Aging*. 2008;29:31-8.
18. van Straaten EC, Harvey D, Scheltens P, Barkhof F, Petersen RC, Thal LJ, Jack CR, Jr. and DeCarli C. Periventricular white matter hyperintensities increase the likelihood of progression from amnesic mild cognitive impairment to dementia. *J Neurol*. 2008;255:1302-8.
19. Bokura H, Kobayashi S, Yamaguchi S, Iijima K, Nagai A, Toyoda G, Oguro H and Takahashi K. Silent brain infarction and subcortical white matter lesions increase the risk of stroke and mortality: a prospective cohort study. *J Stroke Cerebrovasc Dis*. 2006;15:57-63.
20. Conijn MM, Kloppenborg RP, Algra A, Mali WP, Kappelle LJ, Vincken KL, van der Graaf Y, Geerlings MI and Group SS. Cerebral small vessel disease and risk of death, ischemic stroke, and cardiac complications in patients with atherosclerotic disease: the Second Manifestations of ARTERial disease-Magnetic Resonance (SMART-MR) study. *Stroke*. 2011;42:3105-9.
21. DeBette S, Beiser A, Decarli C, Au R, Himali JJ, Kelly-Hayes M, Romero JR, Kase CS, Wolf PA and Seshadri S. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: The framingham offspring study. *Stroke*. 2010;41:600-606.
22. DeCarli C, Mungas D, Harvey D, Reed B, Weiner M, Chui H and Jagust W. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. *Neurology*. 2004;63:220-7.
23. Fribank MJ, Allan LM, Burton EJ, Barber R, O'Brien JT and Kalaria RN. Neuroimaging predictors of death and dementia in a cohort of older stroke survivors. *J Neurol Neurosurg Psychiatry*. 2012;83:263-7.
24. Henneman WJ, Sluimer JD, Barnes J, van der Flier WM, Sluimer IC, Fox NC, Scheltens P, Vrenken H and Barkhof F. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. *Neurology*. 2009;72:999-1007.
25. Ikram MA, Luijckendijk HJ, Vernooij MW, Hofman A, Niessen WJ, van der Lugt A, Tiemeier H and Breteler MM. Vascular brain disease and depression in the elderly. *Epidemiology*. 2010;21:78-81.
26. Ikram MA, Vernooij MW, Vrooman HA, Hofman A and Breteler MM. Brain tissue volumes and small vessel disease in relation to the risk of mortality. *Neurobiol Aging*. 2009;30:450-6.
27. Imaizumi T, Inamura S, Nomura T, Kanno A and Kim SN. The Severity of White Matter Lesions Possibly Influences Stroke Recurrence in Patients with Histories of Lacunar Infarctions. *J Stroke Cerebrovasc Dis*. 2015;24:2154-60.
28. Kantarci K, Weigand SD, Przybelski SA, Shiung MM, Whitwell JL, Negash S, Knopman DS, Boeve BF, O'Brien PC, Petersen RC and Jack CR, Jr. Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS. *Neurology*. 2009;72:1519-25.
29. Kobayashi S, Okada K, Koide H, Bokura H and Yamaguchi S. Subcortical silent brain infarction as a risk factor for clinical stroke. *Stroke*. 1997;28:1932-9.

30. Kumral E, Gulluoglu H, Alakbarova N, Karaman B, Deveci EE, Bayramov A, Evyapan D, Gokcay F and Orman M. Association of leukoaraiosis with stroke recurrence within 5 years after initial stroke. *J Stroke Cerebrovasc Dis.* 2015;24:573-82.
31. Mok VC, Lau AY, Wong A, Lam WW, Chan A, Leung H, Wong E, Soo Y, Leung T and Wong LK. Long-term prognosis of Chinese patients with a lacunar infarct associated with small vessel disease: a five-year longitudinal study. *Int J Stroke.* 2009;4:81-8.
32. Naka H, Nomura E, Takahashi T, Wakabayashi S, Mimori Y, Kajikawa H, Kohriyama T and Matsumoto M. Combinations of the presence or absence of cerebral microbleeds and advanced white matter hyperintensity as predictors of subsequent stroke types. *AJNR Am J Neuroradiol.* 2006;27:830-5.
33. Poels MM, Steyerberg EW, Wieberdink RG, Hofman A, Koudstaal PJ, Ikram MA and Breteler MM. Assessment of cerebral small vessel disease predicts individual stroke risk. *J Neurol Neurosurg Psychiatry.* 2012;83:1174-9.
34. Putaala J, Haapaniemi E, Kurkinen M, Salonen O, Kaste M and Tatlisumak T. Silent brain infarcts, leukoaraiosis, and long-term prognosis in young ischemic stroke patients. *Neurology.* 2011;76:1742-9.
35. Qiu WQ, Himali JJ, Wolf PA, DeCarli DC, Beiser A and Au R. Effects of white matter integrity and brain volumes on late life depression in the Framingham Heart Study. *Int J Geriatr Psychiatry.* 2016.
36. Soo YO, Yang SR, Lam WW, Wong A, Fan YH, Leung HH, Chan AY, Leung C, Leung TW and Wong LK. Risk vs benefit of anti-thrombotic therapy in ischaemic stroke patients with cerebral microbleeds. *J Neurol.* 2008;255:1679-86.
37. Staekenborg SS, Koedam EL, Henneman WJ, Stokman P, Barkhof F, Scheltens P and van der Flier WM. Progression of mild cognitive impairment to dementia: contribution of cerebrovascular disease compared with medial temporal lobe atrophy. *Stroke.* 2009;40:1269-74.
38. Stephan BCM, Tzourio C, Auriacombe S, Amieva H, Dufouil C, Alperovitch A and Kurth T. Usefulness of data from magnetic resonance imaging to improve prediction of dementia: Population based cohort study. *BMJ* 2015;350.
39. van der Holst HM, van Uden IW, Tuladhar AM, de Laat KF, van Norden AG, Norris DG, van Dijk EJ, Rutten-Jacobs LC and de Leeuw FE. Factors Associated With 8-Year Mortality in Older Patients With Cerebral Small Vessel Disease: The Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Cohort (RUN DMC) Study. *JAMA Neurol.* 2016;73:402-9.
40. van Uden IW, van der Holst HM, Tuladhar AM, van Norden AG, de Laat KF, Rutten-Jacobs LC, Norris DG, Claassen JA, van Dijk EJ, Kessels RP and de Leeuw FE. White Matter and Hippocampal Volume Predict the Risk of Dementia in Patients with Cerebral Small Vessel Disease: The RUN DMC Study. *J Alzheimers Dis.* 2015;49:863-73.
41. Vermeer SE, Prins ND, Den Heijer T, Hofman A, Koudstaal PJ and Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. *N Engl J Med.* 2003;348:1215-1222.
42. Weber R, Weimar C, Wanke I, Moller-Hartmann C, Gizewski ER, Blatchford J, Hermansson K, Demchuk AM, Forsting M, Sacco RL, Saver JL, Warach S, Diener HC, Diehl A and Group PRIS. Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) imaging substudy. *Stroke.* 2012;43:350-5.
43. Weinstein G, Beiser AS, Decarli C, Au R, Wolf PA and Seshadri S. Brain imaging and cognitive predictors of stroke and alzheimer disease in the framingham heart study. *Stroke.* 2013;44:2787-2794.

44. Windham BG, Deere B, Griswold ME, Wang W, Bezerra DC, Shibata D, Butler K, Knopman D, Gottesman RF, Heiss G and Mosley TH. Small brain lesions and incident stroke and mortality: A cohort study. *Ann Intern Med.* 2015;163:22-31.
45. Yamamoto Y, Akiguchi I, Oiwa K, Hayashi M, Kasai T and Ozasa K. Twenty-four-hour blood pressure and MRI as predictive factors for different outcomes in patients with lacunar infarct. *Stroke.* 2002;33:297-305.
46. Yamauchi H, Fukuda H and Oyanagi C. Significance of white matter high intensity lesions as a predictor of stroke from arteriolosclerosis. *J Neurol Neurosurg Psychiatry.* 2002;72:576-582.
47. Kaffashian S, Soumare A, Zhu YC, Mazoyer B, Debette S and Tzourio C. Long-Term Clinical Impact of Vascular Brain Lesions on Magnetic Resonance Imaging in Older Adults in the Population. *Stroke.* 2016;47:2865-2869.
48. Buyck JF, Dufouil C, Mazoyer B, Maillard P, Ducimetiere P, Alperovitch A, Bousser MG, Kurth T and Tzourio C. Cerebral white matter lesions are associated with the risk of stroke but not with other vascular events: the 3-City Dijon Study. *Stroke.* 2009;40:2327-31.
49. Andersen SD, Larsen TB, Gørst-Rasmussen A, Yavarian Y, Lip GY and Bach FW. White Matter Hyperintensities Improve Ischemic Stroke Recurrence Prediction. *Cerebrovasc Dis.* 2017;43:17-24.
50. Andersen SD, Skjoth F, Yavarian Y, Bach FW, Lip GY and Larsen TB. Multiple Silent Lacunes Are Associated with Recurrent Ischemic Stroke. *Cerebrovasc Dis.* 2016;42:73-80.
51. Appelros P, Samuelsson M and Lindell D. Lacunar infarcts: functional and cognitive outcomes at five years in relation to MRI findings. *Cerebrovasc Dis.* 2005;20:34-40.
52. Benedictus MR, Prins ND, Goos JD, Scheltens P, Barkhof F and van der Flier WM. Microbleeds, Mortality, and Stroke in Alzheimer Disease: The MISTRAL Study. *JAMA Neurol.* 2015;72:539-45.
53. Boulanger JM, Coutts SB, Eliasziw M, Gagnon AJ, Simon JE, Subramaniam S, Sohn CH, Scott J and Demchuk AM. Cerebral microhemorrhages predict new disabling or fatal strokes in patients with acute ischemic stroke or transient ischemic attack. *Stroke.* 2006;37:911-914.
54. Fan YH, Zhang L, Lam WWM, Mok VCT and Wong KS. Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke. *Stroke.* 2003;34:2459-2462.
55. Fu JH, Lu CZ, Hong Z, Dong Q, Luo Y and Wong KS. Extent of white matter lesions is related to acute subcortical infarcts and predicts further stroke risk in patients with first ever ischaemic stroke. *J Neurol Neurosurg Psychiatry.* 2005;76:793-796.
56. Haji S, Zubair A, Planchard R and Flemming K. Clinical relevance of cerebral microbleeds in patients with atrial fibrillation and stroke. *Stroke.* 2015;46.
57. Kwa VIH, Algra A, Brundel M, Bouvy W and Kappelle LJ. Microbleeds as a predictor of intracerebral hemorrhage in patients receiving oral antithrombotic drugs after a TIA or minor ischemic stroke: A prospective cohort study in Western outpatients. *Cerebrovasc Dis.* 2012;33:779-780.
58. Akoudad S, Portegies MLP, Koudstaal PJ, Hofman A, Van Der Lugt A, Ikram MA and Vernooij MW. Cerebral Microbleeds Are Associated with an Increased Risk of Stroke: The Rotterdam Study. *Circulation.* 2015;132:509-516.
59. Bernick C, Kuller L, Dulberg C, Longstreth WT, Jr., Manolio T, Beauchamp N and Price T. Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. *Neurology.* 2001;57:1222-9.
60. Bokura H, Saika R, Yamaguchi T, Nagai A, Oguro H, Kobayashi S and Yamaguchi S. Microbleeds are associated with subsequent hemorrhagic and ischemic stroke in healthy elderly individuals. *Stroke.* 2011;42:1867-1871.

61. Gioia LC, Tollard E, Dubuc V, Lanthier S, Deschaintre Y, Chagnon M and Poppe AY. Silent ischemic lesions in young adults with first stroke are associated with recurrent stroke. *Neurology*. 2012;79:1208-14.
62. Ishikawa J, Tamura Y, Hoshida S, Eguchi K, Ishikawa S, Shimada K and Kario K. Low-grade inflammation is a risk factor for clinical stroke events in addition to silent cerebral infarcts in Japanese older hypertensives: the Jichi Medical School ABPM Study, wave 1. *Stroke*. 2007;38:911-7.
63. Naganuma T, Takemoto Y, Shoji T, Ishimura E, Okamura M and Nakatani T. Cerebral Microbleeds Predict Intracerebral Hemorrhage in Hemodialysis Patients. *Stroke*. 2015;46:2107-12.
64. Nishikawa T, Ueba T, Kajiura M, Fujisawa I, Miyamatsu N and Yamashita K. Cerebral microbleeds predict first-ever symptomatic cerebrovascular events. *Clin Neurol Neurosurg*. 2009;111:825-8.
65. Thijs V, Lemmens R, Schoofs C, Gerner A, Van Damme P, Schrooten M and Demaerel P. Microbleeds and the risk of recurrent stroke. *Stroke*. 2010;41:2005-2009.
66. Gerdes VE, Kwa VI, ten Cate H, Brandjes DP, Buller HR and Stam J. Cerebral white matter lesions predict both ischemic strokes and myocardial infarctions in patients with established atherosclerotic disease. *Atherosclerosis*. 2006;186:166-72.
67. Kuller LH, Longstreth WT, Jr., Arnold AM, Bernick C, Bryan RN, Beauchamp NJ, Jr. and Cardiovascular Health Study Collaborative Research G. White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke. *Stroke*. 2004;35:1821-5.
68. Melkas S, Sibolt G, Oksala NKJ, Putaala J, Pohjasvaara T, Kaste M, Karhunen PJ and Erkinjuntti T. Extensive white matter changes predict stroke recurrence up to 5 years after a first-ever ischemic stroke. *Cerebrovasc Dis*. 2012;34:191-198.
69. Smith EE, Gurol ME, Eng JA, Engel CR, Nguyen TN, Rosand J and Greenberg SM. White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage. *Neurology*. 2004;63:1606-12.
70. Steffens DC, Krishnan KR, Crump C and Burke GL. Cerebrovascular disease and evolution of depressive symptoms in the cardiovascular health study. *Stroke*. 2002;33:1636-44.
71. Akoudad S, Wolters FJ, Viswanathan A, de Bruijn RF, van der Lugt A, Hofman A, Koudstaal PJ, Ikram MA and Vernooij MW. Association of Cerebral Microbleeds With Cognitive Decline and Dementia. *JAMA Neurol*. 2016;73:934-43.
72. Kitagawa K, Miwa K, Yagita Y, Okazaki S, Sakaguchi M and Mochizuki H. Association between carotid stenosis or lacunar infarction and incident dementia in patients with vascular risk factors. *Eur J Neurol*. 2015;22:187-192.
73. Bombois S, Debette S, Bruandet A, Delbeuck X, Delmaire C, Leys D and Pasquier F. Vascular subcortical hyperintensities predict conversion to vascular and mixed dementia in MCI patients. *Stroke*. 2008;39:2046-51.
74. Fribank MJ, Teodorczuk A, van der Flier WM, Gouw AA, Wallin A, Erkinjuntti T, Inzitari D, Wahlund LO, Pantoni L, Poggesi A, Pracucci G, Langhorne P and O'Brien JT. Relationship between progression of brain white matter changes and late-life depression: 3-year results from the LADIS study. *Br J Psychiatry*. 2012;201:40-5.
75. Ikram MA, Vrooman HA, Vernooij MW, Heijer Td, Hofman A, Niessen WJ, van der Lugt A, Koudstaal PJ and Breteler MMB. Brain tissue volumes in relation to cognitive function and risk of dementia. *Neurobiol Aging*. 2010;31:378-386.
76. Kuller LH. [Risk factors for dementia in the Cardiovascular Health Study cognition study]. *Rev Neurol*. 2003;37:122-6.
77. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A and Breteler MM. Cerebral white matter lesions and the risk of dementia. *Arch Neurol*. 2004;61:1531-4.

78. Smith EE, Egorova S, Blacker D, Killiany RJ, Muzikansky A, Dickerson BC, Tanzi RE, Albert MS, Greenberg SM and Guttman CR. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. *Arch Neurol*. 2008;65:94-100.
79. Verdelho A, Madureira S, Moleiro C, Ferro JM, Santos CO, Erkinjuntti T, Pantoni L, Fazekas F, Visser M, Waldemar G, Wallin A, Hennerici M and Inzitari D. White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. *Neurology*. 2010;75:160-7.
80. Kim S, Choi SH, Lee YM, Kim MJ, Kim YD, Kim JY, Park JH, Myung W, Na HR, Han HJ, Shim YS, Kim JH, Yoon SJ, Kim SY and Kim DK. Periventricular white matter hyperintensities and the risk of dementia: a CREDOS study. *Int Psychogeriatr*. 2015;27:2069-77.
81. Kim S, Woo SY, Kang HS, Lim SW, Choi SH, Myung W, Jeong JH, Lee Y, Hong CH, Kim JH, Na H, Carroll BJ and Kim DK. Factors related to prevalence, persistence, and incidence of depressive symptoms in mild cognitive impairment: vascular depression construct. *Int J Geriatr Psychiatry*. 2016;31:818-26.
82. Akoudad S, Ikram MA, Koudstaal PJ, Hofman A, Van Der Lugt A and Vernooij MW. Cerebral microbleeds and the risk of mortality in the general population. *Eur J Epidemiol*. 2013;28:815-821.
83. Altmann-Schneider I, Trompet S, de Craen AJ, van Es AC, Jukema JW, Stott DJ, Sattar N, Westendorp RG, van Buchem MA and van der Grond J. Cerebral microbleeds are predictive of mortality in the elderly. *Stroke*. 2011;42:638-44.
84. Kerber KA, Whitman GT, Brown DL and Baloh RW. Increased risk of death in community-dwelling older people with white matter hyperintensities on MRI. *J Neurol Sci*. 2006;250:33-8.
85. Kuller LH, Arnold AM, Longstreth WT, Jr., Manolio TA, O'Leary DH, Burke GL, Fried LP and Newman AB. White matter grade and ventricular volume on brain MRI as markers of longevity in the cardiovascular health study. *Neurobiol Aging*. 2007;28:1307-15.
86. Lavretsky H, Zheng L, Weiner MW, Mungas D, Reed B, Kramer JH, Jagust W, Chui H and Mack WJ. Association of depressed mood and mortality in older adults with and without cognitive impairment in a prospective naturalistic study. *Am J Psychiatry*. 2010;167:589-597.
87. Oksala NK, Oksala A, Pohjasvaara T, Vataja R, Kaste M, Karhunen PJ and Erkinjuntti T. Age related white matter changes predict stroke death in long term follow-up. *J Neurol Neurosurg Psychiatry*. 2009;80:762-6.
88. Godin O, Tzourio C, Rouaud O, Zhu Y, Maillard P, Pasquier F, Crivello F, Alperovitch A, Mazoyer B and Dufouil C. Joint effect of white matter lesions and hippocampal volumes on severity of cognitive decline: the 3C-Dijon MRI study. *J Alzheimers Dis*. 2010;20:453-63.
89. Geroldi C, Rossi R, Calvagna C, Testa C, Bresciani L, Binetti G, Zanetti O and Frisoni GB. Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment. *J Neurol Neurosurg Psychiatry*. 2006;77:1219-22.
90. Kario K, Shimada K, Schwartz JE, Matsuo T, Hoshida S and Pickering TG. Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. *J Am Coll Cardiol*. 2001;38:238-45.
91. Levy RM, Steffens DC, McQuoid DR, Provenzale JM, MacFall JR and Krishnan KR. MRI lesion severity and mortality in geriatric depression. *Am J Geriatr Psychiatry*. 2003;11:678-82.
92. Lopez OL, Klunk WE, Mathis C, Coleman RL, Price J, Becker JT, Aizenstein HJ, Snitz B, Cohen A, Ikonomic M, McDade E, DeKosky ST, Weissfeld L and Kuller LH. Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old. *Neurology*. 2014;83:1804-11.
93. Park JH, Lee SB, Lee JJ, Yoon JC, Han JW, Kim TH, Jeong HG, Newhouse PA, Taylor WD, Kim JH, Woo JI and Kim KW. Epidemiology of MRI-defined vascular depression: A longitudinal, community-based study in Korean elders. *J Affect Disord*. 2015;180:200-6.

94. Kaffashian S, Tzourio C, Zhu YC, Mazoyer B and Debette S. Differential Effect of White-Matter Lesions and Covert Brain Infarcts on the Risk of Ischemic Stroke and Intracerebral Hemorrhage. *Stroke*. 2016;47:1923-5.
95. Naganuma T, Takemoto Y, Shoji T, Shima H, Ishimura E, Okamura M and Nakatani T. Cerebral white matter hyperintensity predicts cardiovascular events in haemodialysis patients. *Nephrology*. 2013;18:676-81.
96. Ntaios G, Lip GYH, Lambrou D, Papavasileiou V, Manios E, Milionis H, Spengos K, Makaritsis K and Vemmos K. Leukoaraiosis and stroke recurrence risk in patients with and without atrial fibrillation. *Neurology*. 2015;84:1213-1219.
97. Imaizumi T, Inamura S and Nomura T. Contribution of Deep Microbleeds to Stroke Recurrence: Differences between Patients with Past Deep Intracerebral Hemorrhages and Lacunar Infarctions. *J Stroke Cerebrovasc Dis*. 2015;24:1855-1864.
98. Folsom AR, Yatsuya H, Mosley Jr TH, Psaty BM and Longstreth Jr WT. Risk of intraparenchymal hemorrhage with magnetic resonance imaging-defined leukoaraiosis and brain infarcts. *Annals of Neurology*. 2012;71:552-559.
99. Debette S and Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ*. 2010;341:c3666.
100. Rosano C, Aizenstein HJ, Wu M, Newman AB, Becker JT, Lopez OL and Kuller LH. Focal atrophy and cerebrovascular disease increase dementia risk among cognitively normal older adults. *J Neuroimaging*. 2007;17:148-55.
101. Godin O, Dufouil C, Maillard P, Delcroix N, Mazoyer B, Crivello F, Alperovitch A and Tzourio C. White matter lesions as a predictor of depression in the elderly: the 3C-Dijon study. *Biol Psychiatry*. 2008;63:663-9.
102. Teodorczuk A, O'Brien JT, Firbank MJ, Pantoni L, Poggesi A, Erkinjuntti T, Wallin A, Wahlund LO, Gouw A, Waldemar G, Schmidt R, Ferro JM, Chabriat H, Bazner H and Inzitari D. White matter changes and late-life depressive symptoms: longitudinal study. *Br J Psychiatry*. 2007;191:212-7.
103. Teodorczuk A, Firbank MJ, Pantoni L, Poggesi A, Erkinjuntti T, Wallin A, Wahlund LO, Scheltens P, Waldemar G, Schrotter G, Ferro JM, Chabriat H, Bazner H, Visser M, Inzitari D, O'Brien JT and Group L. Relationship between baseline white-matter changes and development of late-life depressive symptoms: 3-year results from the LADIS study. *Psychol Med*. 2010;40:603-10.
104. Versluis CE, van der Mast RC, van Buchem MA, Bollen EL, Blauw GJ, Eekhof JA, van der Wee NJ and de Craen AJ. Progression of cerebral white matter lesions is not associated with development of depressive symptoms in elderly subjects at risk of cardiovascular disease: The PROSPER Study. *Int J Geriatr Psychiatry*. 2006;21:375-81.

Table S5.1 – Newcastle-Ottawa Scale scores for studies on the association between cerebral small vessel disease and incident ischaemic and haemorrhagic stroke

Study	S1	S2	S3	C1	O1	O2	O3	Total score
Akoudad et al., 2011 ⁵	1	1	0	2	1	1	1	7
Andersen et al., 2016 ²	0	1	0	1	1	0	1	4
Andersen et al., 2017 ³	0	1	0	0	1	1	1	4
Appelros et al., 2005 ⁴	0	0	0	0	1	0	1	2
Benedictus et al., 2015 ⁵	0	0	0	1	1	0	1	3
Bernick et al., 2001 ⁶	1	1	1	1	0	1	0	5
Bokura et al., 2011 ⁷	1	0	1	1	0	0	1	4
Bokura et al., 2006 ⁸	1	0	0	2	1	1	0	5
Boulanger et al., 2006 ⁹	0	1	0	0	0	0	1	2
Buyck et al., 2009 ¹⁰	1	1	1	2	1	1	1	8
Conijn et al., 2011 ¹¹	0	1	0	2	1	1	1	6
Debette et al., 2010 ¹²	1	0	1	2	1	1	0	6
Fan et al., 2003 ¹³	0	1	0	0	0	0	1	2
Fu et al., 2005 ¹⁴	0	1	0	0	0	0	1	2
Gerdes et al., 2006 ¹⁵	0	1	0	0	0	0	0	1
Gioia et al., 2012 ¹⁶	0	1	0	2	0	0	0	3
Haji et al., 2015 ¹⁷	0	0	0	0	0	0	0	0
Imaizumi et al., 2015 ¹⁸	0	1	0	0	0	0	1	2
Inzitari et al., 2009 ¹⁹	0	0	0	0	1	0	0	1
Ishikawa et al., 2007 ²⁰	1	1	1	0	0	0	0	3
Kaffashian et al., 2016a ²¹	1	1	1	2	1	1	1	8
Kaffashian et al., 2016b ²²	1	1	1	2	1	1	1	8
Kario et al., 2001 ²³	0	1	1	1	1	0	1	5
Kobayashi et al., 1997 ²⁴	1	0	1	0	0	0	1	3
Kuller et al., 2004 ²⁵	1	0	1	1	1	0	0	4
Kumral et al., 2015 ²⁶	0	0	0	0	0	1	1	2
Kwa et al., 2012 ²⁷	0	0	0	1	0	0	1	2
Melkas et al., 2012 ²⁸	0	0	0	1	1	1	0	3
Mok et al., 2009 ²⁹	0	1	0	0	0	1	1	3
Naganuma et al., 2013 ³⁰	0	1	1	0	0	0	1	3
Naganuma et al., 2015 ³¹	0	1	1	2	0	1	1	6
Naka et al., 2006 ³²	0	0	0	2	1	0	1	4
Nishikawa et al., 2009 ³³	1	1	1	1	1	0	0	5
Ntaios et al., 2015 ³⁴	0	0	0	0	1	0	0	1
Poels et al., 2012 ³⁵	1	1	1	2	1	1	1	8
Putala et al., 2011 ³⁶	0	0	0	1	0	1	1	3
Smith et al., 2004 ³⁷	0	0	0	0	0	0	0	0
Soo et al., 2008 ³⁸	0	1	0	0	1	0	1	3
Thijs et al., 2010 ³⁹	0	0	0	1	1	0	1	3
van der Veen et al., 2014 ⁴⁰	0	1	0	2	1	1	0	5
Weber et al., 2012 ⁴¹	0	0	0	0	0	0	0	0
Weinstein et al., 2013 ⁴²	1	0	1	2	1	1	0	6
Windham et al., 2015 ⁴³	1	1	1	2	1	1	1	8
Yamauchi et al., 2002 ⁴⁴	0	0	0	2	1	1	0	4

Newcastle-Ottawa Scale score (NOS) for studies on the association between cerebral small vessel disease and incident haemorrhagic and ischaemic stroke. For an explanation of the individual items, see the provided adjusted NOS (Appendix C). Maximal NOS score is 8. Articles indicated in bold are of high methodologic quality (NOS score >4). S1= Representativeness of the cohort; S2 = ascertainment of determinant; S3= presence of outcome of interest at start of study; C1= Comparability of cohorts: use of adjustments; O1= assessment of outcome; O2= follow up duration; O3= adequacy of follow up.

Table S5.2 – Newcastle-Ottawa Scale scores for studies on the association between cerebral small vessel disease and incident all-cause dementia

Study	S1	S2	S3	C1	O1	O2	O3	Total score
Akoudad et al., 2015⁶⁴	1	1	1	2	1	0	1	7
Bombois et al., 2008⁴⁶	0	1	1	2	1	0	1	6
Debette et al., 2010¹²	1	1	1	1	1	1	1	7
DeCarli et al., 2004 ⁴⁷	0	0	0	0	0	0	1	1
Firbank et al., 2012 ⁴⁸	0	1	1	0	1	0	0	3
Geroldi et al., 2006 ⁴⁹	0	0	1	0	1	0	0	2
Godin et al., 2010⁵⁰	1	1	1	2	0	1	1	7
Gomar et al., 2011 ⁵¹	0	0	1	0	1	0	0	2
Ikram et al., 2010⁵²	1	1	1	2	1	1	1	8
Kaffashian et al., 2016a²¹	1	1	1	2	1	1	1	8
Kaffashian et al., 2016b²²	1	1	1	2	1	1	1	8
Kantarci et al., 2009⁵³	0	1	1	1	1	0	1	5
Kim et al., 2015⁵⁴	0	1	1	1	1	0	1	5
Kitagawa et al., 2015⁵⁵	1	1	1	2	1	1	0	7
Korf et al., 2004 ⁵⁶	0	1	1	0	1	0	0	3
Kuller, 2003⁵⁷	1	1	1	1	0	1	0	5
Lopez et al., 2014⁵⁸	1	1	1	1	1	0	1	6
Meguro et al., 2007 ⁵⁹	0	1	1	0	1	1	0	4
Miwa et al., 2014⁶⁰	0	1	1	1	1	1	0	5
Prasad et al., 2011 ⁶¹	0	0	1	0	1	0	0	2
Prins et al., 2004⁶²	1	1	1	0	1	1	1	6
Prins et al., 2013 ⁶³	0	1	1	0	0	0	1	3
Rosano et al., 2007⁶⁴	1	1	1	1	1	1	0	6
Sluimer et al., 2008 ⁶⁵	0	0	1	0	1	0	0	2
Smith et al., 2008 ⁶⁶	0	1	1	0	1	1	0	4
Staekenborg et al., 2009 ⁶⁷	0	0	1	0	1	0	0	2
Steffens et al., 2002 ⁶⁸	0	0	1	0	1	0	0	2
Steffens et al., 2007 ⁶⁹	0	0	1	0	1	1	0	3
Stephan et al., 2015⁷⁰	1	1	1	2	1	1	1	8
Stoub et al., 2014⁷¹	1	1	1	0	1	1	0	5
Tapiola et al., 2008 ⁷²	0	1	1	0	1	0	0	3
van Straaten et al., 2008 ⁷³	0	1	1	0	1	0	0	3
van Uden et al., 2015⁷⁴	0	1	1	1	1	1	1	6
Verdelho et al., 2010 ⁷⁵	0	1	1	0	1	0	0	3
Vermeer et al., 2003⁷⁶	1	1	1	1	1	0	1	6
Weinstein et al., 2013⁴²	1	1	1	2	1	1	0	7
Yamamoto et al., 2002 ⁷⁷	0	1	1	0	1	1	0	4
Zhu et al., 2010⁷⁸	1	1	1	0	1	0	1	5

Newcastle-Ottawa Scale score (NOS) for studies on the association between cerebral small vessel disease and incident dementia. For an explanation of the individual items, see the provided adjusted NOS (Appendix C). Maximal NOS score is 8. Articles indicated with bold are of high methodologic quality (NOS score >4). S1= Representativeness of the cohort; S2 = ascertainment of determinant; S3= presence of outcome of interest at start of study; C1= Comparability of cohorts: use of adjustments; O1= assessment of outcome; O2= follow up duration; O3= adequacy of follow up.

Table S5.3 – Newcastle-Ottawa Scale scores for studies on the association between cerebral small vessel disease and incident depression

Study	S1	S2	S3	C1	O1	O2	O3	Total score
Godin et al., 2009⁸⁷	1	1	1	1	1	1	0	6
Ikram et al., 2009⁸⁰	1	1	1	1	1	1	1	7
Kim et al., 2016 ⁸¹	0	1	1	0	1	0	0	3
Park et al., 2015⁸²	1	1	1	1	1	0	0	5
Perez, 2013⁸³	1	1	1	1	1	0	1	6
Qiu et al., 2016⁸⁴	1	0	1	1	1	1	0	5
Steffens et al., 2002⁸⁵	1	0	1	1	1	1	0	5
Teodorczuk et al., 2007 ⁸⁶	0	1	1	0	1	0	1	4
Teodorczuk et al., 2010 ⁸⁷	0	1	1	0	1	0	1	4
van Sloten et al., 2015⁸⁸	1	1	1	1	1	1	1	7
Versluis et al., 2006⁸⁹	1	1	1	1	1	0	1	6

Newcastle-Ottawa Scale score (NOS) for studies on the association between cerebral small vessel disease and incident depression. For an explanation of the individual items, see the provided adjusted NOS (Appendix C). Maximal NOS score is 8. Articles indicated with bold are of high methodologic quality (NOS score >4). S1= Representativeness of the cohort; S2 = ascertainment of determinant; S3= presence of outcome of interest at start of study; C1= Comparability of cohorts: use of adjustments; O1= assessment of outcome; O2= follow up duration; O3= adequacy of follow up.

Table S5.4 – Newcastle-Ottawa Scale scores for studies on the association between cerebral small vessel disease and incident all-cause mortality

Study	S1	S2	S3	C1	O1	O2	O3	Total score
Akoudad et al., 2015¹	1	1	1	2	1	1	1	8
Altmann-Schneider et al., 2011⁹⁰	0	1	1	2	1	1	1	7
Andersen et al., 2016 ²	0	1	1	1	0	0	1	4
Andersen et al., 2017³	0	1	1	0	1	1	1	5
Appelros et al., 2005 ⁴	0	0	1	0	1	1	0	3
Benedictus et al., 2015 ⁵	0	0	1	1	1	0	1	4
Bokura et al., 2006⁸	1	0	1	2	0	1	0	5
Boulanger et al., 2006 ⁹	0	1	1	0	0	0	1	3
Conijn et al., 2011¹¹	0	1	1	2	1	1	1	7
Debette et al., 2010¹²	1	0	1	2	1	1	0	6
Fan et al., 2003 ¹³	0	1	1	0	0	0	1	3
Firbank et al., 2012 ⁴⁸	0	1	1	0	0	0	0	2
Fu et al., 2005 ¹⁴	0	1	1	0	0	0	1	3
Haji et al., 2015 ¹⁷	0	0	1	0	1	0	0	2
Henneman et al., 2009 ⁹¹	0	1	1	1	1	0	0	4
Ikram et al., 2009⁸⁰	1	1	1	1	1	1	1	7
Inzitari et al., 2009 ¹⁹	0	0	1	0	0	0	0	1
Kerber et al., 2006⁹²	1	1	1	0	1	1	1	6
Kuller et al., 2007⁹³	1	0	1	2	1	1	1	7
Kwa et al., 2012 ²⁷	0	0	1	1	0	0	1	3
Lavretsky et al., 2010 ⁹⁴	0	1	1	0	0	1	0	3
Levy et al., 2003⁹⁵	0	1	1	1	1	1	0	5
Mok et al., 2009 ²⁹	0	1	1	0	0	1	1	4
Oksala et al., 2009⁹⁶	0	0	1	1	2	1	1	6
Putala et al., 2011³⁶	0	0	1	1	1	1	1	5
Staff et al., 2010 ⁹⁷	1	0	1	0	1	1	0	4
van der Holst et al., 2016⁹⁸	1	1	1	2	1	1	1	8
van der Veen et al., 2014⁴⁰	0	1	1	2	1	1	0	6
Weber et al., 2012 ⁴¹	0	0	1	0	0	0	0	1
Windham et al., 2015⁴³	1	1	1	2	1	1	1	8
Yamauchi et al., 2002 ⁴⁴	0	0	1	0	1	1	0	3

Newcastle-Ottawa Scale score (NOS) for studies on the association between cerebral small vessel disease and all-cause mortality. For an explanation of the individual items, see the provided adjusted NOS (Appendix C). Maximal NOS score is 8. Articles indicated with bold are of high methodologic quality (NOS score >4). S1= Representativeness of the cohort; S2 = ascertainment of determinant; S3= presence of outcome of interest at start of study; C1= Comparability of cohorts: use of adjustments; O1= assessment of outcome; O2= follow up duration; O3= adequacy of follow up.

Table S6.1 – Heterogeneity for analyses with incident ischaemic and haemorrhagic stroke

	Main analysis	Blank	Blank	Population-based only	High NOS	High NOS	Visual WMHs	Automated WMHs	DWMHs	Lobar CMBs	Unadjusted	First episode	Stroke study population	HRs only	Extreme groups	NOS > 3	NOS > 5	PVHs only	DWMHs only	Silent infarcts	Silent infarcts excluded	Deep CMBs only	Lobar CMBs only
WMHs dichotomous	37		62	38	42	46	0	46		21		49	24	26	37	26	28	76					
WMHs continuous	56			73	26			56		60			56		63	0							
Lacunes	41		47	52	29			10	26		58	56		49	47				39	60			
CMBs	10			14	0				36		12	28		29	0								
Cerebral atrophy																							

Heterogeneity (I^2) in the main and sensitivity analyses for the association of cerebral small vessel disease with incident ischaemic and haemorrhagic stroke. For a description of the sensitivity analyses, see Figures S2.1 to S2.5. Abbreviations: CMBs: cerebral microbleeds; DWMHs: deep white matter hyperintensities; HRs: hazard ratios; ICH: intracerebral haemorrhage; NOS: Newcastle-Ottawa scale score; pop: population; PVHs: periventricular hyperintensities; WMHs: white matter hyperintensities.

56.2 – Heterogeneity for analyses with incident all-cause dementia

	Main analysis	Ischaemic stroke	Population-based only	High-risk study pop	High NOS	Visual WMHs	Automated WMHs	DWMHs	Lobar CMBs	Unadjusted	First episode	Stroke study population	HRs only	Extreme groups	NOS > 3	NOS > 5	PVHs only	DWMHs only	Silent infarcts	Silent infarcts excluded	Deep CMBs only	Lobar CMBs only
WMHs dichotomous	59	36	65	48	60	38	59	43	59	64	37	51	45	68	58	46	0	59				
WMHs continuous	82				24				82	85	49	82		49	49							
Lacunes	48	0		65	9	0				49	57	6	22		37	0			58			
CMBs	54	59	77	58	40				60	61	31	31	39		58					0	63	
Cerebral atrophy	62					62				72			62									

Stroke

	Main analysis																						
	Alzheimer's dementia																						
	Vascular dementia																						
	Population-based only																						
	High-risk study pop																						
	High NOS																						
	Visual WMHs																						
	Automated WMHs																						
	DWMHs																						
	Lobar CMBs																						
	Unadjusted																						
	First episode																						
	Stroke study population																						
	HRs only																						
	Extreme groups																						
	NOS > 3																						
	NOS > 5																						
	PVHs only																						
	DWMHs only																						
	Silent infarcts																						
	Silent infarcts excluded																						
	Deep CMBs only																						
	Lobar CMBs only																						
WMHs dichotomous	46	0	47	0	61	43	46	58	53	67			56	59	50	15	52	35					
WMHs continuous	62	29		41		41			62	69			62		41	41							
Lacunes	47	25		52	0	52				56			50		57	52				57			
CMBs	34	0				51				34	75		34		51								
Cerebral atrophy	34			56		56				58			34										

Dementia

	Main analysis	Blank	Blank	Population-based only	High-risk study pop	High NOS	Visual WMHs	Automated WMHs	DWMHs	Lobar CMBs	Unadjusted	First episode	Stroke study population	HRs only	Extreme groups	NOS > 3	NOS > 5	PVHs only	DWMHs only	Silent infarcts	Silent infarcts excluded	Deep CMBs only	Lobar CMBs only
WMHs dichotomous	0			0	49	0	46	0	39	0	0		22	0	0	0	0						
WMHs continuous	70			72		72			70	69	70			70	80								
Lacunes																							
CMBs																							
Cerebral atrophy	39			39		39				57	39			39									

Depression

	Main analysis	Blank	Blank	Population-based only	High-risk study pop	High NOS	Visual WMHs	Automated WMHs	DWMHs	Lobar CMBs	Unadjusted	First episode	Stroke study population	HRs only	Extreme groups	NOS > 3	NOS > 5	PVHs only	DWMHs only	Silent infarcts	Silent infarcts excluded	Deep CMBs only	Lobar CMBs only
WMHs dichotomous	37			62	38	42	46	0	46	21		49	24	26	37	26	28	76					
WMHs continuous	56				73	26			56	60		56		63	0								
Lacunes	41			47	52	29			10	26		58	56	49	47				39	60			
CMBs	10				14	0				36		12	28		29	0							
Cerebral atrophy																							

Mortality

Heterogeneity (I^2) in the main and sensitivity analyses for the association of cerebral small vessel disease with incident all-cause dementia. For a description of the sensitivity analyses, see Figures S2.1 to S2.5. Abbreviations: CMBs: cerebral microbleeds; DWMHs: deep white matter hyperintensities; HRs: hazard ratios; ICH: intracerebral haemorrhage; NOS: Newcastle-Ottawa scale score; pop: population; PVHs: periventricular hyperintensities; WMHs: white matter hyperintensities.

Table S6.3 – Heterogeneity for analysis with incident depression

	Main analysis	Ischaemic stroke	ICH	Population-based only	High-risk study pop	High NOS	Visual WMHs	Automated WMHs	DWMHs	Lobar CMBs	Unadjusted	First episode	Stroke study population	HRs only	Extreme groups	NOS > 3	NOS > 5	PVHs only	DWMHs only	Silent infarcts	Silent infarcts excluded	Deep CMBs only	Lobar CMBs only
WMHs dichotomous	59	36	65	48	60	38	59	43	59	64	37	51	45	68	58	46	0	59					
WMHs continuous	82					24			82	85	49	82		49	49								
Lacunes	48	0		65	9	0				49	57	6	22		37	0			58				
CMBs	54	59	77	58	40					60	61	31	31	39		58						0	63
Cerebral atrophy	62					62				72			62										

Stroke

	Main analysis	Alzheimer's dementia	Vascular dementia	Population-based only	High-risk study pop	High NOS	Visual WMHs	Automated WMHs	DWMHs	Lobar CMBs	Unadjusted	First episode	Stroke study population	HRs only	Extreme groups	NOS > 3	NOS > 5	PVHs only	DWMHs only	Silent infarcts	Silent infarcts excluded	Deep CMBs only	Lobar CMBs only
WMHs dichotomous	46	0	47	0	61	43	46	58	53	67			56	59	50	15	52	35					
WMHs continuous	62	29		41		41			62	69			62		41	41							
Lacunes	47	25		52	0	52				56			50		57	52				57			
CMBs	34	0				51				34	75			34		51							
Cerebral atrophy	34			56		56				58			34										

Dementia

	Main analysis	Blank	Blank	Population-based only	High-risk study pop	High NOS	Visual WMHs	Automated WMHs	DWMHs	Lobar CMBs	Unadjusted	First episode	Stroke study population	HRs only	Extreme groups	NOS > 3	NOS > 5	PVHs only	DWMHs only	Silent infarcts	Silent infarcts excluded	Deep CMBs only	Lobar CMBs only
WMHs dichotomous	0			0	49	0	46	0	39	0	0			22	0	0	0	0					
WMHs continuous	70			72		72			70	69	70				70	80							
Lacunes																							
CMBs																							
Cerebral atrophy	39			39		39				57	39				39								

Depression

	Main analysis	Blank	Blank	Population-based only	High-risk study pop	High NOS	Visual WMHs	Automated WMHs	DWMHs	Lobar CMBs	Unadjusted	First episode	Stroke study population	HRs only	Extreme groups	NOS > 3	NOS > 5	PVHs only	DWMHs only	Silent infarcts	Silent infarcts excluded	Deep CMBs only	Lobar CMBs only
WMHs dichotomous	37			62	38	42	46	0	46	21		49	24	26	37	26	28	76					
WMHs continuous	56			73	26				56	60				56		63	0						
Lacunes	41			47	52	29			10	26		58	56		49	47			39	60			
CMBs	10				14	0				36		12	28		29	0							
Cerebral atrophy																							

Mortality

Heterogeneity (I^2) in the main and sensitivity analyses for the association of cerebral small vessel disease with incident depression. For a description of the sensitivity analyses, see Figures S2.1 to S2.5. Abbreviations: CMBs: cerebral microbleeds; DWMHs: deep white matter hyperintensities; HRs: hazard ratios; ICH: intracerebral haemorrhage; NOS: Newcastle-Ottawa scale score; pop: population; PVHs: periventricular hyperintensities; WMHs: white matter hyperintensities.

Table S6.4 – Heterogeneity for analysis with all-cause mortality

	Main analysis	Ischaemic stroke	ICH	Population-based only	High-risk study pop	High NOS	Visual WMHs	Automated WMHs	DWMHs	Lobar CMBs	Unadjusted	First episode	Stroke study population	HRs only	Extreme groups	NOS > 3	NOS > 5	PVHs only	DWMHs only	Silent infarcts	Silent infarcts excluded	Deep CMBs only	Lobar CMBs only
WMHs dichotomous	59	36	65	48	60	38	59	43	59	64	37	51	45	68	58	46	0	59					
WMHs continuous	82								82	85	49	82		49	49								
Lacunes	48	0		65	9	0				49	57	6	22		37	0			58				
CMBs	54	59	77	58	40					60	61	31	31	39	58						0	63	
Cerebral atrophy	62					62				72			62										

Stroke

	Main analysis	Alzheimer's dementia	Vascular dementia	Population-based only	High-risk study pop	High NOS	Visual WMHs	Automated WMHs	DWMHs	Lobar CMBs	Unadjusted	First episode	Stroke study population	HRs only	Extreme groups	NOS > 3	NOS > 5	PVHs only	DWMHs only	Silent infarcts	Silent infarcts excluded	Deep CMBs only	Lobar CMBs only
WMHs dichotomous	46	0	47	0	61	43	46	58	53	67			56	59	50	15	52	35					
WMHs continuous	62	29		41	41				62	69			62		41	41							
Lacunes	47	25		52	0	52				56			50		57	52				57			
CMBs	34	0				51				34	75		34		51								
Cerebral atrophy	34			56		56				58			34										

Dementia

	Main analysis	Blank	Blank	Population-based only	High-risk study pop	High NOS	Visual WMHs	Automated WMHs	DWMHs	Lobar CMBs	Unadjusted	First episode	Stroke study population	HRs only	Extreme groups	NOS > 3	NOS > 5	PVHs only	DWMHs only	Silent infarcts	Silent infarcts excluded	Deep CMBs only	Lobar CMBs only
WMHs dichotomous	0			0	49	0	46	0	39	0	0		22	0	0	0	0	0					
WMHs continuous	70			72		72			70	69	70				70	80							
Lacunes																							
CMBs																							
Cerebral atrophy	39			39		39				57	39				39								

Depression

	Main analysis	Blank	Blank	Population-based only	High-risk study pop	High NOS	Visual WMHs	Automated WMHs	DWMHs	Lobar CMBs	Unadjusted	First episode	Stroke study population	HRs only	Extreme groups	NOS > 3	NOS > 5	PVHs only	DWMHs only	Silent infarcts	Silent infarcts excluded	Deep CMBs only	Lobar CMBs only
WMHs dichotomous	37			62	38	42	46	0	46	21			49	24	26	37	26	28	76				
WMHs continuous	56			73	26				56	60			56		63	0							
Lacunes	41			47	52	29			10	26			58	56	49	47			39	60			
CMBs	10			14	0					36			12	28	29	0							
Cerebral atrophy																							

Mortality

Heterogeneity (I^2) in the main and sensitivity analyses for the association of cerebral small vessel disease with all-cause mortality. For a description of the sensitivity analyses, see Figures S2.1 to S2.5. Abbreviations: CMBs: cerebral microbleeds; DWMHs: deep white matter hyperintensities; HRs: hazard ratios; ICH: intracerebral haemorrhage; NOS: Newcastle-Ottawa scale score; pop: population; PVHs: periventricular hyperintensities; WMHs: white matter hyperintensities.

Table S7 –Egger’s Tests to detect significant funnel plot asymmetry

Association	T-value	df	p-value
WMHs on a dichotomous scale with ischaemic or haemorrhagic stroke	4.70	21	0.0001
Lacunes with ischaemic or haemorrhagic stroke	2.55	13	0.02
CMBs with ischaemic or haemorrhagic stroke	3.01	13	0.01
WMHs on a dichotomous scale with all-cause dementia	0.22	13	0.83
Lacunes with all-cause dementia	2.00	8	0.08
WMHs on a dichotomous scale with all-cause mortality	2.33	14	0.04
Lacunes with all-cause mortality	-0.33	9	0.75
CMBs with all-cause mortality	-0.56	8	0.59

Tests were done when more than 10 studies were available per analysis. Abbreviations: CMBs: cerebral microbleeds; df: degrees of freedom; WMHs: white matter hyperintensities.

Table S8- Trim and fill test for analyses with significant funnel plot asymmetry

Association	Estimated hazard ratio	Estimated 95% CI interval		Estimated number of missing studies
		Lower limit	Upper limit	
WMHs on a dichotomous scale with stroke	1.94	1.54	2.45	7
Lacunes with stroke	2.36	1.84	3.02	4
CMBs with stroke	1.62	1.23	2.13	4
WMHs on a dichotomous scale with mortality	1.68	1.48	1.90	4

Abbreviations: CI: confidence interval; CMBs: cerebral microbleeds; WMHs: white matter hyperintensities.

Figure S1.1a, Forest plot for the association between white matter hyperintensities on a dichotomous scale and incident ischaemic and haemorrhagic stroke

*data from the original cohort of the Framingham Health Study, the main study used data from the Framingham Offspring study.

Figure S1.1b, Forest plot for the association between white matter hyperintensities on a continuous scale and incident ischaemic and haemorrhagic stroke

*data from the original cohort of the Framingham Health Study, the main study used data from the Framingham Offspring study.

Figure S1.1c, Forest plot for the association between lacunes and incident ischaemic and haemorrhagic stroke **Figure S1.1d,** Forest plot for the association between cerebral microbleeds and incident ischaemic and haemorrhagic stroke **Figure S1.1e,** Forest plot for the association between total cerebral atrophy and incident ischaemic and haemorrhagic stroke

*data from the original cohort of the Framingham Health Study, the main study used data from the Framingham Offspring study.

Figure S1.1f, Forest plot for the association between combinations of cerebral small vessel disease features and incident ischaemic and haemorrhagic stroke **Figure S1.2a**, Forest plot for the association between white matter hyperintensities on a dichotomous scale and incident all-cause dementia

*data from the original cohort of the Framingham Health Study, the main study used data from the Framingham Offspring study.

Figure S1.2b, Forest plot for the association between white matter hyperintensities on a continuous scale and incident all-cause dementia

*data from the original cohort of the Framingham Health Study, the main study used data from the Framingham Offspring study.

Figure S1.2c, Forest plot for the association between lacunes and incident all-cause dementia **Figure S1.2d,** Forest plot for the association between cerebral microbleeds and incident all-cause dementia **Figure S1.2e,** Forest plot for the association between total cerebral atrophy and incident all-cause dementia

*data from the original cohort of the Framingham Health Study, the main study used data from the Framingham Offspring study.

Figure S1.3a, Forest plot for the association between white matter hyperintensities on a dichotomous scale and incident depression

Figure S1.3b, Forest plot for the association between white matter hyperintensities on a continuous scale and incident depression **Figure S1.3c,** Forest plot for the association between total cerebral atrophy and incident depression **Figure S1.4a,** Forest plot for the association between white matter hyperintensities on a dichotomous scale and all-cause mortality

Figure S1.4b, Forest plot for the association between white matter hyperintensities on a continuous scale and all-cause mortality **Figure S1.4c,** Forest plot for the association between lacunes and all-cause mortality **Figure S1.4d,** Forest plot for the association between cerebral microbleeds and all-cause mortality

Figures S1.1 to S1.4. Forest plots for the associations between features of cerebral small vessel disease and incident ischaemic and haemorrhagic stroke, all-cause dementia and depression, and all-cause mortality. Abbreviations: CI: confidence interval; df: degrees of freedom; IV: inverse variance; SE: standard error;

Figure S2.1 – Pooled hazard ratios for sensitivity analyses for white matter hyperintensities on a dichotomous scale (High vs. low)*

Figures S2.1. Pooled hazard ratios (HRs) (95% confidence intervals) for the association between features of white matter hyperintensities on a dichotomous scale and incident ischaemic and haemorrhagic stroke, all-cause dementia, depression, and all-cause mortality. *High vs. low as defined by the individual studies. Results were pooled when at least 3 studies were available. The following pre-specified analyses were done: analyses were repeated using only subtypes of stroke (ischaemic and haemorrhage) or dementia (Alzheimer’s disease and presumed vascular dementia) as the outcome; using only population-based cohort studies; using only studies with high-risk populations; using only high-quality studies (defined as Newcastle-Ottawa Scale (NOS) score >4); using only studies that measured white matter hyperintensities (WMHs) on an observer-rated semi-quantitative scale; using only studies that measured WMHs on an automated quantitative scale; replacing the risk estimates for periventricular WMHs with those for deep WMHs; and replacing adjusted risk estimates with unadjusted risk estimates. The following post hoc analyses were done: analyses were repeated using only studies with a first episode of stroke or depression; using only studies with stroke patients; using only hazard ratios (i.e. excluding studies that reported odds ratios or relative risks); using risk estimates comparing highest vs. lowest categories of WMHs (irrespective of the number of participants per category) (indicated in the figures as “extreme groups”), instead of risk estimates comparing higher and lower categories with the highest number of participants and events; using only studies with NOS score >3; using only studies with NOS score >5; using only risk estimates of periventricular white matter hyperintensities (PVHs); and using only risk estimates of deep white matter hyperintensities (DWMHs). Abbreviations: AD: Alzheimer’s disease; CMBs: cerebral microbleeds; DWMHs: deep white matter hyperintensities; HRs: hazard ratios; ICH: intracerebral haemorrhage; IS: ischaemic stroke; NOS: Newcastle-Ottawa scale score; pop: population; PVHs: periventricular hyperintensities; VaD: presumed vascular dementia; WMHs: white matter hyperintensities.

Figure S2.2 – Pooled hazard ratios for sensitivity analyses for white matter hyperintensities on a continuous scale (per 1 SD increase)

Figures S2.2. Pooled hazard ratios (HRs) (95% confidence intervals) for the association between white matter hyperintensities on a continuous scale and incident ischaemic and haemorrhagic stroke, all-cause dementia, depression, and all-cause mortality. Results were pooled when at least 3 studies were available. The following pre-specified analyses were done: analyses were repeated using only subtypes of stroke (ischaemic and haemorrhage) or dementia (Alzheimer’s disease and presumed vascular dementia) as the outcome; using only population-based cohort studies; using only studies with high-risk populations; using only high-quality studies (defined as Newcastle-Ottawa Scale (NOS) score >4); replacing the risk estimates for periventricular WMHs with those for deep WMHs; and replacing adjusted risk estimates with unadjusted risk estimates. The following post hoc analyses were done: analyses were repeated using only studies with a first episode of stroke or depression; using only studies with stroke patients; using only hazard ratios (i.e. excluding studies that reported odds ratios or relative risks); using only studies with NOS score >3; using only studies with NOS score >5; using only risk estimates of periventricular white matter hyperintensities (PVHs); and using only risk estimates of deep white matter hyperintensities (DWMHs). Abbreviations: AD: Alzheimer’s disease; DWMHs: deep white matter hyperintensities; HRs: hazard ratios; ICH: intracerebral haemorrhage; IS: ischaemic stroke; NOS: Newcastle-Ottawa scale score; pop: population; PVHs: periventricular hyperintensities; SD: standard deviation; VaD: presumed vascular dementia; WMHs: white matter hyperintensities.

Figure S2.3 – Pooled hazard ratios for sensitivity analyses for lacunes (absence vs. presence)

Figures S2.3. Pooled hazard ratios (HRs) (95% confidence intervals) for the association between lacunes and incident ischaemic and haemorrhagic stroke, all-cause dementia, depression, and all-cause mortality. Results were pooled when at least 3 studies were available. The following pre-specified analyses were done: analyses were repeated using only subtypes of stroke (ischaemic and haemorrhage) or dementia (Alzheimer’s disease and presumed vascular dementia) as the outcome; using only population-based cohort studies; using only studies with high-risk populations; using only high-quality studies (defined as Newcastle-Ottawa Scale (NOS) score >4); and replacing adjusted risk estimates with unadjusted risk estimates. The following post hoc analyses were done: analyses were repeated using only studies with a first episode of stroke or depression; using only studies with stroke patients; using only hazard ratios (i.e. excluding studies that reported odds ratios or relative risks); using only risk estimates for silent infarcts; excluding studies that reported risk estimates for silent infarcts only; using only studies with NOS score >3; and using only studies with NOS score >5. Abbreviations: AD: Alzheimer’s disease; HRs: hazard ratios; ICH: intracerebral haemorrhage; IS: ischaemic stroke; NOS: Newcastle-Ottawa scale score; pop: population; VaD: presumed vascular dementia.

Figure S2.4 – Pooled hazard ratios for sensitivity analyses for cerebral microbleeds (absence vs. presence)

Figures S2.4. Pooled hazard ratios (HRs) (95% confidence intervals) for the association between cerebral microbleeds and incident ischaemic and haemorrhagic stroke, all-cause dementia, depression, and all-cause mortality. Results were pooled when at least 3 studies were available. The following pre-specified analyses were done: analyses were repeated using only subtypes of stroke (ischaemic and haemorrhage) or dementia (Alzheimer’s disease and presumed vascular dementia) as the outcome; using only population-based cohort studies; using only studies with high-risk populations; using only high-quality studies (defined as Newcastle-Ottawa Scale (NOS) score >4); replacing the risk estimates for deep cerebral microbleeds (CMBs) with those for lobar CMBs; and replacing adjusted risk estimates with unadjusted risk estimates. The following post hoc analyses were done: analyses were repeated using only studies with a first episode of stroke or depression; using only studies with stroke patients; using only hazard ratios (i.e. excluding studies that reported odds ratios or relative risks); using only studies with NOS score >3; using only studies with NOS score >5; using only risk estimates for deep CMBs; and using only risk estimates for lobar CMBs. Abbreviations: AD: Alzheimer’s disease; CMBs: cerebral microbleeds; HRs: hazard ratios; ICH: intracerebral haemorrhage; IS: ischaemic stroke; NOS: Newcastle-Ottawa scale score; pop: population; VaD: presumed vascular dementia.

Figure S2.5 – Pooled hazard ratios for sensitivity analyses for total cerebral atrophy (per 1 SD decrease)

Figures S2.5. Pooled hazard ratios (HRs) (95% confidence intervals) for the association between cerebral atrophy and incident ischaemic and haemorrhagic stroke, all-cause dementia, depression, and all-cause mortality. Results were pooled when at least 3 studies were available. The following pre-specified analyses were done: analyses were repeated using only subtypes of stroke (ischaemic and haemorrhage) or dementia (Alzheimer’s disease and presumed vascular dementia) as the outcome; using only population-based cohort studies; using only studies with high-risk populations; using only high-quality studies (defined as Newcastle-Ottawa Scale (NOS) score >4); and replacing adjusted risk estimates with unadjusted risk estimates. The following post hoc analyses were done: analyses were repeated using only studies with a first episode of stroke or depression; using only studies with stroke patients; using only hazard ratios (i.e. excluding studies that reported odds ratios or relative risks); using only studies with NOS score >3; and using only studies with NOS score >5. Abbreviations: AD: Alzheimer’s disease; HRs: hazard ratios; ICH: intracerebral haemorrhage; IS: ischaemic stroke; NOS: Newcastle-Ottawa scale score; pop: population; SD: standard deviation; VaD: presumed vascular dementia.

Figure S3 – Funnel plots for analyses with significant funnel plot asymmetry

Funnel plot for the association between white matter hyperintensities on a dichotomous scale and incident haemorrhagic and ischaemic stroke (A), lacunes and incident haemorrhagic and ischaemic stroke (B), cerebral microbleeds and incident haemorrhagic and ischaemic stroke (C), and white matter hyperintensities on a dichotomous scale and all-cause mortality (D). Filled dots correspond to the observed risk estimates, blank dots represent missed studies imputed using the trim and fill test. Diagonal lines indicate the expected 95% confidence intervals around the summary estimate. Hazard ratios are plotted on a natural log scale.

References

1. Akoudad S, Portegies MLP, Koudstaal PJ, Hofman A, Van Der Lugt A, Ikram MA and Vernooij MW. Cerebral Microbleeds Are Associated with an Increased Risk of Stroke: The Rotterdam Study. *Circulation*. 2015;132:509-516.
2. Andersen SD, Skjoth F, Yavarian Y, Bach FW, Lip GY and Larsen TB. Multiple Silent Lacunes Are Associated with Recurrent Ischemic Stroke. *Cerebrovasc Dis*. 2016;42:73-80.
3. Andersen SD, Larsen TB, Gorst-Rasmussen A, Yavarian Y, Lip GY and Bach FW. White Matter Hyperintensities Improve Ischemic Stroke Recurrence Prediction. *Cerebrovasc Dis*. 2017;43:17-24.
4. Appelros P, Samuelsson M and Lindell D. Lacunar infarcts: functional and cognitive outcomes at five years in relation to MRI findings. *Cerebrovasc Dis*. 2005;20:34-40.
5. Benedictus MR, Prins ND, Goos JD, Scheltens P, Barkhof F and van der Flier WM. Microbleeds, Mortality, and Stroke in Alzheimer Disease: The MISTRAL Study. *JAMA Neurol*. 2015;72:539-45.
6. Bernick C, Kuller L, Dulberg C, Longstreth WT, Jr., Manolio T, Beauchamp N and Price T. Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. *Neurology*. 2001;57:1222-9.
7. Bokura H, Saika R, Yamaguchi T, Nagai A, Oguro H, Kobayashi S and Yamaguchi S. Microbleeds are associated with subsequent hemorrhagic and ischemic stroke in healthy elderly individuals. *Stroke*. 2011;42:1867-1871.
8. Bokura H, Kobayashi S, Yamaguchi S, Iijima K, Nagai A, Toyoda G, Oguro H and Takahashi K. Silent brain infarction and subcortical white matter lesions increase the risk of stroke and mortality: a prospective cohort study. *J Stroke Cerebrovasc Dis*. 2006;15:57-63.
9. Boulanger JM, Coutts SB, Eliasziw M, Gagnon AJ, Simon JE, Subramaniam S, Sohn CH, Scott J and Demchuk AM. Cerebral microhemorrhages predict new disabling or fatal strokes in patients with acute ischemic stroke or transient ischemic attack. *Stroke*. 2006;37:911-914.
10. Buyck JF, Dufouil C, Mazoyer B, Maillard P, Ducimetiere P, Alperovitch A, Bousser MG, Kurth T and Tzourio C. Cerebral white matter lesions are associated with the risk of stroke but not with other vascular events: the 3-City Dijon Study. *Stroke*. 2009;40:2327-31.
11. Conijn MM, Kloppenborg RP, Algra A, Mali WP, Kappelle LJ, Vincken KL, van der Graaf Y, Geerlings MI and Group SS. Cerebral small vessel disease and risk of death, ischemic stroke, and cardiac complications in patients with atherosclerotic disease: the Second Manifestations of ARterial disease-Magnetic Resonance (SMART-MR) study. *Stroke*. 2011;42:3105-9.
12. Dettette S, Beiser A, Decarli C, Au R, Himali JJ, Kelly-Hayes M, Romero JR, Kase CS, Wolf PA and Seshadri S. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: The framingham offspring study. *Stroke*. 2010;41:600-606.
13. Fan YH, Zhang L, Lam WWM, Mok VCT and Wong KS. Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke. *Stroke*. 2003;34:2459-2462.
14. Fu JH, Lu CZ, Hong Z, Dong Q, Luo Y and Wong KS. Extent of white matter lesions is related to acute subcortical infarcts and predicts further stroke risk in patients with first ever ischaemic stroke. *J Neurol Neurosurg Psychiatry*. 2005;76:793-796.
15. Gerdes VE, Kwa VI, ten Cate H, Brandjes DP, Buller HR and Stam J. Cerebral white matter lesions predict both ischemic strokes and myocardial infarctions in patients with established atherosclerotic disease. *Atherosclerosis*. 2006;186:166-72.

16. Gioia LC, Tollard E, Dubuc V, Lanthier S, Deschaintre Y, Chagnon M and Poppe AY. Silent ischemic lesions in young adults with first stroke are associated with recurrent stroke. *Neurology*. 2012;79:1208-14.
17. Haji S, Zubair A, Planhard R and Flemming K. Clinical relevance of cerebral microbleeds in patients with atrial fibrillation and stroke. *Stroke*. 2015;46.
18. Imaizumi T, Inamura S, Nomura T, Kanno A and Kim SN. The Severity of White Matter Lesions Possibly Influences Stroke Recurrence in Patients with Histories of Lacunar Infarctions. *J Stroke Cerebrovasc Dis*. 2015;24:2154-60.
19. Inzitari D, Pracucci G, Poggesi A, Carlucci G, Barkhof F, Chabriat H, Erkinjuntti T, Fazekas F, Ferro JM, Hennerici M, Langhorne P, O'Brien J, Scheltens P, Visser MC, Wahlund LO, Waldemar G, Wallin A and Pantoni L. Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. *BMJ*. 2009;339:b2477.
20. Ishikawa J, Tamura Y, Hoshide S, Eguchi K, Ishikawa S, Shimada K and Kario K. Low-grade inflammation is a risk factor for clinical stroke events in addition to silent cerebral infarcts in Japanese older hypertensives: the Jichi Medical School ABPM Study, wave 1. *Stroke*. 2007;38:911-7.
21. Kaffashian S, Soumare A, Zhu YC, Mazoyer B, Debette S and Tzourio C. Long-Term Clinical Impact of Vascular Brain Lesions on Magnetic Resonance Imaging in Older Adults in the Population. *Stroke*. 2016;47:2865-2869.
22. Kaffashian S, Tzourio C, Zhu YC, Mazoyer B and Debette S. Differential Effect of White-Matter Lesions and Covert Brain Infarcts on the Risk of Ischemic Stroke and Intracerebral Hemorrhage. *Stroke*. 2016;47:1923-5.
23. Kario K, Shimada K, Schwartz JE, Matsuo T, Hoshide S and Pickering TG. Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. *J Am Coll Cardiol*. 2001;38:238-45.
24. Kobayashi S, Okada K, Koide H, Bokura H and Yamaguchi S. Subcortical silent brain infarction as a risk factor for clinical stroke. *Stroke*. 1997;28:1932-9.
25. Kuller LH, Longstreth WT, Jr., Arnold AM, Bernick C, Bryan RN, Beauchamp NJ, Jr. and Cardiovascular Health Study Collaborative Research G. White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke. *Stroke*. 2004;35:1821-5.
26. Kumral E, Gulluoglu H, Alakbarova N, Karaman B, Deveci EE, Bayramov A, Evyapan D, Gokcay F and Orman M. Association of leukoaraiosis with stroke recurrence within 5 years after initial stroke. *J Stroke Cerebrovasc Dis*. 2015;24:573-82.
27. Kwa VIH, Algra A, Brundel M, Bouvy W and Kappelle LJ. Microbleeds as a predictor of intracerebral hemorrhage in patients receiving oral antithrombotic drugs after a TIA or minor ischemic stroke: A prospective cohort study in Western outpatients. *Cerebrovasc Dis*. 2012;33:779-780.
28. Melkas S, Sibolt G, Oksala NKJ, Putaala J, Pohjasvaara T, Kaste M, Karhunen PJ and Erkinjuntti T. Extensive white matter changes predict stroke recurrence up to 5 years after a first-ever ischemic stroke. *Cerebrovasc Dis*. 2012;34:191-198.
29. Mok VC, Lau AY, Wong A, Lam WW, Chan A, Leung H, Wong E, Soo Y, Leung T and Wong LK. Long-term prognosis of Chinese patients with a lacunar infarct associated with small vessel disease: a five-year longitudinal study. *Int J Stroke*. 2009;4:81-8.
30. Naganuma T, Takemoto Y, Shoji T, Shima H, Ishimura E, Okamura M and Nakatani T. Cerebral white matter hyperintensity predicts cardiovascular events in haemodialysis patients. *Nephrology*. 2013;18:676-81.

31. Naganuma T, Takemoto Y, Shoji T, Ishimura E, Okamura M and Nakatani T. Cerebral Microbleeds Predict Intracerebral Hemorrhage in Hemodialysis Patients. *Stroke*. 2015;46:2107-12.
32. Naka H, Nomura E, Takahashi T, Wakabayashi S, Mimori Y, Kajikawa H, Kohriyama T and Matsumoto M. Combinations of the presence or absence of cerebral microbleeds and advanced white matter hyperintensity as predictors of subsequent stroke types. *AJNR Am J Neuroradiol*. 2006;27:830-5.
33. Nishikawa T, Ueba T, Kajiwaru M, Fujisawa I, Miyamatsu N and Yamashita K. Cerebral microbleeds predict first-ever symptomatic cerebrovascular events. *Clin Neurol Neurosurg*. 2009;111:825-8.
34. Ntaios G, Lip GYH, Lambrou D, Papavasileiou V, Manios E, Milionis H, Spengos K, Makaritsis K and Vemmos K. Leukoaraiosis and stroke recurrence risk in patients with and without atrial fibrillation. *Neurology*. 2015;84:1213-1219.
35. Poels MM, Steyerberg EW, Wieberdink RG, Hofman A, Koudstaal PJ, Ikram MA and Breteler MM. Assessment of cerebral small vessel disease predicts individual stroke risk. *J Neurol Neurosurg Psychiatry*. 2012;83:1174-9.
36. Putaala J, Haapaniemi E, Kurkinen M, Salonen O, Kaste M and Tatlisumak T. Silent brain infarcts, leukoaraiosis, and long-term prognosis in young ischemic stroke patients. *Neurology*. 2011;76:1742-9.
37. Smith EE, Gurol ME, Eng JA, Engel CR, Nguyen TN, Rosand J and Greenberg SM. White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage. *Neurology*. 2004;63:1606-12.
38. Soo YO, Yang SR, Lam WW, Wong A, Fan YH, Leung HH, Chan AY, Leung C, Leung TW and Wong LK. Risk vs benefit of anti-thrombotic therapy in ischaemic stroke patients with cerebral microbleeds. *J Neurol*. 2008;255:1679-86.
39. Thijs V, Lemmens R, Schoofs C, Gerner A, Van Damme P, Schrooten M and Demaerel P. Microbleeds and the risk of recurrent stroke. *Stroke*. 2010;41:2005-2009.
40. van der Veen PH, Muller M, Vincken KL, Mali WP, van der Graaf Y and Geerlings MI. Brain volumes and risk of cardiovascular events and mortality. The SMART-MR study. *Neurobiol Aging*. 2014;35:1624-31.
41. Weber R, Weimar C, Wanke I, Moller-Hartmann C, Gizewski ER, Blatchford J, Hermansson K, Demchuk AM, Forsting M, Sacco RL, Saver JL, Warach S, Diener HC, Diehl A and Group PRIS. Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) imaging substudy. *Stroke*. 2012;43:350-5.
42. Weinstein G, Beiser AS, Decarli C, Au R, Wolf PA and Seshadri S. Brain imaging and cognitive predictors of stroke and alzheimer disease in the framingham heart study. *Stroke*. 2013;44:2787-2794.
43. Windham BG, Deere B, Griswold ME, Wang W, Bezerra DC, Shibata D, Butler K, Knopman D, Gottesman RF, Heiss G and Mosley TH. Small brain lesions and incident stroke and mortality: A cohort study. *Ann Intern Med*. 2015;163:22-31.
44. Yamauchi H, Fukuda H and Oyanagi C. Significance of white matter high intensity lesions as a predictor of stroke from arteriolosclerosis. *J Neurol Neurosurg Psychiatry*. 2002;72:576-582.
45. Akoudad S, Wolters FJ, Viswanathan A, de Bruijn RF, van der Lugt A, Hofman A, Koudstaal PJ, Ikram MA and Vernooij MW. Association of Cerebral Microbleeds With Cognitive Decline and Dementia. *JAMA Neurol*. 2016;73:934-43.
46. Bombois S, Debette S, Bruandet A, Delbeuck X, Delmaire C, Leys D and Pasquier F. Vascular subcortical hyperintensities predict conversion to vascular and mixed dementia in MCI patients. *Stroke*. 2008;39:2046-51.

47. DeCarli C, Mungas D, Harvey D, Reed B, Weiner M, Chui H and Jagust W. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. *Neurology*. 2004;63:220-7.
48. Firbank MJ, Allan LM, Burton EJ, Barber R, O'Brien JT and Kalara RN. Neuroimaging predictors of death and dementia in a cohort of older stroke survivors. *J Neurol Neurosurg Psychiatry*. 2012;83:263-7.
49. Geroldi C, Rossi R, Calvagna C, Testa C, Bresciani L, Binetti G, Zanetti O and Frisoni GB. Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment. *J Neurol Neurosurg Psychiatry*. 2006;77:1219-22.
50. Godin O, Tzourio C, Rouaud O, Zhu Y, Maillard P, Pasquier F, Crivello F, Alperovitch A, Mazoyer B and Dufouil C. Joint effect of white matter lesions and hippocampal volumes on severity of cognitive decline: the 3C-Dijon MRI study. *J Alzheimers Dis*. 2010;20:453-63.
51. Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P and Goldberg TE. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. *Arch Gen Psychiatry*. 2011;68:961-9.
52. Ikram MA, Vrooman HA, Vernooij MW, Heijer Td, Hofman A, Niessen WJ, van der Lugt A, Koudstaal PJ and Breteler MMB. Brain tissue volumes in relation to cognitive function and risk of dementia. *Neurobiol Aging*. 2010;31:378-386.
53. Kantarci K, Weigand SD, Przybelski SA, Shiung MM, Whitwell JL, Negash S, Knopman DS, Boeve BF, O'Brien PC, Petersen RC and Jack CR, Jr. Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS. *Neurology*. 2009;72:1519-25.
54. Kim S, Choi SH, Lee YM, Kim MJ, Kim YD, Kim JY, Park JH, Myung W, Na HR, Han HJ, Shim YS, Kim JH, Yoon SJ, Kim SY and Kim DK. Periventricular white matter hyperintensities and the risk of dementia: a CREDOS study. *Int Psychogeriatr*. 2015;27:2069-77.
55. Kitagawa K, Miwa K, Yagita Y, Okazaki S, Sakaguchi M and Mochizuki H. Association between carotid stenosis or lacunar infarction and incident dementia in patients with vascular risk factors. *Eur J Neurol*. 2015;22:187-192.
56. Korf ES, Wahlund LO, Visser PJ and Scheltens P. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. *Neurology*. 2004;63:94-100.
57. Kuller LH. [Risk factors for dementia in the Cardiovascular Health Study cognition study]. *Rev Neurol*. 2003;37:122-6.
58. Lopez OL, Klunk WE, Mathis C, Coleman RL, Price J, Becker JT, Aizenstein HJ, Snitz B, Cohen A, Ikonomic M, McDade E, DeKosky ST, Weissfeld L and Kuller LH. Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old. *Neurology*. 2014;83:1804-11.
59. Meguro K, Ishii H, Kasuya M, Akanuma K, Meguro M, Kasai M, Lee E, Hashimoto R, Yamaguchi S and Asada T. Incidence of dementia and associated risk factors in Japan: The Osaki-Tajiri Project. *J Neurol Sci*. 2007;260:175-82.
60. Miwa K, Tanaka M, Okazaki S, Yagita Y, Sakaguchi M, Mochizuki H and Kitagawa K. Multiple or mixed cerebral microbleeds and dementia in patients with vascular risk factors. *Neurology*. 2014;83:646-53.
61. Prasad K, Wiryasaputra L, Ng A and Kandiah N. White matter disease independently predicts progression from mild cognitive impairment to Alzheimer's disease in a clinic cohort. *Dement Geriatr Cogn Disord*. 2011;31:431-4.
62. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A and Breteler MM. Cerebral white matter lesions and the risk of dementia. *Arch Neurol*. 2004;61:1531-4.

63. Prins ND, van der Flier WM, Brashear HR, Knol DL, van de Pol LA, Barkhof F and Scheltens P. Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population. *J Alzheimers Dis.* 2013;36:79-85.
64. Rosano C, Aizenstein HJ, Wu M, Newman AB, Becker JT, Lopez OL and Kuller LH. Focal atrophy and cerebrovascular disease increase dementia risk among cognitively normal older adults. *J Neuroimaging.* 2007;17:148-55.
65. Sluimer JD, van der Flier WM, Karas GB, Fox NC, Scheltens P, Barkhof F and Vrenken H. Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. *Radiology.* 2008;248:590-8.
66. Smith EE, Egorova S, Blacker D, Killiany RJ, Muzikansky A, Dickerson BC, Tanzi RE, Albert MS, Greenberg SM and Guttman CR. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. *Arch Neurol.* 2008;65:94-100.
67. Staekenborg SS, Koedam EL, Henneman WJ, Stokman P, Barkhof F, Scheltens P and van der Flier WM. Progression of mild cognitive impairment to dementia: contribution of cerebrovascular disease compared with medial temporal lobe atrophy. *Stroke.* 2009;40:1269-74.
68. Steffens DC, Payne ME, Greenberg DL, Byrum CE, Welsh-Bohmer KA, Wagner HR and MacFall JR. Hippocampal volume and incident dementia in geriatric depression. *Am J Geriatr Psychiatry.* 2002;10:62-71.
69. Steffens DC, Potter GG, McQuoid DR, Macfall JR, Payne ME, Burke JR, Plassman BL and Welsh-Bohmer KA. Longitudinal magnetic resonance imaging vascular changes, apolipoprotein e genotype, and development of dementia in the neurocognitive outcomes of depression in the elderly study. *Am J Geriatr Psychiatry.* 2007;15:839-849.
70. Stephan BCM, Tzourio C, Auriacombe S, Amieva H, Dufouil C, Alperovitch A and Kurth T. Usefulness of data from magnetic resonance imaging to improve prediction of dementia: Population based cohort study. *BMJ* 2015;350.
71. Stoub TR, DeToledo-Morrell L and Dickerson BC. Parahippocampal white matter volume predicts Alzheimer's disease risk in cognitively normal old adults. *Neurobiol Aging.* 2014;35:1855-1861.
72. Tapiola T, Pennanen C, Tapiola M, Tervo S, Kivipelto M, Hanninen T, Pihlajamaki M, Laakso MP, Hallikainen M, Hamalainen A, Vanhanen M, Helkala EL, Vanninen R, Nissinen A, Rossi R, Frisoni GB and Soininen H. MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study. *Neurobiol Aging.* 2008;29:31-8.
73. van Straaten EC, Harvey D, Scheltens P, Barkhof F, Petersen RC, Thal LJ, Jack CR, Jr. and DeCarli C. Periventricular white matter hyperintensities increase the likelihood of progression from amnesic mild cognitive impairment to dementia. *J Neurol.* 2008;255:1302-8.
74. van Uden IW, van der Holst HM, Tuladhar AM, van Norden AG, de Laat KF, Rutten-Jacobs LC, Norris DG, Claassen JA, van Dijk EJ, Kessels RP and de Leeuw FE. White Matter and Hippocampal Volume Predict the Risk of Dementia in Patients with Cerebral Small Vessel Disease: The RUN DMC Study. *J Alzheimers Dis.* 2015;49:863-73.
75. Verdelho A, Madureira S, Moleiro C, Ferro JM, Santos CO, Erkinjuntti T, Pantoni L, Fazekas F, Visser M, Waldemar G, Wallin A, Hennerici M and Inzitari D. White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. *Neurology.* 2010;75:160-7.
76. Vermeer SE, Prins ND, Den Heijer T, Hofman A, Koudstaal PJ and Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. *N Engl J Med.* 2003;348:1215-1222.

77. Yamamoto Y, Akiguchi I, Oiwa K, Hayashi M, Kasai T and Ozasa K. Twenty-four-hour blood pressure and MRI as predictive factors for different outcomes in patients with lacunar infarct. *Stroke*. 2002;33:297-305.
78. Zhu YC, Dufouil C, Soumare A, Mazoyer B, Chabriat H and Tzourio C. High degree of dilated Virchow-Robin spaces on MRI is associated with increased risk of dementia. *J Alzheimers Dis*. 2010;22:663-72.
79. Godin O, Dufouil C, Maillard P, Delcroix N, Mazoyer B, Crivello F, Alperovitch A and Tzourio C. White matter lesions as a predictor of depression in the elderly: the 3C-Dijon study. *Biol Psychiatry*. 2008;63:663-9.
80. Ikram MA, Vernooij MW, Vrooman HA, Hofman A and Breteler MM. Brain tissue volumes and small vessel disease in relation to the risk of mortality. *Neurobiol Aging*. 2009;30:450-6.
81. Kim S, Woo SY, Kang HS, Lim SW, Choi SH, Myung W, Jeong JH, Lee Y, Hong CH, Kim JH, Na H, Carroll BJ and Kim DK. Factors related to prevalence, persistence, and incidence of depressive symptoms in mild cognitive impairment: vascular depression construct. *Int J Geriatr Psychiatry*. 2016;31:818-26.
82. Park JH, Lee SB, Lee JJ, Yoon JC, Han JW, Kim TH, Jeong HG, Newhouse PA, Taylor WD, Kim JH, Woo JI and Kim KW. Epidemiology of MRI-defined vascular depression: A longitudinal, community-based study in Korean elders. *J Affect Disord*. 2015;180:200-6.
83. Perez HCS. Silent brain infarcts: A cause of depression in the elderly? *Psychiatry Res*. 2013;180-182.
84. Qiu WQ, Himali JJ, Wolf PA, DeCarli DC, Beiser A and Au R. Effects of white matter integrity and brain volumes on late life depression in the Framingham Heart Study. *Int J Geriatr Psychiatry*. 2016.
85. Steffens DC, Krishnan KR, Crump C and Burke GL. Cerebrovascular disease and evolution of depressive symptoms in the cardiovascular health study. *Stroke*. 2002;33:1636-44.
86. Teodorczuk A, O'Brien JT, Firkbank MJ, Pantoni L, Poggesi A, Erkinjuntti T, Wallin A, Wahlund LO, Gouw A, Waldemar G, Schmidt R, Ferro JM, Chabriat H, Bazner H and Inzitari D. White matter changes and late-life depressive symptoms: longitudinal study. *Br J Psychiatry*. 2007;191:212-7.
87. Teodorczuk A, Firkbank MJ, Pantoni L, Poggesi A, Erkinjuntti T, Wallin A, Wahlund LO, Scheltens P, Waldemar G, Schrotter G, Ferro JM, Chabriat H, Bazner H, Visser M, Inzitari D, O'Brien JT and Group L. Relationship between baseline white-matter changes and development of late-life depressive symptoms: 3-year results from the LADIS study. *Psychol Med*. 2010;40:603-10.
88. van Sloten TT, Sigurdsson S, van Buchem MA, Phillips CL, Jonsson PV, Ding J, Schram MT, Harris TB, Gudnason V and Launer LJ. Cerebral Small Vessel Disease and Association With Higher Incidence of Depressive Symptoms in a General Elderly Population: The AGES-Reykjavik Study. *Am J Psychiatry*. 2015;172:570-8.
89. Versluis CE, van der Mast RC, van Buchem MA, Bollen EL, Blauw GJ, Eekhof JA, van der Wee NJ and de Craen AJ. Progression of cerebral white matter lesions is not associated with development of depressive symptoms in elderly subjects at risk of cardiovascular disease: The PROSPER Study. *Int J Geriatr Psychiatry*. 2006;21:375-81.
90. Altmann-Schneider I, Trompet S, de Craen AJ, van Es AC, Jukema JW, Stott DJ, Sattar N, Westendorp RG, van Buchem MA and van der Grond J. Cerebral microbleeds are predictive of mortality in the elderly. *Stroke*. 2011;42:638-44.
91. Henneman WJ, Sluimer JD, Barnes J, van der Flier WM, Sluimer IC, Fox NC, Scheltens P, Vrenken H and Barkhof F. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. *Neurology*. 2009;72:999-1007.

92. Kerber KA, Whitman GT, Brown DL and Baloh RW. Increased risk of death in community-dwelling older people with white matter hyperintensities on MRI. *J Neurol Sci.* 2006;250:33-8.
93. Kuller LH, Arnold AM, Longstreth WT, Jr., Manolio TA, O'Leary DH, Burke GL, Fried LP and Newman AB. White matter grade and ventricular volume on brain MRI as markers of longevity in the cardiovascular health study. *Neurobiol Aging.* 2007;28:1307-15.
94. Lavretsky H, Zheng L, Weiner MW, Mungas D, Reed B, Kramer JH, Jagust W, Chui H and Mack WJ. Association of depressed mood and mortality in older adults with and without cognitive impairment in a prospective naturalistic study. *Am J Psychiatry.* 2010;167:589-597.
95. Levy RM, Steffens DC, McQuoid DR, Provenzale JM, MacFall JR and Krishnan KR. MRI lesion severity and mortality in geriatric depression. *Am J Geriatr Psychiatry.* 2003;11:678-82.
96. Oksala NK, Oksala A, Pohjasvaara T, Vataja R, Kaste M, Karhunen PJ and Erkinjuntti T. Age related white matter changes predict stroke death in long term follow-up. *J Neurol Neurosurg Psychiatry.* 2009;80:762-6.
97. Staff RT, Murray AD, Ahearn T, Salarirad S, Mowat D, Starr JM, Deary IJ, Lemmon H and Whalley LJ. Brain volume and survival from age 78 to 85: the contribution of Alzheimer-type magnetic resonance imaging findings. *J Am Geriatr Soc.* 2010;58:688-95.
98. van der Holst HM, van Uden IW, Tuladhar AM, de Laat KF, van Norden AG, Norris DG, van Dijk EJ, Rutten-Jacobs LC and de Leeuw FE. Factors Associated With 8-Year Mortality in Older Patients With Cerebral Small Vessel Disease: The Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Cohort (RUN DMC) Study. *JAMA Neurol.* 2016;73:402-9.

CHAPTER 3

3

Type 2 diabetes, change in depressive symptoms over time, and cerebral small vessel disease – Longitudinal data of the AGES-Reykjavik Study

SP Rensma, TT van Sloten, J Ding, S Sigurdsson, CDA Stehouwer, V Gudnason, LJ Launer

Abstract

Importance: The association between type 2 diabetes and depression has been frequently reported. However, the pathophysiologic mechanisms for this association are not well known. Cerebral small vessel disease is a consequence of type 2 diabetes and may mediate this association.

Objective: To evaluate whether cerebral small vessel disease explains, or mediates, the association between type 2 diabetes and risk of depressive symptoms.

Design, setting and participants: Longitudinal cohort study in a Iceland general community (Age, Gene/Environment Susceptibility-Reykjavik Study) with examinations from 2002/2006 (baseline) and five years later.

Exposures: Type 2 diabetes defined as self-reported history of type 2 diabetes, use of blood glucose-lowering drugs, or fasting blood glucose level ≥ 7.0 mmol/L, and cerebral small vessel disease load that was quantified with a scale reflecting MRI features of high white matter hyperintensity volume, low total brain parenchyma volume and presence of subcortical infarcts, cerebral microbleeds and large perivascular spaces.

Main Outcome: Change in 15-item Geriatric Depression Scale score between baseline and follow-up.

Results: The study population included 2,135 individuals free of dementia and baseline depression (mean age [SD 4.6] at baseline 74.5 years, 1,245 [58.3%] women and 197 [9.2%] with type 2 diabetes). On average, the GDS-15 score increased 0.4 points (SD 1.6) over time. Baseline type 2 diabetes was associated with a greater increase in depressive symptoms score over time (β 0.316; 95%CI 0.074, 0.558), adjusted for age, sex, education and cardiovascular risk factors. Baseline cerebral small vessel disease features and change of cerebral small vessel disease features over time statistically significantly explained, or mediated, a part of this association.

Conclusions and Relevance: Type 2 diabetes is associated with a greater increase in depressive symptoms score over time, and cerebral small vessel disease in part explains this association.

Introduction

Depression is an important health concern in type 2 diabetes. It is twice as common in individuals with type 2 diabetes as in the general population and is associated with a higher risk of diabetes-related complications and mortality.¹ The factors that mediate the relation between type 2 diabetes and depression are, however, incompletely understood. Cerebral microvascular dysfunction and damage may be such a mediator. Cerebral microvascular dysfunction may disrupt deep and frontal brain structures involved in mood regulation, leading to depressive symptoms.^{2,3}

Cerebral small vessel disease (CSVD), a marker of cerebral microvascular dysfunction and damage,⁴ can be measured on brain magnetic resonance imaging (MRI) as higher white matter hyperintensity (WMH) volume, lower total brain parenchyma volume, subcortical infarcts, cerebral microbleeds, and large perivascular spaces.⁴ These MRI features are more prevalent in individuals with type 2 diabetes than in those without.⁵ In addition, CSVD is associated with a higher incidence of depressive symptoms.⁶ However, no previous study has investigated whether the association between type 2 diabetes and depressive symptoms is explained, or mediated, by CSVD.

In view of the above, we investigated in a large population-based cohort the association between baseline type 2 diabetes and change in depressive symptoms over time. In addition, we evaluated whether this association was explained by MRI features of CSVD, i.e. higher WMH volume, lower total brain parenchyma volume, subcortical infarcts, cerebral microbleeds, and large perivascular spaces.

Methods

Participants

Participants were from the population-based Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study cohort originating from the Reykjavik Study, described previously.⁷ Briefly, from 2002–2006, 5,764 surviving participants of the Reykjavik Study were examined and 3,316 (57.5%) were re-examined five years later, from 2007–2011. Reasons for not attending the follow-up examination included: death (n=1,039); refusal (n=1,198); and lost to follow-up (n=211). The AGES-Reykjavik Study was approved by the National Bioethics Committee in Iceland (approval number=VSN-00-063), and by the Institutional Review Board overseeing the National Institute on Aging and the National Institutes of Health. After complete description of the study to the subject, written informed consent was obtained.

Type 2 diabetes mellitus

Baseline type 2 diabetes was defined as self-reported history of type 2 diabetes, use of blood glucose-lowering drugs, or a fasting blood glucose level ≥ 7.0 mmol/L.⁸

Depressive symptoms

Depressive symptoms were assessed with use of the 15-item Geriatric Depression Scale (GDS-15; score range 0-15) at baseline and at follow-up five years later.^{9, 10} We calculated the change in GDS-15 score over time by subtracting the GDS-15 score at baseline from the GDS-15 score at follow-up. In addition, we distinguished an apathy subscale including all three apathy items of the GDS-15 (GDS-3A, range 0-3) and a subscale including the remaining depression items (GDS-12D, range 0-12), as described previously.¹¹ Additionally, use of antidepressant medication (tricyclics, selective serotonin reuptake inhibitors, other nontricyclics and monoamine oxidase inhibitors) was assessed from medication bottles brought to the clinic at baseline and at follow-up.

Brain MRI measures

Image acquisition

All eligible participants were offered high-resolution 1.5T brain MRI (Signa Twinspeed, General Electric Medical Systems). A standardized imaging protocol, described previously,^{12, 13} was used both at baseline and follow-up and included the following sequences: 3D spoiled-gradient recalled T1-weighted, proton density/T2-weighted fast spin-echo, fluid-attenuated inversion recovery (FLAIR) and T2*-weighted gradient-echo type echoplanar image (GRE-EPI). All images were acquired to give full brain coverage with slices angled parallel to the anterior commissure–posterior commissure line to give reproducible image views in the oblique-axial plane.

Image analysis

Five features of CSVD were evaluated: WMH volume, total brain parenchyma volume, subcortical infarcts, cerebral microbleeds and large perivascular spaces. WMH volume and total brain parenchyma volume were computed automatically with a previously described image analysis pipeline,¹⁴ and were expressed as the percentage of total intracranial volume. Subcortical infarcts were defined as subcortical brain parenchyma defects as described previously,¹³ with a diameter of ≥ 4 mm and a signal intensity similar to cerebrospinal fluid on all pulse sequences (T2-weighted, proton density-weighted and FLAIR), surrounded by an area of high signal intensity on FLAIR images, and without evidence of hemosiderin on T2*-weighted GRE-EPI sequence. Cerebral microbleeds were defined as focal areas of signal void visible on T2*-weighted GRE-EPI sequence.¹² Large perivascular spaces were defined as defects in the subcortical area without a rim or area of high signal intensity on FLAIR and without evidence of hemosiderin on T2*-weighted GRE-EPI sequence.¹⁵

Confounding variables

Selection of confounding and co-varying measures was based on previous studies^{16, 17} showing their association with type 2 diabetes or depressive symptoms. The following variables were assessed by questionnaire: education level (primary, secondary and college/university education), alcohol use (high [above median] vs. low [below median], stratified by sex), and smoking history (never, former, current). Body mass index (BMI) was calculated as measured weight in kg divided by height in cm squared. Hypertension was defined as systolic pressure ≥ 140 mmHg, diastolic pressure ≥ 90 mmHg or use of anti-hypertensive medication. Total/HDL cholesterol ratio, baseline coronary artery

disease and stroke, and incident stroke during follow-up were determined as described previously.⁷ Dementia was diagnosed according to international guidelines¹⁸ by a panel that included a geriatrician, a neurologist, a neuropsychologist and a neuroradiologist as described previously.⁷

Analytic sample

Of the 3,316 participants who attended the follow-up examination, 207 were excluded because of a diagnosis of dementia at baseline (n=47) or at follow-up (n=160). In addition, participants were excluded if they had missing data on brain MRI (n=701), GDS-15 score at baseline or at follow-up (n=149), or confounders (n=18). Finally, we excluded participants with baseline clinically relevant depressive symptoms defined as a GDS-15 score ≥ 6 (n=106). In the main analysis, we did not exclude participants using antidepressant medication, because these medications are also prescribed for indications other than depression (e.g. diabetic polyneuropathy). The final study sample for the main analysis consisted of 2,135 participants.

Statistical analysis

We summarized the baseline CSVD features and the change in CSVD features over time into a composite score of baseline CSVD and a composite score of CSVD change over time because we hypothesize that each CSVD feature may mediate the association between type 2 diabetes and depressive symptoms according to similar mechanisms. A composite score reduces the influence of the biological variability of its components¹⁹ and requires fewer statistical tests. We calculated a composite score of baseline CSVD as described previously;³ one point per CSVD feature at baseline was assigned based on the following cut-offs: for high WMH volume quartile 4 vs. quartiles 1 to 3; for low total brain parenchyma volume quartile 1 vs. quartiles 2 to 4; and for subcortical infarcts, cerebral microbleeds and large perivascular spaces presence vs. absence. The points for each feature were summed up to compute the composite score of baseline CSVD (range 0-5). Subsequently, we calculated a composite score of CSVD change over time between the baseline and follow-up examination by assigning one point per change in each CSVD feature over time based on the following cut-offs: for high increase in WMH volume quartile 4 vs. quartiles 1 to 3; for high decrease in total brain parenchyma quartile 4 vs. quartiles 1 to 3; and for new subcortical infarcts, cerebral microbleeds and large perivascular spaces ≥ 1 new lesion(s) vs. no new lesions.

The statistical analysis proceeded in two stages. First, multivariable linear regression analyses were used to estimate the associations between type 2 diabetes at baseline, the composite score of baseline CSVD, the composite score of CSVD change over time, and the change in the GDS-15 score over time. Analyses were adjusted for age, sex, education level (model 1), and additionally for alcohol use, smoking history, BMI and total/HDL cholesterol ratio (model 2). Second, we performed a mediation analysis²⁰ to test the hypothesis that CSVD features explain the association between type 2 diabetes at baseline and change in the GDS-15 score over time. The mediation model quantifies the degree to which a variable statistically explains the association between a determinant and an outcome variable. We tested the potential explained associations of the composite score of baseline CSVD and the composite score of CSVD change over time separately. We used bootstrapping (10,000

samples) to calculate bias-corrected 95% confidence intervals (95% CIs) of the explained associations using the PROCESS statistical package for PASW statistics.²⁰

We did several additional analyses. First, we repeated the analysis with adjustment for each individual CSVD feature in the model separately. Second, we repeated the analysis with the GDS-15 score at follow-up as the outcome instead of the change in GDS-15 score over time, and with additional adjustment for the GDS-15 score at baseline. Third, we repeated the analysis after excluding participants using antidepressant medication at baseline. Fourth, it has been suggested that CSVD features may be most strongly associated with apathy-related symptoms of depression.¹¹ Therefore, we repeated the analysis with the change in GDS3-A and GDS12-D score over time as the outcome, respectively. Fifth, we repeated the analysis additionally adjusting for baseline coronary artery disease. Adjustment for coronary artery disease was not done in the main analysis, because data on coronary artery disease were missing in a relatively large number of participants (n=220). Sixth, we repeated the analysis additionally adjusting for hypertension, baseline stroke or incident stroke during follow-up. Adjustments for hypertension and stroke were not done in the main analysis, because of the risk of overadjustment bias: hypertension and stroke may be confounders, but may also mediate the associations between type 2 diabetes, CSVD features and change in depressive symptoms over time.^{21, 22}

All analyses were done with PASW Statistics (version 23). A P value of <.05 was considered statistically significant.

Results

The mean age of the participants at baseline was 74.5 (SD 4.6) years, 58.3% were women and 9.2% had type 2 diabetes. On average, the GDS-15 score increased 0.4 points (SD 1.6) over time. In participants with type 2 diabetes, the GDS-15 score increased 0.7 (SD 1.9) and in participants without type 2 diabetes 0.3 (SD 1.6). The mean time between baseline and follow-up was 5.2 (SD 0.2) years. Characteristics of the total study population according to presence of type 2 diabetes are given in Table 1. Characteristics of the individuals excluded from the analyses are provided in the Supplementary Material (eTable 1).

Participants with type 2 diabetes as compared to those without had a greater increase in GDS-15 score over time between the baseline and follow-up examination after adjustment for age, sex, education, alcohol use, smoking history, BMI, and total/HDL cholesterol ratio (Table 2). In addition, participants with type 2 diabetes had a higher composite score of baseline CSVD and a higher composite score of CSVD change over time after full adjustment (Table 2). A higher composite score of baseline CSVD and a higher composite score of CSVD change over time were associated with greater increase in GDS-15 score over time after full adjustment (Table 2).

Mediation analysis showed that the composite scores of baseline CSVD and CSVD change over time each statistically significantly explained part of the total association between type 2 diabetes and greater increase in GDS-15 score over time (Figure 1, panels A and B).

Additional analyses

Most individual CSVD features attenuated the association between baseline type 2 diabetes and greater increase in GDS-15 score over time (eFigures 1 and 2). Results were similar when we used the GDS-15 score at follow-up as the outcome, instead of the change in GDS-15 score over time, and with additional adjustment for the GDS-15 score at baseline (eTable 2). The association between type 2 diabetes and change in GDS-15 score over time was qualitatively similar when we excluded participants that used antidepressant medication at baseline (eTable 3). Type 2 diabetes was associated with a greater increase in the GDS3-A score over time, but not with change in the GDS12-D score over time (eTable 4). In addition, the composite score of CSVD change over time explained part of the total association of type 2 diabetes and a greater increase in GDS3-A score over time (eFigures 3 and 4). The results of the main analysis were comparable when we additionally adjusted for baseline coronary artery disease, hypertension, or baseline stroke and incident stroke during follow-up (eTable 5).

Discussion

In this study, type 2 diabetes was independently associated with a greater increase in depressive symptoms over time, and CSVD features explained, or mediated, part of this association.

The study findings are in accordance with the vascular depression hypothesis,² and suggest that cerebral microvascular damage may contribute to the development of depressive symptoms, in individuals with type 2 diabetes. A previous meta-analysis found that CSVD features are associated with a higher risk of incident depressive symptoms.⁶ In addition, a previous systematic review found that type 2 diabetes is associated with presence of CSVD features.⁵ This study extends these previous studies by showing that the association between type 2 diabetes and greater increase in depressive symptoms over time is partially explained by CSVD features.

Type 2 diabetes may lead to CSVD via various mechanisms including impaired insulin-dependent arteriolar dilation, advanced glycation, excessive oxidative stress and epigenetic changes.^{23,24} The cerebral microvasculature, in turn, is involved in the regulation of many cerebral processes, including cerebral perfusion, neurovascular coupling, blood-brain barrier permeability and neurogenesis.²⁴ Impairment of these processes may lead to neuronal dysfunction, ischemia and cell death, which may ultimately contribute to depressive symptoms via damage in deep and frontal brain structures involved in mood regulation.²⁴

Other mechanisms may, however, explain the observed associations. First, CSVD may indirectly lead to depression through incident stroke. However, adjusting for stroke at baseline or incident stroke during follow-up did not change our results. Second, CSVD may indirectly lead to depression through cognitive impairment. For the present study, however, we excluded individuals with dementia at baseline or at follow-up. Third, other confounding factors may explain the association between type 2 diabetes, CSVD features and change in depressive symptoms over time, such as lower socio-economic status and cardiovascular factors. However, the associations between type 2 diabetes, CSVD and depressive symptoms were independent of education level and cardiovascular risk factors.^{25,26} Nevertheless, we cannot exclude the possibility of residual confounding.

Some part of the association between type 2 diabetes and higher depressive symptoms over time remained unexplained after taking into account the effect of CSVD features. This remaining association may be due to microvascular dysfunction that is not directly captured in the MRI scans in the present study (e.g. microinfarctions, increased blood-brain permeability and lower cerebral vasoreactivity). In addition, it is possible that only a subset of individuals with type 2 diabetes develop depressive symptoms that are related to CSVD. Depressive symptoms in type 2 diabetes may be related to other mediators such as psychosocial factors,¹ diabetes-related comorbidities¹ and glucose neurotoxicity.²⁷

Strengths of the present study are the large population-based sample of older participants, the comprehensive brain MRI assessment of various CSVD features at baseline and follow-up five years later and the extensive adjustment for a series of potential confounders.

Our study has certain limitations. First, the construction of a composite score of CSVD assumes that all its components are of equal importance in the association between type 2 diabetes and higher depressive symptoms over time, which may not be necessarily true. However, we found that most individual CSVD features contributed to the effect of CSVD on the association between type 2 diabetes and higher depressive symptoms over time. Second, unavoidable survival bias may change the associations if among the persons who died, associations among type 2 diabetes, CVSD features and depressive symptoms differ from those in the sample. Third, we lacked power to investigate the association of baseline type 2 diabetes to incident depressive symptoms (GDS-15 score ≥ 6). Fourth, because we study associations of change in depressive symptoms with change in CSVD features, we cannot investigate the temporality of the association. However, it is likely that only many repeated measures made at short intervals will resolve temporal relations.

In view of the increased risk of depression in type 2 diabetes, efforts to favorably influence cerebral microvascular function through lifestyle and pharmacological therapy might help to prevent or treat microvascular dysfunction-related depression.^{24, 28} Evidence suggests that weight loss and exercise may improve microvascular function and symptoms of depression.²⁴ In addition, drugs, such as renin-angiotensin-aldosterone system inhibitors and antihyperglycemic agents (i.e. metformin and glucagon-like peptide 1 receptor (GLP-1R) agonists), may improve microvascular function, possibly beyond their blood pressure- or glucose-lowering effects.²⁴

In conclusion, the present study found that type 2 diabetes is independently associated with greater increase depressive symptoms over time, and that this association is in part explained by MRI features of CSVD.

References

1. Badescu SV, Tataru C, Kobylinska L, Georgescu EL, Zahiu DM, Zagrean AM and Zagrean L. The association between Diabetes mellitus and Depression. *J Med Life*. 2016;9:120-5.
2. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D and Charlson M. 'Vascular depression' hypothesis. *Arch Gen Psychiatry*. 1997;54:915-22.
3. van Sloten TT, Sigurdsson S, van Buchem MA, Phillips CL, Jonsson PV, Ding J, Schram MT, Harris TB, Gudnason V and Launer LJ. Cerebral Small Vessel Disease and Association With Higher Incidence of Depressive Symptoms in a General Elderly Population: The AGES-Reykjavik Study. *Am J Psychiatry*. 2015;172:570-8.
4. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge R, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M and nEuroimaging STfRVco. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol*. 2013;12:822-38.
5. Geijselaers SLC, Sep SJS, Stehouwer CDA and Biessels GJ. Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic review. *Lancet Diabetes Endocrinol*. 2015;3:75-89.
6. Rensma SP, van Sloten TT, Launer LJ and Stehouwer CDA. Cerebral small vessel disease and risk of incident stroke, dementia and depression, and all-cause mortality: A systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2018;90:164-173.
7. Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, Sigurdsson G, Thorgeirsson G, Aspelund T, Garcia ME, Cotch MF, Hoffman HJ and Gudnason V. Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. *Am J Epidemiol*. 2007;165:1076-87.
8. Marathe PH, Gao HX and Close KL. American Diabetes Association Standards of Medical Care in Diabetes 2017. *J Diabetes*. 2017;9:320-324.
9. Almeida OP and Almeida SA. Short versions of the geriatric depression scale: a study of their validity for the diagnosis of a major depressive episode according to ICD-10 and DSM-IV. *Int J Geriatr Psychiatry*. 1999;14:858-65.
10. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M and Leirer VO. Development and validation of a geriatric depression screening scale: a preliminary report. *J Psychiatr Res*. 1982;17:37-49.
11. Ligthart SA, Richard E, Fransen NL, Eurelings LS, Beem L, Eikelenboom P, van Gool WA and Moll van Charante EP. Association of vascular factors with apathy in community-dwelling elderly individuals. *Arch Gen Psychiatry*. 2012;69:636-42.
12. Sveinbjornsdottir S, Sigurdsson S, Aspelund T, Kjartansson O, Eiriksdottir G, Valtysdottir B, Lopez OL, van Buchem MA, Jonsson PV, Gudnason V and Launer LJ. Cerebral microbleeds in the population based AGES-Reykjavik study: prevalence and location. *J Neurol Neurosurg Psychiatry*. 2008;79:1002-6.
13. Scher AI, Gudmundsson LS, Sigurdsson S, Ghambaryan A, Aspelund T, Eiriksdottir G, van Buchem MA, Gudnason V and Launer LJ. Migraine headache in middle age and late-life brain infarcts. *JAMA*. 2009;301:2563-70.

14. Sigurdsson S, Aspelund T, Forsberg L, Fredriksson J, Kjartansson O, Oskarsdottir B, Jonsson PV, Eiriksdottir G, Harris TB, Zijdenbos A, van Buchem MA, Launer LJ and Gudnason V. Brain tissue volumes in the general population of the elderly: the AGES-Reykjavik study. *Neuroimage*. 2012;59:3862-3870.
15. Ding J, Sigurethsson S, Jonsson PV, Eiriksdottir G, Charidimou A, Lopez OL, van Buchem MA, Guethnason V and Launer LJ. Large Perivascular Spaces Visible on Magnetic Resonance Imaging, Cerebral Small Vessel Disease Progression, and Risk of Dementia: The Age, Gene/Environment Susceptibility-Reykjavik Study. *JAMA Neurol*. 2017;74:1105-1112.
16. Oladeji BD and Gureje O. The comorbidity between depression and diabetes. *Curr Psychiatry Rep*. 2013;15:390.
17. Renn BN, Feliciano L and Segal DL. The bidirectional relationship of depression and diabetes: a systematic review. *Clin Psychol Rev*. 2011;31:1239-46.
18. Association AP. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, DMS-IV (4th edition). 1994.
19. O'Brien PC. Procedures for comparing samples with multiple endpoints. *Biometrics*. 1984;40:1079-87.
20. Preacher KJ and Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. *Behav Res Methods*. 2008;40:879-91.
21. Lastra G, Syed S, Kurukulasuriya LR, Manrique C and Sowers JR. Type 2 diabetes mellitus and hypertension: an update. *Endocrinol Metab Clin North Am*. 2014;43:103-22.
22. Garcia-Fabela L, Melano-Carranza E, Aguilar-Navarro S, Garcia-Lara JM, Gutierrez-Robledo LM and Avila-Funes JA. Hypertension as a risk factor for developing depressive symptoms among community-dwelling elders. *Rev Invest Clin*. 2009;61:274-80.
23. Forbes JM and Cooper ME. Mechanisms of diabetic complications. *Physiol Rev*. 2013;93:137-88.
24. Stehouwer CDA. Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle With Widespread Consequences. *Diabetes*. 2018;67:1729-1741.
25. Kaplan GA and Keil JE. Socioeconomic factors and cardiovascular disease: a review of the literature. *Circulation*. 1993;88:1973-98.
26. Lopez AD, Mathers CD, Ezzati M, Jamison DT and Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. *Lancet*. 2006;367:1747-57.
27. Tomlinson DR and Gardiner NJ. Glucose neurotoxicity. *Nat Rev Neurosci*. 2008;9:36-45.
28. Lustman PJ and Clouse RE. Depression in diabetic patients: the relationship between mood and glycemic control. *J Diabetes Complications*. 2005;19:113-22.

Table 1. Baseline characteristics of the total study population, and according to presence of type 2 diabetes at baseline

	Total study population (n=2,135)	Participants with type 2 diabetes (n=197; 9.2%)	Participants without type 2 diabetes (n=1,938; 90.8%)
Age			
Baseline	74.5 (4.6)	74.6 (4.3)	74.5 (4.6)
Follow-up	79.7 (4.6)	79.7 (4.3)	79.7 (4.6)
Women	1,245 (58.3)	94 (47.7)	1,151 (59.4)
Education level			
Primary	410 (19.2)	33 (16.8)	377 (19.5)
Secondary	1,106 (51.8)	103 (52.3)	1,003 (51.8)
College/university	619 (29.0)	61 (31.0)	558 (28.8)
Smoking history			
Former smoker	985 (46.1)	101 (51.3)	884 (45.6)
Current smoker	220 (10.3)	18 (9.1)	202 (10.4)
High alcohol use ¹	881 (41.3)	78 (39.6)	803 (41.4)
Body mass index (kg/m ²)	27.2 (4.0)	28.9 (4.0)	27.1 (4.0)
Baseline coronary artery disease ²	488 (26.2)	62 (31.5)	426 (22.0)
Stroke			
Baseline	94 (4.4)	9 (4.6)	85 (4.4)
Incident	24 (1.1)	4 (2.0)	20 (1.0)
Incident depressive symptoms (GDS-15 score ≥6)	92 (4.3)	13 (6.6)	79 (4.1)
Hypertension	1,651 (77.3)	179 (90.9)	1,472 (76.0)
Total/HDL cholesterol ratio	3.7 (1.1)	3.9 (1.2)	3.7 (1.1)
GDS-15 score			
Baseline, median (IQR)	1 (0-3)	1 (1-2.5)	1 (1-3)
Change over time	+0.4 (1.6)	+0.7 (1.9)	+0.3 (1.6)
Follow-up	2 (1-3)	2 (1-3)	2 (1-3)
Use of antidepressant medication			
Baseline	215 (10.1)	19 (9.6)	196 (10.1)
Follow-up	287 (13.4)	23 (11.7)	264 (13.6)
Composite scores of cerebral small vessel disease features			
Baseline	0.8 (0.9)	1.0 (1.0)	0.7 (0.9)
Change over time	+0.6 (0.8)	+0.8 (0.9)	+0.6 (0.8)
Follow-up	0.9 (1.0)	1.3 (1.2)	0.9 (1.0)
Total brain parenchyma volume, ml			
Baseline	1,097.0 (102.4)	1,089.1 (112.7)	1,097.9 (101.3)
Change over time	-31.7 (17.1)	-35.6 (18.8)	-31.3 (16.9)
Follow-up	1,065.4 (99.4)	1,053.4 (110.5)	1,066.6 (98.1)
White matter hyperintensity volume, ml			
Baseline, median (IQR)	11.2 (6.4-20.7)	13.2 (7.3-22.2)	11.1 (6.3-20.5)
Change over time	+5.6 (7.4)	+6.0 (8.2)	+5.6 (7.3)
Follow-up	15.0 (8.1-28.9)	17.2 (9.9-31.9)	14.8 (7.9-28.7)
Subcortical infarcts			
Baseline	154 (7.2)	31 (15.7)	123 (6.3)
Incident	87 (4.1)	13 (6.6)	74 (3.8)
Follow-up	212 (9.9)	37 (18.8)	175 (9.0)

	Total study population (n=2,135)	Participants with type 2 diabetes (n=197; 9.2%)	Participants without type 2 diabetes (n=1,938; 90.8%)
Cerebral microbleeds			
Baseline	355 (16.6)	38 (19.3)	317 (16.4)
Incident	377 (17.7)	45 (22.8)	332 (17.1)
Follow-up	630 (29.5)	74 (37.6)	556 (28.7)
Large perivascular spaces			
Baseline	341 (16.0)	39 (19.8)	302 (15.6)
Incident	60 (2.8)	10 (5.1)	50 (2.6)
Follow-up	373 (17.5)	45 (22.8)	328 (16.9)

Numbers indicate mean (SD) or number of participants, unless otherwise stated. ¹High alcohol use was defined as alcohol use above median, stratified by sex; ²Data missing in n=220. Abbreviations: GDS-15: 15-item Geriatric Depression Scale; IQR: interquartile range.

Table 2. Associations between type 2 diabetes at baseline, composite score of baseline cerebral small vessel disease, composite score of cerebral small vessel disease change over time, and change in GDS-15 score over time

		Change in 15-item Geriatric Depression Scale score over time	Composite score of baseline cerebral small vessel disease	Composite score of cerebral small vessel disease change over time
	Model	β (95%CI)	β (95%CI)	β (95%CI)
Type 2 diabetes vs. no diabetes at baseline	1	0.339 (0.099; 0.579)	0.219 (0.093; 0.345)	0.205 (0.094; 0.316)
	2	0.316 (0.074; 0.558)	0.244 (0.117; 0.371)	0.226 (0.114; 0.338)
Composite score of baseline cerebral small vessel disease	1	0.102 (0.014; 0.176)	-	-
	2	0.095 (0.021; 0.183)	-	-
Composite score of cerebral small vessel disease change over time	1	0.207 (0.116; 0.298)	-	-
	2	0.202 (0.111; 0.294)	-	-

Model 1: adjusted for age, sex, and education level; model 2: model 1 + alcohol use, smoking history, body mass index, and total/HDL cholesterol ratio.

Abbreviations: CI: confidence interval.

Figure 1. Association between type 2 diabetes at baseline and higher 15-item Geriatric Depression Scale score over time between baseline and follow-up examination, and the proportion explained by the composite score of baseline cerebral small vessel disease (panel A), and the composite score of cerebral small vessel disease change over time (panel B). Solid lines indicate associations that are statistically significant; dashed lines indicate associations that are not statistically significant. Associations are given as regression coefficients (β) and corresponding 95% confidence intervals. All associations are adjusted for age, sex, education level, alcohol use, smoking history, body mass index and total/HDL cholesterol ratio. Abbreviations: CI: confidence interval; CSVD: cerebral small vessel disease; GDS-15: 15-item Geriatric Depression Scale.

Supplemental material

Table S1. Characteristics of the study population and individuals excluded from the analyses

Age	Total study population (n=2,135)	Excluded because of a diagnosis of dementia at baseline or at follow-up, or with baseline GDS-15 score ≥6 (n=313)	Excluded because of missing values (n=868)
Baseline	74.5 (4.6)	76.8 (5.6)	75.5 (5.1)
Follow-up	79.7 (4.6)	82.0 (5.7)	80.7 (5.1)
Women	1,245 (58.3)	189 (60.4)	500 (57.6)
Education level			
Primary	410 (19.2)	96 (31.0)	175 (20.6)
Secondary	1,106 (51.8)	154 (49.7)	429 (50.6)
College/university	619 (29.0)	60 (19.4)	244 (28.8)
Smoking history			
Former smoker	985 (46.1)	135 (43.4)	384 (44.8)
Current smoker	220 (10.3)	42 (13.5)	99 (11.5)
High alcohol use ¹	881 (41.3)	101 (32.7)	324 (38.4)
Body mass index (kg/m ²)	27.2 (4.0)	27.1 (4.6)	27.5 (4.6)
Baseline coronary artery disease ²	488 (26.2)	95 (32.6)	239 (30.6)
Stroke			
Baseline	94 (4.4)	28 (8.9)	53 (6.1)
Incident	24 (1.1)	13 (4.2)	16 (1.8)
Incident depressive symptoms (GDS-15 score ≥6)	92 (4.3)	N/A	56 (7.0)
Hypertension	1,651 (77.3)	255 (81.5)	713 (82.1)
Total/HDL cholesterol ratio	3.7 (1.1)	3.7 (1.1)	3.7 (1.2)
GDS-15 score			
Baseline, median (IQR)	1 (0-3)	N/A	2 (1-3)
Change over time	+0.4 (1.6)	N/A	0.3 (1.9)
Follow-up	2 (1-3)	N/A	2 (1-3)
Use of antidepressant medication			
Baseline	215 (10.1)	N/A	106 (12.2)

	Total study population (n=2,135)	Excluded because of a diagnosis of dementia at baseline or at follow-up, or with baseline GDS-15 score ≥6 (n=313)	Excluded because of missing values (n=868)
Follow-up	287 (13.4)	N/A	127 (14.6)
Composite scores of cerebral small vessel disease features			
Baseline	0.8 (0.9)	1.2 (1.1)	0.8 (1.0)
Change over time	+0.6 (0.8)	+1.1 (1.1)	+0.5 (0.7)
Follow-up	0.9 (1.0)	1.6 (1.3)	0.9 (1.0)
Total brain parenchyma volume, ml			
Baseline	1,097.0 (102.4)	1,061.6 (92.8)	1,107.7 (104.0)
Change over time	-31.7 (17.1)	-40.1 (24.5)	-36.8 (18)
Follow-up	1,065.4 (99.4)	1,022 (88.8)	1,069.4 (96.4)
White matter hyperintensity volume, ml			
Baseline, median (IQR)	11.2 (6.4-20.7)	16.0 (8.8-31.2)	12.5 (6.2-21.5)
Change over time	+5.6 (7.4)	+9.8 (11.1)	+4.8 (8.1)
Follow-up	15.0 (8.1-28.9)	23.8 (12.5-47.1)	16.0 (7.9-28.7)
Subcortical infarcts			
Baseline	154 (7.2)	32 (12.1)	16 (5.9)
Incident	87 (4.1)	28 (10.6)	4 (1.5)
Follow-up	212 (9.9)	53 (20.1)	18 (6.6)
Cerebral microbleeds			
Baseline	355 (16.6)	46 (17.4)	55 (20.1)
Incident	377 (17.7)	75 (28.4)	44 (16.1)
Follow-up	630 (29.5)	98 (37.1)	80 (29.3)
Large perivascular spaces			
Baseline	341 (16.0)	57 (21.6)	34 (12.5)
Incident	60 (2.8)	14 (5.3)	10 (3.7)
Follow-up	373 (17.5)	63 (23.9)	39 (14.3)

Numbers indicate mean (SD) or number of participants, unless otherwise stated. ¹High alcohol use was defined as alcohol use above median, stratified by sex; ²Data missing in n=220. Abbreviations: GDS-15: 15-item Geriatric Depression Scale; IQR: interquartile range.

Table S2. Association between type 2 diabetes at baseline and 15-item Geriatric Depression Scale score at follow-up, additionally adjusted for 15-item Geriatric Depression Scale score at baseline

	Model	Change in 15-item Geriatric Depression Scale score over time		
		β	95%CI	95%CI
Type 2 diabetes vs. no diabetes	1	0.299	0.043	0.554
	2	0.219	-0.037	0.475
	3	0.276	0.047	0.505

Model 1: adjusted for age, sex, and education level; model 2: model 1 + alcohol use, smoking history, body mass index, and total/HDL cholesterol ratio; model 3: model 2 + Geriatric Depression Scale score at baseline.

Number of participants (n) available: 2,135.

Abbreviations: CI: confidence interval.

Table S3. Association between type 2 diabetes at baseline and change in 15-item Geriatric Depression Scale score over time - participants excluded using antidepressant medication at baseline

	Model	Change in 15-item Geriatric Depression Scale score over time		
		β	95%CI	95%CI
Type 2 diabetes vs. no diabetes	1	0.239	-0.003	0.481
	2	0.226	0.004	0.493

Model 1: adjusted for age, sex, and education level; model 2: model 1 + alcohol use, smoking history, body mass index, and total/HDL cholesterol ratio.

Number of participants (n) available: 1,920.

Abbreviations: CI: confidence interval.

Table S4. Associations between type 2 diabetes at baseline and change in the apathy and remaining depression items of the 15-item Geriatric Depression Scale score over time

	Model	Change in GDS-3A score over time, excluding participants with apathy (GDS-3A $\geq$ 2) at baseline (n=922) ¹			Change in GDS-12D score over time, excluding participants with remaining depression items (GDS-12D $\geq$ 2) at baseline (n=298) ²		
		β	95%CI		β	95%CI	
Type 2 diabetes vs. no diabetes	1	0.214	0.043	0.386	0.172	0.007	0.337
	2	0.191	0.019	0.363	0.160	-0.007	0.326

Model 1: adjusted for age, sex, and education level; model 2: model 1 + alcohol use, smoking history, body mass index, total/HDL cholesterol ratio

¹Number of participants (n) available: 1,301; ²Number of participants (n) available: 1,898.

Abbreviations: CI: confidence interval; GDS-3A: apathy items of the 15-item Geriatric Depression Scale; GDS-12D: remaining depression items of the 15-item Geriatric Depression Scale.

Table S5. Association between type 2 diabetes at baseline and change in 15-item Geriatric Depression Scale score over time - additionally adjusted for hypertension, baseline coronary artery disease or baseline stroke and incident stroke during follow-up

Model	Change in 15-item Geriatric Depression Scale over time, additionally adjusted for hypertension ¹			Change in 15-item Geriatric Depression Scale score over time, additionally adjusted for baseline coronary artery disease ²			Change in 15-item Geriatric Depression Scale score over time, additionally adjusted for baseline stroke and incident stroke during follow-up ¹		
	β	95%CI		β	95%CI		β	95%CI	
Type 2 diabetes vs. no diabetes									
1	0.339	0.099		0.332	0.082		0.583	0.339	0.579
2	0.316	0.074		0.341	0.065		0.571	0.316	0.558
3	0.337	0.094		0.319	0.066		0.571	0.313	0.556

Model 1: adjusted for age, sex, education level; model 2: model 1 + alcohol use, smoking history, body mass index, hypertension, and total/HDL cholesterol ratio; model 3: model 2 + hypertension, baseline coronary artery disease, or baseline stroke and incident stroke during follow up (where appropriate). ¹number of participants (n) available: 2,135; ²Number of participants (n) available: 1,915.
Abbreviations: CI: confidence interval.

Figure S1. Explained proportion by combined and individual cerebral small vessel disease features at baseline on the association between type 2 diabetes at baseline and higher 15-item Geriatric Depression Scale score over time. Cerebral small vessel disease features explained 6.7% of the association between type 2 diabetes and higher 15-item Geriatric Depression Scale score over time. The proportion of the association explained by individual cerebral small vessel disease features were: for baseline total brain parenchyma volume 3.3%; for baseline white matter hyperintensity volume 6.7%; for baseline subcortical infarcts 53.3%; for baseline large perivascular spaces 36.7%. Baseline cerebral microbleeds did not explain the association between type 2 diabetes and higher 15-item Geriatric Depression Scale score over time.

Figure S2. Explained proportion by combined and individual cerebral small vessel disease features change over time on the association between type 2 diabetes at baseline and higher 15-item Geriatric Depression Scale score over time. Cerebral small vessel disease features explained 13.6% of the association between type 2 diabetes and higher 15-item Geriatric Depression Scale score over time. The proportion of the association explained by individual cerebral small vessel disease features were: for decrease in total brain parenchyma volume over time 19.3%; for increase in white matter hyperintensity volume over time 9.7%; for incident subcortical infarcts 14.5%; for incident cerebral microbleeds 8.1%; and for incident large perivascular spaces 48.4%. Baseline cerebral microbleeds did not explain the association between type 2 diabetes and higher 15-item Geriatric Depression Scale score over time.

Figure S3. Association between type 2 diabetes at baseline and higher apathy items of the 15-item Geriatric Depression Scale score over time, and the proportion explained by the composite score of baseline cerebral small vessel disease (panel A), and the composite score of cerebral small vessel disease change over time (panel B). Solid lines indicate associations that are statistically significant; dashed lines indicate associations that are not statistically significant. Associations are given as regression coefficients (β) and corresponding 95% confidence intervals. All associations are adjusted for: age, sex, education level, alcohol use, smoking history, body mass index, and total/HDL cholesterol ratio. Number of participants (n) available: 1,301. Abbreviations: CI: confidence interval; CSVD: cerebral small vessel disease; GDS-3A: apathy items of the 15-item Geriatric Depression Scale.

Figure S4. Association between type 2 diabetes at baseline and higher remaining items of the 15-item Geriatric Depression Scale score over time, and the proportion explained by the composite score of baseline cerebral small vessel disease (panel A), and the composite score of cerebral small vessel disease change over time (panel B). Solid lines indicate associations that are statistically significant; dashed lines indicate associations that are not statistically significant. Associations are given as regression coefficients (β) and corresponding 95% confidence intervals. All associations are adjusted for: age, sex, education level, alcohol use, smoking history, body mass index, and total/HDL cholesterol ratio. Number of participants (n) available: 1,898. Abbreviations: CI: confidence interval; CSVD: cerebral small vessel disease; GDS-12D: remaining items of the 15-item Geriatric Depression Scale.

CHAPTER 4

Microvascular dysfunction is associated with worse cognitive performance: The Maastricht Study

Sytze P. Rensma, Thomas T. van Sloten, Alfons J.H.M. Houben, Sebastian Köhler, Martin P.J. van Boxtel, Tos T.J.M. Berendschot, Jacobus F.A. Jansen, Frans R.J. Verhey, Abraham A. Kroon, Annemarie Koster, Walter H. Backes, Nicolaas Schaper, Geert-Jan Dinant, Casper G. Schalkwijk, Ronald M.A. Henry, Else M.L. Wolfs, Mike J.A. van Heumen, Miranda T. Schram, Coen D.A. Stehouwer

Abstract

Microvascular dysfunction may be associated with worse cognitive performance. Most previous studies did not adjust for important confounders, evaluated only individual measures of microvascular dysfunction, and showed inconsistent results. We evaluated the association between a comprehensive set of measures of microvascular dysfunction and cognitive performance in the population-based Maastricht Study.

We used cross-sectional data including 3011 participants (age 59.5 ± 8.2 ; 48.9% women; 26.5% type 2 diabetes [oversampled by design]). Measures of microvascular dysfunction included MRI features of cerebral small vessel disease, plasma biomarkers of microvascular dysfunction, albuminuria, flicker light-induced retinal arteriolar and venular dilation response and heat-induced skin hyperaemia. These measures were summarized into a microvascular dysfunction composite score. Cognitive domains assessed were memory, processing speed and executive function. A cognitive function score was calculated as the sum of the scores on these three cognitive domains.

The microvascular dysfunction score was associated with a worse cognitive function score (standardized β , -0.087; 95%CI -0.127; -0.047), independent of age, education level, sex, type 2 diabetes, smoking, alcohol use, hypertension, total/HDL cholesterol ratio, triglycerides, lipid-modifying medication, prior cardiovascular disease, depression and plasma biomarkers of low-grade inflammation. The fully adjusted beta-coefficient of the association between the microvascular dysfunction score and the cognitive function score was equivalent to two (range: one to three) years of aging for each standard deviation higher microvascular dysfunction score. The microvascular dysfunction score was associated with worse memory and processing speed, but not with worse executive function.

The present study shows that microvascular dysfunction is associated with worse cognitive performance.

Introduction

Cognitive impairment and dementia are major health problems and their prevalence rises with the aging of the population¹. The mechanisms underlying cognitive impairment remain, however, incompletely understood, and may include microvascular dysfunction and damage (“microvascular dysfunction”, MVD)².

The microvasculature is involved in the regulation of many cerebral processes, notably neurovascular coupling, cerebral autoregulation, blood-brain barrier permeability and neurogenesis². Impairment of these processes may lead to neuronal dysfunction, ischemia and cell death, which may contribute to cognitive impairment².

Microvascular function can be measured noninvasively in various organs. Indirect measures include magnetic resonance imaging (MRI) features of cerebral small vessel disease (CSVD, e.g. total brain parenchyma volume, white matter hyperintensity volume, and presence of lacunar infarcts and cerebral microbleeds)³; plasma biomarkers of MVD (e.g. soluble intercellular adhesion molecule-1 [sICAM-1], soluble vascular adhesion molecule-1 [sVCAM-1], soluble E-selectin [sE-selectin] and von Willebrand factor [vWF])⁴; and albuminuria (“urinary albumin excretion”, UAE)⁵. In addition, direct measures include flicker light-induced retinal arteriolar and venular dilation response⁶ and heat-induced skin hyperaemia⁶. CSVD features are closely linked to brain microvasculature structure and evidence indicates that these features originate from cerebral microvascular dysfunction^{3, 7, 8}; retinal arteriolar and venular dilation response are also closely linked to the brain microvasculature⁹; in addition, to the extent that MVD is a generalised phenomenon, plasma biomarkers of MVD, UAE, and skin hyperaemia may also reflect brain MVD¹⁰.

These various measures of MVD (i.e. features of CSVD, plasma biomarkers of MVD, UAE, retinal arteriolar and venular dilation response and skin hyperaemia) may therefore be summarized into a total MVD composite score. A composite score reduces the influence of the biological variability of its components, as we assume substantial overlap among mechanisms underlying the associations between the MVD measures and cognitive performance. Furthermore, it reduces the chance of a type 1 error. However, no study evaluated the association between such a MVD composite score and cognitive performance.

Some individual MVD measures, i.e. CSVD features, plasma biomarkers of MVD and UAE, have been associated with worse cognitive performance¹¹⁻¹⁹, although not all measures consistently so^{15, 20, 21}. In the Maastricht Study, we previously found a cross-sectional association between higher UAE and worse cognitive performance²². Previous studies, but not all, were relatively small ($n < 200$)^{11, 20}, used selected populations^{11, 20, 21}, and may have been affected by residual confounding due to incomplete adjustment for education level and cardiovascular risk factors^{11, 12, 14}. Furthermore, most studies did not adjust for depression or low-grade inflammation, although both factors are linked to MVD and worse cognitive performance^{14, 23, 24}. Moreover, the associations between retinal arteriolar and venular dilation response and skin hyperaemia, and cognitive performance have not been investigated.

We therefore investigated, in a large population-based cohort with participants aged 40-75 years, whether a composite score of MVD measures, including CSVD features, plasma biomarkers of MVD, UAE, retinal arteriolar and venular dilation response and skin hyperaemia, is associated with worse cognitive performance. We additionally evaluated whether any such association was independent of age, education level, sex, lifestyle factors, cardiovascular risk factors, current depression and low-grade inflammation.

Methods

Study population

We used data from The Maastricht Study, an observational population-based cohort study. The rationale and methodology have been described previously²⁵. In brief, the study focuses on the aetiology, pathophysiology, complications, and comorbidities of diabetes mellitus type 2 (T2D) and is characterized by an extensive phenotyping approach. Eligible for participation were all individuals aged 40-75 years and living in the southern part of the Netherlands. Participants were recruited through mass media campaigns, the municipal registries, and the regional Diabetes Patient Registry via mailings. Recruitment was stratified according to known T2D status, with an oversampling of individuals with T2D, for reasons of efficiency. The present study includes cross-sectional data from 3451 participants who completed the baseline survey between November 2010 and September 2013. The examinations of each participant were performed within a time window of three months. The study has been approved by the institutional medical ethical committee (NL31329.068.10) and the Ministry of Health, Welfare, and Sports of the Netherlands (Permit 131088-105234-PG). All participants gave written informed consent. Data are available from The Maastricht Study for any researcher who meets the criteria for access to confidential data, and the corresponding author may be contacted to request data.

Microvascular dysfunction

For all MVD measures, participants were asked to refrain from smoking and drinking caffeine-containing beverages three hours before the measurement. A light meal was allowed until ≥ 90 minutes prior to the examination. For retinal measurements, pupils were dilated with 0.5% tropicamide and 2.5% phenylephrine at least 15 minutes before the start of the examination. Skin blood flow measurements were performed in a climate-controlled room at 24°C.

Cerebral small vessel disease

Brain MRI measurements were implemented from December 2013 onwards and were available in 2313 of 3451 participants (67%). Brain MRI was performed on a 3T MRI scanner (Siemens Magnetom Prisma-fit Syngo MR D13D, Erlangen, Germany). We evaluated four CSVD features, i.e. total brain parenchyma volume, white matter hyperintensity volume, and presence of lacunar infarcts and cerebral microbleeds³. A detailed description of the MRI protocol and the definitions of the CSVD features is provided in Item S1 (Supplementary Material). The MRI protocol consisted of a 3D T₁-weighted sequence, a fluid-attenuated inversion recovery sequence, a combined proton density and T₂-weighted turbo spin echo

sequence and a susceptibility-weighted imaging sequence²⁶. Volumes were determined semi-automatically, and lacunar infarcts and cerebral microbleeds were scored manually.

Plasma biomarkers of microvascular dysfunction

We measured four plasma biomarkers of MVD: sICAM-1, sVCAM-1, sE-selectin and vWF⁴. sICAM-1, sVCAM-1 and sE-selectin were measured in EDTA plasma samples with commercially available 4-plex sandwich immunoassay kits with different standards and antibodies (Meso Scale Discovery, Rockville, Maryland, United States of America). For this technique in this study, the intra- and inter-assay coefficients of variation were 10.3 and 8.4% for sICAM-1, 5.0 and 4.7% for sVCAM-1, and 2.9 and 7.4% for sE-selectin, respectively. Von Willebrand Factor (vWF) was quantified in citrate plasma using ELISA (Dako, Glostrup, Denmark). The intra- and inter-assay coefficients of variation were 3.0 and 4.3%, respectively.

Urinary albumin excretion

We assessed UAE in two 24-hour urine samples. Urinary albumin concentration was measured with a standard immunoturbidimetric assay by an automatic analyzer (due to a change of supplier, by the Beckman Synchron LX20 and the Roche Cobas 6000) and multiplied by collection volume to obtain 24-hour UAE²². A urinary albumin concentration below the detection limit of the assay was set at 1.5mg/L (2mg/L for the Beckman Synchron LX20 and 3mg/L for the Roche Cobas 6000) before multiplying by collection volume. Only urine collections with a collection time between 20 and 28 hours were considered valid. If needed, UAE was extrapolated to 24-hour excretion. For this study, UAE was preferably based on the average of two (available in 91.3% of participants) 24-hour urine collections.

Flicker light-induced retinal arteriolar and venular dilation response

We measured retinal arteriolar and venular dilation response to flicker light exposure by the Dynamic Vessel Analyzer (Imedos, Jena, Germany), as previously described^{6,27}. A baseline recording of 50 seconds was followed by 40-second flicker light exposure followed by a 60-second recovery period. We calculated baseline diameters (in measurement units) as the average diameter during the 20-50 seconds recording. For both the arteriolar and venular dilation response, percentage dilation over baseline was calculated using the average dilation achieved at time points 10 and 40 seconds during the flicker stimulation period.

Heat-induced skin hyperaemia

We measured heat-induced skin hyperaemia by laser Doppler flowmetry (Perimed, Järfälla, Sweden), as previously described⁶. We recorded unheated skin blood flow at the wrist, expressed in arbitrary perfusion units (PU), for two minutes to serve as a baseline. After two minutes, the temperature of the laser Doppler probe was rapidly and locally increased to 44°C and was kept constant until the end of the registration. Skin hyperaemia was expressed as the percentage increase in average PU during the 23 minutes heating phase over the two minutes average baseline PU.

Cognitive performance

We assessed cognitive performance by a concise neuropsychological test battery²⁵. For statistical efficiency, we constructed a cognitive function score by summation of standardized test scores of three cognitive domains: memory, information processing speed and executive function. A detailed description of methods used to calculate domain-specific cognitive scores is provided in Item S2 (Supplementary material). We evaluated memory with the Verbal Learning Test²⁸. Information processing speed was evaluated with the Stroop Color-Word Test Part I and II²⁹, Concept Shifting Test Part A and B³⁰, and Letter-Digit Substitution Test³¹. Executive function was evaluated with the Stroop Color-Word Test Part III and Concept Shifting Test Part C.

Covariates

We determined diabetes status according to the World Health Organization 2006 criteria as normal glucose metabolism, prediabetes or T2D²⁵. Education level was classified into three groups: low (none, primary or lower vocational education only), intermediate (intermediate general secondary, intermediate vocational or higher general secondary education) and high (higher vocational education or university level of education). Alcohol consumption (none, low, high), smoking status (never, former, current), prior cardiovascular disease (CVD), medication use, body mass index (BMI), office and ambulatory blood pressure, plasma lipid levels were determined as described previously^{5, 6, 25}. Hypertension was defined as an office blood pressure $\geq 140/90$ mmHg and/or use of antihypertensive medication. The Mini-International Neuropsychiatric Interview was used to assess the presence of a current DSM-IV defined minor or major depressive episode, as described previously²⁵. Plasma biomarkers of low-grade inflammation were determined as described previously³². These included high-sensitive C-reactive protein (CRP), serum amyloid A (SAA), interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor alpha (TNF- α).

Statistical analysis

We selected all participants that had data available on all potential confounders, at least one individual MVD measure, and cognitive function. We did not impute missing values. We inversed total brain parenchyma volume, retinal arteriolar and venular dilation response and skin hyperaemia so higher values indicated MVD. White matter hyperintensity volume was log-transformed (base 2) to normalize its skewed distribution. We analyzed UAE as a categorically (<15 [reference], 15-<30, and ≥ 30 mg/24h), because UAE and cognitive performance were non-linearly associated.

We calculated a MVD composite score ("MVD score") of all individual MVD measures. For the total MVD score, the individual 12 MVD measures (i.e. four CSVD features, four plasma biomarkers of MVD, UAE, retinal arteriolar and venular dilation responses and skin hyperaemia) were standardized into z-scores. These z-scores were averaged, and this average was standardized into the MVD score. The MVD score was calculated only in participants with data available on at least nine of the 12 individual MVD measures. The Cronbach's alpha for measuring internal consistency³³ among the individual MVD measures was .52. This is considered acceptable internal consistency for different measures that may reflect, at least in part, the same underlying construct³⁴.

We used linear regression to investigate the association between the MVD score and the cognitive function score. All analyses were adjusted for age, education level, sex, T2D, BMI, smoking, alcohol use, hypertension, total/HDL cholesterol ratio, triglycerides and lipid-modifying medication (model 1), and additionally for prior CVD, current depression and the plasma biomarkers of low-grade inflammation, i.e. CRP, SAA, IL-6, IL-8 and TNF- α (model 2). Prior CVD, current depression and low-grade inflammation were entered into a separate model, because of the risk of overadjustment bias: these factors may be confounders but may also mediate the association between MVD and cognitive performance.

We tested interaction terms with age (dichotomized into <65 and ≥ 65 years), education level, sex and T2D to evaluate whether the association between MVD and cognitive performance differed according to these factors. Interaction with age and education level was tested because MVD may be more strongly associated with worse cognitive performance in individuals with lower cognitive reserve, i.e. in those with higher age and lower education level³⁵.

Several sensitivity analyses were performed. First, we repeated the analysis using domain-specific cognitive function scores as the outcome, i.e. memory, processing speed and executive function. Second, we repeated the analysis using each individual MVD measure as the determinant. Third, we repeated the analysis with the MVD score in participants with data available on at least one, eight and ten of the 12 individual MVD measures, respectively. Fourth, to test whether the association between the MVD score and cognitive function score was primarily determined by individual MVD measures, we repeated the analysis five times after consecutively excluding from the MVD score the CSVD features, plasma biomarkers of MVD, UAE, retinal arteriolar and venular dilation response and skin hyperaemia, respectively. Fifth, we calculated composite scores for the CSVD features, plasma biomarkers of MVD and retinal arteriolar and venular dilation response, respectively, and evaluated the association between these composite scores and cognitive function score. The CSVD composite score was calculated as described previously³⁶. One point per CSVD feature was assigned for: 4th quartile lower total brain parenchyma volume and higher white matter hyperintensity volume; and presence of lacunar infarcts and cerebral microbleeds. The points for each feature were combined into the CSVD score (range 0-4). For the plasma biomarkers of MVD score and retinal arteriolar and venular dilation response scores, the z-scores of the four plasma biomarkers of MVD and the arteriolar and venular dilation responses were summed and standardized, respectively. Sixth, we repeated the analysis with additional adjustment for average 24-hour ambulatory systolic blood pressure³⁷, and class of antihypertensive medication (i.e. angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers versus other classes)^{38, 39}. Ambulatory systolic blood pressure is a better predictor of cognitive decline than office blood pressure⁴⁰. However, we did not adjust for ambulatory systolic blood pressure in the main analysis, because data on ambulatory systolic blood pressure were missing in a relatively large number of participants (n=424). Seventh, we repeated the analysis after stratification by T2D status, because by design individuals with T2D were oversampled in our cohort.

All analyses were performed with SPSS software (v22.0; IBM, Chicago, USA). A P value of $<.05$, and a P value for interaction of $<.10$ for interaction with sex and T2D were considered statistically significant. For interaction with age and education level, a Bonferroni-corrected P value of $<.05$ was used instead of $<.10$, because higher age and lower education level are considered reflections of the same construct, i.e. lower cognitive reserve.

Results

Figure 1 shows the derivation of the final study population. In total, 3011 participants had data available on all potential confounders and at least one individual MVD measure. The MVD score was available in 2034 participants, CSVD features in 2002, plasma biomarkers of MVD in 2991, UAE in 2987, retinal arteriolar and venular dilation response in 1998, and skin hyperaemia in 1457. These populations were comparable with regard to age, sex and cardiovascular risk profile (Supplementary Table S1). Table 1 shows the characteristics of the study population and according to tertiles of the cognitive function score. Population-characteristics according to tertiles of memory, processing speed and executive function are provided in the Supplementary Material (Tables S2-S4). The study population had a mean age of 59.5 years, 48.9% were women, 26.5% had T2D (oversampled by design), and 41.1% had a high education level.

The MVD score was statistically significantly associated with a worse cognitive function score (Figure 2, models 1 and 2). The regression coefficients of all covariates included in the fully adjusted model are provided in the Supplementary material (Table S5). The fully adjusted beta-coefficient of the association between one standard deviation higher MVD score and the cognitive function score was equivalent to two (range: one-three) years of aging.

Statistically significant interaction was found between the MVD score and age (P value for interaction .045), indicating that the association between MVD and worse cognitive function was stronger in participants aged ≥ 65 as compared to those aged <65 years. The association between the MVD score and cognitive function score stratified by age is provided in the Supplementary Material (Table S6). We found no interactions with education level, sex, and T2D.

Sensitivity analyses

The MVD score was statistically significantly associated with worse memory and processing speed, but not with executive function (Figure 3). The individual MVD measures lower total brain parenchyma volume, higher white matter hyperintensity volume, sE-selectin, and $\text{UAE} >30$ vs. $<15\text{mg}/24\text{h}$ were statistically significantly associated with a worse cognitive function score, but not lacunar infarcts, microbleeds, sICAM-1, sVCAM-1, vWF, $\text{UAE } 15\text{--}<30$ vs. $<15\text{mg}/24\text{h}$, retinal arteriolar and venular dilation responses or skin hyperaemia (Figure 4 and Supplementary Table S7). Results were similar when we repeated the analyses in participants with data available on at least one ($n=3011$), eight ($n=2364$) or ten ($n=1658$) of the 12 individual MVD measures (Supplementary Table S8), and when we consecutively excluded, from the MVD score, the CSVD features, plasma biomarkers of MVD, UAE, retinal

arteriolar and venular dilation response or skin hyperaemia (Supplementary Table S9). The composite scores of CSVD features and plasma biomarkers of MVD, but not of retinal arteriolar and venular dilation responses, were statistically significantly associated with a worse cognitive function score (Supplementary Table S10). Results were similar when we additionally adjusted for ambulatory blood pressure (Supplementary Table S11), or for class of antihypertensive medication (Supplementary Table S12). Furthermore, no statistically significant interaction was found for T2D status in our main analysis (P value for interaction .94), and analysis stratified by T2D status showed that results were qualitatively similar in individuals with and without T2D (Supplementary Table S13).

Discussion

The present cross-sectional study found that MVD is associated with worse cognitive performance. This association was present for various MVD measures, including CSVD features, plasma biomarkers of MVD and UAE, but not retinal arteriolar and venular dilation responses or skin hyperaemia. Furthermore, this association was independent of age, education level, sex, lifestyle factors, cardiovascular risk factors, current depression and low-grade inflammation. The strength of the association of each standard deviation higher MVD score on the cognitive function score was equivalent to the effect of one to three years of aging.

Our study agrees with previous studies that showed an association between individual MVD measures, i.e. CSVD features^{15,41}, plasma biomarkers of MVD¹¹⁻¹⁴ and UAE¹⁶, and worse cognitive performance. Some of these studies, but not all, found an association between MVD and worse cognitive performance or cognitive impairment. Our study expands this knowledge, as it is the first to comprehensively evaluate the association between MVD measures in various vascular beds and cognitive performance in a large population-based study with extensive adjustment for confounders.

The results were consistent across various MVD measures, except for retinal arteriolar and venular dilation responses and skin hyperaemia, which were not statistically significantly associated with cognitive performance. Retinal arteriolar and venular dilation response and skin hyperaemia may mostly reflect a more subtle form of endothelium-dependent MVD, which may change acutely and may be reversible²⁷. For example, microvascular dilation responses in the retina or skin are transiently decreased directly after smoking⁴² and consumption of caffeine⁴³. In contrast, CSVD features, plasma biomarkers of MVD and UAE (all indirect measures of microvascular dysfunction) may reflect a more advanced stage of MVD¹⁰. However, this study is the first to evaluate the association between retinal arteriolar and venular dilation response and skin hyperaemia and cognitive function, and this issue, therefore, requires further study.

In the present study, the association between MVD and worse cognitive performance was stronger in participants aged ≥ 65 years vs. < 65 years. This corresponds to our previous study on UAE and cognitive performance²², and may be explained by a higher susceptibility for the detrimental effects of MVD on cognitive performance in the presence

of a lower cognitive reserve with increasing age, in accordance with the cognitive reserve hypothesis³⁵.

The observation that various MVD measures were associated with worse cognitive performance in our study supports the hypothesis that MVD may play a role in the pathophysiology of cognitive impairment. Earlier studies showed that impaired neurovascular coupling, cerebral autoregulation², blood-brain barrier leakage⁴⁴, and impaired neurogenesis⁴⁵ are present in individuals with mild cognitive impairment and Alzheimer's disease, and these disturbances may be the consequence of MVD².

Other underlying mechanisms may, however, explain the observed associations. First, MVD often coexists with CVD, and CVD is associated with worse cognitive performance⁴⁶. However, our results were independent of a large set of cardiovascular risk factors and prior CVD. Second, depression and low-grade inflammation are related to both MVD and worse cognitive performance. Our results remained, however, after adjustment for these factors. Third, other biological mechanisms may underlie both MVD and worse cognitive performance. For example, oxidative stress and lower brain-derived neurotrophic factor have been associated with both MVD and worse cognitive performance⁴⁷⁻⁵⁰. However, data on oxidative stress and brain-derived neurotrophic factor were unavailable in our study; this requires further study.

Our study has several limitations. First, the cross-sectional observational design precludes reaching causal conclusions about the study findings. Second, the construction of the composite scores assumes that all its components reflect cerebral MVD, which is not necessarily true. Our a-priori defined composite score was calculated with use of indirect and direct measures, which may reflect different forms of microvascular dysfunction (acute and reversible vs. more advanced), and this may have led to an underestimation of the association between (a more advanced stage of) microvascular dysfunction and worse cognitive function. Third, no data were available on Alzheimer's disease pathologies, such as amyloid and tau deposition. It has been hypothesized that these pathologies and MVD may act synergistically (i.e. interact) in the development of cognitive impairment⁵¹. Such interaction might explain our observed association between MVD and worse memory, a domain most strongly associated with Alzheimer's disease, and this issue requires further study. Fourth, lower total brain parenchyma volume is also determined by factors other than microvascular disease, particularly the process of neurodegeneration. Fifth, the study population consisted of middle and early-old aged participants without dementia who were relatively well-educated and whose cardiovascular risk factors were relatively well-controlled. This may have led to an underestimation of the reported findings due to lower variation in cognitive performance and relatively high cognitive reserve.

In conclusion, the present study shows that MVD is associated with worse cognitive performance.

Perspectives

This study supports the hypothesis that MVD contributes to the development cognitive impairment. MVD might therefore be a target for prevention strategies of cognitive impairment. Evidence suggests that lifestyle modifications, such as weight loss and exercise, may, at least in part, favorably influence MVD⁵². In addition, drugs, such as renin-angiotensin-aldosterone system inhibitors and antihyperglycemic agents (i.e. metformin and glucagon-like peptide 1 receptor (GLP-1R) agonists), may improve microvascular function⁵², possibly beyond their blood pressure- or glucose-lowering effects⁵². Future longitudinal studies are needed to further evaluate the association of MVD and cognitive decline and dementia.

References

1. Prince M. World Alzheimer Report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends. *Alzheimer's Disease International*. 2015.
2. De Silva TM and Faraci FM. Microvascular Dysfunction and Cognitive Impairment. *Cell Mol Neurobiol*. 2016;36:241-58.
3. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge R, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M and nEuroimaging STfRVco. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol*. 2013;12:822-38.
4. van Sloten TT, Schram MT, Adriaanse MC, Dekker JM, Nijpels G, Teerlink T, Scheffer PG, Pouwer F, Schalkwijk CG, Stehouwer CD and Henry RM. Endothelial dysfunction is associated with a greater depressive symptom score in a general elderly population: the Hoorn Study. *Psychol Med*. 2014;44:1403-16.
5. Martens RJ, Henry RM, Houben AJ, van der Kallen CJ, Kroon AA, Schalkwijk CG, Schram MT, Sep SJ, Schaper NC, Dagnelie PC, Muris DM, Gronenschild EH, van der Sande FM, Leunissen KM, Kooman JP and Stehouwer CD. Capillary Rarefaction Associates with Albuminuria: The Maastricht Study. *J Am Soc Nephrol*. 2016;27:3748-3757.
6. Sorensen BM, Houben AJ, Berendschot TT, Schouten JS, Kroon AA, van der Kallen CJ, Henry RM, Koster A, Sep SJ, Dagnelie PC, Schaper NC, Schram MT and Stehouwer CD. Prediabetes and Type 2 Diabetes Are Associated With Generalized Microvascular Dysfunction: The Maastricht Study. *Circulation*. 2016;134:1339-1352.
7. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. *Lancet Neurol*. 2010;9:689-701.
8. Ostergaard L, Engedal TS, Moreton F, Hansen MB, Wardlaw JM, Dalkara T, Markus HS and Muir KW. Cerebral small vessel disease: Capillary pathways to stroke and cognitive decline. *J Cereb Blood Flow Metab*. 2016;36:302-25.
9. Umemura T, Kawamura T and Hotta N. Pathogenesis and neuroimaging of cerebral large and small vessel disease in type 2 diabetes: A possible link between cerebral and retinal microvascular abnormalities. *J Diabetes Investig*. 2017;8:134-148.
10. Muris DM, Houben AJ, Schram MT and Stehouwer CD. Microvascular dysfunction: an emerging pathway in the pathogenesis of obesity-related insulin resistance. *Rev Endocr Metab Disord*. 2013;14:29-38.
11. Huang CW, Tsai MH, Chen NC, Chen WH, Lu YT, Lui CC, Chang YT, Chang WN, Chang AY and Chang CC. Clinical significance of circulating vascular cell adhesion molecule-1 to white matter disintegrity in Alzheimer's dementia. *Thromb Haemost*. 2015;114:1230-40.
12. Rafnsson SB, Deary IJ, Smith FB, Whiteman MC, Rumley A, Lowe GD and Fowkes FG. Cognitive decline and markers of inflammation and hemostasis: the Edinburgh Artery Study. *J Am Geriatr Soc*. 2007;55:700-7.
13. Yoon CY, Steffen LM, Gross MD, Launer LJ, Odegaard A, Reiner A, Sanchez O, Yaffe K, Sidney S and Jacobs DR, Jr. Circulating Cellular Adhesion Molecules and Cognitive Function: The Coronary Artery Risk Development in Young Adults Study. *Front Cardiovasc Med*. 2017;4:37.

14. Heringa SM, van den Berg E, Reijmer YD, Nijpels G, Stehouwer CD, Schalkwijk CG, Teerlink T, Scheffer PG, van den Hurk K, Kappelle LJ, Dekker JM and Biessels GJ. Markers of low-grade inflammation and endothelial dysfunction are related to reduced information processing speed and executive functioning in an older population - the Hoorn Study. *Psychoneuroendocrinology*. 2014;40:108-18.
15. Debette S and Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ*. 2010;341:c3666.
16. Georgakis MK, Dimitriou NG, Karalexi MA, Mihos C, Nasothimiou EG, Tousoulis D, Tsiygoulis G and Petridou ET. Albuminuria in Association with Cognitive Function and Dementia: A Systematic Review and Meta-Analysis. *J Am Geriatr Soc*. 2017;65:1190-1198.
17. Li X, Yuan J, Yang L, Qin W, Yang S, Li Y, Fan H and Hu W. The significant effects of cerebral microbleeds on cognitive dysfunction: An updated meta-analysis. *PLoS One*. 2017;12:e0185145.
18. Saczynski JS, Sigurdsson S, Jonsdottir MK, Eiriksdottir G, Jonsson PV, Garcia ME, Kjartansson O, Lopez O, van Buchem MA, Gudnason V and Launer LJ. Cerebral infarcts and cognitive performance: importance of location and number of infarcts. *Stroke*. 2009;40:677-82.
19. Vibha D, Tiemeier H, Mirza SS, Adams HHH, Niessen WJ, Hofman A, Prasad K, van der Lugt A, Vernooij MW and Ikram MA. Brain Volumes and Longitudinal Cognitive Change: A Population-based Study. *Alzheimer Dis Assoc Disord*. 2017.
20. Kearney-Schwartz A, Rossignol P, Bracard S, Felblinger J, Fay R, Boivin JM, Lecompte T, Lacolley P, Benetos A and Zannad F. Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints. *Stroke*. 2009;40:1229-36.
21. Trollor JN, Smith E, Agars E, Kuan SA, Baune BT, Campbell L, Samaras K, Crawford J, Lux O, Kochan NA, Brodaty H and Sachdev P. The association between systemic inflammation and cognitive performance in the elderly: the Sydney Memory and Ageing Study. *Age (Dordr)*. 2012;34:1295-308.
22. Martens RJ, Kooman JP, Stehouwer CD, Dagnelie PC, van der Kallen CJ, Koster A, Kroon AA, Leunissen KM, Nijpels G, van der Sande FM, Schaper NC, Sep SJ, van Bortel MP, Schram MT and Henry RM. Estimated GFR, Albuminuria, and Cognitive Performance: The Maastricht Study. *Am J Kidney Dis*. 2017;69:179-191.
23. van Agtmaal MJM, Houben A, Pouwer F, Stehouwer CDA and Schram MT. Association of Microvascular Dysfunction With Late-Life Depression: A Systematic Review and Meta-analysis. *JAMA Psychiatry*. 2017;74:729-739.
24. Beaudreau SA and O'Hara R. The association of anxiety and depressive symptoms with cognitive performance in community-dwelling older adults. *Psychol Aging*. 2009;24:507-12.
25. Schram MT, Sep SJ, van der Kallen CJ, Dagnelie PC, Koster A, Schaper N, Henry RM and Stehouwer CD. The Maastricht Study: an extensive phenotyping study on determinants of type 2 diabetes, its complications and its comorbidities. *Eur J Epidemiol*. 2014;29:439-51.
26. van Agtmaal MJM, Houben A, de Wit V, Henry RMA, Schaper NC, Dagnelie PC, van der Kallen CJ, Koster A, Sep SJ, Kroon AA, Jansen JFA, Hofman PA, Backes WH, Schram MT and Stehouwer CDA. Prediabetes Is Associated With Structural Brain Abnormalities: The Maastricht Study. *Diabetes Care*. 2018;41:2535-2543.
27. Houben A, Martens RJH and Stehouwer CDA. Assessing Microvascular Function in Humans from a Chronic Disease Perspective. *J Am Soc Nephrol*. 2017;28:3461-3472.

28. Van der Elst W, van Boxtel MP, van Breukelen GJ and Jolles J. Rey's verbal learning test: normative data for 1855 healthy participants aged 24-81 years and the influence of age, sex, education, and mode of presentation. *J Int Neuropsychol Soc.* 2005;11:290-302.
29. Van der Elst W, Van Boxtel MP, Van Breukelen GJ and Jolles J. The Stroop color-word test: influence of age, sex, and education; and normative data for a large sample across the adult age range. *Assessment.* 2006;13:62-79.
30. Van der Elst W, Van Boxtel MP, Van Breukelen GJ and Jolles J. The Concept Shifting Test: adult normative data. *Psychol Assess.* 2006;18:424-32.
31. van der Elst W, van Boxtel MP, van Breukelen GJ and Jolles J. The Letter Digit Substitution Test: normative data for 1,858 healthy participants aged 24-81 from the Maastricht Aging Study (MAAS): influence of age, education, and sex. *J Clin Exp Neuropsychol.* 2006;28:998-1009.
32. van Dooren FE, Schram MT, Schalkwijk CG, Stehouwer CD, Henry RM, Dagnelie PC, Schaper NC, van der Kallen CJ, Koster A, Sep SJ, Denollet J, Verhey FR and Pouwer F. Associations of low grade inflammation and endothelial dysfunction with depression - The Maastricht Study. *Brain Behav Immun.* 2016;56:390-6.
33. European Commission. Joint Research Centre., Organisation for Economic Co-operation and Development. and SourceOECD (Online service). *Handbook on constructing composite indicators : methodology and user guide.* Paris: OECD; 2008.
34. Field AP. *Discovering statistics using IBM SPSS statistics : and sex and drugs and rock 'n' roll.* 4th edition. ed. Los Angeles: Sage; 2013.
35. Whalley LJ, Deary IJ, Appleton CL and Starr JM. Cognitive reserve and the neurobiology of cognitive aging. *Ageing Res Rev.* 2004;3:369-82.
36. van Sloten TT, Sigurdsson S, van Buchem MA, Phillips CL, Jonsson PV, Ding J, Schram MT, Harris TB, Gudnason V and Launer LJ. Cerebral Small Vessel Disease and Association With Higher Incidence of Depressive Symptoms in a General Elderly Population: The AGES-Reykjavik Study. *Am J Psychiatry.* 2015;172:570-8.
37. Yaneva-Sirakova T, Traykov L, Petrova J and Vassilev D. Comparison of Central, Ambulatory, Home and Office Blood Pressure Measurement as Risk Markers for Mild Cognitive Impairment in Hypertensive Patients. *Dement Geriatr Cogn Dis Extra.* 2017;7:274-282.
38. Redon J. Renal protection by antihypertensive drugs: insights from microalbuminuria studies. *J Hypertens.* 1998;16:2091-100.
39. Suhrs HE, Michelsen MM and Prescott E. Treatment strategies in coronary microvascular dysfunction: a systematic review of interventional studies. *Microcirculation.* 2017.
40. White WB, Wolfson L, Wakefield DB, Hall CB, Campbell P, Moscufo N, Schmidt J, Kaplan RF, Pearlson G and Guttmann CR. Average daily blood pressure, not office blood pressure, is associated with progression of cerebrovascular disease and cognitive decline in older people. *Circulation.* 2011;124:2312-9.
41. Rensma SP, van Sloten TT, Launer LJ and Stehouwer CDA. Cerebral small vessel disease and risk of incident stroke, dementia and depression, and all-cause mortality: A systematic review and meta-analysis. *Neurosci Biobehav Rev.* 2018;90:164-173.
42. Ijzerman RG, Serne EH, van Weissenbruch MM, de Jongh RT and Stehouwer CD. Cigarette smoking is associated with an acute impairment of microvascular function in humans. *Clin Sci (Lond).* 2003;104:247-52.
43. Terai N, Spoerl E, Pillunat LE and Stodtmeister R. The effect of caffeine on retinal vessel diameter in young healthy subjects. *Acta Ophthalmol.* 2012;90:524-8.

44. van de Haar HJ, Burgmans S, Jansen JF, van Osch MJ, van Buchem MA, Muller M, Hofman PA, Verhey FR and Backes WH. Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease. *Radiology*. 2016;281:527-535.
45. Lazarov O and Marr RA. Neurogenesis and Alzheimer's disease: at the crossroads. *Exp Neurol*. 2010;223:267-81.
46. Frazier DT, Seider T, Bettcher BM, Mack WJ, Jastrzab L, Chao L, Weiner MW, DeCarli C, Reed BR, Mungas D, Chui HC and Kramer JH. The role of carotid intima-media thickness in predicting longitudinal cognitive function in an older adult cohort. *Cerebrovasc Dis*. 2014;38:441-7.
47. Hajjar I, Hayek SS, Goldstein FC, Martin G, Jones DP and Quyyumi A. Oxidative stress predicts cognitive decline with aging in healthy adults: an observational study. *J Neuroinflammation*. 2018;15:17.
48. Higashi Y, Maruhashi T, Noma K and Kihara Y. Oxidative stress and endothelial dysfunction: clinical evidence and therapeutic implications. *Trends Cardiovasc Med*. 2014;24:165-9.
49. Huang CC, Liu ME, Chou KH, Yang AC, Hung CC, Hong CJ, Tsai SJ and Lin CP. Effect of BDNF Val66Met polymorphism on regional white matter hyperintensities and cognitive function in elderly males without dementia. *Psychoneuroendocrinology*. 2014;39:94-103.
50. Liu ME, Huang CC, Chen MH, Yang AC, Tu PC, Yeh HL, Hong CJ, Chen JF, Hwang JP, Lin CP and Tsai SJ. Effect of the BDNF Val66Met polymorphism on regional gray matter volumes and cognitive function in the Chinese population. *Neuromolecular Med*. 2014;16:127-36.
51. Attems J and Jellinger KA. The overlap between vascular disease and Alzheimer's disease--lessons from pathology. *BMC Med*. 2014;12:206.
52. Stehouwer CDA. Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle With Widespread Consequences. *Diabetes*. 2018;67:1729-1741.

Table 1. Characteristics of the study population

Baseline characteristics	Total study population (n=3011)	Tertiles of cognitive function score		
		Lowest (n=1003)	Middle (n=1004)	Highest (n=1004)
Age, years	59.5 (8.2)	64.0 (6.8)	59.9 (7.3)	54.7 (7.8)
Women, %	48.9 (1471)	36.5 (366)	45.4 (456)	64.6 (649)
Education level, %				
- low	15.7 (472)	31.6 (317)	11.8 (118)	3.7 (37)
- intermediate	43.2 (1301)	44.8 (449)	45.1 (453)	39.7 (399)
- high	41.1 (1238)	23.6 (237)	43.1 (433)	56.6 (568)
Smoking status, %				
- never	34.9 (1051)	31.8 (319)	33.9 (340)	39.0 (392)
- former	51.9 (1564)	52.8 (530)	53.8 (540)	49.2 (494)
- current	13.2 (396)	15.4 (154)	12.4 (124)	11.8 (118)
Alcohol use, %				
- none	18.0 (543)	21.7 (218)	16.0 (161)	16.3 (164)
- low	55.5 (1671)	54.1 (543)	58.6 (588)	53.8 (540)
- high	26.5 (797)	24.1 (242)	25.4 (255)	29.9 (300)
Body mass index (kg/m ²)	27.1 (4.5)	28.0 (4.5)	27.0 (4.6)	26.2 (4.2)
Type 2 diabetes, %	26.5 (797)	41.2 (413)	25.0 (251)	13.2 (133)
Hypertension, %	55.4 (1667)	71.9 (721)	54.9 (551)	39.3 (395)
Total/HDL cholesterol ratio	3.7 (1.2)	3.7 (1.2)	3.8 (1.2)	3.6 (1.2)
Triglycerides (mmol/L)	1.4 (0.9)	1.5 (0.9)	1.4 (0.8)	1.3 (0.8)
Lipid-modifying medication, %	34.9 (1050)	50.3 (505)	33.9 (340)	20.4 (205)
Prior cardiovascular disease, %	16.1 (486)	24.6 (247)	13.9 (140)	9.9 (99)
Current depression, %	3.7 (112)	5.4 (54)	3.6 (36)	2.2 (22)
Plasma biomarkers of low-grade inflammation composite score (SD)*	0.0 (1.0)	0.2 (1.0)	0.0 (1.0)	-0.3 (1.0)
Microvascular dysfunction measures [†]				
Microvascular dysfunction composite score (SD)	0.0 (1.0)	0.4 (1.1)	0.0 (0.9)	-0.4 (0.8)
Cerebral small vessel disease features				
Total brain parenchyma volume (ml)	1138.4 (111.7)	1123.9 (111.8)	1150.3 (117.3)	1138.8 (104.6)
White matter hyperintensity volume (ml)	0.2 (0.1-0.7)	0.4 (0.1-1.3)	0.2 (0.1-0.8)	0.1 (<0.1-0.4)
Presence of cerebral microbleeds	11.8 (237)	9.2 (92)	10.5 (73)	9.9 (72)
Presence of lacunar infarcts	5.4 (110)	6.7 (40)	6.4 (45)	3.4 (25)
Plasma biomarkers of microvascular dysfunction				
Soluble ICAM-1 (µg/l)	352.7 (98.1)	372.3 (116.4)	348.1 (86.7)	337.8 (84.7)
Soluble VCAM-1 (µg/l)	425.1 (99.8)	445.2 (111.4)	422.9 (97.9)	407.1 (84.6)
Soluble E-selectin (µg/l)	117.5 (64.2)	130.1 (76.4)	117.6 (56.3)	104.9 (55.4)
Von Willebrand Factor (%)	131.7 (47.8)	140.9 (51.1)	130.8 (45.9)	123.5 (44.7)
Urinary albumin excretion				
Urinary albumin excretion ≥30mg/24h	8.1 (242)	13.4 (133)	7.0 (70)	3.9 (39)

Baseline characteristics	Total study population (n=3011)	Teriles of cognitive function score		
		Lowest (n=1003)	Middle (n=1004)	Highest (n=1004)
Urinary albumin excretion 15-<30mg/24h	10.3 (308)	13.1 (130)	9.3 (93)	8.5 (85)
Flicker light-induced arteriolar and venular dilation response				
Flicker light-induced arteriolar dilation response (%)	3.1 (2.8)	2.7 (2.9)	3.1 (2.7)	3.3 (2.7)
Flicker light-induced venular dilation response (%)	3.9 (2.2)	3.7 (2.2)	3.9 (2.1)	4.0 (2.2)
Heat-induced skin hyperaemia (%)	1133.2 (781.5)	1006.2 (760.5)	1208.6 (859.6)	1192.0 (701.6)

Data are presented as percentage of participants (n), mean ± standard deviation (SD) or median (interquartile range). *Expressed per standard deviation; †Data available for microvascular dysfunction composite score n=2034; total brain parenchyma volume and white matter hyperintensity volume n=2049; lacunar infarcts n=2046; cerebral microbleeds n=2012; sICAM-1; sVCAM-1; and sE-selectin n=3011; vWF n=2991; urinary albumin excretion n=2987; retinal arteriolar dilation response n=2018; retinal venular dilation response n=2049; and skin hyperaemia n=1457.

Figure 1. Derivation of the final study populations. *Missings were not mutually exclusive.

Figure 2. Association between microvascular dysfunction score and cognitive function score.
*Statistical significance ($p < 0.05$). Data available in $n = 2,034$. Results are expressed as SD (95% confidence interval) worse cognitive function score per SD higher microvascular dysfunction score. Results were adjusted for age, education level, sex, diabetes mellitus type 2, body mass index, smoking status, alcohol use, hypertension, total/HDL cholesterol ratio, triglycerides, and lipid-modifying medication use (model 1), and additionally for prior cardiovascular disease, current depression and plasma biomarkers of low-grade inflammation (model 2).

Figure 3. Associations between microvascular dysfunction score and domain-specific cognitive function score.
*Statistical significance ($p < 0.05$). Data available in $n = 2,034$. Results are expressed as SD (95% confidence interval) worse domain-specific cognitive function score per SD higher microvascular dysfunction score. Adjustments as in Figure 2.

Figure 4. Associations between individual measures of microvascular dysfunction and cognitive function score. *Statistical significance ($p < 0.05$). Results are expressed as (SD (95% confidence interval)) worse cognitive function score per SD lower total brain parenchyma volume and higher white matter hyperintensity volume, presence of lacunar infarcts and microbleeds, per SD higher plasma biomarkers of microvascular dysfunction, urinary albumin excretion ≥ 30 versus < 15 mg/24h, urinary albumin excretion between 15 and < 30 versus < 15 mg/24h, per SD lower retinal arteriolar and venular dilation response, and per SD lower skin hyperaemia. Adjustments as in Figure 2, model 2. Abbreviations: TBV, total brain parenchyma volume; WMH, white matter hyperintensity volume.

Supplemental material

Item S1. Brain magnetic resonance imaging

Brain magnetic resonance imaging (MRI) was performed on a 3T MRI scanner (Siemens Magnetom Prisma-fit Syngo MR D13D, Erlangen, Germany) by use of a 64-element head/neck coil for parallel imaging. The MRI protocol consisted of a 3D T_1 -weighted magnetization prepared rapid acquisition gradient echo (MPRAGE) sequence (TR/TI/TE 2300/900/2.98 ms, 176 slices, 256×240 matrix size, 1.00 mm cubic voxel size); a fluid-attenuated inversion recovery (FLAIR) sequence (TR/TI/TE 5000/1800/394 ms, 176 slices, 512×512 matrix size, 0.49×0.49×1.00 mm voxel size); a combined proton density (PD) and T_2 -weighted turbo spin echo (TSE) pulse sequence (TR/TE1/TE2 3200/9.4/94 ms, 30 slices, 640×540 matrix size, 0.36×0.36×4.00 mm voxel size); and a susceptibility-weighted imaging (SWI) sequence (TR/TE 28/20 ms, 144 slices, 384×312 matrix size, 0.57×0.57×1.00 mm voxel size).

Contra-indications for MRI assessments were the presence of a cardiac pacemaker or implantable cardioverter-defibrillator, neurostimulator, non-detachable insulin pump, metallic vascular clips or stents in the head, cochlear implant, metal-containing intra-uterine device, metal splinters or shrapnel, dentures with magnetic clip, an inside bracket, pregnancy, epilepsy, and claustrophobia.

T_1 -weighted images and FLAIR images were analyzed by use of an ISO-13485:2012 certified, automated method (which included visual inspection)^{1,2}. T_1 -weighted images were segmented into grey matter, white matter and cerebrospinal fluid volumes (1 voxel = 1.00 mm³ = 0.001 ml)¹. Intracranial volume was calculated as the sum of grey matter, white matter (including white matter hyperintensity volume) and cerebrospinal fluid volumes. Total brain parenchyma volume was calculated as the sum of grey and white matter volumes. White matter hyperintensities identified were summed to assess total white matter hyperintensities burden in milliliter. Lacunar infarcts were defined as focal brain parenchyma defects of ≥3 mm and <15 mm in size with a similar signal intensity as cerebrospinal fluid on all sequences and a hyperintense rim on T_2 and FLAIR images³. Cerebral microbleeds were rated on T_2 -weighted and SWI images by use of the Microbleed Anatomical Rating Scale⁴, and were defined as focal lesions of ≥2 mm and ≤10 mm in size with a hypointense signal³. The presence of lacunar infarcts and cerebral microbleeds was rated manually by three neuroradiologists. The two-way mixed effects, consistency, intraclass correlation coefficients for the three raters based on 50 randomly selected scans were 0.84 (95% confidence interval 0.74; 0.91) and 0.83 (0.72; 0.90) for the presence of lacunar infarcts and cerebral microbleeds, respectively.

Item S2. Cognitive assessment

The composite memory score was derived from the Verbal Learning Test by weighting total immediate and delayed recall scores. The domain information processing speed included the Stroop Color-Word Test Part I and II, the Concept Shifting Test Part A and B, and the Letter-Digit Substitution Test. Executive function was assessed by the Stroop Color-Word Test Part III and the Concept Shifting Test Part C. A description of the individual tests is provided below.

Raw test scores were transformed into z-scores. Standardized scores of the Stroop Color-Word Test and Concept Shifting Test were inverted so that higher scores indicated better cognitive performance. Thereafter, domain-specific scores were calculated as the standardized average of the z-scores from (sub)tests within that domain (e.g. memory = $\text{z-score of (z-score immediate recall + z-score delayed recall / 2)}$). The standardized average of these domain scores was then considered a measure of overall cognitive performance (i.e. overall cognitive performance = $\text{z-score of (memory + information processing speed + executive function / 3)}$).

Description of the individual cognitive tests used in the present study

Verbal Learning Test:⁵

Fifteen unrelated, monosyllabic, words were presented on a computer screen in five subsequent trials. After each trial, participants were instructed to recall as many words as possible in any order. Twenty minutes after the last trial, participants were asked again to reproduce the words. Outcomes recorded included the total number of words correctly recalled over the five trials (total immediate recall) and the number of correctly recalled words during delayed recall (delayed recall).

Stroop Color-Word Test:⁶

In this test, which consisted of three parts, participants were firstly asked to read aloud color names (i.e. red, blue, yellow, and green) that were printed in black ink (Part I). Secondly, they were instructed to name solid color patches (Part II). Finally, participants had to name the ink color of color names that were printed in an incongruent color (e.g. participants were asked to say red when the word yellow was printed in red) (Part III). The time needed to complete Part III was adjusted for the average time needed to complete Part I and II.

Concept Shifting Test:⁷

This test, a modification of the Trailing Making Test, consisted of four subtasks. During each subtask, participants were shown 16 small circles aligned along a larger imaginary circle. The small circles contained (a combination of) digits, letters, or were empty. Participants were instructed to cross-out as quickly as possible the digits in ascending order (Part A), the letters in alphabetic order (Part B), and the letters and digits in alternating order (Part C). Thereafter, participants were asked to cross-out empty circles in a clockwise fashion in two consecutive trials (Part D). In this way, test results could be accounted for basic motor speed. The time needed to complete subtasks A and B was adjusted for the average time needed to complete Part D, the time needed to complete Part C for the average time of Part A and B.

Letter-Digit Substitution Test:⁸

Participants were requested to match digits to letters according to a given key. This key included the numbers 1 to 9, each paired with a different letter. The outcome of interest was the number of correct substitutions within 90 seconds.

1. Vrooman HA, Cocosco CA, van der Lijn F, Stokking R, Ikram MA, Vernooij MW, Breteler MM and Niessen WJ. Multi-spectral brain tissue segmentation using automatically trained k-Nearest-Neighbor classification. *NeuroImage*. 2007;37:71-81.
2. de Boer R, Vrooman HA, van der Lijn F, Vernooij MW, Ikram MA, van der Lugt A, Breteler MM and Niessen WJ. White matter lesion extension to automatic brain tissue segmentation on MRI. *NeuroImage*. 2009;45:1151-61.
3. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge R, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M and nEuroimaging STfRVco. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol*. 2013;12:822-38.
4. Gregoire SM, Chaudhary UJ, Brown MM, Yousry TA, Kallis C, Jager HR and Werring DJ. The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. *Neurology*. 2009;73:1759-66.
5. Van der Elst W, van Boxtel MP, van Breukelen GJ and Jolles J. Rey's verbal learning test: normative data for 1855 healthy participants aged 24-81 years and the influence of age, sex, education, and mode of presentation. *J Int Neuropsychol Soc*. 2005;11:290-302.
6. Van der Elst W, Van Boxtel MP, Van Breukelen GJ and Jolles J. The Stroop color-word test: influence of age, sex, and education; and normative data for a large sample across the adult age range. *Assessment*. 2006;13:62-79.
7. Van der Elst W, Van Boxtel MP, Van Breukelen GJ and Jolles J. The Concept Shifting Test: adult normative data. *Psychol Assess*. 2006;18:424-32.
8. van der Elst W, van Boxtel MP, van Breukelen GJ and Jolles J. The Letter Digit Substitution Test: normative data for 1,858 healthy participants aged 24-81 from the Maastricht Aging Study (MAAS): influence of age, education, and sex. *J Clin Exp Neuropsychol*. 2006;28:998-1009.

Table S1. Characteristics of the study populations per measure of microvascular dysfunction

General baseline characteristics		Microvascular dysfunction score (n=2,034)	Cerebral small vessel disease features (n=2,002)	Plasma biomarkers of microvascular dysfunction (n=2,991)	Urinary albumin excretion (n=2,987)	Flicker light-induced retinal arteriolar and venular dilation (n=1,998)	Heat-induced skin hyperaemia (n=1,457)
Age, years		59.0 (8.2)	59.0 (8.1)	59.5 (8.2)	59.6 (8.2)	59.5 (8.2)	60.0 (8.0)
Women, %		48.9 (995)	49.3 (986)	48.8 (1,460)	48.9 (1,461)	49.7 (993)	47.6 (694)
Education level, %							
- low		12.9 (262)	12.7 (255)	15.7 (471)	15.6 (465)	14.8 (296)	15.7 (229)
- intermediate		43.2 (878)	43.5 (870)	43.1 (1,290)	43.2 (1,290)	43.3 (866)	43.9 (639)
- high		44.0 (894)	43.8 (877)	41.1 (1,230)	41.2 (1,232)	41.8 (836)	40.4 (589)
Smoking status, %							
- never		37.8 (768)	37.7 (754)	34.9 (1,044)	35.0 (1,046)	35.6 (711)	32.4 (472)
- former		50.7 (1,031)	50.7 (1,015)	51.9 (1,553)	51.9 (1,550)	52.8 (1,054)	55.7 (811)
- current		11.6 (235)	11.6 (233)	13.2 (394)	13.1 (391)	11.7 (233)	11.9 (174)
Alcohol use, %							
- none		16.9 (343)	16.9 (338)	18.1 (540)	17.9 (534)	17.4 (348)	17.2 (251)
- low		55.8 (1,134)	55.5 (1,111)	55.4 (1,657)	55.6 (1,662)	56.9 (1,137)	54.9 (800)
- high		27.4 (557)	27.6 (553)	26.5 (794)	26.5 (791)	25.7 (513)	27.9 (406)
Body mass index, kg/m ²		26.6 (4.2)	26.5 (4.1)	27.1 (4.5)	27.1 (4.5)	26.9 (4.4)	27.1 (4.4)
Type 2 diabetes, %		21.4 (436)	21.1 (422)	26.5 (792)	26.4 (788)	26.1 (521)	29.0 (422)
Hypertension, %		51.3 (1,044)	50.7 (1,016)	55.4 (1,658)	55.4 (1,656)	54.9 (1,096)	57.4 (836)
Total/HDL cholesterol ratio		3.7 (1.2)	3.7 (1.2)	3.7 (1.2)	3.7 (1.2)	3.6 (1.1)	3.7 (1.1)
Triglycerides, mmol/L		1.4 (0.8)	1.4 (0.8)	1.4 (0.9)	1.4 (0.9)	1.4 (0.8)	1.5 (0.9)
Lipid-modifying medication, %		29.8 (607)	29.6 (593)	34.9 (1,044)	34.8 (1,040)	34.4 (688)	37.9 (552)
Prior cardiovascular disease, %		11.4 (231)	11.4 (228)	16.1 (483)	16.1 (480)	15.3 (305)	16.9 (246)
Current depression, %		3.4 (69)	3.3 (67)	3.7 (111)	3.7 (110)	3.7 (73)	3.9 (57)
Plasma biomarkers of low-grade inflammation composite score, SD*		-0.1 (1.0)	-0.1 (1.0)	0.0 (1.0)	0.0 (1.0)	0.0 (1.0)	0.0 (1.0)
Microvascular dysfunction measures†							
Microvascular dysfunction composite score, SD		0.0 (1.0)	0.0 (1.0)	0.0 (1.0)	0.0 (1.0)	0.0 (1.0)	0.1 (1.0)

General baseline characteristics		Microvascular dysfunction score (n=2,034)	Cerebral small vessel disease features (n=2,002)	Plasma biomarkers of microvascular dysfunction (n=2,991)	Urinary albumin excretion (n=2,987)	Flicker light-induced retinal arteriolar and venular dilation (n=1,998)	Heat-induced skin hyperaemia (n=1,457)
Cerebral small vessel disease features							
Total brain parenchyma volume, ml		1,138.6 (111.7)	1,137.8 (111.7)	1,138.6 (111.8)	1,138.1 (111.6)	1,139.2 (110.1)	1,139.7 (111.0)
White matter hyperintensity volume, ml		0.2 (0.1-0.7)	0.2 (0.1-0.7)	0.2 (0.1-0.7)	0.2 (0.1-0.7)	0.2 (0.1-0.7)	0.3 (0.1-0.8)
Presence of cerebral microbleeds, %		11.8 (236)	11.8 (236)	11.7 (234)	11.8 (236)	11.6 (161)	12.0 (115)
Presence of lacunar infarcts, %		5.3 (108)	5.4 (108)	5.3 (108)	5.3 (107)	4.8 (68)	5.2 (51)
Plasma biomarkers of microvascular dysfunction							
Soluble ICAM-1, µg/l		345.4 (89.0)	344.5 (87.3)	352.6 (98.1)	352.6 (97.8)	355.3 (98.0)	358.1 (97.9)
Soluble VCAM-1, µg/l		421.3 (95.1)	420.0 (92.1)	425.2 (99.7)	425.0 (99.6)	427.5 (103.1)	433.5 (101.8)
Soluble E-selectin, µg/l		112.5 (59.7)	112.0 (57.9)	117.4 (64.3)	117.5 (64.0)	117.0 (65.3)	118.6 (68.5)
Von Willebrand Factor, %		128.4 (46.6)	128.3 (46.3)	131.7 (47.8)	131.5 (47.7)	131.8 (48.6)	132.2 (47.8)
Urinary albumin excretion							
Urinary albumin excretion ≥30mg/24h, %		6.5 (131)	6.3 (126)	8.1 (240)	8.1 (242)	7.8 (155)	8.1 (118)
Urinary albumin excretion 15-30mg/24h, %		8.9 (181)	8.8 (177)	10.3 (307)	10.3 (308)	10.3 (205)	10.5 (152)
Flicker light-induced arteriolar and venular dilation response							
Flicker light-induced arteriolar dilation response, %		3.2 (2.8)	3.2 (2.8)	3.0 (2.8)	3.1 (2.8)	3.1 (2.8)	3.0 (2.8)
Flicker light-induced venular dilation response, %		4.0 (2.2)	4.0 (2.2)	3.9 (2.2)	3.9 (2.2)	3.9 (2.2)	3.8 (2.1)
Heat-induced skin hyperaemia, %		1,156.4 (793.7)	1,162.4 (794.1)	1,132.1 (781.8)	1,132.3 (781.1)	1,138.3 (793.8)	1,133.2 (781.5)

Data are presented as percentage of participants (n), mean ± standard deviation or median (interquartile range). *Expressed per standard deviation (SD). Abbreviations: BMI: body mass index; sE-selectin: soluble E-selectin; sICAM-1: soluble intercellular adhesion molecule-1; sVCAM-1: soluble vascular adhesion molecule-1; MMSE: Mini Mental State Examination; SD: standard deviation; vWF: Von Willebrand Factor.

Table S2. Characteristics of the total study population and according to tertiles of memory

	Total study population (n=3,011)	Lowest tertile memory (n=1,006)	Middle tertile memory (n=1,002)	Highest tertile memory (n=1,003)
General baseline characteristics				
Age, years	59.5 (8.2)	62.5 (7.5)	59.6 (7.9)	56.5 (8.1)
Women, %	48.9 (1,471)	28.4 (286)	46.9 (470)	71.3 (715)
Education level, %				
- low	15.7 (472)	24.1 (242)	15.4 (154)	7.6 (76)
- intermediate	43.2 (1,301)	44.5 (448)	44.2 (443)	40.9 (410)
- high	41.1 (1,238)	31.4 (316)	40.4 (405)	51.5 (517)
Smoking status, %				
- never	34.9 (1,051)	32.0 (322)	35.0 (351)	37.7 (378)
- former	51.9 (1,564)	53.6 (539)	51.7 (518)	50.5 (507)
- current	13.2 (396)	14.4 (145)	13.3 (133)	11.8 (118)
Alcohol use, %				
- none	18.0 (543)	20.4 (205)	16.5 (165)	17.2 (173)
- low	55.5 (1,671)	56.4 (567)	56.0 (561)	54.1 (543)
- high	26.5 (797)	23.3 (234)	27.5 (276)	28.6 (287)
Body mass index, kg/m ²	27.1 (4.5)	27.9 (4.5)	26.9 (4.3)	26.4 (4.5)
Type 2 diabetes, %	26.5 (797)	36.4 (366)	27.4 (275)	15.6 (156)
Hypertension, %	55.4 (1,667)	68.9 (693)	53.8 (539)	43.4 (435)
Total/HDL cholesterol ratio	3.7 (1.2)	3.8 (1.2)	3.7 (1.2)	3.6 (1.2)
Triglycerides, mmol/L	1.4 (0.9)	1.5 (0.9)	1.4 (0.8)	1.3 (0.8)
Lipid-modifying medication, %	34.9 (1,050)	47.0 (473)	34.3 (344)	23.2 (233)
Prior cardiovascular disease, %	16.1 (486)	20.9 (210)	17.2 (172)	10.4 (104)
Current depression, %	3.7 (112)	4.7 (47)	3.4 (34)	3.1 (31)
Plasma biomarkers of low-grade inflammation composite score, SD*	0.0 (1.0)	0.2 (1.0)	-0.1 (1.0)	-0.2 (1.0)
Microvascular dysfunction measures[†]				
Microvascular dysfunction composite score, SD	0.0 (1.0)	0.3 (1.1)	0.0 (0.9)	-0.3 (0.8)
Cerebral small vessel disease features				
Total brain parenchyma volume, ml	1,138.4 (111.7)	1,157.2 (114.2)	1,136.6 (112.9)	1,123.5 (105.8)
White matter hyperintensity volume, ml	0.2 (0.1-0.7)	0.4 (0.1-1.3)	0.2 (0.1-0.6)	0.2 (<0.1-0.5)
Presence of cerebral microbleeds, %	11.8 (237)	15.1 (94)	11.4 (77)	9.2 (66)
Presence of lacunar infarcts, %	5.4 (110)	7.3 (46)	4.8 (33)	4.3 (31)
Plasma biomarkers of microvascular dysfunction				
Soluble ICAM-1, µg/l	352.7 (98.1)	367.0 (112.1)	349.6 (91.9)	341.5 (86.9)
Soluble VCAM-1, µg/l	425.1 (99.8)	441.8 (109.4)	425.4 (100.6)	407.9 (84.9)
Soluble E-selectin, µg/l	117.5 (64.2)	127.8 (75.5)	116.3 (58.4)	108.5 (55.5)
Von Willebrand Factor, %	131.7 (47.8)	139.0 (49.6)	131.4 (47.7)	124.8 (45.0)
Urinary albumin excretion				
Urinary albumin excretion ≥30mg/24h, %	8.1 (242)	12.1 (121)	7.4 (74)	4.7 (47)

	Total study population (n=3,011)	Lowest tertile memory (n=1,006)	Middle tertile memory (n=1,002)	Highest tertile memory (n=1,003)
Urinary albumin excretion 15-<30mg/24h, %	10.3 (308)	12.8 (127)	10.4 (103)	7.8 (78)
Flicker light-induced arteriolar and venular dilation response				
Flicker light-induced arteriolar dilation response, %	3.1 (2.8)	3.1 (2.8)	3.2 (2.7)	3.1 (2.8)
Flicker light-induced venular dilation response,%	3.9 (2.2)	3.9 (2.2)	4.0 (2.2)	3.9 (2.2)
Heat-induced skin hyperaemia, %	1,133.2 (781.5)	1,005.1 (745.4)	1,164.3 (827.1)	1,230.4 (753.0)

Data are presented as percentage of participants (n), mean ± standard deviation or median (interquartile range). *Expressed per standard deviation (SD); †Data available for total brain parenchyma volume and white matter hyperintensity volume n=2,049; for lacunar infarctions n=2,046 and for cerebral microbleeds n=2,012; for sICAM-1; sVCAM-1; and sE-selectin n=3,011; for vWF n=2,991; for albuminuria n=2,987; for flicker light-induced arteriolar dilation n=2,018; for flicker light-induced venular dilation n=2,049; and for heat-induced skin hyperaemia n=1,457.

Abbreviations: BMI: body mass index; sE-selectin: soluble E-selectin; sICAM-1: soluble intercellular adhesion molecule-1; sVCAM-1: soluble vascular adhesion molecule-1; MMSE: Mini Mental State Examination; SD: standard deviation; vWF: Von Willebrand Factor.

Table S3. Characteristics of the total study population and according to tertiles of processing speed

	Total study population (n=3,011)	Lowest tertile processing speed (n=1,003)	Middle tertile processing speed (n=1,004)	Highest tertile processing speed (n= 1,004)
General baseline characteristics				
Age, years	59.5 (8.2)	63.6 (7.1)	60.0 (7.3)	55.1 (7.9)
Women, %	48.9 (1,471)	41.2 (413)	46.3 (465)	59.1 (593)
Education level, %				
- low	15.7 (472)	30.6 (307)	11.8 (118)	4.7 (47)
- intermediate	43.2 (1,301)	43.9 (440)	43.2 (434)	42.5 (427)
- high	41.1 (1,238)	25.5 (256)	45.0 (452)	52.8 (530)
Smoking status, %				
- never	34.9 (1,051)	31.5 (316)	33.8 (339)	39.4 (396)
- former	51.9 (1,564)	53.1 (533)	53.5 (537)	49.2 (494)
- current	13.2 (396)	15.4 (154)	12.7 (128)	11.4 (114)
Alcohol use, %				
- none	18.0 (543)	21.2 (213)	15.9 (160)	16.9 (170)
- low	55.5 (1,671)	56.4 (566)	54.1 (543)	56.0 (562)
- high	26.5 (797)	22.3 (224)	30.0 (301)	27.1 (272)
Body mass index, kg/m ²	27.1 (4.5)	27.8 (4.6)	27.0 (4.4)	26.4 (4.3)
Type 2 diabetes, %	26.5 (797)	39.5 (396)	24.8 (249)	15.1 (152)
Hypertension, %	55.4 (1,667)	68.6 (688)	54.9 (551)	42.6 (428)
Total/HDL cholesterol ratio	3.7 (1.2)	3.7 (1.2)	3.7 (1.2)	3.7 (1.2)
Triglycerides, mmol/L	1.4 (0.9)	1.5 (0.9)	1.4 (0.9)	1.4 (0.8)
Lipid-modifying medication, %	34.9 (1,050)	48.0 (481)	33.8 (339)	22.9 (230)
Prior cardiovascular disease, %	16.1 (486)	23.8 (239)	13.6 (137)	11.0 (110)
Current depression, %	3.7 (112)	5.1 (51)	3.3 (33)	2.8 (28)
Plasma biomarkers of low-grade inflammation composite score, SD*	0.0 (1.0)	0.2 (1.0)	0.0 (1.0)	-0.2 (1.0)
Microvascular dysfunction measures[†]				
Microvascular dysfunction composite score, SD	0.0 (1.0)	0.4 (1.2)	0.0 (0.9)	-0.3 (0.8)
Cerebral small vessel disease features				
Total brain parenchyma volume, ml	1,138.4 (111.7)	1,115.5 (112.2)	1,148.0 (110.7)	1,148.8 (109.4)
White matter hyperintensity volume, ml	0.2 (0.1-0.7)	0.3 (0.1-1.2)	0.2 (0.1-0.8)	0.1 (<0.1-0.4)
Presence of cerebral microbleeds, %	11.8 (237)	15.2 (93)	11.4 (78)	9.2 (66)
Presence of lacunar infarcts, %	5.4 (110)	7.4 (46)	5.8 (40)	3.3 (24)
Plasma biomarkers of microvascular dysfunction				
Soluble ICAM-1, µg/l	352.7 (98.1)	365.0 (112.4)	352.8 (95.4)	340.3 (82.8)
Soluble VCAM-1, µg/l	425.1 (99.8)	439.1 (109.4)	424.9 (99.6)	411.1 (87.2)
Soluble E-selectin, µg/l	117.5 (64.2)	126.4 (71.1)	119.2 (65.3)	107.0 (53.6)
Von Willebrand Factor, %	131.7 (47.8)	139.1 (50.9)	132.2 (47.6)	123.9 (43.4)
Urinary albumin excretion				
Urinary albumin excretion ≥30mg/24h, %	8.1 (242)	12.6 (125)	7.4 (74)	4.3 (43)

	Total study population (n=3,011)	Lowest tertile processing speed (n=1,003)	Middle tertile processing speed (n=1,004)	Highest tertile processing speed (n= 1,004)
Urinary albumin excretion 15-<30mg/24h, %	10.3 (308)	11.9 (118)	10.2 (102)	8.8 (88)
Flicker light-induced arteriolar and venular dilation response				
Flicker light-induced arteriolar dilation response, %	3.1 (2.8)	2.6 (2.8)	3.1 (2.8)	3.4 (2.7)
Flicker light-induced venular dilation response,%	3.9 (2.2)	3.7 (2.2)	4.0 (2.1)	4.0 (2.2)
Heat-induced skin hyperaemia, %	1,133.2 (781.5)	1,022.7 (728.4)	1,164.1 (791.6)	1,220.8 (813.5)

Data are presented as percentage of participants (n), mean ± standard deviation or median (interquartile range). *Expressed per standard deviation (SD); †Data available for total brain parenchyma volume and white matter hyperintensity volume n=2,049; for lacunar infarctions n=2,046 and for cerebral microbleeds n=2,012; for sICAM-1; sVCAM-1; and sE-selectin n=3,011; for vWF n=2,991; for albuminuria n=2,987; for flicker light-induced arteriolar dilation n=2,018; for flicker light-induced venular dilation n=2,049; and for heat-induced skin hyperaemia n=1,457.

Abbreviations: BMI: body mass index; sE-selectin: soluble E-selectin; sICAM-1: soluble intercellular adhesion molecule-1; sVCAM-1: soluble vascular adhesion molecule-1; MMSE: Mini Mental State Examination; SD: standard deviation; vWF: Von Willebrand Factor.

Table S4. Characteristics of the total study population and according to tertiles of executive function

	Total study population (n=3,011)	Lowest tertile executive function (n=1,003)	Middle tertile executive function (n=1,004)	Highest tertile executive function (n=1,004)
General baseline characteristics				
Age, years	59.5 (8.2)	63.2 (7.2)	59.4 (7.8)	56.0 (8.0)
Women, %	48.9 (1,471)	45.9 (460)	49.7 (499)	51.0 (512)
Education level, %				
- low	15.7 (472)	28.1 (282)	13.6 (137)	5.3 (53)
- intermediate	43.2 (1,301)	46.7 (468)	42.9 (431)	40.0 (402)
- high	41.1 (1,238)	25.2 (253)	43.4 (436)	54.7 (549)
Smoking status, %				
- never	34.9 (1,051)	31.8 (319)	35.7 (358)	37.3 (374)
- former	51.9 (1,564)	53.3 (535)	52.0 (522)	50.5 (507)
- current	13.2 (396)	14.9 (149)	12.4 (124)	12.3 (123)
Alcohol use, %				
- none	18.0 (543)	21.4 (215)	16.4 (165)	16.2 (163)
- low	55.5 (1,671)	54.5 (547)	57.6 (578)	54.4 (546)
- high	26.5 (797)	24.0 (241)	26.0 (261)	29.4 (295)
Body mass index, kg/m ²	27.1 (4.5)	27.7 (4.5)	26.9 (4.5)	26.5 (4.4)
Type 2 diabetes, %	26.5 (797)	37.2 (373)	24.4 (245)	17.8 (179)
Hypertension, %	55.4 (1,667)	68.4 (686)	52.6 (528)	45.1 (453)
Total/HDL cholesterol ratio	3.7 (1.2)	3.7 (1.2)	3.7 (1.2)	3.7 (1.2)
Triglycerides, mmol/L	1.4 (0.9)	1.5 (0.9)	1.4 (0.9)	1.4 (0.8)
Lipid-modifying medication, %	34.9 (1,050)	47.2 (473)	30.4 (305)	27.1 (272)
Prior cardiovascular disease, %	16.1 (486)	21.4 (215)	15.2 (153)	11.8 (118)
Current depression, %	3.7 (112)	5.0 (50)	3.5 (35)	2.7 (27)
Plasma biomarkers of low-grade inflammation composite score, SD*	0.0 (1.0)	0.2 (1.0)	0.0 (1.0)	-0.2 (1.0)
Microvascular dysfunction measures[†]				
Microvascular dysfunction composite score, SD	0.0 (1.0)	0.3 (1.1)	0.0 (1.0)	-0.2 (0.9)
Cerebral small vessel disease features				
Total brain parenchyma volume, ml	1,138.4 (111.7)	1,110.7 (109.4)	1,144.2 (113.0)	1,156.0 (108.0)
White matter hyperintensity volume, ml	0.2 (0.1-0.7)	0.4 (0.1-1.1)	0.2 (0.1-0.7)	0.2 (<0.1-0.5)
Presence of cerebral microbleeds, %	11.8 (237)	13.8 (84)	11.8 (80)	10.0 (73)
Presence of lacunar infarcts, %	5.4 (110)	6.3 (39)	5.6 (38)	4.4 (33)
Plasma biomarkers of microvascular dysfunction				
Soluble ICAM-1, µg/l	352.7 (98.1)	365.3 (105.4)	353.4 (98.2)	339.4 (88.4)
Soluble VCAM-1, µg/l	425.1 (99.8)	436.7 (106.6)	423.1 (97.5)	415.4 (93.7)
Soluble E-selectin, µg/l	117.5 (64.2)	127.6 (72.5)	119.4 (64.8)	105.5 (51.8)
Von Willebrand Factor, %	131.7 (47.8)	138.6 (49.8)	129.9 (47.1)	126.8 (45.7)
Urinary albumin excretion				
Urinary albumin excretion ≥30mg/24h, %	8.1 (242)	11.7 (116)	7.6 (76)	5.0 (50)
Urinary albumin excretion 15-<30mg/24h, %	10.3 (308)	12.6 (125)	9.5 (95)	8.8 (88)

	Total study population (n=3,011)	Lowest tertile executive function (n=1,003)	Middle tertile executive function (n=1,004)	Highest tertile executive function (n= 1,004)
Flicker light-induced arteriolar and venular dilation response				
Flicker light-induced arteriolar dilation response, %	3.1 (2.8)	2.8 (2.8)	3.1 (2.8)	3.2 (2.7)
Flicker light-induced venular dilation response,%	3.9 (2.2)	3.8 (2.1)	3.9 (2.2)	3.9 (2.2)
Heat-induced skin hyperaemia, %	1,133.2 (781.5)	1,097.9 (828.3)	1,159.8 (793.4)	1,144.2 (716.6)

Data are presented as percentage of participants (n), mean ± standard deviation or median (interquartile range). *Expressed per standard deviation (SD); †Data available for total brain parenchyma volume n=2,049; for lacunar infarctions n=2,046 and for cerebral microbleeds n=2,012; for sICAM-1; sVCAM-1; and sE-selectin n=3,011; for vWF n=2,991; for albuminuria n=2,987; for flicker light-induced arteriolar dilation n=2,018; for flicker light-induced venular dilation n=2,049; and for heat-induced skin hyperaemia n=1,457.

Abbreviations: BMI: body mass index; sE-selectin: soluble E-selectin; sICAM-1: soluble intercellular adhesion molecule-1; sVCAM-1: soluble vascular adhesion molecule-1; MMSE: Mini Mental State Examination; SD: standard deviation; vWF: Von Willebrand Factor.

Table S5. Associations between the individual covariates and cognitive function score

Covariates	β	95% Confidence Interval		P value
		Lower Bound	Upper Bound	
Microvascular dysfunction score (per SD)	-0.088	-0.131	-0.046	<0.001
Age (per year)	-0.045	-0.050	-0.041	<0.001
Education level (per category)	0.419	0.369	0.469	<0.001
Sex (men vs. women)	0.351	0.279	0.423	<0.001
T2D (without T2D vs. with T2D)	-0.099	-0.197	-0.001	0.047
Body Mass Index (per point)	-0.003	-0.012	0.006	0.486
Active smoker (non-smoker vs. active smoker)	-0.141	-0.252	-0.030	0.013
Former smoker (non-smoker vs. former smoker)	0.091	0.018	0.163	0.014
Alcohol use (per category)	0.042	-0.011	0.094	0.123
Hypertension (without hypertension vs. with hypertension)	-0.054	-0.129	0.021	0.160
Total/HDL cholesterol ratio (per point)	-0.024	-0.062	0.013	0.200
Triglycerides (per mmol)	-0.008	-0.061	0.045	0.761
Lipid-modifying medication (without medication use vs. with medication 4use)	0.000	-0.091	0.091	0.999
Prior CVD (without prior CVD vs. with prior CVD)	0.020	-0.088	0.128	0.717
Current depression (without current depression vs. with current depression)	-0.121	-0.303	0.061	0.191
Plasma markers of low-grade inflammation score (per SD)	0.004	-0.057	0.065	0.901

Results are expressed as standard deviation difference in the cognitive function score per unit difference in covariate. Abbreviations: CVD: cardiovascular disease; T2D: type 2 diabetes.

Table S6. Associations between the microvascular dysfunction score and cognitive function score in individuals <65 years and ≥65 years

Model	Participants <65 years (n=1,459)				Participants ≥65 years (n=575)			
	β	95% Confidence Interval		P value	β	95% Confidence Interval		P value
		Lower Bound	Upper Bound			Lower Bound	Upper Bound	
1	-0.067	-0.117	-0.016	0.003	-0.118	-0.185	-0.051	0.003
2	-0.063	-0.116	-0.010	0.004	-0.134	-0.207	-0.060	0.004

Results are expressed as standard deviation worse cognitive function score per standard deviation higher microvascular dysfunction score. Results were adjusted for age, education level, sex, diabetes mellitus type 2, body mass index, smoking status, alcohol use, hypertension, total/HDL cholesterol ratio, triglycerides, and lipid-modifying medication use (model 1), and additionally for prior cardiovascular disease, current depression and plasma biomarkers of low-grade inflammation (model 2).

Table S7. Associations between individual measures of microvascular dysfunction and cognitive function score

Individual microvascular dysfunction measure	Model	β	95% Confidence Interval		P value
			Lower Bound	Upper Bound	
Total brain parenchyma volume (per lower SD) (n=2,049)	1	-0.059	-0.099	-0.019	0.004
	2	-0.057	-0.097	-0.017	0.005
White matter hyperintensities (per higher SD) (n=2,049)	1	-0.087	-0.124	-0.050	<0.001
	2	-0.085	-0.122	-0.048	<0.001
Cerebral microbleeds (presence vs. absence) (n=2,012)	1	-0.072	-0.174	0.031	0.170
	2	-0.067	-0.170	0.037	0.206
Lacunar infarcts (presence vs. absence) (n=2,046)	1	-0.044	-0.190	0.101	0.550
	2	-0.037	-0.183	0.109	0.619
Soluble intercellular adhesion molecule-1 (per SD) (n=3,011)	1	-0.024	-0.053	0.006	0.113
	2	-0.016	-0.048	0.016	0.330
Soluble vascular adhesion molecule-1 (per SD) (n=3,011)	1	-0.014	-0.043	0.015	0.341
	2	-0.008	-0.038	0.022	0.603
Soluble E-selectin (per SD) (n=3,011)	1	-0.058	-0.089	-0.028	<0.001
	2	-0.054	-0.084	-0.023	0.001
Von Willebrand factor (per SD) (n=2,991)	1	-0.005	-0.034	0.023	0.714
	2	0.000	-0.029	0.030	0.986
Urinary albumin excretion (≥30 mg/24h vs. <15 mg/24h) (n=2,987)	1	-0.131	-0.237	-0.025	0.015
	2	-0.117	-0.223	-0.011	0.031
Urinary albumin excretion (15-<30 mg/24h vs. <15 mg/24h) (n=2,987)	1	-0.032	-0.124	0.061	0.505
	2	-0.018	-0.111	0.075	0.701
Flicker light-induced retinal arteriolar dilation (per lower SD) (n=2,018)	1	-0.016	-0.050	0.018	0.349
	2	-0.016	-0.050	0.019	0.371
Flicker light-induced retinal venular dilation (per lower SD) (n=2,049)	1	-0.023	-0.057	0.010	0.173
	2	-0.022	-0.056	0.011	0.190
Skin hyperemic response (per lower SD) (n=1,457)	1	0.010	-0.031	0.052	0.626
	2	0.013	-0.029	0.054	0.552

Results are expressed as standard deviation worse cognitive function score per standard deviation higher microvascular dysfunction score. Results were adjusted for age, education level, sex, diabetes mellitus type 2, body mass index, smoking status, alcohol use, hypertension, total/HDL cholesterol ratio, triglycerides, lipid-modifying medication use (model 1), and additionally for prior cardiovascular disease, current depression and plasma biomarkers of low-grade inflammation (model 2).

Table S8. Associations between the microvascular dysfunction score and cognitive function in individuals with data available on at least one, eight and ten of the 12 individual measures of microvascular dysfunction

Determinant	Model	β	95% Confidence Interval		P value
			Lower Bound	Upper Bound	
Microvascular dysfunction score calculated in individuals with data on at least one of the 12 measures (per higher SD) (n=3,011)	1	-0.077	-0.111	-0.044	<0.001
	2	-0.073	-0.109	-0.037	<0.001
Microvascular dysfunction score calculated in individuals with data on at least eight of the 12 measures (per higher SD) (n=2,364)	1	-0.087	-0.124	-0.050	<0.001
	2	-0.083	-0.123	-0.043	<0.001
Microvascular dysfunction score calculated in individuals with data on at least ten of the 12 measures (per higher SD) (n=1,658)	1	-0.077	-0.121	-0.033	0.001
	2	-0.079	-0.126	-0.033	0.001

Results are expressed as standard deviation worse cognitive function score per standard deviation higher microvascular dysfunction score. Results were adjusted for age, education level, sex, diabetes mellitus type 2, body mass index, smoking status, alcohol use, hypertension, total/HDL cholesterol ratio, triglycerides, lipid-modifying medication use (model 1), and additionally for prior cardiovascular disease, current depression and plasma biomarkers of low-grade inflammation (model 2).

Table S9. Associations between the microvascular dysfunction score and cognitive function after excluding consecutively each individual measure of microvascular dysfunction

Variable excluded from the microvascular dysfunction score [†]	Model	β	95% Confidence Interval		P value
			Lower Bound	Upper Bound	
Cerebral small vessel disease features	1	-0.046	-0.081	-0.012	0.009
	2	-0.042	-0.079	-0.005	0.026
Plasma biomarkers of microvascular dysfunction	1	-0.087	-0.130	-0.043	<0.001
	2	-0.085	-0.129	-0.042	<0.001
Urinary albumin excretion	1	-0.079	-0.119	-0.040	<0.001
	2	-0.080	-0.122	-0.038	<0.001
Flicker light-induced retinal arteriolar and venular dilation responses	1	-0.090	-0.130	-0.051	<0.001
	2	-0.090	-0.132	-0.048	<0.001
Heat-induced skin hyperaemia	1	-0.092	-0.131	-0.052	<0.001
	2	-0.094	-0.136	-0.052	<0.001

[†]Data available for analyses after excluding cerebral small vessel disease features n=2,426; for plasma biomarkers of microvascular dysfunction n=1,659, for urinary albumin excretion n=2,039; for flicker light-induced retinal arteriolar and venular dilation response n=2,050 and for heat-induced skin hyperaemia n=2,051. Results are expressed as standard deviation worse cognitive function score per standard deviation higher microvascular dysfunction score. Results were adjusted for age, education level, sex, diabetes mellitus type 2, body mass index, smoking status, alcohol use, hypertension, total/HDL cholesterol ratio, triglycerides, lipid-modifying medication use (model 1), and additionally for prior cardiovascular disease, current depression and plasma biomarkers of low-grade inflammation (model 2).

Table S10. Associations between composite scores of cerebral small vessel disease features, plasma biomarkers of microvascular dysfunction and retinal arteriolar and venular dilation responses and cognitive function

Determinant	Model	β	95% Confidence Interval		P value
			Lower Bound	Upper Bound	
Cerebral small vessel disease features (per point) (n=2,002)	1	-0.085	-0.133	-0.038	<0.001
	2	-0.082	-0.129	-0.035	0.001
Plasma biomarkers of microvascular dysfunction (per SD) (n=2,991)	1	-0.040	-0.071	-0.009	0.010
	2	-0.035	-0.069	-0.001	0.042
Flicker light-induced retinal arteriolar and venular dilation responses (per SD) (n=1,998)	1	-0.026	-0.060	0.008	0.136
	2	-0.025	-0.059	0.009	0.152

Results are expressed as standard deviation worse cognitive function score per standard deviation higher microvascular dysfunction score. Results were adjusted for age, education level, sex, diabetes mellitus type 2, body mass index, smoking status, alcohol use, hypertension, total/HDL cholesterol ratio, triglycerides, lipid-modifying medication use (model 1), and additionally for prior cardiovascular disease, current depression and plasma biomarkers of low-grade inflammation (model 2).

Table S11. Associations between the microvascular dysfunction score and cognitive function additionally adjusted for ambulatory blood pressure

Model	B	95% Confidence Interval		P value
		Lower Bound	Upper Bound	
1	-0.092	-0.135	-0.050	<0.001
2	-0.101	-0.147	-0.056	<0.001

†Data available for analyses n=1,799. Results are expressed as standard deviation worse cognitive function score per standard deviation higher microvascular dysfunction score. Results were adjusted for age, education level, sex, diabetes mellitus type 2, body mass index, smoking status, alcohol use, total/HDL cholesterol ratio, triglycerides, lipid-modifying medication use, antihypertensive medication use, and ambulatory blood pressure (model 1), and additionally for prior cardiovascular disease, current depression and plasma biomarkers of low-grade inflammation (model 2).

Table S12. Associations between the microvascular dysfunction score and cognitive function additionally adjusted for class of antihypertensive medication

Model	B	95% Confidence Interval		P value
		Lower Bound	Upper Bound	
1	-0.083	-0.123	-0.043	<0.001
2	-0.084	-0.127	-0.041	<0.001

†Data available for analyses n=2,034. Results are expressed as standard deviation worse cognitive function score per standard deviation higher microvascular dysfunction score. Results were adjusted for age, education level, sex, diabetes mellitus type 2, body mass index, smoking status, alcohol use, total/HDL cholesterol ratio, triglycerides, lipid-modifying medication use, use of angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers, use of other antihypertensive medications, office systolic and diastolic blood pressure (model 1), and additionally for prior cardiovascular disease, current depression and plasma biomarkers of low-grade inflammation (model 2). This additional analysis was performed, because angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have additional beneficial effects on microvascular function independent of their antihypertensive properties.¹

Table S13. Associations between the microvascular dysfunction score and cognitive function score, stratified by diabetes status (without type 2 diabetes and with type 2 diabetes)

Participants without type 2 diabetes (n=1,598)					Participants with type 2 diabetes (n=436)			
Model	β	95% Confidence Interval		P value	β	95% Confidence Interval		P value
		Lower Bound	Upper Bound			Lower Bound	Upper Bound	
1	-0.081	-0.130	-0.032	0.001	-0.099	-0.171	-0.028	0.007
2	-0.073	-0.124	-0.021	0.005	-0.140	-0.222	-0.058	0.001

Results are expressed as standard deviation worse cognitive function score per standard deviation higher microvascular dysfunction score. Results were adjusted for age, education level, sex, body mass index, smoking status, alcohol use, hypertension, total/HDL cholesterol ratio, triglycerides, and lipid-modifying medication use (model 1), and additionally for prior cardiovascular disease, current depression and plasma biomarkers of low-grade inflammation (model 2).

CHAPTER 5

5

Associations of arterial stiffness with cognitive performance, and the role of microvascular dysfunction: The Maastricht Study

S.P. Rensma, C.D.A. Stehouwer, M.P.J. Van Boxtel, A.J.H.M. Houben, T.T.J.M. Berendschot, J.F.A. Jansen, C.G. Schalkwijk, F.R.J. Verhey, A.A. Kroon, R.M.A. Henry, W.H. Backes, P.C. Dagnelie, M.C.J.M. van Dongen, S.J.P.M. Eussen, J.H.A. Bosma, S. Köhler, K. Reesink, M.T. Schram, T.T. van Sloten

Abstract

Background and aims

The mechanisms underlying cognitive impairment and dementia are incompletely understood but may include arterial stiffness and microvascular dysfunction. We investigated, in the population-based Maastricht Study, the association between greater arterial stiffness and worse cognitive performance, and whether any such association was statistically explained, or mediated, by various measures of microvascular dysfunction.

Materials and methods

We included cross-sectional data of 2,544 participants (age 59.7 years; 51.0% men; 26.0% type 2 diabetes [oversampled by design]). We used carotid-femoral pulse wave velocity and carotid distensibility coefficient as measures of aortic and carotid stiffness, respectively. We calculated a composite score of microvascular dysfunction based on MRI features of cerebral small vessel disease (lower total brain parenchymal volume, higher white matter hyperintensity volume, lacunar infarcts and cerebral microbleeds), retinal arteriolar and venular dilation response, albuminuria, and plasma biomarkers of microvascular dysfunction (sICAM-1, sVCAM-1, sE-selectin and von Willebrand Factor). Cognitive domains assessed were memory, processing speed and executive function. A cognitive function composite score was calculated as the average of the scores on these three cognitive domains.

Results

Higher carotid-femoral pulse wave velocity was associated with a lower cognitive function composite score after adjustment for age, sex, education level, glucose metabolism status, body mass index, smoking, alcohol use, total/high density cholesterol ratio, triglycerides, mean arterial pressure, heart rate and use of anti-hypertensive and/or lipid-modifying medication. Higher carotid stiffness was not associated with the cognitive function composite score. Mediation analysis showed that higher carotid-femoral pulse wave velocity was associated with a higher microvascular dysfunction score, and a higher microvascular dysfunction score was associated with a lower cognitive function composite score. Thus, a higher microvascular dysfunction score statistically significantly explained 16.2% of the total effect of carotid-femoral pulse wave velocity on the cognitive function composite score.

Conclusion

The present study found that aortic stiffness, but not carotid stiffness, is independently associated with worse cognitive performance, and that this association is in part explained by microvascular dysfunction.

Introduction

Cognitive impairment and dementia have an enormous impact on patients, their families and society, and the prevalence of dementia is rising.² The mechanisms underlying cognitive impairment and dementia remain, however, incompletely understood, but may include arterial stiffness and microvascular dysfunction (MVD).³

Greater arterial stiffness leads to excessive intra-arterial pressure and flow pulsatility which may transmit distally and damage the cerebral microcirculation.^{4, 5} The cerebral microvasculature is involved in the regulation of many processes potentially affecting cognition, i.e. cerebral perfusion, neurogenesis, neurovascular coupling, blood-brain barrier permeability and cerebral autoregulation.⁶ Impairment of these processes may lead to neuronal dysfunction and ischemia, which may ultimately lead to lower cognitive performance.^{3, 6-8} In accordance, previous studies^{3 9-22} have shown an association between greater arterial stiffness and both cognitive decline and incident dementia. Most of these studies^{3, 9-16, 19-22} focused on carotid-femoral pulse wave velocity (cfPWV), a measure of aortic stiffness, but only some¹⁷⁻²² on carotid stiffness. In addition, MVD has been associated with worse cognitive performance.^{8, 23} However, whether any association between aortic or carotid stiffness and worse cognitive performance is explained, or mediated, by MVD remains largely unknown.

Microvascular function and structure can be measured noninvasively in various organs. These measures include magnetic resonance imaging (MRI) features of cerebral small vessel disease (CSVD, e.g. lower total brain parenchyma volume, higher white matter hyperintensity volume, and presence of lacunar infarcts and cerebral microbleeds);²⁴ flicker light-induced retinal arteriolar and venular dilation response;²⁵ albuminuria ("urinary albumin excretion", UAE);²⁶ and plasma biomarkers of MVD (e.g. soluble intercellular adhesion molecule-1 [sICAM-1], soluble vascular adhesion molecule-1 [sVCAM-1], soluble E-selectin [sE-selectin] and von Willebrand factor [vWF]).²⁷

These various measures of MVD (i.e. CSVD features, retinal arteriolar and venular dilation response, UAE and plasma biomarkers of MVD) can be summarized into a total MVD composite score. The CSVD features and the retinal arteriolar and venular dilation responses are closely linked to the cerebral microvasculature and, thus, may reflect its function.^{28, 29} In addition, to the extent that MVD is a generalised phenomenon, UAE, and plasma biomarkers of MVD may also reflect cerebral MVD.³⁰ We previously showed that such a total MVD composite score is associated with worse cognitive performance.

In view of the above, the aims of the present study were to investigate the associations between aortic and carotid stiffness and cognitive performance, and whether any such associations are statistically mediated by a composite score of various MVD measures, including CSVD features, retinal arteriolar and venular dilation response, UAE and plasma biomarkers of MVD.

Material and methods

Study population and design

We used data from The Maastricht Study, an observational population-based cohort study. The rationale and methodology have been described previously.³¹ In brief, the study focuses on the aetiology, pathophysiology, complications and comorbidities of diabetes mellitus type 2 (T2D) and is characterized by an extensive phenotyping approach. Eligible for participation were all individuals aged between 40 and 75 years and living in the southern part of the Netherlands. Participants were recruited through mass media campaigns, the municipal registries and the regional Diabetes Patient Registry via mailings. Recruitment was stratified according to known T2D status, with an oversampling of individuals with T2D for reasons of efficiency. The present report includes cross-sectional data from 3,451 participants who completed the baseline survey between November 2010 and September 2013. The examinations of each participant were performed within a time window of three months. The study has been approved by the institutional medical ethical committee (NL31329.068.10) and the Ministry of Health, Welfare, and Sports of the Netherlands (Permit 131088-105234-PG). All participants gave written informed consent.

Vascular measures

For all vascular measures, participants were asked to refrain from smoking and drinking caffeine-containing beverages three hours before the measurement.³² A light meal was allowed until ≥ 90 minutes prior to the examination. For retinal measurements, pupils were dilated with 0.5% tropicamide and 2.5% phenylephrine ≥ 15 minutes before the start of the examination.

Assessment of arterial stiffness

A more detailed description of the arterial stiffness measures is provided in the Supplementary Material (Item S1), and has been described previously.^{33, 34} During the arterial stiffness measurements, brachial blood pressure and heart rate were obtained with a validated commercial oscillometric device (Accutorr Plus, Datascope Inc., Montvale, NJ, USA).

Carotid-femoral pulse wave velocity

We determined cfPWV with the use of applanation tonometry (SphygmoCor, Atcor Medical, Sydney, Australia).³⁵ Pressure waveforms were determined at the right common carotid and right common femoral arteries. Difference in the time of pulse wave arrival from the R-wave of the electrocardiogram between the two sites (transit time) was determined. The pulse wave travel distance was calculated as 80% of the direct straight distance between the two arterial sites. The median of three consecutive cfPWV (defined as traveled distance/transit time) recordings was used in the analyses.

Carotid stiffness

We assessed local diameter, distension and intima-media thickness of the left common carotid artery with the use of an ultrasound scanner equipped with a 7.5-MHz linear probe (MyLab 70, Esaote Europe B.V., Maastricht, the Netherlands).³⁶ We quantified carotid stiffness by calculating the carotid distensibility coefficient (carDC) based on the following

formula: $\text{carDC} = (2 \cdot \Delta D \cdot D + \Delta D^2) / (PP \cdot D^2)$, where D is arterial diameter, ΔD distension, and PP brachial pulse pressure.³⁷ Carotid compliance coefficient and Young's elastic modulus were also determined.

Microvascular dysfunction measures

Features of cerebral small vessel disease

Brain MRI measurements were implemented from December 2013 onwards and were available in 2,313 of 3,451 participants (67%). Brain MRI was performed on a 3T MRI scanner (Siemens Magnetom Prisma-fit Syngo MR D13D, Erlangen, Germany). We evaluated four CSVD features, i.e. lower total brain parenchyma volume, higher white matter hyperintensity volume, and presence of lacunar infarcts and cerebral microbleeds.²⁴ A detailed description of the MRI protocol and the definitions of the CSVD features is provided in the Supplementary Material (Item S2), and has been described previously.³⁸ The MRI protocol consisted of a 3D T_1 -weighted sequence, a fluid-attenuated inversion recovery sequence, a combined proton density and T_2 -weighted turbo spin echo sequence and a susceptibility-weighted imaging sequence.³⁸ Volumes were determined semi-automatically, and lacunar infarcts and cerebral microbleeds were scored manually.

Flicker light-induced retinal arteriolar and venular dilation response

We measured retinal arteriolar and venular dilation response to flicker light exposure by the Dynamic Vessel Analyzer (Imedos, Jena, Germany), as previously described.^{25, 39} A baseline recording of 50 seconds was followed by 40-second flicker light exposure followed by a 60-second recovery period. We calculated baseline diameters (in measurement units) as the average diameter during the 20-50 seconds recording. For both the arteriolar and venular dilation, percentage dilation over baseline was calculated using the average dilation achieved at time points 10 and 40 seconds during the flicker light stimulation period.

Urinary albumin excretion

We assessed UAE in two 24-hour urine samples. Urinary albumin concentration was measured with a standard immunoturbidimetric assay by an automatic analyzer (due to a change of supplier, by the Beckman Synchron LX20 and the Roche Cobas 6000) and multiplied by collection volume to obtain 24-hour UAE.⁴⁰ A urinary albumin concentration below the detection limit of the assay was set at 1.5mg/L (2mg/L for the Beckman Synchron LX20 and 3mg/L for the Roche Cobas 6000) before multiplying by collection volume. Only urine collections with a collection time between 20 and 28 hours were considered valid. If needed, UAE was extrapolated to 24-hour excretion. For this study, UAE was preferably based on the average of two (available in 91.3% of participants) 24-hour urine collections.

Plasma biomarkers of microvascular dysfunction

We measured four plasma biomarkers of MVD: sICAM-1, sVCAM-1, sE-selectin and vWF.³⁰ sICAM-1, sVCAM-1 and sE-selectin were measured in EDTA plasma samples with commercially available 4-plex sandwich immunoassay kits with different standards and antibodies (Meso Scale Discovery, Rockville, Maryland, United States of America). For this technique in this study, the intra- and inter-assay coefficients of variation were 10.3 and 8.4% for sICAM-1, 5.0 and 4.7% for sVCAM-1, and 2.9 and 7.4% for sE-selectin,

respectively. Von Willebrand Factor (vWF) was quantified in citrate plasma using ELISA (Dako, Glostrup, Denmark). The intra- and inter-assay coefficients of variation were 3.0 and 4.3%, respectively.

Cognitive performance

We assessed cognitive performance using a concise neuropsychological test battery, as described previously.³¹ For statistical efficiency, we constructed a cognitive function composite score by averaging of standardized test scores in three cognitive domains: memory, processing speed and executive function. A detailed description of methods used to calculate domain-specific cognitive function scores is provided in Item S3 (Supplementary material). We evaluated memory with the Verbal Learning Test,⁴¹ processing speed with the Stroop Color-Word Test Part I and II,⁴² Concept Shifting Test Part A and B,⁴³ and Letter-Digit Substitution Test,⁴⁴ and executive function with the Stroop Color-Word Test Part III⁴² and Concept Shifting Test Part C.⁴³

Covariates

We determined glucose metabolism status according to the World Health Organization 2006 criteria as normal glucose metabolism, prediabetes or T2D.⁴⁵ Education level was classified into three groups: low (none, primary or lower vocational education only), intermediate (intermediate general secondary, intermediate vocational or higher general secondary education) and high (higher vocational education or university level of education). Body mass index (BMI), smoking status (never, former, current), alcohol use (none, low, high), office blood pressure, plasma lipid levels, medication use and prior cardiovascular disease (CVD) were determined as described previously.^{25, 26, 31} We used questionnaires to assess adherence to the Mediterranean diet score ("diet score"),⁴⁶ moderate-to-vigorous physical activity (CHAMPS questionnaire),³¹ and socio-economic status (income level and occupational status).⁴⁷ The Mini-International Neuropsychiatric Interview (MINI) was used to assess the presence of a current DSM-IV defined major depressive episode.³¹ Plasma biomarkers of low-grade inflammation were determined as described previously.^{31, 48} These included high-sensitive C-reactive protein (CRP), serum amyloid A (SAA), interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor alpha (TNF- α). In addition, 24-hour ambulatory systolic blood pressure was determined.⁴⁹

Statistical analysis

We inversed (multiplying by -1) total brain parenchyma volume, and the flicker light-induced retinal arteriolar and venular dilation responses so that higher values indicated worse microvascular function. White matter hyperintensity volume and UAE were log-transformed (base 2) to normalize their skewed distribution.

We summarized the 11 MVD measures (i.e. four CSVD features, flicker light-induced retinal arteriolar and venular dilation responses, UAE and four plasma biomarkers of MVD) into a MVD composite score, as done previously. We hypothesized that each MVD measure is associated with arterial stiffness and cognitive performance according to similar underlying mechanisms. The use of a composite score reduces the influence of the biological variability of its components⁵⁰ and it reduces the chance of a type 1 error. The

MVD composite score was calculated when at least data on one of the 11 MVD measures were available. The composite score was calculated by averaging the 11 standardized MVD measures, respectively. On average, individuals included in the analysis had data available on nine of the 11 measures (Figure S1).

The statistical analysis proceeded in two stages. First, we used linear regression analysis to evaluate associations between cPWV and carDC and the cognitive function composite score. We adjusted for the following potential confounders: age, sex, and education level (model 1), additionally for glucose metabolism status, BMI, smoking, alcohol use, total/high density cholesterol (HDL) ratio and triglycerides (model 2) and then additionally for mean arterial pressure, heart rate and use of anti-hypertensive and/or lipid-modifying medication (model 3). Second, we performed a formal mediation analysis to test the hypothesis that MVD explains the association between greater arterial stiffness and worse cognitive performance.⁵¹ The mediation model quantifies the degree to which a variable statistically explains the association between a determinant and an outcome variable. We used bootstrapping (10,000 samples) to calculate bias-corrected 95% confidence intervals (95% CIs) of the explained associations using the PROCESS statistical package for PASW statistics.⁵¹ The magnitude of the explained association was calculated as a percentage of the total association.

We tested interaction terms with age,⁵² sex,⁵³ education level⁵⁴ and glucose metabolism status¹⁶ to evaluate whether the association between arterial stiffness and cognitive performance differed according to these factors.

We performed several additional analyses. First, we repeated the analysis using carotid compliance coefficient and Young's elastic modulus instead of carDC as the determinant. Second, we repeated the analysis using domain-specific cognitive function scores, i.e. memory, processing speed and executive function, as the outcome. Third, to test whether the association between the MVD score and cognitive function composite score was primarily determined by any individual MVD measure, we repeated the analysis five times after consecutively excluding from the MVD score the four CSVD features, the retinal arteriolar and venular dilation responses, UAE and the four plasma biomarkers of MVD. Fifth, we repeated the analysis additionally adjusting for prior CVD, current depression and the plasma biomarkers of low-grade inflammation. Adjustments for these covariates were not included in the main analysis, because of the risk of overadjustment bias: these factors may be confounders but may also mediate the associations between arterial stiffness, MVD and cognitive performance. Sixth, we repeated the analysis additionally adjusting for type of antihypertensive medication (i.e. beta blockers, diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers). Seventh, we repeated the analysis additionally adjusting for the diet score, for moderate-to-vigorous physical activity and for the socio-economic status variables income level and occupational status. Adjustments for these covariates were not included in the main analysis, because data were missing in a relatively large number of participants (n=774 missed data on one or more of these variables).

All analyses were performed with SPSS software (v22.0, IBM, Chicago, USA). A P value of <.05 was considered statistically significant.

Results

Figure 1 shows the derivation of the final study population. In total, 2,544 participants had data available on arterial stiffness, at least one MVD measure, the cognitive function composite score and all potential confounders. Table 1 shows the characteristics of the study population and according to tertiles of the cognitive function composite score. Characteristics of the individuals excluded from the analyses due to missing values are provided in the Supplementary Material (Table S1). On average, these individuals were older, more often male, had received lower education and had a worse cardiovascular risk profile. The study population for current analyses had a mean age of 59.7 years, 51.0% were men, 26.0% had T2D (oversampled by design) and 41.5% had received a high education.

Higher cfPWV was associated with a lower cognitive function composite score after adjustments for all potential confounders but without adjustment for the total MVD score (Table 2). CarDC was not associated with the cognitive function composite score after adjustment for all potential confounders (Table 2).

Mediation analysis showed that higher cfPWV was associated with a higher MVD score, and a higher MVD score was associated with a lower cognitive function composite score (Figure 2). When we additionally adjusted the association between cfPWV and the cognitive function composite score for the MVD score, the association was attenuated and no longer statistically significant. The effect explained by the MVD score was statistically significant and was 16.2% of the total direct effect of cfPWV on the cognitive function composite score (Figure 2). CarDC was not associated with a higher MVD score, and the MVD score did not statistically significantly mediate the association between CarDC and the cognitive function composite score (Figure S2).

We found no interactions with age, sex, education level and glucose metabolism status (P values for interaction >.10).

Additional analyses

The carotid compliance coefficient and Young's elastic modulus were not statistically significantly associated with the cognitive function composite score (Table S2). CfPWV and carDC were not statistically significantly associated with domain-specific cognitive function scores, i.e. memory, processing speed and executive function (Table S3). Results were similar when we consecutively excluded from the MVD score the CSVD features, the retinal arteriolar and venular dilation responses, UAE and the plasma biomarkers of MVD (Table S4). Results did not materially change when we additionally adjusted for prior CVD, current depression or the plasma biomarkers of low-grade inflammation (Table S5), type of antihypertensive medication (Table S6), or the diet score, moderate-to-vigorous physical activity or income level and occupational status (Table S7).

Discussion

In this cross-sectional study, higher cfPWV, but not lower carDC, was associated with a lower cognitive function composite score. In addition, the association between cfPWV and the cognitive function composite score was in part (16.2%) explained or mediated by a composite score of various MVD measures, including CSVD features, flicker light-induced retinal arteriolar and venular dilation response, UAE and plasma biomarkers of MVD.

The study findings are in accordance with the hypothesis that higher aortic stiffness increases the risk of worse cognitive performance in part via cerebral MVD.^{3,55} Higher aortic stiffness may lead to MVD via an increased pulsatile load on the microcirculation. This increased load may cause direct microvascular damage and may induce a microvascular remodelling response. This response initially serves to limit the penetration of the pulsatile load into the microvasculature by raising vascular resistance.⁵⁶ However, this protective response may ultimately become unfavorable, leading to cerebral hypoperfusion, impaired neurogenesis and vasoreactivity, and blood-brain barrier hyperpermeability.

Previous studies have shown associations between higher cfPWV and various measures of MVD, including MRI features of CSVD³ and albuminuria.⁵⁷⁻⁶⁰ In addition, previous studies have shown an association between various MVD measures (i.e. CSVD features, albuminuria and plasma biomarkers of MVD) and worse cognitive performance,^{8, 61-69} and higher cfPWV and worse cognitive performance.^{3, 16, 70} However, only one previous study⁷ evaluated arterial stiffness, cognitive performance and MVD at the same time. This study found an association between higher cfPWV and worse memory, and showed that this association was attenuated after adjustments for higher white matter hyperintensity volume.⁷ The present study extends previous research by showing, with use of a formal mediation analysis, that the association between higher cfPWV and worse cognitive performance is in part mediated, or explained, by a composite score of various direct and indirect measures of MVD. It thereby provides additional evidence consistent with the role of arterial stiffness as a contributor to MVD and cognitive decline.

Surprisingly, carotid stiffness was not associated with worse cognitive performance in our study, although the 95% confidence intervals of the effect estimates do not exclude the possibility of such an association. In contrast, we previously found, in a smaller dataset of The Maastricht Study of the first 866 individuals included in the study i.e. from November 2010 to March 2012, that greater carotid stiffness was weakly associated with worse cognitive performance.²² We cannot fully explain this difference, although it may be related to the slightly different characteristics of the two data samples. Although individuals included in the first study period were of the same age (60 years), they were more often men (54.6% vs 51.0%) and had a slightly worse cardiovascular risk profile, i.e. had more often type 2 diabetes (27.2% vs. 26.0%), were more often current smokers (15.9% vs. 13.4%), and more often had a high level of alcohol consumption (30.9% vs. 26.9%) and prior CVD (17.2% vs. 16.2%). Although both analyses adjusted for these potential confounders, we cannot exclude the possibility of residual confounding. In addition, we cannot exclude that the difference in results are due to the play of chance. Only six other studies^{17-21, 71} evaluated the association between carotid stiffness and cognitive performance and also

had inconsistent results. Some,^{17-19, 21} but not all,^{20, 71} studies found an association between higher carotid stiffness and worse cognitive performance. These conflicting results may be due to the differences in cognitive tests used and inconsistent adjustments for potential confounders (e.g. only one²⁰ study adjusted for heart rate, whereas the others^{17-19, 21, 71} did not). The association between carotid stiffness and cognitive performance, therefore, remains unclear, and requires further study.

A relatively large part of the association between cfPWV and cognitive performance remained unexplained after taking into account the effect of MVD. This remaining association may be due to MVD that is not directly captured in our MVD composite score (e.g. blood-brain barrier leakage and altered cerebrovascular reactivity). In addition, it is possible that only a subset of individuals with cognitive impairment have vascular-related disease. Finally, although we adjusted for a large set of potential confounders, we cannot exclude the possibility of residual confounding.

Strengths of the present study are the large population-based sample, the comprehensive assessment of various measures of MVD, and the extensive characterization of participants, which enabled us to adjust for a series of potential confounders.

Our study has certain limitations. First, the cross-sectional observational design precludes reaching strong causal conclusions about the study findings. Second, the construction of the composite scores assumes that all its components either directly or indirectly reflect cerebral MVD, which is not necessarily true. However, results did not materially change after exclusion of individual MVD measures from the MVD composite score. Third, the study population consisted mostly of middle-aged participants without dementia who were relatively well-educated and whose cardiovascular risk factors were relatively well-controlled. This may have led to an underestimation of the reported findings due to lower variation in cognitive performance and relatively high cognitive reserve.

From a clinical point of view, the present study is important, because insight in the pathophysiological mechanisms between arterial stiffness, MVD and cognitive performance might help to design prevention strategies of cognitive impairment. Evidence suggests that lifestyle modifications, such as weight loss and exercise, may favorably influence arterial stiffness and MVD.^{72, 73} In addition, drugs, such as renin-angiotensin-aldosterone system inhibitors, antihyperglycemic agents (i.e. metformin and glucagon-like peptide 1 receptor (GLP-1R) agonists) and statins, may improve arterial elasticity and microvascular function,^{72, 74-76} possibly beyond their blood pressure-, glucose- or lipid-lowering effects.^{72, 76}

In conclusion, the present study found that aortic stiffness, but not carotid stiffness, is independently associated with worse cognitive performance, and that this association is in part explained by MVD.

References

1. Suhrs HE, Michelsen MM and Prescott E. Treatment strategies in coronary microvascular dysfunction: a systematic review of interventional studies. *Microcirculation*. 2017.
2. Prince M. World Alzheimer Report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends. *Alzheimer's Disease International*. 2015.
3. van Sloten TT, Protogerou AD, Henry RM, Schram MT, Launer LJ and Stehouwer CD. Association between arterial stiffness, cerebral small vessel disease and cognitive impairment: A systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2015;53:121-30.
4. Fazekas F, Kleinert R, Offenbacher H, Payer F, Schmidt R, Kleinert G, Radner H and Lechner H. The morphologic correlate of incidental punctate white matter hyperintensities on MR images. *AJNR Am J Neuroradiol*. 1991;12:915-21.
5. Saji N, Toba K and Sakurai T. Cerebral Small Vessel Disease and Arterial Stiffness: Tsunami Effect in the Brain? *Pulse (Basel)*. 2016;3:182-9.
6. De Silva TM and Faraci FM. Microvascular Dysfunction and Cognitive Impairment. *Cell Mol Neurobiol*. 2016;36:241-58.
7. Cooper LL, Woodard T, Sigurdsson S, van Buchem MA, Torjesen AA, Inker LA, Aspelund T, Eiriksdottir G, Harris TB, Gudnason V, Launer LJ and Mitchell GF. Cerebrovascular Damage Mediates Relations Between Aortic Stiffness and Memory. *Hypertension*. 2016;67:176-82.
8. Rensma SP, van Sloten TT, Launer LJ and Stehouwer CDA. Cerebral small vessel disease and risk of incident stroke, dementia and depression, and all-cause mortality: A systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2018;90:164-173.
9. Taniguchi Y, Fujiwara Y, Nofuji Y, Nishi M, Murayama H, Seino S, Tajima R, Matsuyama Y and Shinkai S. Prospective Study of Arterial Stiffness and Subsequent Cognitive Decline Among Community-Dwelling Older Japanese. *J Epidemiol*. 2015;25:592-9.
10. Hajjar I, Goldstein FC, Martin GS and Quyyumi AA. Roles of Arterial Stiffness and Blood Pressure in Hypertension-Associated Cognitive Decline in Healthy Adults. *Hypertension*. 2016;67:171-5.
11. Tsao CW, Himali JJ, Beiser AS, Larson MG, DeCarli C, Vasan RS, Mitchell GF and Seshadri S. Association of arterial stiffness with progression of subclinical brain and cognitive disease. *Neurology*. 2016;86:619-26.
12. Meyer ML, Palta P, Tanaka H, Deal JA, Wright J, Knopman DS, Griswold ME, Mosley TH and Heiss G. Association of Central Arterial Stiffness and Pressure Pulsatility with Mild Cognitive Impairment and Dementia: The Atherosclerosis Risk in Communities Study-Neurocognitive Study (ARIC-NCS). *J Alzheimers Dis*. 2017;57:195-204.
13. Muela HCS, Costa-Hong VA, Yassuda MS, Moraes NC, Memoria CM, Machado MF, Bor-Seng-Shu E, Nogueira RC, Mansur AJ, Massaro AR, Nitrini R, Macedo TA and Bortolotto LA. Higher arterial stiffness is associated with lower cognitive performance in patients with hypertension. *J Clin Hypertens (Greenwich)*. 2018;20:22-30.
14. Rouch L, Cestac P, Sallerin B, Andrieu S, Bailly H, Beunardeau M, Cohen A, Dubail D, Hernandorena I, Seux ML, Vidal JS and Hanon O. Pulse Wave Velocity Is Associated With Greater Risk of Dementia in Mild Cognitive Impairment Patients. *Hypertension*. 2018;72:1109-1116.
15. Palta P, Sharrett AR, Wei J, Meyer ML, Kucharska-Newton A, Power MC, Deal JA, Jack CR, Knopman D, Wright J, Griswold M, Tanaka H, Mosley TH and Heiss G. Central Arterial Stiffness Is Associated With Structural Brain Damage and Poorer Cognitive Performance: The ARIC Study. *J Am Heart Assoc*. 2019;8:e011045.

16. Pase MP, Beiser A, Himali JJ, Tsao C, Satizabal CL, Vasan RS, Seshadri S and Mitchell GF. Aortic Stiffness and the Risk of Incident Mild Cognitive Impairment and Dementia. *Stroke*. 2016;47:2256-61.
17. Huck DM, Hanna DB, Rubin LH, Maki P, Valcour V, Springer G, Xue X, Lazar J, Hodis HN, Anastos K, Kaplan RC and Kizer JR. Carotid Artery Stiffness and Cognitive Decline Among Women With or at Risk for HIV Infection. *J Acquir Immune Defic Syndr*. 2018;78:338-347.
18. DuBose LE, Voss MW, Weng TB, Kent JD, Dubishar KM, Lane-Cordova A, Sigurdsson G, Schmid P, Barlow PB and Pierce GL. Carotid beta-stiffness index is associated with slower processing speed but not working memory or white matter integrity in healthy middle-aged/older adults. *J Appl Physiol (1985)*. 2017;122:868-876.
19. Lim SL, Gao Q, Nyunt MS, Gong L, Lunaria JB, Lim ML, Ling A, Lam CS, Richards AM, Ling LH and Ng TP. Vascular Health Indices and Cognitive Domain Function: Singapore Longitudinal Ageing Studies. *J Alzheimers Dis*. 2016;50:27-40.
20. Poels MM, van Oijen M, Mattace-Raso FU, Hofman A, Koudstaal PJ, Witteman JC and Breteler MM. Arterial stiffness, cognitive decline, and risk of dementia: the Rotterdam study. *Stroke*. 2007;38:888-92.
21. Tarumi T, Gonzales MM, Fallow B, Nualnim N, Pyron M, Tanaka H and Haley AP. Central artery stiffness, neuropsychological function, and cerebral perfusion in sedentary and endurance-trained middle-aged adults. *J Hypertens*. 2013;31:2400-9.
22. Geijselaers SL, Sep SJ, Schram MT, van Boxtel MP, van Sloten TT, Henry RM, Reesink KD, Kroon AA, Koster A, Schaper NC, Dagnelie PC, van der Kallen CJ, Biessels GJ and Stehouwer CD. Carotid stiffness is associated with impairment of cognitive performance in individuals with and without type 2 diabetes. The Maastricht Study. *Atherosclerosis*. 2016;253:186-193.
23. Wardlaw JM, Smith C and Dichgans M. Small vessel disease: mechanisms and clinical implications. *Lancet Neurol*. 2019;18:684-696.
24. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge R, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M and nEuroimaging STfRVco. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol*. 2013;12:822-38.
25. Sorensen BM, Houben AJ, Berendschot TT, Schouten JS, Kroon AA, van der Kallen CJ, Henry RM, Koster A, Sep SJ, Dagnelie PC, Schaper NC, Schram MT and Stehouwer CD. Prediabetes and Type 2 Diabetes Are Associated With Generalized Microvascular Dysfunction: The Maastricht Study. *Circulation*. 2016;134:1339-1352.
26. Martens RJ, Henry RM, Houben AJ, van der Kallen CJ, Kroon AA, Schalkwijk CG, Schram MT, Sep SJ, Schaper NC, Dagnelie PC, Muris DM, Gronenschild EH, van der Sande FM, Leunissen KM, Kooman JP and Stehouwer CD. Capillary Rarefaction Associates with Albuminuria: The Maastricht Study. *J Am Soc Nephrol*. 2016;27:3748-3757.
27. van Sloten TT, Schram MT, Adriaanse MC, Dekker JM, Nijpels G, Teerlink T, Scheffer PG, Pouwer F, Schalkwijk CG, Stehouwer CD and Henry RM. Endothelial dysfunction is associated with a greater depressive symptom score in a general elderly population: the Hoorn Study. *Psychol Med*. 2014;44:1403-16.
28. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. *Lancet Neurol*. 2010;9:689-701.

29. Umemura T, Kawamura T and Hotta N. Pathogenesis and neuroimaging of cerebral large and small vessel disease in type 2 diabetes: A possible link between cerebral and retinal microvascular abnormalities. *J Diabetes Investig.* 2017;8:134-148.
30. Muris DM, Houben AJ, Schram MT and Stehouwer CD. Microvascular dysfunction: an emerging pathway in the pathogenesis of obesity-related insulin resistance. *Rev Endocr Metab Disord.* 2013;14:29-38.
31. Schram MT, Sep SJ, van der Kallen CJ, Dagnelie PC, Koster A, Schaper N, Henry RM and Stehouwer CD. The Maastricht Study: an extensive phenotyping study on determinants of type 2 diabetes, its complications and its comorbidities. *Eur J Epidemiol.* 2014;29:439-51.
32. Garhofer G, Resch H, Sacu S, Weigert G, Schmidl D, Lasta M and Schmetterer L. Effect of regular smoking on flicker induced retinal vasodilatation in healthy subjects. *Microvasc Res.* 2011;82:351-5.
33. Geijselaers SL, Sep SJ, Schram MT, van Boxtel MP, van Sloten TT, Op Het Roodt J, Henry RM, Reesink KD, Schaper NC, Dagnelie PC, van der Kallen CJ, Biessels GJ and Stehouwer CD. Carotid circumferential wall stress is not associated with cognitive performance among individuals in late middle age: The Maastricht Study. *Atherosclerosis.* 2018;276:15-22.
34. van Sloten TT, Czernichow S, Houben AJ, Protogerou AD, Henry RM, Muris DM, Schram MT, Sep SJ, Dagnelie PC, van der Kallen CJ, Schaper NC, Blacher J, Hercberg S, Levy BI and Stehouwer CD. Association Between Arterial Stiffness and Skin Microvascular Function: The SUVIMAX2 Study and The Maastricht Study. *Am J Hypertens.* 2015;28:868-76.
35. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H and European Network for Non-invasive Investigation of Large A. Expert consensus document on arterial stiffness: methodological issues and clinical applications. *Eur Heart J.* 2006;27:2588-605.
36. Willekes C, Hoeks AP, Bots ML, Brands PJ, Willigers JM and Reneman RS. Evaluation of off-line automated intima-media thickness detection of the common carotid artery based on M-line signal processing. *Ultrasound Med Biol.* 1999;25:57-64.
37. Reneman RS, Meinders JM and Hoeks AP. Non-invasive ultrasound in arterial wall dynamics in humans: what have we learned and what remains to be solved. *Eur Heart J.* 2005;26:960-6.
38. van Agtmaal MJM, Houben A, de Wit V, Henry RMA, Schaper NC, Dagnelie PC, van der Kallen CJ, Koster A, Sep SJ, Kroon AA, Jansen JFA, Hofman PA, Backes WH, Schram MT and Stehouwer CDA. Prediabetes Is Associated With Structural Brain Abnormalities: The Maastricht Study. *Diabetes Care.* 2018;41:2535-2543.
39. Houben A, Martens RJH and Stehouwer CDA. Assessing Microvascular Function in Humans from a Chronic Disease Perspective. *J Am Soc Nephrol.* 2017;28:3461-3472.
40. Martens RJ, Kooman JP, Stehouwer CD, Dagnelie PC, van der Kallen CJ, Koster A, Kroon AA, Leunissen KM, Nijpels G, van der Sande FM, Schaper NC, Sep SJ, van Boxtel MP, Schram MT and Henry RM. Estimated GFR, Albuminuria, and Cognitive Performance: The Maastricht Study. *Am J Kidney Dis.* 2017;69:179-191.
41. Van der Elst W, van Boxtel MP, van Breukelen GJ and Jolles J. Rey's verbal learning test: normative data for 1855 healthy participants aged 24-81 years and the influence of age, sex, education, and mode of presentation. *J Int Neuropsychol Soc.* 2005;11:290-302.
42. Van der Elst W, Van Boxtel MP, Van Breukelen GJ and Jolles J. The Stroop color-word test: influence of age, sex, and education; and normative data for a large sample across the adult age range. *Assessment.* 2006;13:62-79.

43. Van der Elst W, Van Boxtel MP, Van Breukelen GJ and Jolles J. The Concept Shifting Test: adult normative data. *Psychol Assess.* 2006;18:424-32.
44. van der Elst W, van Boxtel MP, van Breukelen GJ and Jolles J. The Letter Digit Substitution Test: normative data for 1,858 healthy participants aged 24-81 from the Maastricht Aging Study (MAAS): influence of age, education, and sex. *J Clin Exp Neuropsychol.* 2006;28:998-1009.
45. World Health Organization & International Diabetes Federation. (2006) . Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia : report of a WHO/IDF consultation. Geneva : World Health Organization.
46. Trichopoulou A, Orfanos P, Norat T, Bueno-de-Mesquita B, Ocke MC, Peeters PH, van der Schouw YT, Boeing H, Hoffmann K, Boffetta P, Nagel G, Masala G, Krogh V, Panico S, Tumino R, Vineis P, Bamia C, Naska A, Benetou V, Ferrari P, Slimani N, Pera G, Martinez-Garcia C, Navarro C, Rodriguez-Barranco M, Dorronsoro M, Spencer EA, Key TJ, Bingham S, Khaw KT, Kesse E, Clavel-Chapelon F, Boutron-Ruault MC, Berglund G, Wirfalt E, Hallmans G, Johansson I, Tjonneland A, Olsen A, Overvad K, Hundborg HH, Riboli E and Trichopoulos D. Modified Mediterranean diet and survival: EPIC-elderly prospective cohort study. *BMJ.* 2005;330:991.
47. Qi Y, Koster A, van Boxtel M, Kohler S, Schram M, Schaper N, Stehouwer C and Bosma H. Adulthood Socioeconomic Position and Type 2 Diabetes Mellitus-A Comparison of Education, Occupation, Income, and Material Deprivation: The Maastricht Study. *Int J Environ Res Public Health.* 2019;16.
48. van Dooren FE, Schram MT, Schalkwijk CG, Stehouwer CD, Henry RM, Dagnelie PC, Schaper NC, van der Kallen CJ, Koster A, Sep SJ, Denollet J, Verhey FR and Pouwer F. Associations of low grade inflammation and endothelial dysfunction with depression - The Maastricht Study. *Brain Behav Immun.* 2016;56:390-6.
49. Zhou TL, Kroon AA, Reesink KD, Schram MT, Koster A, Schaper NC, Dagnelie PC, van der Kallen CJH, Sep SJS, Stehouwer CDA and Henry RMA. Blood pressure variability in individuals with and without (pre)diabetes: The Maastricht Study. *J Hypertens.* 2018;36:259-267.
50. O'Brien PC. Procedures for comparing samples with multiple endpoints. *Biometrics.* 1984;40:1079-87.
51. Preacher KJ and Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. *Behav Res Methods.* 2008;40:879-91.
52. Elias MF, Robbins MA, Budge MM, Abhayaratna WP, Dore GA and Elias PK. Arterial pulse wave velocity and cognition with advancing age. *Hypertension.* 2009;53:668-73.
53. Schiebinger L, Leopold SS and Miller VM. Editorial policies for sex and gender analysis. *Lancet.* 2016;388:2841-2842.
54. Whalley LJ, Deary IJ, Appleton CL and Starr JM. Cognitive reserve and the neurobiology of cognitive aging. *Ageing Res Rev.* 2004;3:369-82.
55. Cooper LL and Mitchell GF. Aortic Stiffness, Cerebrovascular Dysfunction, and Memory. *Pulse (Basel).* 2016;4:69-77.
56. van Sloten TT, Mitchell GF, Sigurdsson S, van Buchem MA, Jonsson PV, Garcia ME, Harris TB, Henry RM, Levey AS, Stehouwer CD, Gudnason V and Launer LJ. Associations between arterial stiffness, depressive symptoms and cerebral small vessel disease: cross-sectional findings from the AGES-Reykjavik Study. *J Psychiatry Neurosci.* 2016;41:162-8.
57. Huang N, Foster MC, Mitchell GF, Andresdottir MB, Eiríksdóttir G, Gudmundsdóttir H, Harris TB, Launer LJ, Palsson R, Gudnason V, Levey AS and Inker LA. Aortic stiffness and change in glomerular filtration rate and albuminuria in older people. *Nephrol Dial Transplant.* 2017;32:677-684.

58. Wu S, Chen D, Zeng X, Wen J, Zhou C, Xiao K, Hu P and Chen W. Arterial stiffness is associated with target organ damage in subjects with pre-hypertension. *Arch Med Sci*. 2018;14:1374-1380.
59. Michener KH, Mitchell GF, Noubary F, Huang N, Harris T, Andresdottir MB, Palsson R, Gudnason V and Levey AS. Aortic stiffness and kidney disease in an elderly population. *Am J Nephrol*. 2015;41:320-8.
60. Bouchi R, Babazono T, Mugishima M, Yoshida N, Nyumura I, Toya K, Hanai K, Tanaka N, Ishii A, Uchigata Y and Iwamoto Y. Arterial stiffness is associated with incident albuminuria and decreased glomerular filtration rate in type 2 diabetic patients. *Diabetes Care*. 2011;34:2570-5.
61. Huang CW, Tsai MH, Chen NC, Chen WH, Lu YT, Lui CC, Chang YT, Chang WN, Chang AY and Chang CC. Clinical significance of circulating vascular cell adhesion molecule-1 to white matter disintegrity in Alzheimer's dementia. *Thromb Haemost*. 2015;114:1230-40.
62. Rafnsson SB, Deary IJ, Smith FB, Whiteman MC, Rumley A, Lowe GD and Fowkes FG. Cognitive decline and markers of inflammation and hemostasis: the Edinburgh Artery Study. *J Am Geriatr Soc*. 2007;55:700-7.
63. Yoon CY, Steffen LM, Gross MD, Launer LJ, Odegaard A, Reiner A, Sanchez O, Yaffe K, Sidney S and Jacobs DR, Jr. Circulating Cellular Adhesion Molecules and Cognitive Function: The Coronary Artery Risk Development in Young Adults Study. *Front Cardiovasc Med*. 2017;4:37.
64. Heringa SM, van den Berg E, Reijmer YD, Nijpels G, Stehouwer CD, Schalkwijk CG, Teerlink T, Scheffer PG, van den Hurk K, Kappelle LJ, Dekker JM and Biessels GJ. Markers of low-grade inflammation and endothelial dysfunction are related to reduced information processing speed and executive functioning in an older population - the Hoorn Study. *Psychoneuroendocrinology*. 2014;40:108-18.
65. DeBette S and Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ*. 2010;341:c3666.
66. Georgakis MK, Dimitriou NG, Karalexi MA, Mihos C, Nasothimiou EG, Tousoulis D, Tsiygoulis G and Petridou ET. Albuminuria in Association with Cognitive Function and Dementia: A Systematic Review and Meta-Analysis. *J Am Geriatr Soc*. 2017;65:1190-1198.
67. Li X, Yuan J, Yang L, Qin W, Yang S, Li Y, Fan H and Hu W. The significant effects of cerebral microbleeds on cognitive dysfunction: An updated meta-analysis. *PLoS One*. 2017;12:e0185145.
68. Saczynski JS, Sigurdsson S, Jonsdottir MK, Eiriksdottir G, Jonsson PV, Garcia ME, Kjartansson O, Lopez O, van Buchem MA, Gudnason V and Launer LJ. Cerebral infarcts and cognitive performance: importance of location and number of infarcts. *Stroke*. 2009;40:677-82.
69. Vibha D, Tiemeier H, Mirza SS, Adams HHH, Niessen WJ, Hofman A, Prasad K, van der Lugt A, Vernooij MW and Ikram MA. Brain Volumes and Longitudinal Cognitive Change: A Population-based Study. *Alzheimer Dis Assoc Disord*. 2017.
70. Rabkin SW. Arterial stiffness: detection and consequences in cognitive impairment and dementia of the elderly. *J Alzheimers Dis*. 2012;32:541-9.
71. Nieboer D, Douw L, van Dijk BW, Heymans MW, Stam CJ and Twisk JW. Relation between carotid stiffness, cognitive performance and brain connectivity in a healthy middle-aged population: an observational neurophysiological cohort study with magnetoencephalography. *BMJ Open*. 2016;6:e013441.
72. Stehouwer CDA. Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle With Widespread Consequences. *Diabetes*. 2018;67:1729-1741.
73. Ferreira I, Boreham CA and Stehouwer CD. The benefits of exercise for arterial stiffness. *Am J Hypertens*. 2006;19:1037-8.

74. Batzias K, Antonopoulos AS, Oikonomou E, Siasos G, Bletsas E, Stampouloglou PK, Mistakidi CV, Noutsou M, Katsiki N, Karopoulos P, Charalambous G, Thanopoulou A, Tentolouris N and Tousoulis D. Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis. *J Diabetes Res.* 2018;2018:1232583.
75. Upala S, Wirunsawanya K, Jaruvongvanich V and Sanguankee A. Effects of statin therapy on arterial stiffness: A systematic review and meta-analysis of randomized controlled trial. *Int J Cardiol.* 2017;227:338-341.
76. D'Elia L, La Fata E, Iannuzzi A and Rubba PO. Effect of statin therapy on pulse wave velocity: A meta-analysis of randomized controlled trials. *Clin Exp Hypertens.* 2018;40:601-608.

Figure 1. Flowchart showing the derivation of the total study population. *Missings not mutually exclusive.

Table 1 General study population characteristics

	Tertiles of the cognitive function composite score			
	Total study population (n=2,544)	Lowest tertile (n=848)	Middle tertile (n=848)	Highest tertile (n=848)
Demographics				
Age, years	59.7 ± 8.1	64.1 ± 6.7	60.2 ± 7.1	54.9 ± 7.7
Men	51.0 (1,297)	63.7 (540)	53.2 (451)	36.1 (306)
Education level				
Low	15.4 (393)	29.7 (252)	12.4 (105)	4.2 (36)
Intermediate	43.1 (1,096)	45.3 (384)	45.5 (386)	38.4 (326)
High	41.5 (1,055)	25.0 (212)	42.1 (357)	57.3 (486)
Cardiovascular risk factors				
Glucose metabolism status				
Normal glucose metabolism	58.8 (1,496)	42.6 (361)	59.9 (508)	73.9 (627)
Prediabetes	15.2 (387)	16.7 (142)	15.7 (133)	13.2 (112)
Type 2 diabetes	26.0 (661)	40.7 (345)	24.4 (207)	12.9 (109)
Body mass index, kg/m ²	26.9 ± 4.4	27.8 ± 4.3	26.9 ± 4.5	26.1 ± 4.1
Smoking status:				
Never	33.8 (860)	30.7 (260)	32.3 (274)	38.4 (326)
Former	52.8 (1,342)	53.4 (453)	55.2 (468)	49.6 (421)
Current	13.4 (342)	15.9 (135)	12.5 (106)	11.9 (101)
Alcohol consumption				
None	17.7 (451)	21.7 (184)	15.7 (133)	15.8 (134)
Low, women ≤7; men ≤14 units/week	55.4 (1,409)	54.7 (464)	57.3 (486)	54.1 (459)
High, women >7; men >14 units/week	26.9 (684)	23.6 (200)	27.0 (229)	30.1 (255)
Total/HDL cholesterol ratio	3.7 ± 1.2	3.8 ± 1.2	3.8 ± 1.2	3.6 ± 1.2
Triglycerides, mmol/L	1.4 ± 0.9	1.5 ± 0.9	1.4 ± 0.9	1.3 ± 0.8
Office systolic pressure, mmHg	134.9 ± 18.2	139.6 ± 18.8	135.7 ± 17.6	129.3 ± 16.6
Office diastolic pressure, mmHg	76.2 ± 9.9	76.4 ± 9.9	76.6 ± 9.6	75.7 ± 10.2
Heart rate during vascular measurement, bpm	62.5 ± 9.3	63.0 ± 9.8	62.0 ± 9.0	62.6 ± 9.0
Use of antihypertensive medication	37.7 (959)	53.7 (455)	35.7 (303)	23.7 (201)
Use of lipid-modifying medication	35.1 (893)	49.5 (420)	35.1 (298)	20.6 (175)
Prior cardiovascular disease	16.2 (405)	24.5 (204)	14.7 (123)	9.3 (78)
Current depression	3.5 (88)	4.8 (40)	3.6 (30)	2.1 (18)
Composite score of plasma biomarkers of low-grade inflammation, SD	0.0 ± 1.0	0.2 ± 0.7	0.0 ± 0.6	-0.2 ± 0.6
Measures of arterial stiffness				
Carotid-femoral pulse wave velocity, m/s	9.0 ± 2.1	9.7 ± 2.4	8.9 ± 2.0	8.3 ± 1.7
Carotid distensibility coefficient, 10 ⁻³ /kPa	14.3 ± 5.1	12.9 ± 4.7	14.2 ± 4.8	15.9 ± 5.3
Carotid compliance coefficient, mm ² /kPa	0.7 ± 0.7	0.7 ± 0.3	0.7 ± 0.3	0.7 ± 0.3
Carotid Young's elastic modulus, 10 ³ /kPa	0.7 ± 0.4	0.8 ± 0.4	0.7 ± 0.3	0.7 ± 0.3
Measures of microvascular dysfunction*				
Microvascular dysfunction composite score	0.0 ± 1.0	0.4 ± 1.2	-0.1 ± 0.8	-0.3 ± 0.7
Cerebral small vessel disease features				
Total brain parenchyma volume, ml	1,136.1 ± 111.4	1,123.0 ± 113.4	1,146.0 ± 116.7	1,137.4 ± 103.3
White matter hyperintensity volume, ml	0.23 [0.07-0.75]	0.40 [0.15-1.35]	0.25 [0.08-0.90]	0.13 [0.04-0.38]
Presence of cerebral microbleeds	12.0 (203)	15.8 (79)	10.9 (64)	9.8 (60)
Presence of lacunar infarcts	5.3 (91)	6.3 (32)	6.6 (39)	3.2 (20)

	Tertiles of the cognitive function composite score			
	Total study population (n=2,544)	Lowest tertile (n=848)	Middle tertile (n=848)	Highest tertile (n=848)
Flicker light-induced arteriolar and venular dilation				
Flicker light-induced arteriolar dilation, %	3.1 ± 2.8	2.7 ± 2.9	3.1 ± 2.8	3.3 ± 2.8
Flicker light-induced venular dilation, %	3.9 ± 2.2	3.7 ± 2.1	3.9 ± 2.2	4.0 ± 2.3
Urinary albumin excretion				
0-15 mg/24h	81.9 (2,066)	73.9 (618)	83.9 (706)	87.8 (742)
15-30 mg/24h	10.5 (266)	13.6 (114)	10.0 (84)	8.0 (68)
≥30 mg/24h	7.5 (190)	12.4 (104)	6.1 (51)	4.1 (35)
Plasma biomarkers of microvascular dysfunction				
Soluble ICAM-1, ng/ml	352.6 ± 96.8	372.4 ± 116.3	349.2 ± 85.9	336.4 ± 81.1
Soluble VCAM-1, ng/ml	425.4 ± 98.1	447.1 ± 111.3	423.1 ± 94.4	406.2 ± 82.1
Soluble E-selectin, ng/ml	117.1 ± 64.8	130.2 ± 79.1	116.9 ± 55.2	104.1 ± 54.4
Von Willebrand Factor, %	131.8 ± 47.2	141.4 ± 50.1	131.0 ± 45.7	123.2 ± 43.9
Cognitive performance				
Cognitive function composite score, SD	0.0 ± 1.0	-1.1 ± 0.6	0.1 ± 0.2	1.1 ± 0.5
Memory, SD	0.0 ± 1.0	-0.9 ± 0.8	0.0 ± 0.7	0.8 ± 0.7
Processing speed, SD	0.0 ± 1.0	-0.9 ± 0.8	0.0 ± 0.6	0.9 ± 0.6
Executive function, SD	0.0 ± 1.0	-0.9 ± 0.8	0.1 ± 0.6	0.8 ± 0.7

Data are presented as mean ± standard deviation (SD), median [interquartile range] or n (%).

*We calculated a microvascular dysfunction (MVD) composite score ("MVD composite score") of all individual MVD measures. For the total MVD composite score, the individual 11 MVD measures (i.e. four cerebral small vessel disease features, the flicker light-induced retinal arteriolar and venular dilation responses, urinary albumin excretion and the four plasma biomarkers of MVD) were standardized into z-scores. These z-scores were then averaged into the MVD composite score. The MVD composite score was calculated when data were available on at least one of the 11 individual MVD measures. Data available for: total brain parenchyma volume, n=1,726; white matter hyperintensity volume, n=1,726; cerebral microbleeds, n=1,697; lacunar infarcts, n=1,724; flicker light-induced arteriolar dilation, n=1,649; flicker light-induced venular dilation, n=1,679; urinary albumin excretion, n=2,522; soluble intercellular adhesion molecule-1, n=2,520; soluble vascular adhesion molecule-1, n=2,520; soluble E-selectin, n=2,520; von Willebrand factor, n=2,517.

Abbreviations: HDL, high-density lipoprotein; ICAM-1: intracellular adhesion molecule-1; VCAM-1: vascular adhesion molecule-1.

Table 2. Associations between arterial stiffness and the cognitive function composite score

Arterial stiffness measure	Cognitive function composite score, per SD	
	Model	β (95% CI)
Carotid-femoral pulse wave velocity, m/s	1	-0.032 (-0.048; -0.016)
	2	-0.019 (-0.035; -0.003)
	3	-0.018 (-0.036; -0.000)
Carotid distensibility coefficient, 10 ⁻³ /kPa	1	-0.007 (-0.014; -0.000)
	2	-0.005 (-0.012; 0.002)
	3	-0.004 (-0.012; 0.003)

Results indicate SD (95% confidence intervals) lower cognitive function composite score per m/s higher carotid-femoral pulse wave velocity and per 10⁻³/kPa lower in carotid distensibility. **Model 1:** adjusted for age, sex, education level, **Model 2:** additionally adjusted for glucose metabolism status, body mass index, smoking, alcohol use, total/high density cholesterol ratio and triglycerides, and **Model 3:** additionally adjusted for mean arterial pressure, heart rate and use of anti-hypertensive and/or lipid-modifying medication. Abbreviations: CI = confidence interval; SD = standard deviation.

Figure 2. Association between carotid-femoral pulse wave velocity (per m/s) and the cognitive function composite score (per SD), and the proportion explained by the microvascular dysfunction score (per SD). Solid lines indicate associations that are statistically significant; dashed lines indicate associations that are not statistically significant. Associations are presented as regression coefficients (β) and corresponding 95% confidence intervals. All associations are adjusted for potential confounders: age, sex, education level, glucose metabolism status, body mass index, smoking, alcohol use, total/high density cholesterol ratio, triglycerides, mean arterial pressure, heart rate and use of anti-hypertensive and/or lipid-modifying medication.

Supplemental Material

Item S1. Assessment of arterial stiffness

All measurements were done by trained vascular technicians unaware of the participants' clinical or diabetes status, in a dark, quiet, temperature-controlled room (21-23°C). Participants were asked to refrain from smoking and drinking coffee or tea or alcoholic beverages three hours prior to the study. Participants were allowed to have a light meal (breakfast and/or lunch). All measurements were performed in a supine position after 10 minutes of rest. Talking or sleeping was not allowed during the examination. During the vascular measurements (approximately 45 minutes), brachial systolic, diastolic and mean arterial pressure (MAP) were determined every five minutes with an oscillometric device (Accutorr Plus, Datascope Inc., Montvale, NJ, USA). The mean MAP and heart rate (HR) of these measurements were used in the statistical analysis. A three-lead electrocardiogram was recorded continuously during the measurements to facilitate automatic signal processing.

Carotid-femoral pulse wave velocity

Carotid-femoral pulse wave velocity (cfPWV) was determined according to recent guidelines¹ with the use of applanation tonometry (SphygmoCor, Atcor Medical, Sydney, Australia). Pressure waveforms were determined at the right common carotid and right common femoral arteries. Difference in the time of pulse arrival from the R-wave of the electrocardiogram between the two sites (transit time) was determined with the intersecting tangents algorithm. The pulse wave travel distance was calculated as 80% of the direct straight distance (measured with an infantometer) between the two arterial sites. The median of three consecutive cfPWV (defined as traveled distance/transit time) recordings was used in the analyses.

Local arterial elastic properties

Data acquisition. Measurements were done at the left common carotid (10 mm proximal to the carotid bulb) artery, with the use of an ultrasound scanner equipped with a 7.5-MHz linear probe (MyLab 70, Esaote Europe B.V., Maastricht, the Netherlands). This setup enables the measurement of diameter, distension and intima-media thickness (IMT) as described previously.^{2,3} Briefly, during the ultrasound measurements a B-mode image on the basis of 19 M-lines was depicted on screen and an online echo-tracking algorithm showed real-time anterior and posterior arterial wall displacements. The M-mode recordings were composed of 19 simultaneous recordings at a frame rate of 498 Hz. The distance between the M-line recording positions was 0.96 mm; thus, a total segment of 18.24 mm of each artery was covered by the scan plane. For offline processing, the radiofrequency signal was fed into a dedicated PC-based acquisition system (ART.LAB, Esaote Europe B.V. Maastricht, the Netherlands) with a sampling frequency of 50 MHz. Data processing was performed in MatLab (version 7.5, Mathworks, Natick, MA, USA). The distension waveforms were obtained from the radio frequency data with the use of a wall track algorithm.² Carotid IMT was defined as the distance of the posterior wall from the leading edge interface between lumen and intima to the leading edge interface between

media and adventitia.³ The median diameter, distension, and IMT of three measurements were used in the analyses.

Data analysis. Local arterial elastic properties were quantified by calculating the following indices:⁴

- Carotid Distensibility Coefficient (CarDC)
- $DC = (2\Delta D * D + \Delta D^2) / (PP * D^2)$ (10^{-3} kPa^{-1})
- Carotid Young's elastic modulus (CarYEM)
- $YEM = D / (IMT * DC)$ (10^3 kPa)
- Carotid Compliance Coefficient (CarCC)
- $CC = \pi * (2D * \Delta D + \Delta D^2) / 4PP$ ($\text{mm}^2 \text{ kPa}^{-1}$)

Where D is arterial diameter; ΔD distension; IMT intima-media thickness; and PP brachial pulse pressure (calculated as systolic minus diastolic blood pressure).

CarDC represents arterial stiffness; CarYEM, the stiffness of the arterial wall material at operating pressure; and CarCC, arterial buffering capacity.

Reproducibility

Reproducibility was assessed in 12 individuals (6 men; 60.8 ± 6.8 years; 6 type 2 diabetes) who were examined by two observers at two occasions spaced one week apart. The intra- and inter-observer intra-class correlation coefficients were for cfPWV 0.87 and 0.69; for carDC 0.85 and 0.73; for CarYEM 0.72 and 0.71; for CarCC 0.95 and 0.72.

Item S2. Brain magnetic resonance imaging measures

Brain magnetic resonance imaging (MRI) was performed on a 3T MRI scanner (Siemens Magnetom Prisma-fit Syngo MR D13D, Erlangen, Germany) by use of a 64-element head/neck coil for parallel imaging. The MRI protocol consisted of a 3D T_1 -weighted magnetization prepared rapid acquisition gradient echo (MPRAGE) sequence (TR/TI/TE 2300/900/2.98 ms, 176 slices, 256×240 matrix size, 1.00 mm cubic voxel size); a fluid-attenuated inversion recovery (FLAIR) sequence (TR/TI/TE 5000/1800/394 ms, 176 slices, 512×512 matrix size, 0.49×0.49×1.00 mm voxel size); a combined proton density (PD) and T_2 -weighted turbo spin echo (TSE) pulse sequence (TR/TE1/TE2 3200/9.4/94 ms, 30 slices, 640×540 matrix size, 0.36×0.36×4.00 mm voxel size); and a susceptibility-weighted imaging (SWI) sequence (TR/TE 28/20 ms, 144 slices, 384×312 matrix size, 0.57×0.57×1.00 mm voxel size).

Contra-indications for MRI assessments were the presence of a cardiac pacemaker or implantable cardioverter-defibrillator, neurostimulator, non-detachable insulin pump, metallic vascular clips or stents in the head, cochlear implant, metal-containing intra-uterine device, metal splinters or shrapnel, dentures with magnetic clip, an inside bracket, pregnancy, epilepsy, and claustrophobia.

T_1 -weighted images and FLAIR images were analyzed by use of an ISO-13485:2012 certified, automated method (which included visual inspection).^{5,6} T_1 -weighted images were segmented into grey matter, white matter and cerebrospinal fluid volumes (1 voxel = 1.00 mm³ = 0.001 ml).⁵ Intracranial volume was calculated as the sum of grey matter, white matter (including white matter hyperintensity volume) and cerebrospinal fluid volumes. Total brain parenchyma volume was calculated as the sum of grey and white matter volumes. White matter hyperintensities identified were summed to assess total white matter hyperintensities burden in milliliter. Lacunar infarcts were defined as focal brain parenchyma defects of ≥3 mm and <15 mm in size with a similar signal intensity as cerebrospinal fluid on all sequences and a hyperintense rim on T_2 and FLAIR images⁷. Cerebral microbleeds were rated on T_2 -weighted and SWI images by use of the Microbleed Anatomical Rating Scale⁸, and were defined as focal lesions of ≥2 mm and ≤10 mm in size with a hypointense signal⁷. The presence of lacunar infarcts and cerebral microbleeds was rated manually by three neuroradiologists. The two-way mixed effects, consistency, intraclass correlation coefficient for the three raters based on 50 randomly selected scans was 0.84 (95% confidence interval 0.74; 0.91) and 0.83 (0.72; 0.90) for the presence of lacunar infarcts and cerebral microbleeds, respectively.

Item S3. Assessment of cognitive performance

The composite memory score was derived from the Verbal Learning Test by weighting total immediate and delayed recall scores. The domain information processing speed included the Stroop Color-Word Test Part I and II, the Concept Shifting Test Part A and B, and the Letter-Digit Substitution Test. Executive function was assessed by the Stroop Color-Word Test Part III and the Concept Shifting Test Part C. A description of the individual tests is provided below.

Raw test scores were transformed into z-scores. Standardized scores of the Stroop Color-Word Test and Concept Shifting Test were inverted so that higher scores indicated better cognitive function. Thereafter, domain-specific scores were calculated as the standardized average of the z-scores from (sub)tests within that domain (e.g. memory = z-score of (z-score immediate recall + z-score delayed recall/ 2)). The standardized average of these domain scores was then considered a measure of overall cognitive function (i.e. overall cognitive function = z-score of (memory + information processing speed + executive function / 3)).

Description of the individual cognitive tests used in the present study

*Verbal Learning Test:*⁹

Fifteen unrelated, monosyllabic, words were presented on a computer screen in five subsequent trials. After each trial, participants were instructed to recall as many words as possible in any order. Twenty minutes after the last trial, participants were asked again to reproduce the words. Outcomes recorded included the total number of words correctly recalled over the five trials (total immediate recall) and the number of correctly recalled words during delayed recall (delayed recall).

*Stroop Color-Word Test:*¹⁰

In this test, which consisted of three parts, participants were firstly asked to read aloud color names (i.e. red, blue, yellow, and green) that were printed in black ink (Part I). Secondly, they were instructed to name solid color patches (Part II). Finally, participants had to name the ink color of color names that were printed in an incongruent color (e.g. participants were asked to say red when the word yellow was printed in red) (Part III). The time needed to complete Part III was adjusted for the average time needed to complete Part I and II.

*Concept Shifting Test:*¹¹

This test, a modification of the Trailing Making Test, consisted of four subtasks. During each subtask, participants were shown 16 small circles aligned along a larger imaginary circle. The small circles contained (a combination of) digits, letters, or were empty. Participants were instructed to cross-out as quickly as possible the digits in ascending order (Part A), the letters in alphabetic order (Part B), and the letters and digits in alternating order (Part C). Thereafter, participants were asked to cross-out empty circles in a clockwise fashion in two consecutive trials (Part D). In this way, test results could be accounted for basic motor speed. The time needed to complete subtasks A and B was adjusted for the average time

needed to complete Part 0, the time needed to completed Part C for the average time of Part A and B.

Letter-Digit Substitution Test:¹²

Participants were requested to match digits to letters according to a given key. This key included the numbers 1 to 9, each paired with a different letter. The outcome of interest was the number of correct substitutions within 90 seconds.

References

1. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, Filipovsky J, Huybrechts S, Mattace-Raso FU, Protogerou AD, Schillaci G, Segers P, Vermeersch S, Weber T, Artery S, European Society of Hypertension Working Group on Vascular S, Function and European Network for Noninvasive Investigation of Large A. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. *J Hypertens*. 2012;30:445-8.
2. Hermeling E, Reesink KD, Kornmann LM, Reneman RS and Hoeks AP. The dicrotic notch as alternative time-reference point to measure local pulse wave velocity in the carotid artery by means of ultrasonography. *J Hypertens*. 2009;27:2028-35.
3. Willekes C, Hoeks AP, Bots ML, Brands PJ, Willigers JM and Reneman RS. Evaluation of off-line automated intima-media thickness detection of the common carotid artery based on M-line signal processing. *Ultrasound in medicine & biology*. 1999;25:57-64.
4. Reneman RS, Meinders JM and Hoeks AP. Non-invasive ultrasound in arterial wall dynamics in humans: what have we learned and what remains to be solved. *European heart journal*. 2005;26:960-6.
5. Vrooman HA, Cocosco CA, van der Lijn F, Stokking R, Ikram MA, Vernooij MW, Breteler MM and Niessen WJ. Multi-spectral brain tissue segmentation using automatically trained k-Nearest-Neighbor classification. *NeuroImage*. 2007;37:71-81.
6. de Boer R, Vrooman HA, van der Lijn F, Vernooij MW, Ikram MA, van der Lugt A, Breteler MM and Niessen WJ. White matter lesion extension to automatic brain tissue segmentation on MRI. *NeuroImage*. 2009;45:1151-61.
7. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge R, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M and nEuroimaging STFRVco. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol*. 2013;12:822-38.
8. Gregoire SM, Chaudhary UJ, Brown MM, Yousry TA, Kallis C, Jager HR and Werring DJ. The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. *Neurology*. 2009;73:1759-66.
9. Van der Elst W, van Boxtel MP, van Breukelen GJ and Jolles J. Rey's verbal learning test: normative data for 1855 healthy participants aged 24-81 years and the influence of age, sex, education, and mode of presentation. *J Int Neuropsychol Soc*. 2005;11:290-302.
10. Van der Elst W, Van Boxtel MP, Van Breukelen GJ and Jolles J. The Stroop color-word test: influence of age, sex, and education; and normative data for a large sample across the adult age range. *Assessment*. 2006;13:62-79.
11. Van der Elst W, Van Boxtel MP, Van Breukelen GJ and Jolles J. The Concept Shifting Test: adult normative data. *Psychol Assess*. 2006;18:424-32.
12. van der Elst W, van Boxtel MP, van Breukelen GJ and Jolles J. The Letter Digit Substitution Test: normative data for 1,858 healthy participants aged 24-81 from the Maastricht Aging Study (MAAS): influence of age, education, and sex. *J Clin Exp Neuropsychol*. 2006;28:998-1009.

Table S1. Characteristics of the study population and individuals excluded from the analyses due to missing values

	Complete (N=2,544)	Missing (n=907)
Demographics		
Age, years	59.7 ± 8.1	59.9 ± 8.7
Men	51.0 (1,297)	52.7 (478)
Education level		
Low	15.4 (393)	22.0 (175)*
Intermediate	43.1 (1,096)	42.5 (338)*
High	41.5 (1,055)	35.5 (282)*
Cardiovascular risk factors		
Glucose metabolism status		
Normal glucose metabolism	58.8 (1,496)	49.4 (428)*
Prediabetes	15.2 (387)	14.3 (124)*
Type 2 diabetes	26.0 (661)	36.3 (314)*
Body mass index, kg/m ²	26.9 ± 4.4	27.5 ± 5.1*
Smoking status:		
Never	33.8 (860)	36.7 (310)
Former	52.8 (1,342)	48.2 (407)
Current	13.4 (342)	15.0 (127)
Alcohol consumption		
None	17.7 (451)	21.2 (178)*
Low, women ≤7; men ≤14 units/week	55.4 (1,409)	55.6 (466)*
High, women >7; men >14 units/week	26.9 (684)	23.2 (194)*
Total/high-density lipoprotein cholesterol ratio	3.7 ± 1.2	3.5 ± 1.1*
Triglycerides, mmol/L	1.4 ± 0.9	1.5 ± 0.8
Office systolic pressure, mmHg	134.9 ± 18.2	135.6 ± 18.3
Office diastolic pressure, mmHg	76.2 ± 9.9	75.8 ± 9.6
Heart rate during vascular measurement, bpm	62.5 ± 9.3	64.1 ± 9.9*
Use of antihypertensive medication	37.7 (959)	46.4 (419)*
Use of lipid-modifying medication	35.1 (893)	40.4 (365)*
Prior cardiovascular disease	16.2 (405)	18.3 (153)
Current depression	3.5 (88)	34 (4.4)
Composite score of plasma biomarkers of low-grade inflammation, SD	0.0 ± 1.0	0.0 ± 0.6
Measures of arterial stiffness		
Carotid-femoral pulse wave velocity, m/s	9.0 ± 2.1	9.5 ± 2.4*
Carotid artery – distensibility coefficient, 10 ⁻³ kPa	14.3 ± 5.1	14.1 ± 5.4
Carotid artery – compliance coefficient, mm ² /kPa	0.7 ± 0.7	0.7 ± 0.3
Carotid artery – Young's elastic modulus, 10 ³ kPa	0.7 ± 0.4	0.8 ± 0.4
Measures of microvascular dysfunction		
Microvascular dysfunction composite score	0.0 ± 1.0	-
Cerebral small vessel disease features		
Total brain parenchyma volume, ml	1,136.1 ± 111.4	1,131.5 ± 113.7*
White matter hyperintensity volume, ml	0.23 [0.07-0.75]	0.22 [0.07-0.74]
Presence of cerebral microbleeds	12.0 (203)	68 (12.1)
Presence of lacunar infarcts	5.3 (91)	5.7 (33)
Flicker light-induced arteriolar and venular dilation		
Flicker light-induced arteriolar dilation, %	3.1 ± 2.8	2.9 ± 2.7
Flicker light-induced venular dilation, %	3.9 ± 2.2	3.8 ± 2.3

	Complete (N=2,544)	Missing (n=907)
Urinary albumin excretion		
0-15 mg/24h	81.9 (2,066)	77.5 (687)*
15-30 mg/24h	10.5 (266)	10.3 (91)*
≥30 mg/24h	7.5 (190)	12.3 (109)*
Plasma biomarkers of microvascular dysfunction		
Soluble ICAM-1, ng/ml	352.6 ± 96.8	361.6 ± 107.6*
Soluble VCAM-1, ng/ml	425.4 ± 98.1	437.4 ± 110.8*
Soluble E-selectin, ng/ml	117.1 ± 64.8	122.6 ± 66.1*
von Willebrand Factor, %	131.8 ± 47.2	135.9 ± 51.9*
Cognitive performance		
Cognitive function composite score, SD	0.0 ± 1.0	-
Memory function, SD	0.0 ± 1.0	-
Processing speed, SD	0.0 ± 1.0	-
Executive function, SD	0.0 ± 1.0	-

Data are presented as mean ± standard deviation, median [interquartile range] or n(%). *denotes a statistically significantly difference from the complete group, assessed by the student's t-test for normally distributed variables, Mann-Whitney U-test for skewed variables or Chi-square test for categorical variables.

Table S2. Associations between carotid artery compliance coefficient and Young's elastic modulus and the cognitive function composite score

Cognitive function composite score, per SD		
Carotid stiffness measure	Model	β (95% CI)
Compliance coefficient, 10 ⁻³ /kPa	1	-0.086 (-0.209; 0.037)
	2	-0.075 (-0.197; 0.046)
	3	-0.062 (-0.189; 0.066)
Young's elastic modulus, 10 ³ /kPa	1	-0.096 (-0.183; -0.008)
	2	-0.058 (-0.145; 0.029)
	3	-0.045 (-0.137; 0.048)

Participants included in the analyses were n=2,544. Model 1: adjusted for age, sex, education level, Model 2: additionally adjusted for glucose metabolism status, body mass index, smoking, alcohol use, total/high-density lipoprotein ratio, triglycerides, and Model 3: additionally adjusted for mean arterial pressure, heart rate and use of anti-hypertensive and/or lipid-modifying medication. Abbreviations: CI = confidence interval; SD = standard deviation.

Table S3. Associations between arterial stiffness and domain-specific cognitive function scores

Arterial stiffness	Model	Memory function, per SD		Processing speed, per SD		Executive function, per SD	
		β (95% CI)		β (95% CI)		β (95% CI)	
Carotid-femoral pulse wave velocity, m/s ⁻¹	1	-0.022	(-0.04; -0.004)	-0.024	(-0.041; -0.007)	-0.030	(-0.048; -0.012)
	2	-0.016	(-0.034; 0.002)	-0.013	(-0.030; 0.004)	-0.017	(-0.035; 0.001)
	3	-0.013	(-0.033; 0.007)	-0.019	(-0.038; 0.000)	-0.012	(-0.032; 0.008)
Carotid distensibility coefficient, 10 ⁻³ /kPa	1	-0.001	(-0.008; 0.007)	-0.006	(-0.013; 0.001)	-0.010	(-0.018; -0.003)
	2	0.000	(-0.007; 0.008)	-0.004	(-0.011; 0.003)	-0.008	(-0.016; -0.001)
	3	0.003	(-0.005; 0.012)	-0.007	(-0.015; 0.001)	-0.007	(-0.015; 0.002)

Participants included in the analyses were n=2,544. Model 1: adjusted for age, sex, education level, Model 2: additionally adjusted for glucose metabolism status, body mass index, smoking, alcohol use, total/high-density lipoprotein ratio, triglycerides, and Model 3: additionally adjusted for mean arterial pressure, heart rate and use of anti-hypertensive and/or lipid-modifying medication. Abbreviations: CI = confidence interval; SD = standard deviation.

Table S4. Associations between arterial stiffness and the cognitive function composite score, and the proportion explained by the microvascular dysfunction score after consecutively excluding from the microvascular dysfunction score each individual measure of microvascular dysfunction

		Cognitive function composite score, per SD		% effect explained by microvascular dysfunction*
Arterial stiffness measure	Variable excluded from the microvascular dysfunction score†	β (95% CI)		
Carotid-femoral pulse wave velocity, m/s	Cerebral small vessel disease features	-0.018	(-0.036; -0.000)	10.8%
	Flicker light-induced retinal arteriolar and venular dilation response	-0.018	(-0.036; -0.000)	14.1%
	Urinary albumin excretion	-0.018	(-0.036; -0.000)	11.5%
	Plasma biomarkers of microvascular disease	-0.018	(-0.036; -0.000)	9.4%
Carotid distensibility coefficient, 10 ⁻³ /kPa	Cerebral small vessel disease features	-0.004	(-0.012; 0.003)	-
	Flicker light-induced retinal arteriolar and venular dilation response	-0.004	(-0.012; 0.003)	-
	Urinary albumin excretion	-0.004	(-0.012; 0.003)	-
	Plasma biomarkers of microvascular disease	-0.004	(-0.012; 0.003)	-

*The effect explained by the 'total' microvascular dysfunction score was 16.2% of the total direct effect of cfPWV on the cognitive function composite score. †Data available for analyses after excluding cerebral small vessel disease features $n=2,544$; after excluding flicker light-induced retinal arteriolar and venular dilation response $n=2,544$; after excluding urinary albumin excretion $n=2,541$; and after excluding plasma biomarkers of microvascular dysfunction $n=2,541$. Results were adjusted for age, sex, education level, glucose metabolism status, body mass index, smoking, alcohol use, total/high density cholesterol ratio, triglycerides, mean arterial pressure, heart rate and use of anti-hypertensive and/or lipid-modifying medication. Abbreviations: CI = confidence interval; SD = standard deviation.

Table S5. Associations between arterial stiffness and the cognitive function composite score additionally adjusted for prior cardiovascular disease, current depression, and plasma biomarkers of low-grade inflammation

Arterial stiffness	Model	Cognitive function composite score, per SD	
		β (95% CI)	
Carotid-femoral pulse wave velocity, per m/s	1	-0.032	(-0.048; -0.016)
	2	-0.019	(-0.035; -0.003)
	3	-0.018	(-0.036; -0.000)
	4a	-0.019	(-0.037; -0.001)
	4b	-0.016	(-0.034; 0.002)
	4c	-0.019	(-0.037; -0.001)
Carotid artery distensibility coefficient, $10^{-3}/\text{kPa}$	1	-0.007	(-0.014; -0.000)
	2	-0.005	(-0.012; 0.002)
	3	-0.004	(-0.012; 0.003)
	4a	-0.004	(-0.011; 0.004)
	4b	-0.004	(-0.011; 0.004)
	4c	-0.005	(-0.012; 0.003)

Participants included in the analyses in model 1 to 3 were $n=2,544$. For analysis adjusted for prior cardiovascular disease, $n=2,505$; for analysis adjusted for current depression $n=2,526$; and for analysis adjusted for plasma biomarkers of low-grade inflammation $n=2,520$. Model 1: adjusted for age, sex, education level, Model 2: additionally adjusted for glucose metabolism status, body mass index, smoking, alcohol use, total/high-density lipoprotein ratio, triglycerides, Model 3: additionally adjusted for mean arterial pressure, heart rate and use of anti-hypertensive and/or lipid-modifying medication, Model 4a: Model 3 + prior cardiovascular disease, Model 4b: Model 3 + current depression, and Model 4c: Model 3 + plasma biomarkers of low-grade inflammation. Abbreviations: CI = confidence interval; SD = standard deviation.

Table S6. Associations between arterial stiffness and the cognitive function composite score additionally adjusted for type of antihypertensive medication

Arterial stiffness	Cognitive function composite score, per SD	
	Model	β (95% CI)
Carotid-femoral pulse wave velocity, per m/s	1	-0.032 (-0.048; -0.016)
	2	-0.019 (-0.035; -0.003)
	3	-0.018 (-0.036; 0.000)
Carotid artery distensibility coefficient, 10^{-3} /kPa	1	-0.007 (-0.014; -0.000)
	2	-0.005 (-0.012; 0.002)
	3	-0.004 (-0.012; 0.003)

Participants included in the analyses were n=2,544. Model 1: adjusted for age, sex, education level, Model 2: additionally adjusted for glucose metabolism status, body mass index, smoking, alcohol use, total/high-density lipoprotein ratio, triglycerides, Model 3: additionally adjusted for mean arterial pressure, heart rate, use of lipid-modifying medication and the individual classes of antihypertensive medication (i.e. beta blockers, diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers). Abbreviations: CI = confidence interval; SD = standard deviation.

Table S7. Associations between arterial stiffness and the cognitive function composite score additionally adjusted for the diet score, moderate-to-vigorous physical activity, income level and occupational status

Arterial stiffness	Cognitive function composite score, per SD	
	Model	β (95% CI)
Carotid-femoral pulse wave velocity, per m/s	1	-0.036 (-0.055; -0.016)
	2	-0.024 (-0.043; -0.004)
	3	-0.028 (-0.050; -0.007)
	4	-0.029 (-0.051; -0.007)
Carotid artery distensibility coefficient, 10^{-3} /kPa	1	-0.003 (-0.011; 0.005)
	2	-0.000 (-0.008; 0.008)
	3	-0.000 (-0.009; 0.009)
	4	-0.000 (-0.009; 0.009)

Participants included in the analyses were n=1,752. Model 1: adjusted for age, sex, education level, Model 2: additionally adjusted for glucose metabolism status, body mass index, smoking, alcohol use, total/high-density lipoprotein ratio, triglycerides, Model 3: additionally adjusted for mean arterial pressure, heart rate and use of anti-hypertensive and/or lipid-modifying medication, and Model 4: additionally adjusted for the diet score, moderate-to-vigorous physical activity and income level and occupational status. Abbreviations: CI = confidence interval; SD = standard deviation.

Figure S1. Cumulative percentage of participants with data available on microvascular dysfunction measures

Figure S2. Association between lower carotid artery distensibility coefficient (per 10^{-3} /kPa) and a lower cognitive function composite score (per SD), and the proportion explained by the microvascular dysfunction score (per SD). Solid lines indicate associations that are statistically significant; dashed lines indicate associations that are not statistically significant. Associations are presented as regression coefficients (β) and corresponding 95% confidence intervals. All associations are adjusted for the potential confounders age, sex, education level, glucose metabolism status, body mass index, smoking, alcohol use, total/high-density lipoprotein ratio, triglycerides, mean arterial pressure, heart rate and use of anti-hypertensive and/or lipid-modifying medication.

CHAPTER 6

Blood Pressure Variability And Microvascular Dysfunction: The Maastricht Study

Tan Lai Zhou*, Sytze P. Rensma*, Frank C.T. van der Heide*, Ronald M.A. Henry, Abraham A. Kroon, Alfons J.H.M. Houben, Jacobus F.A. Jansen, Walter H. Backes, Tos T.J.M. Berendschot, Jan S.A.G. Schouten, Martien C.J.M van Dongen, Simone J.P.M. Eussen, Pieter C. Dagnelie, Carroll A.B. Webers, Miranda T. Schram, Casper G. Schalkwijk, Thomas T. van Sloten, Coen D.A. Stehouwer

*These authors contributed equally to the manuscript

Abstract

Microvascular dysfunction (MVD) contributes to stroke, dementia, depression, retinopathy and chronic kidney disease. The determinants of MVD, however, are incompletely identified. Greater blood pressure variability (BPV) may be such a determinant. To investigate whether greater very short- to mid-term BPV is associated with various MVD measures, we used cross-sectional data of The Maastricht Study ($n=2,773$, age 59.9 years; 51.9% men; 28.2% type 2 diabetes mellitus [oversampled by design]). We standardized and averaged within-visit, 24-hour and 7-day BPV into a systolic and a diastolic BPV composite score. Measures of MVD included a composite score of MRI cerebral small vessel disease (CSVD) features (total brain parenchymal volume, white matter hyperintensity volume, lacunar infarcts and cerebral microbleeds), a composite score of retinal arteriolar and venular dilation response, albuminuria, skin hyperaemia and a composite score of plasma biomarkers of MVD (sICAM-1, sVCAM-1, sE-selectin and von Willebrand Factor). We used linear regression analyses with adjustments for age, sex, glucose metabolism status, mean 24-hour systolic or diastolic blood pressure and cardiovascular risk factors. We found that higher systolic and diastolic BPV composite scores (per SD) were associated with higher albuminuria (higher ratio in albuminuria, 1.04 [95%CI 1.00-1.08] and 1.07 [1.03-1.11], respectively), but not with other MVD measures. In conclusion, greater systolic and diastolic BPV was associated with higher albuminuria, but not with CSVD features, retinal arteriolar and venular dilation response, skin hyperaemia and plasma biomarkers of MVD. This may suggest that the microvasculature of the kidneys is most vulnerable to the detrimental effects of greater BPV.

Introduction

Microvascular dysfunction (MVD) is an important contributor to various diseases that are (in part) of microvascular origin, including stroke,¹ dementia,¹ depression,¹ retinopathy,² and chronic kidney disease.³ However, the determinants of MVD are incompletely identified, but greater blood pressure variability (BPV), i.e. greater fluctuations of blood pressure over time, may be involved.

Greater BPV may lead to MVD both via increases in pulsatile pressure that can penetrate distally and damage the microcirculation,⁴ and sudden falls in blood pressure leading to reduced microvascular perfusion.⁵ The microvascular beds of organs with low vascular impedance (i.e. the microvasculature of the brain, eyes and kidneys) may be particularly vulnerable for these fluctuations in blood pressure.⁴

Microvascular function can be measured noninvasively in various organs. These measures include magnetic resonance imaging (MRI) features of cerebral small vessel disease (CSVD, i.e. lower total brain parenchyma volume, higher white matter hyperintensity volume, and presence of lacunar infarcts and cerebral microbleeds);⁶ flicker light-induced retinal arteriolar and venular dilation response;⁷ albuminuria ("urinary albumin excretion", UAE);⁸ heat-induced skin hyperaemia;⁷ and plasma biomarkers of MVD (i.e. soluble intercellular adhesion molecule-1 [sICAM-1], soluble vascular adhesion molecule-1 [sVCAM-1], soluble E-selectin [sE-selectin] and von Willebrand factor [vWF]).⁹

The associations between BPV and most of these various MVD measures remain, however, incompletely understood. To date, only five studies have evaluated the association between BPV and CSVD features. These studies found an association between greater very short- to short-term systolic and diastolic BPV and cerebral atrophy,^{10, 11} higher white matter hyperintensity volume,¹⁰⁻¹³ lacunar infarcts,^{10, 12} and enlarged perivascular spaces.^{10, 14} However, these studies were relatively small ($n < 155$),^{11, 13} done in selected populations (i.e. individuals with hypertension,¹² aged 70 years and older,¹⁵ or admitted to the hospital^{10, 14}) or did not adjust for potentially important confounders (i.e. mean blood pressure^{11, 13} or lifestyle factors¹²). For UAE, most previous studies,¹⁶⁻²⁷ but not all,²⁸⁻³⁰ found an association with greater very short- to mid-term systolic or diastolic BPV. However, these studies did not adjust for potentially important confounders, including dietary habits and physical activity. For plasma biomarkers of MVD, only one study has been done, which included 190 individuals with newly diagnosed hypertension. This study found an association between greater short-term systolic BPV and higher sE-selectin.³¹ Currently, no studies have investigated the association between BPV and retinal arteriolar and venular dilation or skin hyperaemia.

In view of the above, we investigated, in a large population-based cohort, whether very short- to mid-term BPV (i.e. within-visit, 24-hour and 7-day BPV) is associated with a comprehensive set of MVD measures, including CSVD features, retinal arteriolar and venular dilation response, UAE, skin hyperaemia and plasma biomarkers of MVD. We hypothesized that greater BPV would be more strongly associated with MVD in organs with a low vascular impedance, i.e. brain, eyes and kidneys, and would not be associated with MVD in organs with a high vascular impedance, e.g. skin.

Material and methods

Study population and design

We used data from The Maastricht Study, an observational population-based cohort study. The rationale and methodology have been described previously.³² In brief, the study focuses on the aetiology, pathophysiology, complications and comorbidities of diabetes mellitus type 2 (T2D) and is characterized by an extensive phenotyping approach. Eligible for participation were all individuals aged between 40 and 75 years and living in the southern part of the Netherlands. Participants were recruited through mass media campaigns, the municipal registries and the regional Diabetes Patient Registry via mailings. Recruitment was stratified according to known T2D status, with an oversampling of individuals with T2D for reasons of efficiency. The present report includes cross-sectional data from 3,451 participants who completed the baseline survey between November 2010 and September 2013. The examinations of each participant were performed within a time window of three months. The study has been approved by the institutional medical ethical committee (NL31329.068.10) and the Minister of Health, Welfare, and Sports of the Netherlands (Permit 131088-105234-PG). All participants gave written informed consent. Data are available from The Maastricht Study for any researcher who meets the criteria for access to confidential data, and the corresponding author may be contacted to request data.

Blood pressure measurements and determination of blood pressure variability

A detailed description of the office, 24-hour ambulatory and 7-day home blood pressure measurements and determination of BPV has been reported previously.³³ Briefly, within-visit BPV was calculated as the standard deviation (SD) of three consecutive office blood pressure measurements, with a 1-minute interval, after ten minutes of rest. 24-hour BPV was calculated as the average real variability of blood pressure readings taken every 15 minutes between 08:00 A.M. and 11:00 P.M., and every 30 minutes between 11:00 P.M. – 08:00 A.M.. 7-day BPV was calculated as the SD of home blood pressure measurements taken twice, with a 1-minute interval, each morning and evening, for 7 consecutive days.

Microvascular dysfunction measures

For all MVD measures, participants were asked to refrain from smoking and drinking caffeine-containing beverages three hours before the measurement.³⁴ A light meal was allowed until ≥ 90 minutes prior to the examination. For retinal measurements, pupils were dilated with 0.5% tropicamide and 2.5% phenylephrine ≥ 15 minutes before the start of the examination. Skin blood flow measurements were performed in a climate-controlled room at 24 °C.³⁵

Features of cerebral small vessel disease

Brain MRI measurements were implemented from December 2013 onwards and were available in 2,313 of the 3,451 participants (67%). Brain MRI was performed on a 3T MRI scanner (Siemens Magnetom Prisma-fit Syngo MR D13D, Erlangen, Germany). We evaluated four MRI CSVD features, i.e. total brain parenchyma volume, white matter hyperintensity volume, lacunar infarcts and cerebral microbleeds. A detailed description of the MRI protocol is provided in Item S1 (Supplementary Material). Briefly, the MRI

protocol consisted of a 3D T1-weighted sequence, T2-weighted fluid-attenuated inversion recovery (FLAIR), and a gradient recalled echo (GRE) pulse sequence with susceptibility-weighted imaging (SWI).³⁶ T1-weighted images and FLAIR images were analyzed by use of an automated method.^{37, 38} T1-weighted images were segmented into grey matter, white matter and cerebrospinal fluid volumes.³⁷ Intracranial volume was calculated as the sum of grey matter, white matter (including white matter hyperintensity volume) and cerebrospinal fluid volumes. Total brain parenchyma volume was calculated as the sum of grey and white matter volumes. T1-weighted and FLAIR images were used to identify white matter hyperintensities.³⁸ White matter hyperintensity volume was summed to assess total white matter hyperintensity burden. Lacunar infarcts were defined as focal brain parenchyma defects of ≥ 3 mm and < 15 mm in size with a similar signal intensity as cerebrospinal fluid on all sequences and a hyperintense rim on FLAIR images.⁶ Cerebral microbleeds were rated on three-dimensional T2* GRE imaging with SWI by use of the Microbleed Anatomical Rating Scale,³⁹ and were defined as focal lesions of ≥ 2 mm and ≤ 10 mm in size with a hypointense signal.⁶ The presence of lacunar infarcts and cerebral microbleeds was rated manually by three neuroradiologists. The intraclass correlation coefficients for the three raters based on 50 randomly selected scans were 0.84 (95% confidence interval [95%CI] 0.74-0.91) and 0.83 (0.72-0.90) for the presence of lacunar infarcts and cerebral microbleeds, respectively.

Flicker light-induced retinal arteriolar and venular dilation response

We measured retinal arteriolar and venular dilation to flicker light exposure by the Dynamic Vessel Analyzer (Imedos, Jena, Germany), as previously described.^{7, 40} Briefly, a baseline recording of 50 seconds was followed by 40-second flicker light exposure followed by a 60-second recovery period. We calculated baseline diameters (in measurement units) as the average diameter during the 20-50 seconds recording. For both the arteriolar and venular dilation, percentage dilation over baseline was calculated using the average dilation achieved at time points 10 and 40 seconds during the flicker stimulation period.

Urinary albumin excretion

To assess UAE, participants were requested to collect two 24-hour urine samples. Urinary albumin concentration was measured with a standard immunoturbidimetric assay by an automatic analyzer (due to a change of supplier, by the Beckman Synchron LX20 and the Roche Cobas 6000) and multiplied by collection volume to obtain 24-hour UAE. A urinary albumin concentration below the detection limit of the assay was set at 1.5 mg/L (2 mg/L for the Beckman Synchron LX20 and 3 mg/L for the Roche Cobas 6000) before multiplying by collection volume. Only urine collections with a collection time between 20 and 28 hours were considered valid. If needed, UAE was extrapolated to 24-hour excretion. For this study, UAE was preferably based on the average of two (available in 91.3% of participants) 24-hour urine collections.

Heat-induced skin hyperaemia

We measured heat-induced skin hyperaemia by laser Doppler flowmetry (Perimed, Järfälla, Sweden), as previously described.⁷ Briefly, skin blood flow at the wrist, expressed in arbitrary perfusion units (PU), was recorded unheated for two minutes to serve as a baseline. After two minutes, the temperature of the laser Doppler probe was rapidly

and locally increased to 44°C and was kept constant until the end of the registration. Skin hyperaemia was expressed as the percentage increase in average PU during the 23 minutes heating phase over the two minutes average baseline PU.

Plasma biomarkers of microvascular dysfunction

We measured four plasma biomarkers of MVD: sICAM-1, sVCAM-1, sE-selectin and vWF.⁴¹ sICAM-1, sVCAM-1 and sE-selectin were measured in EDTA plasma samples with commercially available 4-plex sandwich immunoassay kits with different standards and antibodies (Meso Scale Discovery, Rockville, Maryland, United States of America). For this technique in this study, the intra- and inter-assay coefficients of variation were 10.3 and 8.4% for sICAM-1, 5.0 and 4.7% for sVCAM-1, and 2.9 and 7.4% for sE-selectin, respectively. Von Willebrand Factor (vWF) was quantified in citrate plasma using ELISA (Dako, Glostrup, Denmark). The intra- and inter-assay coefficients of variation were 3.0 and 4.3%, respectively.

Covariates

We determined glucose metabolism status according to the World Health Organization 2006 criteria as normal glucose metabolism, prediabetes or T2D.⁴² Education level was classified into three groups: low (none, primary or lower vocational education only), intermediate (intermediate general secondary, intermediate vocational or higher general secondary education) and high (higher vocational education or university level of education). We determined alcohol consumption (none, low [women ≤7, men ≤14 units/week], high [women >7, men >14 units/week]), smoking status (never, former, current), medication use, body mass index, total/high density lipoprotein (HDL) cholesterol ratio and prior cardiovascular disease as described previously.^{7, 8, 32} Estimated glomerular filtration rate (eGFR) was computed with the CKD-EPI (Chronic Kidney Disease Epidemiology collaboration) formula using serum creatinine and cystatin C.⁴³ Plasma biomarkers of low-grade inflammation (i.e. high-sensitive C-reactive protein, serum amyloid A, interleukin-6, interleukin-8 and tumor necrosis factor alpha) were determined as described previously.^{32, 44} Carotid-femoral pulse wave velocity, a measure of aortic stiffness,⁴⁴ was measured according to international guidelines⁴⁵ with the use of applanation tonometry (Sphygmocor, Atcor Medical, Sydney Australia) at the right common carotid and right common femoral arteries. As described previously, we used questionnaires to assess the Mediterranean diet score ("diet score"),⁴⁶ moderate-to-vigorous physical activity³² and socio-economic status (income level and occupation status).⁴⁷

Statistical analysis

We inverted (multiplying by -1) total brain parenchyma volume, retinal arteriolar and venular dilation response and skin hyperaemia so that higher values indicated worse microvascular function. White matter hyperintensity volume and UAE were log-transformed (base 2) to normalize their skewed distribution.

We summarized the three BPV measures (i.e. within-visit, 24-hour and 7-day BPV) into a systolic and diastolic BPV composite score, as done previously.⁴⁸ We hypothesized that each BPV measure is associated with MVD according to similar underlying mechanisms. Furthermore, a composite score reduces the influence of the biological variability of its components,⁴⁹ and it reduces the chance of a type 1 error. The BPV composite scores were calculated when at least data on two of the three BPV measures were available. The scores were calculated by summation and averaging of the z-scores of the three systolic and diastolic BPV measures, respectively.

We also calculated separate composite scores for the CSVD features, for the retinal arteriolar and venular dilation response and for the plasma biomarkers of MVD, respectively. The CSVD composite score was calculated as described previously;⁵⁰ one point per CSVD feature was assigned based on the following cut-offs: for lower total brain parenchyma volume quartile 1 vs. quartiles 2 to 4; for higher white matter hyperintensity volume quartile 4 vs. quartiles 1 to 3; and for lacunar infarcts and cerebral microbleeds presence vs. absence. The points for each feature were combined to compute the CSVD composite score (range 0-4). The composite scores for retinal arteriolar and venular dilation and plasma biomarkers of MVD were calculated by summation and averaging of the z-scores of the retinal arteriolar and venular dilation responses and the four plasma biomarkers of MVD, respectively.

We used linear regression to investigate the association between the systolic and diastolic BPV composite scores and the CSVD composite score, the retinal arteriolar and venular dilation composite score, UAE, skin hyperaemia and the plasma biomarkers of MVD composite score. All analyses were adjusted for age and sex (model 1), and additionally for glucose metabolism status (model 2), mean 24-hour systolic or diastolic blood pressure (where appropriate) (model 3), and education level, body mass index, smoking status, alcohol consumption, total/HDL cholesterol ratio, lipid-modifying medication, and the individual classes of antihypertensive medication (i.e. beta blockers, diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers) (model 4). For analyses with log-transformed UAE as the outcome, regression coefficients were back-transformed and expressed as higher ratio per SD higher systolic and diastolic BPV.

We tested interaction terms with age,⁵¹ sex⁵² and glucose metabolism status⁵³ to evaluate whether the association between the BPV composite scores and the MVD measures differed according to these factors.

Several sensitivity analyses were performed. First, we repeated the analysis with the individual BPV measures as the determinant, i.e. within-visit, 24-hour and 7-day systolic and diastolic BPV. Second, we repeated the analysis using as the outcome the individual CSVD features, the individual retinal arteriolar and venular dilation response and the individual plasma biomarkers of MVD, respectively. Third, we repeated the analysis with additional adjustment for eGFR, prior cardiovascular disease, plasma biomarkers of low-grade inflammation, and carotid-femoral pulse wave velocity. These covariates were entered into a separate model because of the risk of overadjustment bias: these factors may be confounders, but may also mediate any association between BPV and MVD. Fourth, we repeated the analysis additionally adjusting for the diet score, and moderate-to-vigorous physical activity, and for income level and occupation status (instead of education level). Adjustment for these potential confounders was not included in the main analysis, because data were missing in a relatively large number of participants ($n=1,133$ missed data on one or more of these variables). Fifth, we used micro-albuminuria defined as ≥ 30 mg/24h vs. <30 mg/24h as the outcome instead of UAE per mg/24h.⁵⁴ Sixth, we repeated the analysis with eGFR (continuously and categorically [≥ 60 vs. <60 ml/min/1.73m²]) as the outcome.

All statistical analyses were performed with Statistical Package for Social Sciences (v22.0; IBM, Chicago, Illinois). A P value of $<.05$ was considered statistically significant.

Results

Study population

Figure 1 shows the derivation of the study population. In total, 2,773 participants had data available on the BPV composite scores, all potential confounders and at least one MVD measure, and were included in the analysis. CSVD features were available in 1,837 participants, retinal arteriolar and venular dilation response in 1,844, UAE in 2,748, skin hyperaemia in 1,320, and plasma biomarkers of MVD in 2,726. These subpopulations were comparable with regard to age, sex and cardiovascular risk profile (Supplemental Table S1). Participants excluded due to missing data had greater BPV and higher body mass index and more often had prior cardiovascular disease compared with those without missing data (Supplemental Table S1).

Table 1 and Supplemental Table S2 show the general characteristics for the total study population and according to tertiles of the systolic BPV composite score. Supplemental Table S3 shows the characteristics according to tertiles of the diastolic BPV composite score. The mean age was 59.9 years, 51.9% were men and 26.9% had T2D. In general, participants with the highest compared with the lowest tertile of the systolic BPV composite score were older, less often male, had a worse cardiovascular risk profile and more often used lipid-modifying and antihypertensive medication.

Blood pressure variability and microvascular dysfunction

Higher systolic and diastolic BPV composite scores were associated with higher UAE (1.04 [95%CI 1.00-1.08] and 1.07 [1.03-1.11] higher ratio per 1 SD higher systolic and diastolic

BPV composite score, respectively), after adjustment for all potential confounders (Table 2, model 4). Systolic and diastolic BPV composite scores were not associated with the other MVD measures: the CSVD composite score, the retinal arteriolar and venular dilation response composite score, skin hyperaemia, and the plasma biomarkers of MVD composite score, after full adjustment (Table 2, model 4).

We did not observe consistent interactions with age, sex or glucose metabolism status for the associations between systolic and diastolic BPV and any of the MVD measures (Supplemental Table S4).

Sensitivity analyses

Of the individual systolic and diastolic BPV measures, 24-hour diastolic BPV was associated with a higher CSVD composite score, retinal arteriolar and venular dilation response composite score and UAE; 7-day systolic BPV was associated with a higher CSVD composite score and plasma biomarkers of MVD composite score; and 7-day diastolic BPV with higher UAE and a higher plasma biomarkers of MVD composite score (Supplemental Table S5). When we repeated the analysis using each individual MVD measure as the outcome, the systolic and diastolic BPV composite scores were associated with higher levels of sVCAM-1 and the systolic BPV composite score with higher levels of vWF (Supplemental Table S6). Results were similar when we additionally adjusted for eGFR, prior cardiovascular disease, plasma biomarkers of low-grade inflammation, carotid-femoral pulse wave velocity, the diet score, moderate-to-vigorous physical activity, or income level and occupation status (Supplemental Tables S7-S14). Each SD higher BPV composite score was associated with higher odds of UAE ≥ 30 mg/24h; odds ratios were 1.19 (95%CI 1.02 – 1.38) for systolic BPV and 1.19 (95%CI 1.02 – 1.37) for diastolic BPV (Figure 2 and Supplemental Table S15). The systolic and diastolic BPV composite scores were not associated with eGFR (Supplemental Table S16).

Discussion

We found that greater very short- to mid-term systolic and diastolic BPV are associated with higher UAE, but not with other measures of MVD tested, i.e. the CSVD composite score, retinal arteriolar and venular dilation response composite score, skin hyperaemia and the plasma biomarkers of MVD composite score. The association with higher UAE was independent of age, sex, mean 24-hour systolic or diastolic blood pressure, education level, and lifestyle and cardiovascular risk factors. The strength of this association corresponds to a 1.2 higher odds of UAE ≥ 30 mg/24h as compared to a UAE of <30 mg/24h per SD higher systolic or diastolic BPV composite score.

Our study findings are in agreement with most,¹⁶⁻²⁷ but not all,²⁸⁻³⁰ previous studies that investigated the association between BPV and UAE. Our study adds to the existing literature on UAE, because we were able to study this association in the context of various other MVD measures, and adjusted for potentially important confounders, including dietary habits physical activity. Previous studies on BPV and UAE did not adjust for these potential confounders.

In disagreement with our hypothesis, we did not find an association between greater BPV and MVD measured in organs with low microvascular impedance other than the kidneys, i.e. the brain and eyes, and with plasma biomarkers of MVD, which at least partly reflect MVD in organs with low microvascular impedance. A possible explanation is that the kidney microvasculature has a lower impedance than the brain and eye microvasculature, e.g. blood flow to the kidneys relative to organ weight (360 ml/min/100 g kidney tissue) is higher than to the brain (50 ml/min/100 g brain tissue).⁵⁵ The kidney microvasculature may, therefore, in comparison be most vulnerable to the detrimental effects of BPV.

Although we found no significant associations between greater BPV and CSVD features, retinal arteriolar and venular dilation response and plasma biomarkers of MVD, these measures nevertheless reflect MVD in organs with low vascular impedance and may thus be vulnerable to an increased pulsatile load,⁵⁶ albeit to a lesser extent than UAE. Indeed, we found positive associations that were quantitatively similar for CSVD features, retinal arteriolar and venular dilation response, and plasma biomarkers of MVD. Estimations of these associations may have been more inaccurate (i.e. broader confidence intervals), because of higher measurement errors in these MVD measures as compared with UAE; CSVD features, retinal arteriolar and venular dilation response, and plasma biomarkers of MVD were measured only once, whereas UAE was based on two 24-hour urine samples. In addition, estimations of the associations may also have been more inaccurate with CSVD features and retinal arteriolar and venular dilation response due to relatively few available data (n=1,837 and n=1,844, respectively) as compared with UAE (n=2,748).

As expected, we did not find an association between BPV and skin hyperaemia. The skin has relatively high microvascular impedance,⁴ and, therefore, most of the increased pulsatile energy related to greater BPV may be dissipated by arteries and large arterioles proximal to the skin capillaries.⁵⁷

Strengths of this study include the large study population of community-dwelling participants, assessment of microvascular function in various vascular beds and the extensive adjustment for potential confounders.

Our study has several limitations. First, our cross-sectional data preclude reaching causal conclusions about the study findings. Indeed, the reverse association may hold true as well, i.e. higher UAE (as a reflection of worse kidney function) may lead to greater BPV.⁵⁸ However, when we additionally adjusted our analyses for estimated glomerular filtration rate, results were similar. Second, the association between greater BPV and UAE may be the result of residual confounding due to low-grade inflammation,^{59, 60} arterial stiffening,^{4, 61} activation of the renin-angiotensin system,^{62, 63} unhealthy dietary habits,^{64, 65} physical inactivity^{66, 67} and lower socio-economic status.^{68, 69} However, when we adjusted for low-grade inflammation, carotid-femoral pulse wave velocity, the diet score, moderate-to-vigorous physical activity and factors related to socio-economic status (i.e. education, income level and occupation status), results did not materially change. In this study, no data were available on activation of the renin-angiotensin system, however, and this issue requires further study. Third, we may have underestimated the association between greater BPV and MVD, because individuals excluded for the present analysis due to

missing data had greater BPV and a higher prevalence of prior cardiovascular disease than those included in the analysis. Fourth, the study population consisted mainly of middle-aged individuals who were relatively well-educated and whose cardiovascular risk factors were relatively well-controlled. This may have led to an underestimation of the association between BPV and MVD. Finally, the study population consisted mainly of individuals from Caucasian ethnicity and the results may not be generalizable to other ethnicities.

Perspectives

In conclusion, this large, relatively healthy population-based study showed that greater very short- to mid-term systolic and diastolic BPV was associated with higher UAE, but not with other measures of MVD tested, i.e. CSVD features, retinal arteriolar and venular dilation response, skin hyperaemia and plasma biomarkers of MVD. This may suggest that the microvasculature of the kidneys is most vulnerable to the detrimental effects of greater BPV. Future longitudinal studies should be performed to assess the temporality of these associations, and, if confirmed, intervention studies should assess whether lowering BPV will prevent albuminuria.

References

1. Rensma SP, van Sloten TT, Launer LJ and Stehouwer CDA. Cerebral small vessel disease and risk of incident stroke, dementia and depression, and all-cause mortality: A systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2018;90:164-173.
2. Stehouwer CDA. Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle With Widespread Consequences. *Diabetes*. 2018;67:1729-1741.
3. Bidani AK, Polichnowski AJ, Loutzenhiser R and Griffin KA. Renal microvascular dysfunction, hypertension and CKD progression. *Curr Opin Nephrol Hypertens*. 2013;22:1-9.
4. Mitchell GF. Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. *J Appl Physiol (1985)*. 2008;105:1652-60.
5. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. *Lancet*. 2010;375:938-48.
6. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge R, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M and nEuroimaging STfRVco. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol*. 2013;12:822-38.
7. Sorensen BM, Houben AJ, Berendschot TT, Schouten JS, Kroon AA, van der Kallen CJ, Henry RM, Koster A, Sep SJ, Dagnelie PC, Schaper NC, Schram MT and Stehouwer CD. Prediabetes and Type 2 Diabetes Are Associated With Generalized Microvascular Dysfunction: The Maastricht Study. *Circulation*. 2016;134:1339-1352.
8. Martens RJ, Henry RM, Houben AJ, van der Kallen CJ, Kroon AA, Schalkwijk CG, Schram MT, Sep SJ, Schaper NC, Dagnelie PC, Muris DM, Gronenschild EH, van der Sande FM, Leunissen KM, Kooman JP and Stehouwer CD. Capillary Rarefaction Associates with Albuminuria: The Maastricht Study. *J Am Soc Nephrol*. 2016;27:3748-3757.
9. van Sloten TT, Schram MT, Adriaanse MC, Dekker JM, Nijpels G, Teerlink T, Scheffer PG, Pouwer F, Schalkwijk CG, Stehouwer CD and Henry RM. Endothelial dysfunction is associated with a greater depressive symptom score in a general elderly population: the Hoorn Study. *Psychol Med*. 2014;44:1403-16.
10. Yang S, Yuan J, Qin W, Yang L, Fan H, Li Y and Hu W. Twenty-four-hour ambulatory blood pressure variability is associated with total magnetic resonance imaging burden of cerebral small-vessel disease. *Clin Interv Aging*. 2018;13:1419-1427.
11. Goldstein IB, Bartzokis G, Guthrie D and Shapiro D. Ambulatory blood pressure and the brain: a 5-year follow-up. *Neurology*. 2005;64:1846-52.
12. Filomena J, Riba-Llena I, Vinyoles E, Tovar JL, Mundet X, Castane X, Vilar A, Lopez-Rueda A, Jimenez-Balado J, Cartanya A, Montaner J, Delgado P and Investigators I. Short-Term Blood Pressure Variability Relates to the Presence of Subclinical Brain Small Vessel Disease in Primary Hypertension. *Hypertension*. 2015;66:634-40.
13. Gunstad J, Cohen RA, Tate DF, Paul RH, Poppas A, Hoth K, Macgregor KL and Jefferson AL. Blood pressure variability and white matter hyperintensities in older adults with cardiovascular disease. *Blood Press*. 2005;14:353-8.

14. Yang S, Qin W, Yang L, Fan H, Li Y, Yin J and Hu W. The relationship between ambulatory blood pressure variability and enlarged perivascular spaces: a cross-sectional study. *BMJ Open*. 2017;7:e015719.
15. Yamaguchi Y, Wada M, Sato H, Nagasawa H, Koyama S, Takahashi Y, Kawanami T and Kato T. Impact of ambulatory blood pressure variability on cerebral small vessel disease progression and cognitive decline in community-based elderly Japanese. *Am J Hypertens*. 2014;27:1257-67.
16. Kawai T, Ohishi M, Kamide K, Onishi M, Takeya Y, Tatara Y, Oguro R, Yamamoto K, Sugimoto K and Rakugi H. The impact of visit-to-visit variability in blood pressure on renal function. *Hypertens Res*. 2012;35:239-43.
17. Kilpatrick ES, Rigby AS and Atkin SL. The role of blood pressure variability in the development of nephropathy in type 1 diabetes. *Diabetes Care*. 2010;33:2442-7.
18. Okada H, Fukui M, Tanaka M, Inada S, Mineoka Y, Nakanishi N, Senmaru T, Sakabe K, Ushigome E, Asano M, Yamazaki M, Hasegawa G and Nakamura N. Visit-to-visit variability in systolic blood pressure is correlated with diabetic nephropathy and atherosclerosis in patients with type 2 diabetes. *Atherosclerosis*. 2012;220:155-9.
19. Kristensen KS, Hoegholm A, Bang LE, Gustavsen PH and Poulsen CB. No impact of blood pressure variability on microalbuminuria and left ventricular geometry: analysis of daytime variation, diurnal variation and 'white coat' effect. *Blood Press Monit*. 2001;6:125-31.
20. de la Sierra A, Pareja J, Yun S, Acosta E, Aiello F, Oliveras A, Vazquez S, Armario P, Blanch P, Sierra C, Calero F and Fernandez-Llama P. Central blood pressure variability is increased in hypertensive patients with target organ damage. *J Clin Hypertens (Greenwich)*. 2018;20:266-272.
21. Tatasciore A, Renda G, Zimarino M, Soccio M, Bilo G, Parati G, Schillaci G and De Caterina R. Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. *Hypertension*. 2007;50:325-32.
22. Yin LH, Yan WJ, Guo ZX, Zhou FZ and Zhang HY. Relation between blood pressure variability and early renal damage in hypertensive patients. *Eur Rev Med Pharmacol Sci*. 2017;21:2226-2231.
23. Kagitani H, Hoshida S and Kario K. Optimal indicators of home BP variability in perimenopausal women and associations with albuminuria and reproducibility: The J-HOT home BP study. *Am J Hypertens*. 2015;28:586-94.
24. Ushigome E, Fukui M, Hamaguchi M, Senmaru T, Sakabe K, Tanaka M, Yamazaki M, Hasegawa G and Nakamura N. The coefficient variation of home blood pressure is a novel factor associated with macroalbuminuria in type 2 diabetes mellitus. *Hypertens Res*. 2011;34:1271-5.
25. Matsumoto S, Ushigome E, Matsushita K, Fukuda T, Mitsuhashi K, Majima S, Hasegawa G, Nakamura N, Ushigome H, Yamazaki M and Fukui M. Home Blood Pressure Variability From the Stored Memory Is Correlated With Albuminuria, but From the Logbook Is not. *Am J Hypertens*. 2017;30:993-998.
26. Li CL, Liu R, Wang JR and Yang J. Relationship between blood pressure variability and target organ damage in elderly patients. *Eur Rev Med Pharmacol Sci*. 2017;21:5451-5455.
27. Mule G, Calcaterra I, Costanzo M, Geraci G, Guarino L, Foraci AC, Vario MG, Cerasola G and Cottone S. Relationship Between Short-Term Blood Pressure Variability and Subclinical Renal Damage in Essential Hypertensive Patients. *J Clin Hypertens (Greenwich)*. 2015;17:473-80.
28. Ceriello A, De Cosmo S, Rossi MC, Lucisano G, Genovese S, Pontremoli R, Fioretto P, Giorda C, Pacilli A, Viazzi F, Russo G, Nicolucci A and Group AM-AS. Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. *Diabetes Obes Metab*. 2017;19:1570-1578.

29. Wei FF, Li Y, Zhang L, Xu TY, Ding FH, Wang JG and Staessen JA. Beat-to-beat, reading-to-reading, and day-to-day blood pressure variability in relation to organ damage in untreated Chinese. *Hypertension*. 2014;63:790-6.
30. Madden JM, O'Flynn AM, Dolan E, Fitzgerald AP and Kearney PM. Short-term blood pressure variability over 24 h and target organ damage in middle-aged men and women. *J Hum Hypertens*. 2015;29:719-25.
31. Tatasciore A, Zimarino M, Renda G, Zurro M, Soccio M, Prontera C, Emdin M, Flacco M, Schillaci G and R DEC. Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension. *Hypertens Res*. 2008;31:2137-46.
32. Schram MT, Sep SJ, van der Kallen CJ, Dagnelie PC, Koster A, Schaper N, Henry RM and Stehouwer CD. The Maastricht Study: an extensive phenotyping study on determinants of type 2 diabetes, its complications and its comorbidities. *Eur J Epidemiol*. 2014;29:439-51.
33. Zhou TL, Kroon AA, Reesink KD, Schram MT, Koster A, Schaper NC, Dagnelie PC, van der Kallen CJH, Sep SJS, Stehouwer CDA and Henry RMA. Blood pressure variability in individuals with and without (pre)diabetes: The Maastricht Study. *J Hypertens*. 2018;36:259-267.
34. Garhofer G, Resch H, Sacu S, Weigert G, Schmidl D, Lasta M and Schmetterer L. Effect of regular smoking on flicker induced retinal vasodilatation in healthy subjects. *Microvasc Res*. 2011;82:351-5.
35. Pettersson A, Bostrom KB, Gustavsson P and Ekselius L. Which instruments to support diagnosis of depression have sufficient accuracy? A systematic review. *Nord J Psychiatry*. 2015;69:497-508.
36. van Agtmaal MJM, Houben A, de Wit V, Henry RMA, Schaper NC, Dagnelie PC, van der Kallen CJ, Koster A, Sep SJ, Kroon AA, Jansen JFA, Hofman PA, Backes WH, Schram MT and Stehouwer CDA. Prediabetes Is Associated With Structural Brain Abnormalities: The Maastricht Study. *Diabetes Care*. 2018;41:2535-2543.
37. Vrooman HA, Cocosco CA, van der Lijn F, Stokking R, Ikram MA, Vernooij MW, Breteler MM and Niessen WJ. Multi-spectral brain tissue segmentation using automatically trained k-Nearest-Neighbor classification. *NeuroImage*. 2007;37:71-81.
38. de Boer R, Vrooman HA, van der Lijn F, Vernooij MW, Ikram MA, van der Lugt A, Breteler MM and Niessen WJ. White matter lesion extension to automatic brain tissue segmentation on MRI. *NeuroImage*. 2009;45:1151-61.
39. Gregoire SM, Chaudhary UJ, Brown MM, Yousry TA, Kallis C, Jager HR and Werring DJ. The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. *Neurology*. 2009;73:1759-66.
40. Houben A, Martens RJH and Stehouwer CDA. Assessing Microvascular Function in Humans from a Chronic Disease Perspective. *J Am Soc Nephrol*. 2017;28:3461-3472.
41. Muris DM, Houben AJ, Schram MT and Stehouwer CD. Microvascular dysfunction: an emerging pathway in the pathogenesis of obesity-related insulin resistance. *Rev Endocr Metab Disord*. 2013;14:29-38.
42. Correction: Neighbourhood socioeconomic position and risks of major chronic diseases and all-cause mortality: a quasi-experimental study. *BMJ Open*. 2019;9:e018793corr1.
43. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS and Investigators C-E. Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med*. 2012;367:20-9.

44. van Dooren FE, Schram MT, Schalkwijk CG, Stehouwer CD, Henry RM, Dagnelie PC, Schaper NC, van der Kallen CJ, Koster A, Sep SJ, Denollet J, Verhey FR and Pouwer F. Associations of low grade inflammation and endothelial dysfunction with depression - The Maastricht Study. *Brain Behav Immun*. 2016;56:390-6.
45. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, Filipovsky J, Huybrechts S, Mattace-Raso FU, Protogerou AD, Schillaci G, Segers P, Vermeersch S, Weber T, Artery S, European Society of Hypertension Working Group on Vascular S, Function and European Network for Noninvasive Investigation of Large A. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. *J Hypertens*. 2012;30:445-8.
46. Trichopoulou A, Orfanos P, Norat T, Bueno-de-Mesquita B, Ocke MC, Peeters PH, van der Schouw YT, Boeing H, Hoffmann K, Boffetta P, Nagel G, Masala G, Krogh V, Panico S, Tumino R, Vineis P, Bamia C, Naska A, Benetou V, Ferrari P, Slimani N, Pera G, Martinez-Garcia C, Navarro C, Rodriguez-Barranco M, Dorronsoro M, Spencer EA, Key TJ, Bingham S, Khaw KT, Kesse E, Clavel-Chapelon F, Boutron-Ruault MC, Berglund G, Wirfalt E, Hallmans G, Johansson I, Tjonneland A, Olsen A, Overvad K, Hundborg HH, Riboli E and Trichopoulos D. Modified Mediterranean diet and survival: EPIC-elderly prospective cohort study. *BMJ*. 2005;330:991.
47. Qi Y, Koster A, van Boxtel M, Kohler S, Schram M, Schaper N, Stehouwer C and Bosma H. Adulthood Socioeconomic Position and Type 2 Diabetes Mellitus-A Comparison of Education, Occupation, Income, and Material Deprivation: The Maastricht Study. *Int J Environ Res Public Health*. 2019;16.
48. Zhou TL, Henry RMA, Stehouwer CDA, van Sloten TT, Reesink KD and Kroon AA. Blood Pressure Variability, Arterial Stiffness, and Arterial Remodeling. *Hypertension*. 2018;72:1002-1010.
49. O'Brien PC. Procedures for comparing samples with multiple endpoints. *Biometrics*. 1984;40:1079-87.
50. van Sloten TT, Sigurdsson S, van Buchem MA, Phillips CL, Jonsson PV, Ding J, Schram MT, Harris TB, Gudnason V and Launer LJ. Cerebral Small Vessel Disease and Association With Higher Incidence of Depressive Symptoms in a General Elderly Population: The AGES-Reykjavik Study. *Am J Psychiatry*. 2015;172:570-8.
51. James MA, Tullett J, Hemsley AG and Shore AC. Effects of aging and hypertension on the microcirculation. *Hypertension*. 2006;47:968-74.
52. Schiebinger L, Leopold SS and Miller VM. Editorial policies for sex and gender analysis. *Lancet*. 2016;388:2841-2842.
53. Burke M, Pabbidi MR, Farley J and Roman RJ. Molecular mechanisms of renal blood flow autoregulation. *Curr Vasc Pharmacol*. 2014;12:845-58.
54. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis*. 2002;39:S1-266.
55. Hall J.E. *Guyton and Hall textbook of medical physiology*. 13th ed. Philadelphia, PA: Elsevier; 206.
56. van Sloten TT, Protogerou AD, Henry RM, Schram MT, Launer LJ and Stehouwer CD. Association between arterial stiffness, cerebral small vessel disease and cognitive impairment: A systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2015;53:121-30.
57. van Sloten TT, Czernichow S, Houben AJ, Protogerou AD, Henry RM, Muris DM, Schram MT, Sep SJ, Dagnelie PC, van der Kallen CJ, Schaper NC, Blacher J, Hercberg S, Levy BI and Stehouwer CD. Association Between Arterial Stiffness and Skin Microvascular Function: The SUVIMAX2 Study and The Maastricht Study. *Am J Hypertens*. 2015;28:868-76.

58. Sarafidis PA, Ruilope LM, Loutradis C, Gorostidi M, de la Sierra A, de la Cruz JJ, Vinyoles E, Divison-Garrote JA, Segura J and Banegas JR. Blood pressure variability increases with advancing chronic kidney disease stage: a cross-sectional analysis of 16 546 hypertensive patients. *J Hypertens.* 2018;36:1076-1085.
59. Pietri P, Vlachopoulos C and Tousoulis D. Inflammation and Arterial Hypertension: From Pathophysiological Links to Risk Prediction. *Curr Med Chem.* 2015;22:2754-61.
60. Virdis A, Masi S, Colucci R, Chiriaco M, Uliana M, Puxeddu I, Bernardini N, Blandizzi C and Taddei S. Microvascular Endothelial Dysfunction in Patients with Obesity. *Curr Hypertens Rep.* 2019;21:32.
61. Zhou TL, Henry RMA, Stehouwer CDA, van Sloten TT, Reesink KD and Kroon AA. Blood Pressure Variability, Arterial Stiffness, and Arterial Remodeling: The Maastricht Study. *Hypertension.* 2018;72:1002-1010.
62. Ozkayar N, Dede F, Akyel F, Yildirim T, Ates I, Turhan T and Altun B. Relationship between blood pressure variability and renal activity of the renin-angiotensin system. *Journal of Human Hypertension.* 2016;30:297-302.
63. Min SH, Kong SH, Lee JE, Lee DH, Oh TJ, Kim KM, Park KS, Jang HC and Lim S. Association of angiotensin-II levels with albuminuria in subjects with normal glucose metabolism, prediabetes, and type 2 diabetes mellitus. *Journal of Diabetes and Its Complications.* 2017;31:1499-1505.
64. Maseli A, Aeschbacher S, Schoen T, Fischer A, Jung M, Risch M, Risch L and Conen D. Healthy Lifestyle and Blood Pressure Variability in Young Adults. *Am J Hypertens.* 2017;30:690-699.
65. Schwingshackl L and Hoffmann G. Mediterranean dietary pattern, inflammation and endothelial function: a systematic review and meta-analysis of intervention trials. *Nutr Metab Cardiovasc Dis.* 2014;24:929-39.
66. Simmons GH, Wong BJ, Holowatz LA and Kenney WL. Changes in the control of skin blood flow with exercise training: where do cutaneous vascular adaptations fit in? *Exp Physiol.* 2011;96:822-8.
67. Pagonas N, Dimeo F, Bauer F, Seibert F, Kiziler F, Zidek W and Westhoff TH. The impact of aerobic exercise on blood pressure variability. *J Hum Hypertens.* 2014;28:367-71.
68. Campbell TS, Seguin JR, Vitaro F, Tremblay RE and Ditto B. Childhood socioeconomic position and blood pressure dipping in early adulthood: a longitudinal study. *Ann Behav Med.* 2013;46:227-31.
69. Kim D, Glazier RH, Zagorski B, Kawachi I and Oreopoulos P. Neighbourhood socioeconomic position and risks of major chronic diseases and all-cause mortality: a quasi-experimental study. *BMJ Open.* 2018;8:e018793.

Figure legend

Figure 1 Flowchart delineating the derivation of the study population.

*not mutually exclusive.

Abbreviations: BPV, blood pressure variability

Figure 2. Associations of systolic and diastolic blood pressure variability composite scores with urinary albumin excretion dichotomized as ≥ 30 mg/24h vs. < 30 mg/24h. Point estimates represent the odds ratio of urinary albumin excretion per standard deviation higher systolic or diastolic BPV composite score. Results are adjusted for age, sex, glucose metabolism status, mean 24-hour systolic or diastolic blood pressure (where appropriate), education level, body mass index, smoking status, alcohol consumption, total/high density lipoprotein cholesterol ratio, lipid-modifying medication, and the individual classes of antihypertensive medication. Abbreviations: BPV, blood pressure variability; CI, confidence interval; OR, odds ratio; UAE, urinary albumin excretion.

Table 1. General study population characteristics

Characteristic	Total study population (n = 2,773)	Teriles of systolic BPV composite score		
		Lowest tertile (n = 921)	Middle tertile (n = 934)	Highest tertile (n = 918)
Demographics				
Age, years	59.9 ± 8.2	57.8 ± 8.6	60.3 ± 7.8	61.7 ± 7.6
Men	1,440 (51.9)	490 (53.2)	486 (52.0)	464 (50.5)
Lifestyle factors				
Smoking status:				
Never	980 (35.3)	366 (39.7)	297 (31.8)	317 (34.5)
Former	1,441 (52.0)	453 (49.2)	506 (54.2)	482 (52.5)
Current	352 (12.7)	102 (11.1)	131 (14.0)	119 (13.0)
Alcohol consumption				
None	509 (18.4)	148 (16.1)	179 (19.2)	182 (19.8)
Low (women ≤7, men ≤14 units/week)	1,550 (55.9)	562 (61.0)	516 (55.2)	472 (51.4)
High (women >7, men >14 units/week)	714 (25.7)	211 (22.9)	239 (25.6)	264 (28.8)
Body mass index, kg/m²	27.0 ± 4.4	26.3 ± 4.3	27.0 ± 4.3	27.6 ± 4.5
Cardiovascular risk factors				
Total/HDL cholesterol ratio	3.7 ± 1.2	3.6 ± 1.2	3.6 ± 1.2	3.8 ± 1.2
Glucose metabolism status				
Normal glucose metabolism	1,575 (56.8)	612 (67.4)	522 (55.9)	432 (47.1)
Prediabetes	416 (15.0)	112 (12.2)	151 (16.2)	153 (16.7)
Type 2 diabetes	782 (28.2)	188 (20.4)	261 (27.9)	333 (36.3)
Use of lipid-modifying medication	1,004 (36.2)	278 (30.2)	330 (35.3)	396 (43.1)
Use of antihypertensive medication	1,101 (39.7)	284 (30.8)	371 (39.7)	446 (48.6)
Beta blockers	488 (17.6)	130 (14.1)	162 (17.3)	196 (21.4)
Diuretics	448 (16.2)	104 (11.3)	170 (18.2)	174 (19.0)
Calcium channel blockers	244 (8.8)	72 (7.8)	88 (9.4)	84 (9.2)
Angiotensin-converting enzyme inhibitors	342 (12.3)	77 (8.4)	107 (11.5)	158 (17.2)
Angiotensin II receptor blockers	491 (17.7)	122 (13.2)	174 (18.6)	195 (21.2)
Mean BP				
24-hour systolic BP, mmHg	120.1 ± 11.7	115.9 ± 9.7	120.0 ± 11.7	124.3 ± 12.7
24-hour diastolic BP, mmHg	74.4 ± 7.1	72.7 ± 6.3	74.4 ± 7.2	76.1 ± 7.4

Characteristic	Total study population (n = 2,773)	Tertiles of systolic BPV composite score		
		Lowest tertile (n = 921)	Middle tertile (n = 934)	Highest tertile (n = 918)
BPV measures				
Within-visit systolic BPV, mmHg	4.69 ± 2.91	2.77 ± 1.46	4.43 ± 1.99	6.88 ± 3.30
Within-visit diastolic BPV, mmHg	2.51 ± 1.68	2.14 ± 1.31	2.41 ± 1.46	2.99 ± 2.07
24-hour systolic BPV, mmHg	10.03 ± 2.50	8.16 ± 1.32	9.88 ± 1.58	12.07 ± 2.61
24-hour diastolic BPV, mmHg	7.01 ± 1.86	6.24 ± 1.35	6.88 ± 1.65	7.91 ± 2.10
7-day systolic BPV, mmHg	9.25 ± 3.83	6.91 ± 1.70	8.84 ± 2.28	12.15 ± 4.80
7-day diastolic BPV, mmHg	5.76 ± 2.93	4.76 ± 1.65	5.37 ± 1.80	7.24 ± 4.14
Measures of MVD				
Cerebral small vessel disease composite score, per point	0.66 ± 0.84	0.52 ± 0.77	0.70 ± .086	0.78 ± 0.87
Retinal arteriolar and venular dilation response composite score, SD	-0.01 ± 1.00	-0.05 ± 1.01	-0.04 ± 0.99	0.05 ± 0.99
Urinary albumin excretion, mg/24 hours	6.8 [4.1 – 11.8]	5.8 [3.7 – 9.9]	6.9 [4.0 – 12.5]	7.6 [4.7 – 13.6]
Skin hyperaemia, %	1,124 ± 781	1,164 ± 841	1,130 ± 745	1,083 ± 756
Plasma biomarkers of MVD composite score, SD	-0.01 ± 0.99	-0.12 ± 0.99	-0.04 ± 0.98	0.12 ± 0.99

Data are presented as mean ± standard deviation, median [interquartile range] or n (%).

Data were available for: within-visit blood pressure variability, n=2,768; 24-hour blood pressure variability, n=2,773 7-day blood pressure variability, n=1,950; cerebral small vessel disease composite score, n=1,837; flicker light-induced arteriolar and venular dilation, n=1,844; urinary albumin excretion, n=2,748; skin hyperaemia, n=1,320, and plasma biomarkers of microvascular dysfunction, n=2,685. Abbreviations: BP, blood pressure; BPV, blood pressure variability; HDL, high-density lipoprotein; MVD, microvascular dysfunction.

Table 2. Associations between systolic and diastolic blood pressure variability composite scores and microvascular dysfunction measures

Microvascular dysfunction measure	Model	Systolic blood pressure variability composite score, per SD		Diastolic blood pressure variability composite score, per SD	
		β	(95% CI)	β	(95% CI)
Cerebral small vessel disease features composite score, per point	1	0.047	(0.011 – 0.083)	0.049	(0.013 – 0.088)
	2	0.036	(0.000 – 0.073)	0.043	(0.005 – 0.081)
	3	0.023	(-0.015 – 0.051)	0.036	(-0.003 – 0.074)
	4	0.016	(-0.021 – 0.054)	0.030	(-0.008 – 0.069)
Retinal arteriolar and venular dilation composite score, per SD	1	0.033	(-0.014 – 0.081)	0.021	(-0.030 – 0.071)
	2	0.021	(-0.027 – 0.069)	0.014	(-0.036 – 0.064)
	3	0.030	(-0.020 – 0.081)	0.027	(-0.023 – 0.078)
	4	0.031	(-0.019 – 0.082)	0.025	(-0.025 – 0.076)
Urinary albumin excretion, higher ratio	1	1.14	(1.10 – 1.18)	1.13	(1.09 – 1.17)
	2	1.11	(1.07 – 1.15)	1.11	(1.09 – 1.15)
	3	1.05	(1.01 – 1.09)	1.09	(1.09 – 1.13)
	4	1.04	(1.00 – 1.08)	1.07	(1.03 – 1.11)
Skin hyperaemia, per SD	1	0.027	(-0.029 – 0.083)	0.007	(-0.050 – 0.064)
	2	0.006	(-0.051 – 0.063)	-0.009	(-0.066 – 0.048)
	3	-0.001	(-0.060 – 0.058)	-0.006	(-0.064 – 0.052)
	4	0.005	(-0.054 – 0.065)	-0.003	(-0.061 – 0.055)
Plasma biomarkers of microvascular dysfunction composite score, per SD	1	0.089	(0.052 – 0.126)	0.082	(0.043 – 0.120)
	2	0.052	(0.015 – 0.088)	0.054	(0.017 – 0.092)
	3	0.057	(0.019 – 0.095)	0.056	(0.018 – 0.093)
	4	0.035	(-0.001 – 0.072)	0.023	(-0.013 – 0.060)

Model 1: adjusted for age, sex; model 2: model 1 + glucose metabolism status; model 3: model 2 + mean 24-hour systolic or diastolic blood pressure (where appropriate); model 4: model 3 + education level, body mass index, smoking status, alcohol consumption, total/high density lipoprotein cholesterol ratio, lipid-modifying medication, and the individual classes of antihypertensive medication (i.e. beta blockers, diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers).

Abbreviations: CI: confidence interval; SD: standard deviation.

Supplemental Material

Item S1 Brain magnetic resonance imaging

Brain magnetic resonance imaging (MRI) was performed on a 3T MRI scanner (Siemens Magnetom Prisma-fit Syngo MR D13D, Erlangen, Germany) by use of a 64-element head/neck coil for parallel imaging. The MRI protocol consisted of a 3D T_1 -weighted magnetization prepared rapid acquisition gradient echo (MPRAGE) sequence (TR/TI/TE 2300/900/2.98 ms, 176 slices, 256×240 matrix size, 1.00 mm cubic voxel size); a fluid-attenuated inversion recovery (FLAIR) sequence (TR/TI/TE 5000/1800/394 ms, 176 slices, 512×512 matrix size, 0.49×0.49×1.00 mm voxel size); a combined proton density (PD) and T_2 -weighted turbo spin echo (TSE) pulse sequence (TR/TE1/TE2 3200/9.4/94 ms, 30 slices, 640×540 matrix size, 0.36×0.36×4.00 mm voxel size); and a susceptibility-weighted imaging (SWI) sequence (TR/TE 28/20 ms, 144 slices, 384×312 matrix size, 0.57×0.57×1.00 mm voxel size).

Contra-indications for MRI assessments were the presence of a cardiac pacemaker or implantable cardioverter-defibrillator, neurostimulator, non-detachable insulin pump, metallic vascular clips or stents in the head, cochlear implant, metal-containing intra-uterine device, metal splinters or shrapnel, dentures with magnetic clip, an inside bracket, pregnancy, epilepsy, and claustrophobia.

T_1 -weighted images and FLAIR images were analyzed by use of an ISO-13485:2012 certified, automated method (which included visual inspection).^{1,2} T_1 -weighted images were segmented into grey matter, white matter and cerebrospinal fluid volumes (1 voxel = 1.00 mm³ = 0.001 ml).¹ Intracranial volume was calculated as the sum of grey matter, white matter (including white matter hyperintensity volume) and cerebrospinal fluid volumes. Total brain parenchyma volume was calculated as the sum of grey and white matter volumes. White matter hyperintensities identified were summed to assess total white matter hyperintensities burden in milliliter. Lacunar infarcts were defined as focal brain parenchyma defects of ≥3 mm and <15 mm in size with a similar signal intensity as cerebrospinal fluid on all sequences and a hyperintense rim on T_2 and FLAIR images.³ Cerebral microbleeds were rated on T_2 -weighted and SWI images by use of the Microbleed Anatomical Rating Scale,⁴ and were defined as focal lesions of ≥2 mm and ≤10 mm in size with a hypointense signal.³ The presence of lacunar infarcts and cerebral microbleeds was rated manually by three neuroradiologists. The two-way mixed effects, consistency, intraclass correlation coefficients for the three raters based on 50 randomly selected scans were 0.84 (95% confidence interval 0.74; 0.91) and 0.83 (0.72; 0.90) for the presence of lacunar infarcts and cerebral microbleeds, respectively.

References

1. Vrooman HA, Cocosco CA, van der Lijn F, Stokking R, Ikram MA, Vernooij MW, Breteler MM and Niessen WJ. Multi-spectral brain tissue segmentation using automatically trained k-Nearest-Neighbor classification. *NeuroImage*. 2007;37:71-81.
2. de Boer R, Vrooman HA, van der Lijn F, Vernooij MW, Ikram MA, van der Lugt A, Breteler MM and Niessen WJ. White matter lesion extension to automatic brain tissue segmentation on MRI. *NeuroImage*. 2009;45:1151-61.
3. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge R, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M and nEuroimaging STfRVco. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol*. 2013;12:822-38.
4. Gregoire SM, Chaudhary UJ, Brown MM, Yousry TA, Kallis C, Jager HR and Werring DJ. The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. *Neurology*. 2009;73:1759-66.

Supplemental Table S1. Characteristics of the study population and individuals excluded from the analyses due to missing values, according to measure of microvascular dysfunction

	CSDV features				Flicker light-induced arteriolar and venular dilation				Urinary albumin excretion				Skin hyperaemia				Plasma biomarkers of microvascular dysfunction			
	Complete (n=1,837)	No. of participants in complete / missing	Missing (n=1,614)	Complete (n=1,844)	No. of participants in complete / missing	Missing (n=1,607)	Complete (n=2,748)	No. of participants in complete / missing	Missing (n=703)	Complete (n=1,320)	No. of participants in complete / missing	Missing (n=2,131)	Complete (n=2,726)	No. of participants in complete / missing	Missing (n=725)					
Demographics																				
Age, years	59.3 ± 8.1	0/0	60.3 ± 8.4 *	59.8 ± 8.2	0/0	59.8 ± 8.3	60.0 ± 8.2	0/0	59.0 ± 8.7 *	60.4 ± 8.0	0/0	59.4 ± 8.4 *	59.9 ± 8.2	0/0	59.3 ± 8.6					
Men	940 (51.2%)	0/0	835 (51.7%)	944 (51.2%)	0/0	831 (51.7%)	1,427 (51.9%)	0/0	348 (49.5%)	699 (53.0%)	0/0	1,076 (50.5%)	1,426 (52.3%)	0/0	349 (48.1%) *					
Lifestyle factors																				
Smoking behaviour		0/63	*		0/63	*		0/63	*		0/63	*		0/63	*					
Never	697 (37.9%)		473 (30.5%)	660 (35.8%)		510 (33.0%)	974 (35.4%)		196 (30.6%)	439 (33.3%)		731 (35.3%)	964 (35.4%)		206 (31.1%)					
Former	934 (53.4%)		815 (52.5%)	969 (52.5%)		780 (50.5%)	1,428 (52.0%)		321 (50.2%)	727 (55.1%)		1,022 (49.4%)	1,416 (51.9%)		333 (50.3%)					
Current	206 (11.2%)		263 (17.0%)	215 (11.7%)		254 (16.5%)	346 (12.6%)		123 (19.2%)	154 (11.7%)		315 (15.2%)	346 (12.7%)		123 (18.6%)					
Alcohol use																				
None	314 (17.1%)	0/69	315 (20.4%)	338 (18.3%)	0/69	291 (18.9%)	499 (18.2%)	0/69	130 (20.5%)	235 (17.8%)	0/69	394 (19.1%)	497 (18.2%)	0/69	132 (20.1%)					
Low	1032 (56.2%)		843 (54.6%)	1,052 (57.0%)		823 (53.5%)	1,541 (56.1%)		334 (52.5%)	730 (55.3%)		1,145 (55.5%)	1,522 (55.8%)		353 (53.8%)					
High	491 (26.7%)		387 (25.0%)	454 (24.6%)		454 (27.6%)	708 (25.8%)		170 (26.8%)	255 (26.9%)		523 (25.4%)	707 (25.9%)		171 (26.1%)					
BMI, kg/m ²																				
26.5 ± 4.1	0/3		27.8 ± 5.0 *	26.9 ± 4.3	0/3	27.3 ± 4.8 *	27.0 ± 4.4	0/3	27.5 ± 5.2 *	26.9 ± 4.3	0/3	27.2 ± 4.7	27.0 ± 4.4	0/3	27.4 ± 5.1					
MVPA, h/wk																				
4.8 [2.5 - 8.3]	186/271	4.5 [1.8 - 7.5] *	4.5 [2.3 - 8.0]	187/270	4.5 [2.3 - 7.8]	4.5 [2.3 - 8.0]	311/46	4.5 [1.8 - 7.5] *	4.5 [2.3 - 7.8]	140/317	4.5 [2.3 - 8.0]	4.5 [2.3 - 8.0]	315/42	4.5 [1.8 - 7.5]						
CV risk factors																				
History of CVD	216 (11.9%)	20/88	342 (22.4%) *	281 (15.2%)	20/88	277 (18.2%) *	453 (16.7%)	34/74	105 (16.7%)	235 (18.0%)	14/94	323 (15.9%)	448 (16.6%)	35/73	110 (16.9%)					
Total-to-HDL ratio	3.7 ± 1.2	0/4	3.7 ± 1.2	3.6 ± 1.1	0/4	3.7 ± 1.2 *	3.7 ± 1.2	0/4	3.6 ± 1.2	3.7 ± 1.1	0/4	3.7 ± 1.2	3.7 ± 1.2	0/4	3.6 ± 1.2					
eGFR	88.8 ± 14.2	15/18	87.4 ± 15.7 *	88.1 ± 14.7	13/20	88.1 ± 15.2	88.0 ± 14.6	9/24	88.6 ± 16.1	88.2 ± 14.6	11/22	88.1 ± 15.1	88.1 ± 14.7	6/27	88.4 ± 15.9					
GMS																				
NGM	1,139 (62.0%)	0/41	785 (49.9%)	1,052 (57.0%)	0/41	872 (55.7%)	1,561 (56.8%)	0/41	363 (54.8%)	706 (53.5%)	0/41	1,218 (58.3%)	1,547 (56.7%)	0/41	377 (55.1%)					
Prediabetes	284 (15.5%)		277 (14.4%)	278 (15.1%)		233 (14.9%)	511 (15.1%)		96 (14.5%)	210 (15.9%)		301 (14.4%)	411 (15.1%)		100 (14.6%)					
Type 2 diabetes	414 (22.5%)		561 (34.8%)	514 (27.9%)		461 (29.4%)	772 (28.1%)		203 (30.7%)	404 (30.6%)		571 (27.3%)	768 (28.2%)		207 (30.3%)					
Use of lipid medication																				
Use of lipid	561 (30.5%)	0/4	697 (43.3%) *	655 (35.5%)	0/4	603 (37.6%)	998 (36.3%)	0/4	260 (37.2%)	523 (39.6%)	0/4	735 (34.6%) *	998 (36.3%)	0/4	260 (37.2%)					
medication																				
Use of AHT	624 (34.0%)	0/4	754 (46.8%) *	707 (38.3%)	0/4	671 (41.9%) *	1,093 (39.8%)	0/4	285 (40.8%)	559 (42.3%)	0/4	819 (38.5%) *	990 (36.3%)	0/4	268 (37.2%)					
β-blockers	251 (13.7%)	0/4	369 (22.9%) *	308 (16.7%)	0/4	312 (19.5%) *	483 (17.6%)	0/4	137 (19.6%)	238 (18.0%)	0/4	382 (18.0%)	481 (17.6%)	0/4	139 (19.3%)					
Diuretics	236 (12.8%)	0/4	329 (20.4%) *	291 (15.8%)	0/4	274 (17.1%)	446 (16.2%)	0/4	119 (17.0%)	226 (17.1%)	0/4	339 (15.9%)	444 (16.3%)	0/4	121 (16.8%)					
CCB	117 (6.4%)	0/4	209 (13.0%) *	162 (8.8%)	0/4	164 (10.2%)	243 (8.8%)	0/4	83 (11.9%) *	134 (10.2%)	0/4	192 (9.0%)	241 (8.8%)	0/4	85 (11.8%) *					
ACE-I	172 (9.4%)	0/4	254 (15.8%) *	218 (11.8%)	0/4	208 (13.0%)	338 (12.3%)	0/4	88 (12.6%)	173 (13.1%)	0/4	253 (11.9%)	337 (12.4%)	0/4	89 (12.3%)					
ARBs	282 (15.4%)	0/4	339 (21.1%) *	314 (17.0%)	0/4	307 (19.2%)	489 (17.8%)	0/4	132 (18.9%)	253 (19.2%)	0/4	368 (17.3%)	486 (17.8%)	0/4	135 (18.7%)					
Plasma biomarkers of LGI																				
CRP, µg/ml	1.14	17/21	1.39	1.20	16/22	1.33	1.23	1.34	1.20	1.29	13/25	1.29	1.22	0/38	1.36					
SAAs, µg/ml	[0.58-2.51]		[0.66-3.07] *	[0.62-2.66]		[0.61-2.94]	[0.61-2.76]		[0.64-2.99]	[0.62-2.72]		[0.61-2.86]	[0.61-2.78]		[0.64-2.92]					
IL-6, pg/ml	3.16		3.37 [2.12-5.65]	3.28		3.26	3.24	3.33	3.30	3.24		3.24	3.24		3.33					
IL-8, pg/ml	[1.97-5.32]		[1.04-5.37]	0.57		[2.04-5.61]	[1.04-5.39]		[2.05-5.79]	[1.10-5.45]		[2.00-5.46]	[1.03-5.40]		[2.09-5.75]					
TNF-α, pg/ml	0.54		0.65	0.57		0.60	0.58	0.62	0.58	0.58		0.59	0.58		0.62					
	[0.37-0.84]		[0.43-0.99] *	[0.39-0.88]		[0.40-0.94]	[0.39-0.89]		[0.40-0.96]	[0.40-0.88]		[0.39-0.92]	[0.39-0.89]		[0.41-0.95]					
	4.01		4.32 [3.41-5.60]	4.06		4.24	4.13	4.16	4.14	4.13		4.13	4.13		4.18					
	[3.21-5.09]		[2.15-5.23]	[3.21-5.23]		[3.40-5.45]	[3.28-5.32]		[3.32-5.35]	[3.30-5.27]		[3.28-5.36]	[3.28-5.33]		[3.36-5.34]					
	2.15		2.23 [1.92-2.63]	2.21		2.18	2.19	2.21	2.19	2.21		2.19	2.21		2.21					
	[1.86-2.51]		[1.89-2.59]	[1.89-2.59]		[1.88-2.53]	[1.88-2.57]		[1.91-2.54]	[1.88-2.55]		[1.89-2.57]	[1.88-2.56]		[1.92-2.55]					
Mean BP																				

	CSVD features			Flicker light-induced arteriolar and venular dilation			Urinary albumin excretion			Skin hyperaemia			Plasma biomarkers of microvascular dysfunction		
	Complete (n=1,837)	No. of participants in complete / missing	Missing (n=1,614)	Complete (n=1,844)	No. of participants in complete / missing	Missing (n=1,607)	Complete (n=2,748)	No. of participants in complete / missing	Missing (n=703)	Complete (n=1,320)	No. of participants in complete / missing	Missing (n=2,131)	Complete (n=2,726)	No. of participants in complete / missing	Missing (n=725)
Office SBP, mmHg	133.8 ± 17.2	0/2	136.5 ± 19.2 *	134.9 ± 17.9	1/1	135.2 ± 18.5	135.0 ± 18.1	1/1	135.3 ± 18.5	135.9 ± 18.3	2/0	134.5 ± 18.2 *	135.0 ± 18.1	1/1	135.4 ± 18.5
Office DBP, mmHg	76.0 ± 9.7	0/2	76.3 ± 10.0	76.4 ± 9.9	1/1	75.9 ± 9.8	76.2 ± 9.9	1/1	75.8 ± 9.8	76.6 ± 9.6	2/0	75.9 ± 9.7	76.2 ± 9.9	1/1	75.8 ± 9.7
24-hour SBP, mmHg	119.7 ± 11.3	0/559	121.0 ± 12.8 *	120.1 ± 11.5	0/559	120.1 ± 12.5	120.1 ± 11.8	0/559	121.9 ± 13.7	120.9 ± 11.6	0/559	119.5 ± 12.0 *	120.1 ± 11.8	0/559	120.7 ± 13.5
24-hour DBP, mmHg	74.6 ± 7.0	0/559	76.9 ± 7.4 *	74.4 ± 7.1	0/559	74.2 ± 7.2	74.4 ± 7.1	0/559	73.9 ± 7.6	74.6 ± 6.9	0/559	74.2 ± 7.4	74.4 ± 7.1	0/559	73.4 ± 7.5
7-day SBP, mmHg	126.0 ± 12.8	526/478	129.5 ± 14.2 *	126.8 ± 13.2	580/424	128.4 ± 13.9 *	127.4 ± 13.5	791/213	128.3 ± 14.0 *	127.6 ± 13.1	333/1,004	127.6 ± 13.9	127.4 ± 13.5	792/212	128.2 ± 14.0
7-day DBP, mmHg	77.2 ± 8.2	526/478	77.4 ± 8.2	77.0 ± 8.1	580/424	77.6 ± 8.2	77.2 ± 8.1	791/213	77.5 ± 8.6	77.3 ± 7.8	333/1,004	77.3 ± 8.4	77.3 ± 8.2	792/212	77.3 ± 8.0
BPV															
WW-BPV, mmHg	4.6 ± 2.9	1/7	4.6 ± 2.9	4.6 ± 2.9	5/3	4.7 ± 2.9	4.7 ± 2.9	5/3	4.5 ± 2.9	4.8 ± 3.0	3/5	4.5 ± 2.8 *	4.7 ± 2.9	5/3	4.4 ± 2.8 *
WW-sBPV, mmHg	2.5 ± 1.6	1/7	2.6 ± 1.8	2.5 ± 1.6	5/3	2.6 ± 1.8 *	2.5 ± 1.7	5/3	2.5 ± 1.9	2.6 ± 1.7	3/5	2.5 ± 1.7	2.5 ± 1.7	5/3	2.5 ± 1.9
24-h sBPV, mmHg	9.9 ± 2.4	0/559	10.4 ± 2.7 *	10.0 ± 2.5	0/559	10.1 ± 2.6	10.0 ± 2.5	0/559	10.2 ± 2.5	10.1 ± 2.4	0/559	10.0 ± 2.5	10.0 ± 2.5	0/559	10.4 ± 2.8
24-h sDBP, mmHg	6.9 ± 1.7	0/559	7.3 ± 2.0 *	6.9 ± 1.8	0/559	7.2 ± 2.0 *	7.0 ± 1.9	0/559	7.1 ± 1.9	7.0 ± 1.8	0/559	7.0 ± 1.9	7.0 ± 1.8	0/559	7.2 ± 2.1
7-d sBPV, mmHg	8.9 ± 3.6	539/486	9.9 ± 4.1 *	9.1 ± 3.8	597/428	9.6 ± 4.0 *	9.2 ± 3.8	597/428	9.8 ± 4.3 *	9.2 ± 3.6	539/486	9.5 ± 4.1	9.3 ± 3.8	812/213	9.6 ± 4.1 *
7-d sDBP, mmHg	5.5 ± 2.7	539/486	6.2 ± 3.5 *	5.7 ± 2.9	597/428	6.1 ± 3.2 *	5.7 ± 2.9	597/428	6.4 ± 3.8 *	5.7 ± 2.8	539/486	6.0 ± 3.2 *	5.8 ± 2.9	812/213	6.2 ± 3.7 *
Microvascular dysfunction															
CSVD features															
TBV, ml	1,133 ± 112	0/1,149	1,140 ± 111	-	-	-	-	-	-	-	-	-	-	-	-
WMH volume, ml	0.22	0/1,149	0.25 [0.07-0.81]	-	-	-	-	-	-	-	-	-	-	-	-
Presence of CMB	[0.07-0.73]	0/1,195	64 (5.3%) *	-	-	-	-	-	-	-	-	-	-	-	-
Presence of lacunar infarcts	207 (11.3%)	0/1,152	30 (6.5%)	-	-	-	-	-	-	-	-	-	-	-	-
Flicker light-induced arteriolar and venular dilation															
Flicker light-induced arteriolar dilation, %	-	-	-	3.04 ± 2.81	0/1,161	2.84 ± 2.69	-	-	-	-	-	-	-	-	-
Flicker light-induced venular dilation, %	-	-	-	3.89 ± 2.20	0/1,120	3.72 ± 2.25	-	-	-	-	-	-	-	-	-
Urinary albumin excretion															
<15 mg/24h	-	-	-	-	-	-	2237 (81.4%)	0/42	516 (78.1%)	-	-	-	-	-	-
≥15-30 mg/24h	-	-	-	-	-	-	279 (10.2%)	0/42	78 (11.8%)	-	-	-	-	-	-
≥30 mg/24h	-	-	-	-	-	-	232 (8.4%)	0/42	67 (10.1%)	-	-	-	-	-	-
Skin hyperaemia, %															
Plasma biomarkers of microvascular dysfunction	-	-	-	-	-	-	-	-	-	1,124 ± 781	0/1,775	1,107 ± 723	-	-	-
sICAM-1, ng/ml	-	-	-	-	-	-	-	-	-	-	-	-	353 ± 99	0/251	361 ± 103
sVCAM-1, ng/ml	-	-	-	-	-	-	-	-	-	-	-	-	427 ± 101	0/251	433 ± 102
sE-selectin, ng/ml	-	-	-	-	-	-	-	-	-	-	-	-	119 ± 66.2	0/251	118 ± 60.8
vWF, %	-	-	-	-	-	-	-	-	-	-	-	-	132 ± 48	0/253	135 ± 50

Data are presented as mean ± standard deviation, median [interquartile range] or n(%). *denotes a statistically significant difference from the complete group, assessed by the student's t-test for normally distributed variables, Mann-Whitney U-test for skewed variables or Chi-square test for categorical variables. Abbreviations: BMI, body mass index; MVP, MVP, moderate-to-vigorous physical activity; CSVD, cerebral small vessel disease; CV, cardiovascular; CVD, cardiovascular disease; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate; GMS, glucose metabolism status; NGM, normal glucose metabolism status; AHT, antihypertensive treatment; CCB, calcium channel blocker; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; BPV, blood pressure variability; WW, within-visit; TBV, total parenchymal brain volume; WMH, white matter hyperintensity; CMB, cerebral microbleeds; UAE, urinary albumin excretion; WMH, white matter hyperintensity; sICAM, soluble intercellular adhesion molecule-1; sVCAM, soluble vascular adhesion molecule-1; sE-selectin, soluble E-selectin; vWF, von Willebrand factor.

Supplemental Table S2. Study population characteristics of variables used in the additional analyses

Characteristic	Total study population (n=2,773)	Teriles of systolic BPV composite score		
		Lowest tertile (n= 921)	Middle tertile (n= 934)	Highest tertile (n= 918)
Demographics				
Income level, euros	2,017 ± 814	2,050 ± 814	1,968 ± 795	2,032 ± 831
Occupation status				
Low	704 (30.4)	225 (27.9)	245 (32.2)	234 (31.3)
Middle	814 (35.2)	285 (35.4)	262 (34.4)	267 (35.7)
High	797 (34.4)	296 (36.7)	254 (33.4)	247 (33.0)
Lifestyle factors				
Greek Mediterranean diet score	4.4 ± 1.6	4.4 ± 1.7	4.4 ± 1.6	4.4 ± 1.6
Moderate-to-vigorous physical activity, h/wk	4.5 [2.3 – 8.0]	4.5 [2.3 – 7.5]	4.5 [2.3 – 8.3]	4.5 [2.3 – 7.7]
Cardiovascular risk factors				
History of cardiovascular disease	458 (16.5)	127 (14.0)	159 (17.2)	172 (18.7)
Estimated glomerular filtration rate, ml/min/1.73m ²	88.1 ± 14.7	90.3 ± 14.8	87.5 ± 14.2	86.3 ± 14.8
Estimated glomerular filtration rate <60 ml/min/1.73m ²	114 (4.1)	28 (3.0)	34 (3.7)	52 (5.7)
Markers of low-grade inflammation				
C-reactive protein (µg/ml)	1.23 [0.61 – 2.76]	1.10 [0.54 – 2.39]	1.20 [0.59 – 2.90]	1.44 [0.69 – 3.08]
Serum amyloid A (µg/ml)	3.24 [2.04 – 5.39]	3.08 [1.86 – 5.20]	3.18 [2.00 – 5.25]	3.51 [2.26 – 5.71]
Interleukin-6 (pg/ml)	0.58 [0.39 – 0.89]	0.52 [0.37 – 0.83]	0.58 [0.39 – 0.93]	0.65 [0.43 – 0.93]
Interleukin-8 (pg/ml)	4.12 [3.28 – 5.33]	3.92 [3.10 – 5.17]	4.17 [3.29 – 5.35]	4.27 [3.50 – 5.46]
Tumour necrosis factor alpha (pg/ml)	2.19 [1.88 – 2.57]	2.16 [1.83 – 2.51]	2.18 [1.88 – 2.54]	2.23 [1.92 – 2.66]
Carotid-femoral pulse wave velocity, m/s	9.0 ± 2.1	8.4 ± 1.9	9.0 ± 2.1	9.6 ± 2.2
Mean BP				
Office systolic BP, mmHg	135.0 ± 18.1	127.5 ± 15.3	135.1 ± 17.2	142.4 ± 18.7
Office diastolic BP, mmHg	76.2 ± 9.9	73.9 ± 9.0	76.4 ± 9.9	78.3 ± 10.1
7-day systolic BP, mmHg	127.5 ± 13.6	120.7 ± 10.4	126.9 ± 12.2	135.3 ± 13.9
7-day diastolic BP, mmHg	77.3 ± 8.2	75.1 ± 7.1	77.3 ± 7.9	79.6 ± 8.9

Characteristic	Total study population (n=2,773)	Teriles of systolic BPV composite score		
		Lowest tertile (n= 921)	Middle tertile (n= 934)	Highest tertile (n= 918)
Microvascular dysfunction measures				
Cerebral small vessel disease features				
Total brain parenchyma volume, ml	1,133 ± 112.2	1,145 ± 116.6	1,131 ± 108.1	1,123 ± 110.2
White matter hyperintensity volume, ml	0.22 [0.07 – 0.73]	0.16 [0.05 – 0.48]	0.26 [0.08 – 0.81]	0.30 [0.10 – 1.01]
Presence of cerebral microbleeds	207 (11.3)	67 (10.1)	67 (10.9)	73 (13.1)
Presence of lacunar infarcts	94 (5.1)	22 (3.3)	38 (6.2)	34 (6.1)
Flicker light-induced arteriolar and venular dilation				
Flicker light-induced arteriolar dilation, %	3.04 ± 2.81	3.20 ± 2.82	3.13 ± 2.81	2.77 ± 2.79
Flicker light-induced venular dilation, %	3.89 ± 2.20	3.89 ± 2.21	3.94 ± 2.16	3.85 ± 2.22
Urinary albumin excretion				
≥30 mg/24h				
Plasma biomarkers of microvascular dysfunction				
sICAM-1, ng/ml	232 (8.4)	48 (5.2)	87 (9.5)	97 (10.6)
sVCAM-1, ng/ml	353 ± 99	348 ± 98	350 ± 94	363 ± 104
sE-selectin, ng/ml	427 ± 101	422 ± 99	422 ± 98	438 ± 106
vWF, %	119 ± 66	112 ± 68	121 ± 68	123 ± 62
	132 ± 48	129 ± 47	131 ± 48	137 ± 50

Data are presented as mean ± standard deviation, median [interquartile range] or n (%). Data were available for: income level, n=2,137; diet score, n=2,632; occupation status, n=2,315; moderate-to-vigorous physical activity, n=2,464; carotid-femoral pulse wave velocity, n=2,354; history of cardiovascular disease, n=2,737; estimated glomerular filtration rate, n=2,749; markers of low-grade inflammation, n=2,745; within-visit blood pressure variability, n=2,768; 24-hour blood pressure variability, n=2,773; 7-day blood pressure variability, n=1,950; cerebral small vessel disease features, n=1,837; flicker light-induced arteriolar and venular dilation, n=1,844; urinary albumin excretion, n=2,748; plasma biomarkers of microvascular dysfunction, n=2,685. Abbreviations: BP, blood pressure; BPV, blood pressure variability; sICAM-1, soluble intercellular adhesion molecule 1; sVCAM-1, soluble vascular cell adhesion molecule 1; sE-selectin, soluble E-selectin; vWF, von Willebrand factor.

Supplemental Table S3. Study population characteristics according to tertiles of diastolic blood pressure variability

Characteristic	Study population (n=2,773)	Tertiles of diastolic BPV composite score		
		Lowest tertile (n= 924)	Middle tertile (n= 925)	Highest tertile (n= 924)
Demographics				
Age, years	59.9 ± 8.2	59.0 ± 8.3	59.6 ± 7.9	61.2 ± 8.2
Men	1,440 (51.9)	463 (50.1)	484 (52.3)	493 (53.4)
Lifestyle factors				
Smoking status:				
Never	980 (35.3)	351 (38.0)	320 (34.6)	309 (33.4)
Former	1,441 (52.0)	465 (50.3)	484 (55.3)	484 (53.2)
Current	352 (12.7)	108 (11.7)	121 (13.1)	121 (13.1)
Alcohol consumption				
None	509 (18.4)	168 (18.2)	161 (17.4)	180 (19.5)
Low (women ≤7, men ≤14 units/week)	1,550 (55.9)	534 (57.8)	507 (54.8)	509 (55.1)
High (women >7, men >14 units/week)	714 (25.7)	222 (24.0)	257 (27.8)	235 (25.4)
Body mass index, kg/m²	27.0 ± 4.4	26.2 ± 4.1	26.8 ± 4.2	28.0 ± 4.8
Cardiovascular risk factors				
History of cardiovascular disease	458 (16.5)	126 (13.6)	141 (15.5)	191 (21.0)
Total/high density lipoprotein cholesterol ratio	3.7 ± 1.2	3.6 ± 1.1	3.7 ± 1.2	3.8 ± 1.2
Estimate glomerular filtration rate, ml/min/1.73m²	88.1 ± 14.7	88.9 ± 14.4	89.2 ± 14.2	85.9 ± 15.1
Glucose metabolism status				
Normal glucose metabolism	1,575 (56.8)	590 (63.9)	537 (58.1)	448 (48.5)
Prediabetes	416 (15.0)	119 (12.9)	152 (16.4)	145 (15.7)
Type 2 diabetes	782 (28.2)	215 (23.3)	236 (25.5)	331 (35.8)
Use of lipid-modifying medication	1,004 (36.2)	307 (33.2)	309 (33.4)	388 (42.0)
Use of antihypertensive medication	1,101 (39.7)	308 (33.3)	336 (36.3)	457 (49.5)
Beta blockers	488 (17.6)	134 (14.5)	146 (15.8)	208 (22.5)
Diuretics	448 (16.2)	120 (13.0)	137 (14.8)	191 (20.7)
Calcium channel blockers	244 (8.8)	80 (8.7)	75 (8.1)	89 (9.6)
Angiotensin-converting enzyme inhibitors	342 (12.3)	81 (8.8)	100 (10.8)	161 (17.4)
Angiotensin II receptor blockers	491 (17.7)	130 (14.1)	157 (17.0)	204 (22.1)
Markers of low-grade inflammation				
C-reactive protein (µg/ml)	1.23 [0.61 – 2.76]	1.19 [0.54 – 2.55]	1.12 [0.58 – 2.56]	1.43 [0.70 – 3.17]
Serum amyloid A (µg/ml)	3.24 [2.04 – 5.39]	3.09 [1.84 – 5.20]	3.20 [2.10 – 5.39]	3.49 [2.19 – 5.60]
Interleukin-6 (pg/ml)	0.58 [0.39 – 0.89]	0.54 [0.36 – 0.85]	0.56 [0.38 – 0.86]	0.65 [0.44 – 0.98]

Interleukin-8 (pg/ml) 4.12 [3.28 – 5.33] 4.02 [3.18 – 5.03] 4.08 [3.29 – 5.32] 4.23 [3.37 – 5.48]

Tumour necrosis factor alpha (pg/ml) 2.19 [1.88 – 2.57] 2.15 [1.83 – 2.53] 2.19 [1.87 – 2.54] 2.23 [1.91 – 2.64]

Mean BP

Office systolic BP, mmHg 135.0 ± 18.1 130.7 ± 16.9 134.6 ± 17.9 139.7 ± 18.5

Office diastolic BP, mmHg 76.2 ± 9.9 74.5 ± 9.3 76.4 ± 9.6 77.8 ± 10.3

24-hour systolic BP, mmHg 120.1 ± 11.7 117.7 ± 10.7 120.1 ± 11.6 122.3 ± 12.5

24-hour diastolic BP, mmHg 74.4 ± 7.1 73.0 ± 6.7 74.7 ± 7.1 75.5 ± 7.3

7-day systolic BP, mmHg 127.5 ± 13.6 122.4 ± 11.5 127.3 ± 13.2 133.2 ± 13.9

7-day diastolic BP, mmHg 77.3 ± 8.2 75.2 ± 7.6 77.6 ± 7.6 79.2 ± 8.9

BPV

Within-visit systolic BPV, mmHg 4.69 ± 2.91 4.13 ± 2.52 4.67 ± 2.88 5.27 ± 3.19

Within-visit diastolic BPV, mmHg 2.51 ± 1.68 1.55 ± 0.83 2.31 ± 1.01 3.69 ± 2.10

24-hour systolic BPV, mmHg 10.03 ± 2.50 8.78 ± 1.85 10.00 ± 2.22 11.32 ± 2.67

24-hour diastolic BPV, mmHg 7.01 ± 1.86 5.63 ± 0.89 6.92 ± 1.18 8.48 ± 2.02

7-day systolic BPV, mmHg 9.25 ± 3.83 7.60 ± 2.30 8.89 ± 2.92 11.49 ± 4.89

7-day diastolic BPV, mmHg 5.76 ± 2.93 4.38 ± 1.15 5.42 ± 1.58 7.68 ± 4.19

Microvascular dysfunction measures

Cerebral small vessel disease features

Total brain parenchyma volume, ml 1,133 ± 112.2 1,140 ± 116.6 1,134 ± 112.3 1,125 ± 106.1

White matter hyperintensity volume, ml 0.22 [0.07 – 0.73] 0.21 [0.06 – 0.64] 0.20 [0.07 – 0.64] 0.31 [0.09 – 1.00]

Presence of cerebral microbleeds 207 (11.3) 65 (10.0) 72 (11.3) 70 (12.8)

Presence of lacunar infarcts 94 (5.1) 25 (3.8) 31 (4.9) 38 (6.9)

Flicker light-induced arteriolar and venular dilation

Flicker light-induced arteriolar dilation, % 3.04 ± 2.81 3.15 ± 2.89 3.01 ± 2.67 2.95 ± 2.85

Flicker light-induced venular dilation, % 3.89 ± 2.20 3.90 ± 2.18 3.83 ± 2.13 3.95 ± 2.29

Urinary albumin excretion ≥30 mg/24h 6.8 [4.1 – 11.8] 6.1 [3.8 – 9.9] 6.5 [3.9 – 11.4] 7.9 [4.8 – 14.6]

Skin hyperaemia, % 232 (8.4) 51 (5.5) 72 (7.8) 109 (12.0)

1124 ± 781 1153 ± 791 1103 ± 790 1116 ± 763

Plasma biomarkers of microvascular dysfunction

sICAM-1, ng/ml 353 ± 99 348 ± 92 349 ± 91 363 ± 112

sVCAM-1, ng/ml 427 ± 101 422 ± 92 425 ± 102 436 ± 109

sE-selectin, ng/ml 119 ± 66 115 ± 66 116 ± 61 124 ± 71

vWF, % 132 ± 48 130 ± 47 131 ± 48 136 ± 49

Data are presented as mean ± standard deviation, median [interquartile range] or n (%). Data available for: estimated glomerular filtration rate, n=2,749; history of cardiovascular disease, n=2,737; markers of low-grade inflammation, n=2,745; within-visit blood pressure variability, n=2,768; 7-day blood pressure variability, n=1,950; cerebral small vessel disease features, n=1,837; flicker light-induced arteriolar and venular dilation, n=1,844; urinary albumin excretion, n=2,748; plasma biomarkers of microvascular dysfunction, n=2,685. Abbreviations: BP blood pressure; BPV blood pressure variability; sICAM, soluble intercellular adhesion molecule-1; sVCAM, soluble vascular adhesion molecule-1; sE-selectin, soluble E-selectin; vWF, von Willebrand factor.

Supplemental Table S4. P values of interactions with age, sex, and glucose metabolism status

	Systolic blood pressure variability composite score	Diastolic blood pressure variability composite score		
Interaction with age (<60 vs. ≥60 years)				
Cerebral small vessel disease features	0.465	0.226		
Retinal arteriolar and venular dilation	0.916	0.461		
Urinary albumin excretion	0.039 *	0.171		
Skin hyperaemia	0.579	0.779		
Plasma biomarkers of MVD	0.389	0.046 *		
Interaction with sex				
Cerebral small vessel disease features	0.782	0.955		
Retinal arteriolar and venular dilation	0.458	0.788		
Urinary albumin excretion	<0.001 †	<0.001 †		
Skin hyperaemia	0.450	0.413		
Plasma biomarkers of MVD	0.150	0.013 †		
Interaction with glucose metabolism status	Prediabetes	Type 2 diabetes	Prediabetes	Type 2 diabetes
Cerebral small vessel disease features	0.803	0.030 ‡	0.503	0.080
Retinal arteriolar and venular dilation	0.959	0.132	0.473	0.066
Urinary albumin excretion	0.639	0.121	0.628	0.057
Skin hyperaemia	0.681	0.799	0.449	0.816
Plasma biomarkers of MVD	0.050	0.652	0.107	0.011 ‡

*For statistically significant interactions with age, associations appeared stronger in individuals ≥ 60 years. †For statistically significant interactions with sex, associations appeared stronger in men. ‡For statistically significant interactions with glucose metabolism status, associations with cerebral small vessel disease features appeared stronger in individuals with normal glucose metabolism status, whereas associations with plasma biomarkers of MVD appeared stronger in individuals with type 2 diabetes. Abbreviations: MVD, microvascular dysfunction.

Supplemental Table S5. Associations between within-visit, 24-hour and 7-day systolic and diastolic blood pressure variability and measures of microvascular dysfunction

Microvascular dysfunction	Systolic blood pressure variability			Diastolic blood pressure variability		
	Within-visit	24-hour	7-day	Within-visit	24-hour	7-day
Model	β (95%CI)	β (95%CI)	β (95%CI)	β (95%CI)	β (95%CI)	β (95%CI)
Cerebral small vessel disease features, per point						
	n=1,836	n=1,839	n=1,298	n=1,836	n=1,839	n=1,298
1	0.024 (-0.010; 0.057)	0.013 (-0.023; 0.049)	0.071 (0.028; 0.114)	0.013 (-0.023; 0.049)	0.054 (0.018; 0.090)	0.054 (-0.017; 0.074)
2	0.021 (-0.012; 0.054)	0.002 (-0.034; 0.053)	0.061 (0.018; 0.053)	0.013 (-0.023; 0.048)	0.049 (0.014; 0.085)	0.028 (-0.026; 0.054)
3	0.011 (-0.016; 0.050)	-0.020 (-0.058; 0.019)	0.053 (0.010; 0.097)	0.009 (-0.027; 0.045)	0.042 (0.006; 0.078)	0.019 (-0.031; 0.060)
4	0.013 (-0.020; 0.046)	-0.021 (-0.059; 0.018)	0.045 (0.001; 0.088)	0.002 (-0.033; 0.038)	0.047 (0.010; 0.083)	0.014 (-0.040; 0.051)
Flicker light-induced arteriolar and venular dilation, per SD						
	n=1,841	n=1,846	n=1,247	n=1,842	n=1,846	n=1,247
1	0.010 (-0.035; 0.055)	0.032 (-0.015; 0.079)	0.025 (-0.034; 0.083)	-0.021 (-0.070; 0.029)	0.045 (-0.003; 0.092)	0.000 (-0.059; 0.059)
2	0.005 (-0.040; 0.051)	0.022 (-0.025; 0.069)	0.015 (-0.044; 0.074)	-0.021 (-0.064; 0.034)	0.039 (-0.009; 0.086)	-0.005 (-0.065; 0.054)
3	0.008 (-0.038; 0.053)	0.034 (-0.016; 0.085)	0.019 (-0.041; 0.078)	-0.015 (-0.064; 0.034)	0.053 (0.005; 0.101)	0.000 (-0.059; 0.059)
4	0.006 (-0.040; 0.051)	0.040 (-0.012; 0.091)	0.022 (-0.039; 0.083)	-0.018 (-0.067; 0.031)	0.055 (0.006; 0.103)	0.000 (-0.060; 0.060)
Urinary albumin excretion, ratio increase						
	n=2,743	n=2,748	n=1,936	n=2,744	n=2,748	n=1,936
1	1.04 (1.00 - 1.07)	1.13 (1.09 - 1.17)	1.11 (1.07 - 1.16)	1.04 (1.00 - 1.08)	1.11 (1.07 - 1.15)	1.09 (1.04 - 1.16)
2	1.03 (1.00 - 1.07)	1.10 (1.06 - 1.14)	1.08 (1.04 - 1.13)	1.04 (1.00 - 1.02)	1.09 (1.05 - 1.13)	1.07 (1.02 - 1.14)
3	1.01 (0.98 - 1.04)	1.04 (1.00 - 1.07)	1.05 (1.01 - 1.10)	1.03 (1.00 - 1.07)	1.07 (1.04 - 1.11)	1.06 (1.01 - 1.10)
4	1.02 (0.99 - 1.05)	1.02 (0.98 - 1.05)	1.04 (1.00 - 1.08)	1.03 (0.99 - 1.06)	1.05 (1.02 - 1.09)	1.05 (1.00 - 1.09)
Skin hyperaemia, per SD						
	n=1,317	n=1,322	n=983	n=1,318	n=1,322	n=983
1	0.025 (-0.027; 0.076)	0.028 (-0.028; 0.084)	-0.021 (-0.086; 0.044)	0.017 (-0.036; 0.070)	0.000 (-0.054; 0.055)	-0.018 (-0.084; 0.047)
2	0.016 (-0.036; 0.067)	0.015 (-0.041; 0.071)	-0.042 (-0.108; 0.023)	0.012 (-0.040; 0.065)	-0.009 (-0.063; 0.044)	-0.035 (-0.100; 0.031)
3	0.015 (-0.036; 0.067)	0.010 (-0.050; 0.070)	-0.052 (-0.119; 0.015)	0.013 (-0.040; 0.066)	-0.005 (-0.060; 0.050)	-0.035 (-0.101; 0.032)
4	0.019 (-0.032; 0.071)	0.020 (-0.041; 0.082)	-0.051 (-0.119; 0.016)	0.014 (-0.038; 0.067)	-0.001 (-0.057; 0.055)	-0.034 (-0.101; 0.032)

Microvascular dysfunction	Systolic blood pressure variability			Diastolic blood pressure variability		
	Within-visit	24-hour	7-day	Within-visit	24-hour	7-day
Model	β (95%CI)	β (95%CI)	β (95%CI)	β (95%CI)	β (95%CI)	β (95%CI)
Plasma biomarkers of microvascular dysfunction, per SD						
	n=2,721	n=2,728	n=1,914	n=2,722	n=2,728	n=1,914
1	0.007 (-0.030; 0.043)	0.080 (0.043; 0.117)	0.121 (0.077; 0.166)	0.010 (-0.028; 0.047)	0.064 (0.027; 0.100)	0.103 (0.057; 0.149)
2	-0.007 (-0.042; 0.028)	0.047 (0.011; 0.083)	0.083 (0.040; 0.126)	0.004 (-0.032; 0.039)	0.041 (0.006; 0.077)	0.074 (0.030; 0.119)
3	-0.007 (-0.042; 0.028)	0.054 (0.016; 0.093)	0.087 (0.043; 0.131)	0.004 (-0.032; 0.040)	0.042 (0.006; 0.078)	0.074 (0.030; 0.119)
4	0.003 (-0.030; 0.037)	0.016 (-0.021; 0.054)	0.065 (0.022; 0.107)	0.005 (-0.030; 0.039)	0.001 (-0.034; 0.036)	0.049 (0.005; 0.092)

Regression coefficients (β) represent difference in microvascular dysfunction measures per standard deviation, for every 1 standard deviation increase in blood pressure variability composite score. For cerebral small vessel disease features, β 's are expressed per point; for urinary albumin excretion, β 's are expressed as ratio increase. Model 1: age, sex; model 2: model 1 + glucose metabolism status; model 3: model 2 + mean 24-hour systolic or diastolic blood pressure (where appropriate); model 4: model 3 + education level, body mass index, smoking status, alcohol consumption, total/high density lipoprotein cholesterol ratio, lipid-modifying medication, and the individual classes of antihypertensive medication (i.e. beta blockers, diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers). Abbreviations: CI: confidence interval; SD: standard deviation.

Supplemental Table 6. Associations between systolic and diastolic blood pressure variability and individual measures of microvascular dysfunction

		Systolic blood pressure variability composite score, per SD		Diastolic blood pressure variability composite score, per SD	
Microvascular dysfunction	Model	OR	(95% CI)	OR	(95% CI)
Cerebral small vessel disease features					
Total parenchymal brain volume, low vs. high	1	1.05	(0.93 – 1.19)	1.12	(0.98 – 1.28)
	2	1.02	(0.90 – 1.16)	1.11	(0.97 – 1.27)
	3	1.05	(0.92 – 1.20)	1.12	(0.98 – 1.29)
	4	1.01	(0.88 – 1.16)	1.09	(0.94 – 1.25)
White matter hyperintensity volume, high vs. low	1	1.13	(1.01 – 1.28)	1.06	(0.93 – 1.20)
	2	1.11	(0.98 – 1.25)	1.04	(0.92 – 1.19)
	3	1.01	(0.89 – 1.15)	0.97	(0.85 – 1.11)
	4	1.00	(0.87 – 1.14)	0.96	(0.84 – 1.11)
Cerebral microbleeds, presence vs. absence	1	1.12	(0.96 – 1.30)	1.09	(0.92 – 1.28)
	2	1.11	(0.96 – 1.29)	1.08	(0.92 – 1.27)
	3	1.08	(0.92 – 1.27)	1.07	(0.91 – 1.26)
	4	1.09	(0.92 – 1.28)	1.07	(0.91 – 1.27)
Lacunar infarcts, presence vs. absence	1	1.20	(0.98 – 1.47)	1.25	(1.01 – 1.55)
	2	1.17	(0.95 – 1.45)	1.23	(0.99 – 1.53)
	3	1.15	(0.93 – 1.44)	1.23	(0.99 – 1.52)
	4	1.16	(0.93 – 1.45)	1.22	(0.98 – 1.52)
Flicker light-induced retinal arteriolar and venular dilation	Model	β	(95% CI)	β	(95% CI)
Flicker light-induced arteriolar dilation, per SD	1	-0.028	(-0.076; 0.020)	-0.013	(-0.064; 0.037)
	2	-0.010	(-0.058; 0.038)	-0.004	(-0.054; 0.046)
	3	-0.021	(-0.071; 0.029)	-0.014	(-0.064; 0.037)
	4	-0.021	(-0.072; 0.030)	-0.014	(-0.066; 0.037)
Flicker light-induced venular dilation, per SD	1	-0.015	(-0.063; 0.032)	-0.018	(-0.067; 0.032)
	2	-0.013	(-0.061; 0.035)	-0.016	(-0.066; 0.033)
	3	-0.014	(-0.064; 0.036)	-0.027	(-0.077; 0.024)
	4	-0.016	(-0.066; 0.034)	-0.022	(-0.073; 0.028)
Plasma biomarkers of microvascular dysfunction	Model	β	(95% CI)	β	(95% CI)
Soluble intracellular adhesion molecule-1, per SD	1	0.074	(0.035 – 0.112)	0.055	(0.016 – 0.094)
	2	0.041	(0.003 – 0.079)	0.032	(-0.007 – 0.070)
	3	0.041	(0.002 – 0.081)	0.031	(-0.008 – 0.069)
	4	0.022	(-0.016 – 0.060)	0.005	(-0.033 – 0.042)
Soluble vascular adhesion molecule-1, per SD	1	0.056	(0.018 – 0.094)	0.067	(0.028 – 0.105)
	2	0.038	(0.000 – 0.076)	0.054	(0.016 – 0.093)
	3	0.044	(0.005 – 0.084)	0.057	(0.018 – 0.096)
	4	0.042	(0.003 – 0.082)	0.045	(0.006 – 0.084)
E-selectin, per SD	1	0.053	(0.014 – 0.092)	0.047	(0.007 – 0.087)
	2	0.009	(-0.028 – 0.047)	0.016	(-0.022 – 0.055)
	3	0.002	(-0.037 – 0.042)	0.009	(-0.030 – 0.048)
	4	-0.019	(-0.057 – 0.019)	-0.022	(-0.059 – 0.016)
Von Willebrand Factor, per SD	1	0.058	(0.021 – 0.096)	0.054	(0.015 – 0.093)

Microvascular dysfunction	Model	Systolic blood pressure variability composite score, per SD		Diastolic blood pressure variability composite score, per SD	
		OR	(95% CI)	OR	(95% CI)
	2	0.045	(0.007 – 0.083)	0.045	(0.006 – 0.083)
	3	0.062	(0.023 – 0.102)	0.054	(0.014 – 0.093)
	4	0.051	(0.012 – 0.091)	0.036	(-0.003 – 0.075)

Regression coefficients (β) represent difference in markers of microvascular dysfunction for every 1 standard deviation increase in blood pressure variability composite score. Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 3: model 2 + mean 24-hour systolic or diastolic blood pressure (where appropriate). Model 4: model 3 + body mass index, smoking behaviour, alcohol use, education level, total-to-high density lipoprotein cholesterol ratio, (individual classes of) antihypertensive medication, lipid-modifying medication. Abbreviations: CI, confidence interval; SD, standard deviation; OR, odds ratio.

Supplemental Table S7. Associations between systolic and diastolic blood pressure variability and measures of microvascular dysfunction, additionally adjusted for estimated glomerular filtration rate

Microvascular dysfunction	Model	Systolic blood pressure variability composite score, per SD		Diastolic blood pressure variability composite score, per SD	
		β	(95% CI)	β	(95% CI)
Cerebral small vessel disease features, per point n=1,822	1	0.045	(0.009 – 0.082)	0.048	(0.009 – 0.086)
	2	0.035	(0.001 – 0.071)	0.041	(0.003 – 0.079)
	3	0.021	(-0.017 – 0.059)	0.034	(-0.005 – 0.073)
	4	0.014	(-0.023 – 0.052)	0.027	(-0.011 – 0.066)
	5	0.014	(-0.024 – 0.052)	0.028	(-0.010 – 0.067)
Flicker light-induced arteriolar and venular dilation, per SD n=1,831	1	0.033	(-0.015 – 0.081)	0.019	(-0.031 – 0.070)
	2	0.020	(-0.028 – 0.069)	0.013	(-0.037 – 0.063)
	3	0.030	(-0.021 – 0.080)	0.026	(-0.024 – 0.077)
	4	0.031	(-0.020 – 0.082)	0.025	(-0.026 – 0.076)
	5	0.031	(-0.020 – 0.082)	0.025	(-0.026 – 0.076)
Urinary albumin excretion, ratio increase n=2,724	1	1.14	(1.10 – 1.18)	1.13	(1.09 – 1.17)
	2	1.10	(1.07 – 1.14)	1.10	(1.07 – 1.15)
	3	1.05	(1.01 – 1.09)	1.09	(1.05 – 1.13)
	4	1.04	(1.00 – 1.08)	1.07	(1.03 – 1.11)
	5	1.04	(1.00 – 1.08)	1.07	(1.03 – 1.11)
Skin hyperaemia, per SD n=1,309	1	0.028	(-0.028 – 0.085)	0.006	(-0.051 – 0.064)
	2	0.007	(-0.050 – 0.064)	-0.009	(-0.067 – 0.048)
	3	-0.000	(-0.060 – 0.059)	-0.007	(-0.065 – 0.051)
	4	0.007	(-0.053 – 0.066)	-0.003	(-0.061 – 0.055)
	5	0.007	(-0.053 – 0.066)	-0.003	(-0.061 – 0.055)
Plasma biomarkers of microvascular dysfunction, per SD n=2,720	1	0.090	(0.053 – 0.127)	0.083	(0.044 – 0.121)
	2	0.053	(0.016 – 0.089)	0.055	(0.018 – 0.092)
	3	0.057	(0.019 – 0.095)	0.056	(0.019 – 0.094)
	4	0.036	(-0.001 – 0.072)	0.024	(-0.013 – 0.060)
	5	0.037	(0.001 – 0.073)	0.025	(-0.010 – 0.061)

Regression coefficients (β) represent difference in microvascular dysfunction measures per standard deviation, for every 1 standard deviation increase in blood pressure variability composite score. For cerebral small vessel disease features, β 's are expressed per point; for urinary albumin excretion, β 's are expressed as ratio increase. Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 3: model 2 + mean 24-hour systolic or diastolic blood pressure (where appropriate). Model 4: model 3 + body mass index, smoking behaviour, alcohol use, education level, total-to-high density lipoprotein cholesterol ratio, (individual classes of) antihypertensive medication, lipid-modifying medication. Model 5: model 4 + estimated glomerular filtration rate. Abbreviations: CI, confidence interval; SD, standard deviation.

Supplemental Table S8. Associations between systolic and diastolic blood pressure variability and measures of microvascular dysfunction, additionally adjusted for prior cardiovascular disease

Microvascular dysfunction	Model	Systolic blood pressure variability composite score, per SD		Diastolic blood pressure variability composite score, per SD	
		β	(95% CI)	β	(95% CI)
Cerebral small vessel disease features, per point n=1,817	1	0.044	(0.008 – 0.080)	0.049	(0.011 – 0.088)
	2	0.034	(-0.002 – 0.070)	0.043	(0.005 – 0.081)
	3	0.020	(-0.018 – 0.058)	0.036	(-0.003 – 0.074)
	4	0.013	(-0.025 – 0.051)	0.030	(-0.009 – 0.069)
	5	0.012	(-0.026 – 0.050)	0.028	(-0.011 – 0.066)
Flicker light-induced arteriolar and venular dilation, per SD n=1,824	1	0.032	(-0.015 – 0.080)	0.019	(-0.032 – 0.069)
	2	0.020	(-0.028 – 0.068)	0.012	(-0.038 – 0.062)
	3	0.031	(-0.019 – 0.081)	0.026	(-0.025 – 0.076)
	4	0.030	(-0.020 – 0.081)	0.023	(-0.027 – 0.074)
	5	0.029	(-0.021 – 0.080)	0.023	(-0.028 – 0.074)
Urinary albumin excretion, ratio increase n=2,714	1	1.14	(1.07 – 1.15)	1.13	(1.06 – 1.14)
	2	1.11	(1.01 – 1.09)	1.10	(1.05 – 1.12)
	3	1.05	(1.00 – 1.08)	1.08	(1.03 – 1.10)
	4	1.04	(1.00 – 1.08)	1.07	(1.03 – 1.10)
	5	1.04	(1.09 – 1.17)	1.07	(1.03 – 1.10)
Skin hyperaemia, per SD n=1,306	1	0.022	(-0.034 – 0.079)	0.008	(-0.050 – 0.065)
	2	0.002	(-0.055 – 0.059)	-0.008	(-0.065 – 0.050)
	3	-0.004	(-0.064 – 0.056)	-0.004	(-0.062 – 0.054)
	4	0.002	(-0.057 – 0.062)	0.000	(-0.059 – 0.058)
	5	0.002	(-0.057 – 0.062)	0.000	(-0.059 – 0.058)
Plasma biomarkers of microvascular dysfunction, per SD n=2,691	1	0.092	(0.055 – 0.129)	0.081	(0.042 – 0.120)
	2	0.056	(0.019 – 0.092)	0.054	(0.016 – 0.092)
	3	0.061	(0.023 – 0.099)	0.056	(0.017 – 0.093)
	4	0.040	(0.003 – 0.077)	0.023	(-0.014 – 0.059)
	5	0.038	(0.001 – 0.075)	0.020	(-0.017 – 0.056)

Regression coefficients (β) represent difference in microvascular dysfunction measures per standard deviation, for every 1 standard deviation increase in blood pressure variability composite score. For cerebral small vessel disease features, β 's are expressed per point; for urinary albumin excretion, β 's are expressed as ratio increase. Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 3: model 2 + mean 24-hour systolic or diastolic blood pressure (where appropriate). Model 4: model 3 + body mass index, smoking behaviour, alcohol use, education level, total-to-high density lipoprotein cholesterol ratio, (individual classes of) antihypertensive medication, lipid-modifying medication. Model 5: model 4 + prior cardiovascular disease. Abbreviations: CI, confidence interval; SD, standard deviation.

Supplemental Table S9. Associations between systolic and diastolic blood pressure variability and measures of microvascular dysfunction, additionally adjusted for plasma biomarkers of low-grade inflammation

Microvascular dysfunction	Model	Systolic blood pressure variability composite score, per SD		Diastolic blood pressure variability composite score, per SD	
		β	(95% CI)	β	(95% CI)
Cerebral small vessel disease features, per point n=1,820	1	0.046	(0.010 – 0.083)	0.051	(0.012 – 0.090)
	2	0.036	(-0.001 – 0.072)	0.045	(0.007 – 0.083)
	3	0.021	(-0.017 – 0.059)	0.037	(-0.002 – 0.076)
	4	0.015	(-0.023 – 0.053)	0.031	(-0.008 – 0.070)
	5	0.015	(-0.023 – 0.053)	0.031	(-0.007 – 0.070)
Flicker light-induced arteriolar and venular dilation, per SD n=1,828	1	0.035	(-0.013 – 0.083)	0.019	(-0.031 – 0.069)
	2	0.023	(-0.026 – 0.071)	0.013	(-0.038 – 0.063)
	3	0.032	(-0.018 – 0.083)	0.026	(-0.025 – 0.077)
	4	0.034	(-0.017 – 0.085)	0.024	(-0.027 – 0.075)
	5	0.033	(-0.018 – 0.083)	0.025	(-0.026 – 0.076)
Urinary albumin excretion, ratio increase n=2,721	1	1.14	(1.10 - 1.18)	1.13	(1.09 - 1.17)
	2	1.10	(1.07 - 1.14)	1.10	(1.07 - 1.15)
	3	1.05	(1.01 - 1.09)	1.09	(1.05 - 1.13)
	4	1.04	(1.00 - 1.08)	1.07	(1.03 - 1.11)
	5	1.04	(1.00 - 1.08)	1.07	(1.03 - 1.11)
Skin hyperaemia, per SD n=1,307	1	0.025	(-0.031 – 0.082)	0.005	(-0.052 – 0.063)
	2	0.005	(-0.052 – 0.062)	-0.010	(-0.068 – 0.047)
	3	-0.002	(-0.061 – 0.058)	-0.007	(-0.066 – 0.051)
	4	0.005	(-0.054 – 0.065)	-0.004	(-0.062 – 0.054)
	5	0.002	(-0.054 – 0.065)	-0.004	(-0.062 – 0.054)
Plasma biomarkers of microvascular dysfunction, per SD n=2,726	1	0.089	(0.052 – 0.126)	0.082	(0.043 – 0.120)
	2	0.056	(0.015 – 0.088)	0.054	(0.017 – 0.092)
	3	0.057	(0.019 – 0.095)	0.056	(0.018 – 0.093)
	4	0.035	(-0.001 – 0.072)	0.023	(-0.013 – 0.060)
	5	0.033	(-0.002 – 0.069)	0.026	(-0.009 – 0.061)

Regression coefficients (β) represent difference in microvascular dysfunction measures per standard deviation, for every 1 standard deviation increase in blood pressure variability composite score. For cerebral small vessel disease features, β 's are expressed per point; for urinary albumin excretion, β 's are expressed as ratio increase. Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 3: model 2 + mean 24-hour systolic or diastolic blood pressure (where appropriate). Model 4: model 3 + body mass index, smoking behaviour, alcohol use, education level, total-to-high density lipoprotein cholesterol ratio, (individual classes of) antihypertensive medication, lipid-modifying medication. Model 5: model 4 + composite score of plasma biomarkers of low-grade inflammation. Abbreviations: CI, confidence interval; SD, standard deviation; OR, odds ratio.

Supplemental Table S10. Associations between systolic and diastolic blood pressure variability and measures of microvascular dysfunction, additionally adjusted for carotid-femoral pulse wave velocity

Microvascular dysfunction	Model	Systolic blood pressure variability composite score, per SD		Diastolic blood pressure variability composite score, per SD	
		β	(95% CI)	β	(95% CI)
Cerebral small vessel disease features, per point n=1552	1	0.053	(0.013; 0.092)	0.048	(0.006; 0.089)
	2	0.043	(0.004; 0.082)	0.041	(0.001; 0.082)
	3	0.032	(-0.009; 0.072)	0.031	(-0.010; 0.073)
	4	0.021	(-0.020; 0.061)	0.022	(-0.020; 0.063)
	5	0.018	(-0.023; 0.059)	0.022	(-0.020; 0.063)
Flicker light-induced retinal arteriolar and venular dilation, per SD n=1,519	1	0.013	(-0.039; 0.065)	0.020	(-0.035; 0.074)
	2	0.002	(-0.05; 0.055)	0.013	(-0.041; 0.068)
	3	0.015	(-0.040; 0.070)	0.027	(-0.028; 0.082)
	4	0.013	(-0.042; 0.069)	0.023	(-0.032; 0.079)
	5	0.013	(-0.042; 0.069)	0.024	(-0.031; 0.079)
Urinary albumin excretion, ratio increase n=2,335	1	1.13	(1.09 - 1.17)	1.12	(1.08 - 1.16)
	2	1.10	(1.06 - 1.14)	1.10	(1.06 - 1.14)
	3	1.05	(1.01 - 1.09)	1.08	(1.04 - 1.13)
	4	1.04	(1.00 - 1.08)	1.07	(1.03 - 1.11)
	5	1.04	(1.00 - 1.08)	1.07	(1.03 - 1.11)
Skin hyperaemia, per SD n=1,142	1	0.047	(-0.014; 0.109)	0.024	(-0.037; 0.086)
	2	0.025	(-0.037; 0.087)	0.007	(-0.054; 0.069)
	3	0.019	(-0.046; 0.084)	0.011	(-0.052; 0.073)
	4	0.030	(-0.036; 0.095)	0.017	(-0.046; 0.080)
	5	0.030	(-0.035; 0.095)	0.017	(-0.046; 0.080)
Plasma biomarkers of microvascular dysfunction, per SD n=2,313	1	0.072	(0.032; 0.112)	0.083	(0.043; 0.124)
	2	0.038	(-0.001; 0.077)	0.059	(0.020; 0.098)
	3	0.045	(0.005; 0.086)	0.060	(0.021; 0.100)
	4	0.029	(-0.010; 0.068)	0.031	(-0.007; 0.069)
	5	0.028	(-0.011; 0.067)	0.031	(-0.007; 0.069)

Regression coefficients (β) represent difference in microvascular dysfunction measures per standard deviation, for every 1 standard deviation increase in blood pressure variability composite score. For cerebral small vessel disease features, β 's are expressed per point; for urinary albumin excretion, β 's are expressed as ratio increase. Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 3: model 2 + mean 24-hour systolic or diastolic blood pressure (where appropriate). Model 4: model 3 + body mass index, smoking behaviour, alcohol use, education level, total-to-high density lipoprotein cholesterol ratio, (individual classes of) antihypertensive medication, lipid-modifying medication. Model 5: model 4 + carotid-femoral pulse wave velocity. Abbreviations: BPV, blood pressure variability; CI, confidence interval; SD, standard deviation; OR, odds ratio.

Supplemental Table S11. Associations between systolic and diastolic blood pressure variability and measures of microvascular dysfunction, additionally adjusted for diet score

Microvascular dysfunction	Model	Systolic blood pressure variability composite score, per SD		Diastolic blood pressure variability composite score, per SD	
		β	(95% CI)	β	(95% CI)
Cerebral small vessel disease features, per point n=1,748	1	0.050	(0.013; 0.087)	0.048	(0.009; 0.088)
	2	0.040	(0.003; 0.076)	0.042	(0.003; 0.081)
	3	0.026	(-0.013; 0.064)	0.034	(-0.006; 0.074)
	4	0.021	(-0.017; 0.060)	0.030	(-0.009; 0.069)
	5	0.021	(-0.017; 0.060)	0.030	(-0.009; 0.069)
Flicker light-induced retinal arteriolar and venular dilation, per SD n=1,758	1	0.033	(-0.017; 0.082)	0.014	(-0.038; 0.065)
	2	0.021	(-0.029; 0.070)	0.008	(-0.044; 0.059)
	3	0.029	(-0.022; 0.081)	0.021	(-0.031; 0.073)
	4	0.032	(-0.021; 0.084)	0.021	(-0.032; 0.073)
	5	0.032	(-0.021; 0.084)	0.021	(-0.032; 0.073)
Urinary albumin excretion, ratio increase n=2,602	1	1.14	(1.09 - 1.18)	1.12	(1.08 - 1.17)
	2	1.10	(1.07 - 1.15)	1.10	(1.06 - 1.14)
	3	1.05	(1.01 - 1.09)	1.08	(1.04 - 1.12)
	4	1.04	(1.00 - 1.08)	1.06	(1.03 - 1.10)
	5	1.04	(1.00 - 1.08)	1.06	(1.03 - 1.10)
Skin hyperaemia, per SD n=1,249	1	0.040	(-0.018; 0.098)	0.019	(-0.039; 0.078)
	2	0.019	(-0.039; 0.078)	0.004	(-0.054; 0.063)
	3	0.014	(-0.047; 0.075)	0.008	(-0.051; 0.067)
	4	0.018	(-0.043; 0.079)	0.009	(-0.050; 0.068)
	5	0.018	(-0.043; 0.08)	0.010	(-0.050; 0.069)
Plasma biomarkers of microvascular dysfunction, per SD n=2,575	1	0.090	(0.051; 0.128)	0.081	(0.041; 0.121)
	2	0.052	(0.014; 0.089)	0.055	(0.016; 0.094)
	3	0.057	(0.018; 0.097)	0.057	(0.018; 0.096)
	4	0.036	(-0.002; 0.074)	0.025	(-0.013; 0.062)
	5	0.036	(-0.002; 0.074)	0.025	(-0.013; 0.063)

Regression coefficients (β) represent difference in microvascular dysfunction measures per standard deviation, for every 1 standard deviation increase in blood pressure variability composite score. For cerebral small vessel disease features, β 's are expressed per point; for urinary albumin excretion, β 's are expressed as ratio increase. Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 3: model 2 + mean 24-hour systolic or diastolic blood pressure (where appropriate). Model 4: model 3 + body mass index, smoking behaviour, alcohol use, education level, total-to-high density lipoprotein cholesterol ratio, (individual classes of) antihypertensive medication, lipid-modifying medication. Model 5: model 4 + diet score. Abbreviations: CI, confidence interval; SD, standard deviation .

Supplemental Table S12. Associations between systolic and diastolic blood pressure variability and measures of microvascular dysfunction, additionally adjusted for physical activity

Microvascular dysfunction	Model	Systolic blood pressure variability composite score, per SD		Diastolic blood pressure variability composite score, per SD	
		β	(95% CI)	β	(95% CI)
Cerebral small vessel disease features, per point n=1,651	1	0.048	(0.010; 0.086)	0.042	(0.000; 0.083)
	2	0.039	(0.001; 0.077)	0.036	(-0.005; 0.076)
	3	0.023	(-0.016; 0.063)	0.027	(-0.015; 0.068)
	4	0.017	(-0.023; 0.056)	0.021	(-0.020; 0.062)
	5	0.016	(-0.023; 0.056)	0.021	(-0.020; 0.062)
Flicker light-induced retinal arteriolar and venular dilation, per SD n=1,657	1	0.029	(-0.021; 0.079)	0.014	(-0.040; 0.068)
	2	0.017	(-0.034; 0.067)	0.006	(-0.048; 0.060)
	3	0.025	(-0.028; 0.077)	0.020	(-0.035; 0.074)
	4	0.023	(-0.030; 0.076)	0.017	(-0.038; 0.072)
	5	0.023	(-0.030; 0.076)	0.017	(-0.038; 0.072)
Urinary albumin excretion, ratio increase n=2,437	1	1.14	(1.10 - 1.19)	1.13	(1.08 - 1.17)
	2	1.11	(1.07 - 1.16)	1.10	(1.06 - 1.15)
	3	1.05	(1.01 - 1.10)	1.08	(1.04 - 1.12)
	4	1.04	(1.00 - 1.08)	1.06	(1.02 - 1.11)
	5	1.04	(1.00 - 1.08)	1.06	(1.02 - 1.11)
Skin hyperaemia, per SD n=1,180	1	0.036	(-0.024; 0.097)	0.014	(-0.048; 0.076)
	2	0.017	(-0.044; 0.078)	-0.001	(-0.063; 0.061)
	3	0.011	(-0.053; 0.075)	0.004	(-0.059; 0.067)
	4	0.020	(-0.044; 0.084)	0.006	(-0.057; 0.070)
	5	0.019	(-0.045; 0.083)	0.006	(-0.058; 0.069)
Plasma biomarkers of microvascular dysfunction, per SD n=2,411	1	0.089	(0.050; 0.128)	0.073	(0.032; 0.115)
	2	0.055	(0.016; 0.093)	0.048	(0.008; 0.088)
	3	0.056	(0.016; 0.096)	0.046	(0.006; 0.087)
	4	0.036	(-0.002; 0.075)	0.016	(-0.023; 0.055)
	5	0.037	(-0.002; 0.076)	0.017	(-0.022; 0.057)

Regression coefficients (β) represent difference in microvascular dysfunction measures per standard deviation, for every 1 standard deviation increase in blood pressure variability composite score. For cerebral small vessel disease features, β 's are expressed per point; for urinary albumin excretion, β 's are expressed as ratio increase. Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 3: model 2 + mean 24-hour systolic or diastolic blood pressure (where appropriate). Model 4: model 3 + body mass index, smoking behaviour, alcohol use, education level, total-to-high density lipoprotein cholesterol ratio, (individual classes of) antihypertensive medication, lipid-modifying medication. Model 5: model 4 + physical activity. Abbreviations: CI, confidence interval; SD, standard deviation.

Supplemental table S13. Associations between systolic and diastolic blood pressure variability and measures of microvascular dysfunction, additionally adjusted for income level

Microvascular dysfunction	Model	Systolic blood pressure variability composite score, per SD		Diastolic blood pressure variability composite score, per SD	
		β	(95% CI)	β	(95% CI)
Cerebral small vessel disease features, per point n=1,445	1	0.054	(0.014; 0.095)	0.048	(0.005; 0.091)
	2	0.042	(0.003; 0.082)	0.038	(-0.004; 0.081)
	3	0.026	(-0.015; 0.068)	0.031	(-0.011; 0.074)
	4	0.026	(-0.016; 0.068)	0.031	(-0.012; 0.074)
Flicker light-induced retinal arteriolar and venular dilation, per SD n=1,439	1	0.017	(-0.037; 0.071)	0.006	(-0.052; 0.065)
	2	0.005	(-0.049; 0.060)	-0.002	(-0.061; 0.056)
	3	0.011	(-0.045; 0.068)	0.010	(-0.05; 0.069)
	4	0.017	(-0.040; 0.075)	0.010	(-0.05; 0.07)
Urinary albumin excretion, ratio increase n=2,121	1	1.14	(1.10 - 1.19)	1.13	(1.08 - 1.17)
	2	1.11	(1.06 - 1.15)	1.10	(1.05 - 1.14)
	3	1.05	(1.01 - 1.10)	1.08	(1.03 - 1.12)
	4	1.05	(1.01 - 1.09)	1.06	(1.02 - 1.11)
Skin hyperaemia, per SD n=1,017	1	0.031	(-0.030; 0.092)	0.027	(-0.037; 0.091)
	2	0.014	(-0.048; 0.077)	0.012	(-0.052; 0.077)
	3	0.006	(-0.059; 0.071)	0.015	(-0.050; 0.080)
	4	0.011	(-0.054; 0.077)	0.021	(-0.045; 0.087)
Plasma biomarkers of microvascular dysfunction, per SD n=2,097	1	0.094	(0.052; 0.137)	0.087	(0.042; 0.131)
	2	0.058	(0.016; 0.099)	0.057	(0.014; 0.100)
	3	0.067	(0.023; 0.110)	0.058	(0.014; 0.102)
	4	0.048	(0.006; 0.090)	0.025	(-0.018; 0.067)

Regression coefficients (β) represent difference in microvascular dysfunction measures per standard deviation, for every 1 standard deviation increase in blood pressure variability composite score. For cerebral small vessel disease features, β 's are expressed per point; for urinary albumin excretion, β 's are expressed as ratio increase. Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 3: model 2 + mean 24-hour systolic or diastolic blood pressure (where appropriate). Model 4: model 3 + body mass index, smoking behaviour, alcohol use, education level, total-to-high density lipoprotein cholesterol ratio, (individual classes of) antihypertensive medication, lipid-modifying medication. Model 5: model 4 + income level. Abbreviations: CI, confidence interval; SD, standard deviation.

Supplemental table S14. Associations between systolic and diastolic blood pressure variability and measures of microvascular dysfunction, additionally adjusted for occupation status

Microvascular dysfunction	Model	Systolic blood pressure variability composite score, per SD		Diastolic blood pressure variability composite score, per SD	
		β	(95% CI)	β	(95% CI)
Cerebral small vessel disease features, per point n=1,568	1	0.037	(-0.002; 0.077)	0.050	(0.008; 0.091)
	2	0.025	(-0.014; 0.064)	0.040	(-0.001; 0.081)
	3	0.012	(-0.030; 0.053)	0.034	(-0.007; 0.075)
	4	0.007	(-0.035; 0.048)	0.029	(-0.013; 0.070)
Flicker light-induced retinal arteriolar and venular dilation, per SD n=1,552	1	0.038	(-0.016; 0.091)	0.025	(-0.031; 0.080)
	2	0.024	(-0.029; 0.078)	0.017	(-0.038; 0.073)
	3	0.031	(-0.026; 0.087)	0.030	(-0.026; 0.086)
	4	0.033	(-0.024; 0.090)	0.030	(-0.027; 0.086)
Urinary albumin excretion, ratio increase n=2,302	1	1.15	(1.11 - 1.20)	1.14	(1.09 - 1.18)
	2	1.12	(1.07 - 1.16)	1.11	(1.07 - 1.16)
	3	1.06	(1.02 - 1.10)	1.09	(1.05 - 1.14)
	4	1.06	(1.01 - 1.10)	1.08	(1.04 - 1.12)
Skin hyperaemia, per SD n=1,113	1	0.068	(0.007; 0.128)	0.048	(-0.013; 0.110)
	2	0.046	(-0.016; 0.107)	0.031	(-0.031; 0.093)
	3	0.041	(-0.023; 0.105)	0.032	(-0.031; 0.094)
	4	0.044	(-0.021; 0.108)	0.028	(-0.035; 0.091)
Plasma biomarkers of microvascular dysfunction, per SD n=2,284	1	0.099	(0.058; 0.141)	0.087	(0.043; 0.130)
	2	0.058	(0.017; 0.098)	0.057	(0.015; 0.098)
	3	0.064	(0.022; 0.107)	0.057	(0.015; 0.099)
	4	0.042	(0.001; 0.083)	0.028	(-0.014; 0.069)

Regression coefficients (β) represent difference in microvascular dysfunction measures per standard deviation, for every 1 standard deviation increase in blood pressure variability composite score. For cerebral small vessel disease features, β 's are expressed per point; for urinary albumin excretion, β 's are expressed as ratio increase. Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 3: model 2 + mean 24-hour systolic or diastolic blood pressure (where appropriate). Model 4: model 3 + body mass index, smoking behaviour, alcohol use, education level, total-to-high density lipoprotein cholesterol ratio, (individual classes of) antihypertensive medication, lipid-modifying medication. Model 5: model 4 + occupation status. Abbreviations: CI, confidence interval; SD, standard deviation.

Supplemental Table S15. Associations between systolic and diastolic blood pressure variability and urinary albumin excretion as a categorical variable

Microvascular dysfunction	Model	Systolic blood pressure variability composite score, per SD		Diastolic blood pressure variability composite score, per SD	
		OR	(95% CI)	OR	(95% CI)
Urinary albumin excretion, ≥ 30 mg/24h vs. <30 mg/24h n=2,748	1	1.39	(1.22 – 1.59)	1.32	(1.16 – 1.50)
	2	1.30	(1.14 – 1.49)	1.25	(1.10 – 1.43)
	3	1.19	(1.03 – 1.38)	1.20	(1.05 – 1.38)
	4	1.19	(1.02 – 1.38)	1.19	(1.02 – 1.37)

Regression coefficients (β) represent odds ratio of ≥ 30 mg/24h urinary albumin excretion per 1 SD increase in blood pressure variability composite score. Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 3: model 2 + mean 24-hour systolic or diastolic blood pressure (where appropriate). Model 4: model 3 + body mass index, smoking behaviour, alcohol use, education level, total-to-high density lipoprotein cholesterol ratio, (individual classes of) antihypertensive medication, lipid-modifying medication. Abbreviations: BPV, blood pressure variability; CI, confidence interval; OR, odds ratio.

Supplemental Table S16. Associations between systolic and diastolic blood pressure variability and estimated glomerular filtration rate

Estimated glomerular filtration rate	Model	Systolic blood pressure variability composite score, per SD		Diastolic blood pressure variability composite score, per SD	
		β	(95% CI)	β	(95% CI)
Lower estimated glomerular filtration rate, per SD n=2,748	1	0.007	(-0.026 - 0.041)	0.026	(-0.008 - 0.060)
	2	0.002	(-0.032 - 0.035)	0.022	(-0.012 - 0.057)
	3	0.017	(-0.018 - 0.053)	0.026	(-0.008 - 0.061)
	4	-0.004	(-0.038 - 0.030)	-0.006	(-0.040 - 0.028)
Estimated glomerular filtration rate, ≥ 60 vs. <60 ml/min/1.73m ² , odds ratio n=2,748	Model	OR	(95%CI)	OR	(95%CI)
	1	1.135	(0.947 - 1.36)	1.173	(0.984 - 1.397)
	2	1.055	(0.874 - 1.274)	1.103	(0.923 - 1.318)
	3	1.098	(0.906 - 1.332)	1.142	(0.957 - 1.363)
	4	1.042	(0.842 - 1.29)	1.021	(0.842 - 1.239)

Regression coefficients (β) represent standard deviation lower estimated glomerular filtration rate, and odds ratio for ≥ 60 vs. <60 ml/min/1.73m² estimated glomerular filtration rate, for every 1 SD increase in blood pressure variability composite score. Model 1: age, sex. Model 2: model 1 + glucose metabolism status. Model 3: model 2 + mean 24-hour systolic or diastolic blood pressure (where appropriate). Model 4: model 3 + body mass index, smoking behaviour, alcohol use, education level, total-to-high density lipoprotein cholesterol ratio, (individual classes of) antihypertensive medication, lipid-modifying medication. Abbreviations: CI, confidence interval; SD, standard deviation.

7

CHAPTER 7

General discussion

General discussion

The microvasculature (i.e., the vascular meshwork comprised of arterioles, capillaries and venules) provides local blood perfusion, blood-tissue diffusion and haemostatic balance¹ needed for nutrient distribution and waste product collection in tissues. Deterioration of the microvasculature (i.e., microvascular dysfunction) is emerging as a possible factor in adverse cerebral outcome, such as dementia, late-life depression and stroke.²⁻⁶ With the ageing of the population⁷ and the increasing amount of individuals with a high burden of cardiovascular risk factors,⁸ the identification of possible contributors to the development of adverse cerebral outcomes is needed.⁵ Several possible risk factors for microvascular dysfunction have thus far been identified, such as arterial stiffening,⁹ type 2 diabetes,^{10, 11} hypertension, ageing and obesity.⁴ However, other determinants of microvascular dysfunction may be present, and the mechanisms by which microvascular dysfunction may lead to adverse cerebral outcome remains poorly understood.

In this thesis, we evaluated the causes of microvascular dysfunction and investigated whether microvascular dysfunction is associated with adverse cerebral outcomes (i.e., dementia, late-life depression and stroke). In addition, we evaluated whether microvascular dysfunction mediates the pathways between cardiovascular risk factors and adverse cerebral outcome. In this thesis, we had several key findings, which we will discuss in this chapter. The key findings are:

1. Microvascular dysfunction is associated with dementia, late-life depression, stroke and all-cause mortality.
2. Cerebral small vessel disease features additively increase stroke risk.
3. Microvascular dysfunction is implicated in the pathway between arterial stiffness and type 2 diabetes, and adverse cerebral outcome.
4. Greater blood pressure variability is associated with albuminuria.
5. In addition, we will propose a pathophysiological model that links these findings, and we will discuss several methodological considerations that apply to the findings of this thesis. Finally, we will discuss the clinical implications of the findings in this thesis and propose recommendations for future studies.

Key findings

Microvascular dysfunction is associated with dementia, late-life depression, stroke and all-cause mortality

In chapter two of this thesis, we tested the hypothesis that cerebral microvascular dysfunction is associated with incident adverse cerebral outcome.^{1, 2, 5} For this, we conducted a systematic review and meta-analysis on the association between cerebral small vessel disease and incident dementia, late-life depression and stroke, and all-cause mortality. We found a strong and consistent association between various cerebral small vessel disease features and these adverse cerebral outcomes during follow-up. Presence of cerebral small vessel disease increases the risk of adverse outcome with a degree similar to that of presence of type 2 diabetes¹²⁻¹⁵ or hypertension.¹⁶⁻²⁰ These findings imply that the cerebral microvasculature is important for optimal organ function, at least in cerebral tissue. The longitudinal design of the analysis sheds light on the temporality of the associations; if these associations are causal, cerebral small vessel disease is implicated in the pathophysiological processes that later lead to adverse cerebral outcome.

In addition, it has been hypothesised that measures of generalised microvascular dysfunction also reflect microvascular dysfunction in cerebral tissue and that this is associated with adverse cerebral outcome. In accordance, previous studies have shown that measures of generalised microvascular dysfunction (i.e., albuminuria²¹ and plasma biomarkers of microvascular dysfunction)²²⁻²⁵ are associated with worse cognitive performance. To further test this hypothesis, we investigated, in chapter four, whether a composite score of microvascular dysfunction measures (i.e., cerebral small vessel disease features, flicker light-induced retinal arteriolar and venular dilation response, albuminuria, plasma biomarkers of microvascular dysfunction and heat-induced skin hyperaemia) was associated with worse cognitive performance. We found that this composite score was indeed associated with worse cognitive performance, even after excluding cerebral microvascular dysfunction (i.e., cerebral small vessel disease) from this score. These findings contribute to the hypothesis that generalised microvascular dysfunction reflects cerebral microvascular disease and is implicated in the pathophysiological process of adverse cerebral outcome.

Cerebral small vessel disease features additively increase stroke risk

In chapter two, we showed that the combination of two cerebral small vessel disease features was more strongly associated with incident stroke than individual features. The existence of additive effects among cerebral small vessel disease features implies that a dose-response relationship may be present between cerebral small vessel disease severity and adverse cerebral outcome. From a clinical point of view, this finding may be important, because it may help better predict disease course and identify patients at risk for adverse cerebral outcome. This suggests that imaging scales that integrate multiple cerebral small vessel disease features²⁶ are most suitable to assess cerebral small vessel disease and most likely to enable improved risk prediction of clinical outcomes beyond established risk factors.

Microvascular dysfunction is implicated in the pathway between arterial stiffness and type 2 diabetes, and adverse cerebral outcome

Several cardiovascular risk factors are associated with adverse cerebral outcome, and this association may be mediated by microvascular dysfunction.^{11,27-29} In chapter three and five, we therefore investigated whether microvascular dysfunction mediates the associations between arterial stiffness and type 2 diabetes, and adverse cerebral outcome.

Greater arterial stiffness leads to excessive pressure and flow pulsatility, which may transmit distally and damage the microcirculation.^{27,28} Previous studies^{9,30-43} have shown an association between greater arterial stiffness and measures of adverse cerebral outcomes (i.e., cognitive decline and incident dementia). In chapter five, we investigated the associations between arterial stiffness (measured as aortic stiffness and carotid stiffness) and worse cognitive performance, and whether any such associations were mediated by a composite score of various microvascular dysfunction measures. Aortic stiffness, but not carotid stiffness, was associated with worse cognitive performance, and this association was mediated, in part, by a composite score of microvascular dysfunction. Although aortic stiffness (i.e., higher carotid-femoral pulse wave velocity) and carotid stiffness (i.e., higher carotid distensibility coefficient) reflect, at least partly, a similar process of arterial stiffening,⁴⁴ aortic stiffness may be a more precise reflection.^{44,45} Accordingly, aortic stiffness may be more strongly associated with microvascular dysfunction and worse cognitive performance.

Type 2 diabetes is associated with hyperglycaemia, impaired insulin-dependent arteriolar dilation, advanced glycation, excessive oxidative stress and epigenetic changes, which may damage the microcirculation.^{11,29,46} In addition, type 2 diabetes is associated with a higher incidence of depressive symptoms.⁴⁷ However, no previous study has investigated whether the association between type 2 diabetes and depressive symptoms is mediated by microvascular dysfunction. In chapter 3, we showed, in a longitudinal study, that baseline type 2 diabetes is associated with greater change in depressive symptoms over time, and that this association was, in part, mediated by cerebral microvascular dysfunction (i.e., cerebral small vessel disease features).

From a clinical point of view, the finding that microvascular dysfunction mediates, in part, the association between classical cardiovascular risk factors and adverse cerebral outcome is important, as it identifies microvascular dysfunction as potential target for prevention of brain diseases in patients with cardiovascular risk factors. However, a significant portion of the associations between arterial stiffness and type 2 diabetes, and adverse cerebral outcome, was not mediated by microvascular dysfunction. This remaining association may be due to microvascular dysfunction that is not directly captured in our measures of microvascular dysfunction. For example, cerebral microvascular dysfunction measures such as microinfarctions, loss of white matter integrity and lower cerebral blood flow reactivity may contain additional information but were not available in this thesis. In addition, it is possible that only a subset of individuals with arterial stiffness or type 2 diabetes develop adverse cerebral outcome that are related to microvascular dysfunction. Worse cognitive performance in arterial stiffness may be related to macrovascular disease or A β deposition.⁴⁸ Additionally, depressive symptoms in type 2 diabetes may be related

to other mediators such as psychosocial factors,⁴⁷ diabetes-related comorbidities⁴⁷ and glucose neurotoxicity.⁴⁹

Greater blood pressure variability is associated with albuminuria

It has been hypothesised that greater blood pressure variability (i.e., greater fluctuations of blood pressure) is associated with microvascular dysfunction.^{50, 51} This association may be implicated in the pathway between arterial stiffness and type 2 diabetes, and microvascular dysfunction.^{52, 53} However, the association between blood pressure variability and microvascular dysfunction remains incompletely understood. In chapter six, we therefore investigated whether blood pressure variability (i.e., within-visit, 24-hour and 7-day blood pressure variability) is associated with microvascular dysfunction measures including brain (i.e., cerebral small vessel disease features), eye (i.e., flicker light-induced retinal arteriolar and venular dilation response), kidney (i.e., albuminuria), plasma biomarkers of microvascular dysfunction and skin measures (i.e., heat-induced skin hyperaemia). We hypothesised that the effect of greater blood pressure variability on microvascular dysfunction is stronger in organs with a low vascular impedance (i.e., brain, eyes and kidneys) and weaker in organs with a high vascular impedance (e.g., skin). In partial disagreement with this hypothesis, we found that greater very short- to mid-term blood pressure variability was associated with higher albuminuria but not with other measures of microvascular dysfunction tested. Kidney microvasculature has a lower impedance than the brain and eye microvasculature; e.g., blood flow to the kidneys relative to organ weight (360 ml/min/100 g) is higher than to the brain (50 ml/min/100 g brain).⁵⁴ Therefore, the kidney microvasculature may be comparatively more vulnerable to the detrimental effects of blood pressure variability.

Microvascular dysfunction and brain diseases: mechanisms

The findings of this thesis may be summarized into the following pathophysiological model (see Figure 7.1). Microvascular dysfunction is associated with a marked increase in adverse cerebral outcome, irrespective of whether microvascular dysfunction is located in brain tissue or in other organs; these measures appear to reflect overlapping changes that hamper brain tissue function. In addition, type 2 diabetes and arterial stiffness are associated with adverse cerebral outcome, and microvascular dysfunction is at least partly implicated in this pathway. Blood pressure variability may, at least in the kidney, lead to microvascular dysfunction. Microvascular dysfunction may lead to adverse cerebral outcome through multiple pathways, including impaired cerebral perfusion, impaired neurogenesis, impaired neurovascular coupling, impaired blood-brain barrier permeability, impaired haemostatic regulation and impaired cerebral autoregulation, which eventually causes ischaemia and neuronal dysfunction.⁵⁵

Figure 7.1. Potential pathways for causes and consequences of microvascular dysfunction.

Methodological considerations

There are several methodological aspects of this thesis that need to be taken into consideration when interpreting the results. First, this thesis includes a collection of observational cohort studies, and data in these studies are subject to biases such as confounding bias, overadjustment bias and reverse causation. Second, in this thesis, composite scores are often used to summarize measures of the same (patho)physiological construct. The construction of composite scores is based on certain assumptions, and these need to be taken into consideration when interpreting the results.

Confounding bias

Confounding bias arises when an observed association between an exposure variable and an outcome variable is erroneously assumed to be direct, although in reality, they are both separately associated with another variable (i.e., a 'confounder factor').⁵⁶ Changes (or variation) in a confounding factor are reflected in both the exposure variable and the

outcome variable, which creates statistical dependence between the two (illustrated in Figure 7.2). Alternatively, the exposure variable may influence the confounding factor (and thus the outcome variable) via a mechanism that is unrelated to the causal pathway of interest.

Due to the non-randomized nature of observational studies, confounder bias has an important influence on the validity of the results. However, all analysis with observational studies in this thesis are adjusted for a large set of possible confounding factors, which helps reduce this bias. Nevertheless, residual confounding remains possible due to or an unknown or unmeasured factor or due to complex factor interaction.

Figure 7.2. A confounding factor is associated with both the exposure variable and the outcome variable (solid lines). An erroneous direct association between the exposure variable and the outcome variable may be assumed (dashed line).

Overadjustment bias

Adjustment for a large set of variables may, on the one hand, help reduce confounding bias, but may, on the other hand, induce overadjustment bias. Overadjustment bias occurs when the adjustment variable mediates the causal pathway of interest between the exposure variable and the outcome variable (illustrated in Figure 7.3). Some of the potential confounding factors that were adjusted for in this thesis may also, in part, mediate the association between the exposure variables and the outcome variables. For example, the association between microvascular dysfunction and cognitive function may be confounded by type 2 diabetes but also be mediated.^{3, 11, 57} In general, adjustment for these factors will (partly) mask the observed association between the exposure variable and the outcome variable.⁵⁸

In addition to overadjustment by a mediating factor, overadjustment bias may occur when the adjusted factor is a proxy of the exposure variable or outcome variable, and is measured with greater precision (illustrated in Figure 7.3). Because this proxy variable

reflects one of the variable, it may account for part of the covariation that is attributable to the exposure variable and the outcome variable.⁵⁸

The effect of overadjustment bias needs to be taken into consideration when interpreting the results of this thesis. The possible adjustment for mediating factors may have led to an underestimation of the strength of the associations in this thesis. However, when overadjustment bias risk was present, these variables were often added to separate models, and its results were interpreted with caution.

Figure 7.3. A mediating factor is associated with the exposure variable, and subsequently influences the outcome variable (solid lines). A proxy variable reflects the exposure variable or the outcome variable with higher precision. Adjustment for the mediating factor or proxy variable will mask the observed association between the exposure variable and outcome variable (dashed line).

Reverse causation

Most of the analyses in this thesis are based on cross-sectional data, making it difficult to ascertain the temporality of the relationship between the exposure variable and the outcome variable.⁵⁹ In other words, for causal inference, it is important to know which of the variables changes before the other. With cross-sectional measurements, it is not possible to discern the temporal relationship from the data, and any interpretation regarding causation should thus be done carefully. However, in chapter two and three, we established longitudinal relationships between cerebral small vessel disease and dementia, late-life depression, stroke and all-cause mortality. From this, the argument can be made that the associations found in chapter four and five follow the same temporal relation. Nevertheless, even when temporality has been established, it is not possible to discern correlation from causation in observational studies.⁶⁰ To discern correlation from causation, interventional studies are needed.

Composite scores

A composite score is used to organize multiple correlated variables into more meaningful, conceptual information. By grouping together multiple measures of the same construct, the influence of the biological variability of its components is reduced. Furthermore, when a single composite score is used instead of all its components separately, it reduces the chance of a type 1 error. Substantial conceptual or statistical overlap among the components of the composite score must be present.⁶¹ In this thesis, we often constructed composite scores for microvascular dysfunction and for cognitive function, based on prior evidence that all measures used for the composite scores reflect microvascular

dysfunction^{1-3, 5, 10, 57, 62, 63} or cognitive function.⁶⁴⁻⁶⁷ Nevertheless, these components may vary in relationship strength with the outside variables (e.g., outcome variables) and may reflect slightly varying underlying pathophysiological processes, which influences statistical power and interpretability of the composite scores. Therefore, these factors should be taken into consideration when interpreting the results. In this thesis, robustness of composite scores that were not yet established in literature was tested by individually excluding components of the composite scores.

Clinical implications and recommendations for future studies

The present thesis contributes to increasing evidence that microvascular dysfunction contributes to adverse cerebral outcome. In addition, this thesis shows that individuals with cerebral microvascular dysfunction (i.e., the presence of cerebral small vessel disease features) are at high risk of developing dementia, late-life depression, stroke and mortality; a risk similar to that of individuals with type 2 diabetes¹²⁻¹⁵ or hypertension.¹⁶⁻²⁰ The presence of microvascular dysfunction should be recognized as a prognostic factor for adverse cerebral outcome and should prompt work-up and treatment of relevant risk factors, including type 2 diabetes, hypertension and hypercholesterolaemia. Additionally, hospital-admitted patients with microvascular dysfunction may be at a higher risk of low tissue oxygenation in the presence of dehydration and poor saturation and may correspondingly benefit from fluid supplementation and oxygen therapy.¹

Provided that the associations described in this thesis are causal, microvascular dysfunction might be an important target for prevention strategies of adverse cerebral outcome. However, effective evidence for treatment of microvascular dysfunction is presently lacking. Trials are therefore needed that target suspected mechanisms of microvascular dysfunction, including capillary rarefaction, glycocalyx degeneration, impaired capillary flow regulation, impaired arteriolar and venular dilation response, blood-brain barrier dysfunction, increased inflammatory response and procoagulant activation.^{1, 3, 55} Recent research suggests that lifestyle modifications, such as weight loss and exercise, may, at least in part, favorably influence microvascular function.¹¹ In addition, drugs such as renin-angiotensin-aldosterone system inhibitors, antihyperglycemic agents (i.e., metformin and glucagon-like peptide 1 receptor [GLP-1R] agonists) and statins may improve microvascular function,^{11, 68, 69} possibly beyond their blood pressure- or glucose-lowering effects.^{11, 68} However, only one previous study^{70, 71} found that inhibiting the progression of microvascular dysfunction correlated with reduced occurrence of cognitive decline and stroke, whereas others^{72, 73} did not. Future longitudinal studies are needed to further evaluate the association between microvascular dysfunction and adverse cerebral outcome, and the effect of microvascular dysfunction treatment.

1. Ostergaard L, Engedal TS, Moreton F, Hansen MB, Wardlaw JM, Dalkara T, Markus HS and Muir KW. Cerebral small vessel disease: Capillary pathways to stroke and cognitive decline. *J Cereb Blood Flow Metab.* 2016;36:302-25.
2. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge R, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M and nEuroimaging STfRVco. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol.* 2013;12:822-38.
3. Muris DM, Houben AJ, Schram MT and Stehouwer CD. Microvascular dysfunction: an emerging pathway in the pathogenesis of obesity-related insulin resistance. *Rev Endocr Metab Disord.* 2013;14:29-38.
4. Houben A, Martens RJH and Stehouwer CDA. Assessing Microvascular Function in Humans from a Chronic Disease Perspective. *J Am Soc Nephrol.* 2017;28:3461-3472.
5. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. *Lancet Neurol.* 2010;9:689-701.
6. Wardlaw JM, Smith C and Dichgans M. Small vessel disease: mechanisms and clinical implications. *Lancet Neurol.* 2019;18:684-696.
7. Christensen K, Doblhammer G, Rau R and Vaupel JW. Ageing populations: the challenges ahead. *Lancet.* 2009;374:1196-208.
8. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. *Curr Hypertens Rep.* 2018;20:12.
9. van Sloten TT, Protogerou AD, Henry RM, Schram MT, Launer LJ and Stehouwer CD. Association between arterial stiffness, cerebral small vessel disease and cognitive impairment: A systematic review and meta-analysis. *Neurosci Biobehav Rev.* 2015;53:121-30.
10. Umemura T, Kawamura T and Hotta N. Pathogenesis and neuroimaging of cerebral large and small vessel disease in type 2 diabetes: A possible link between cerebral and retinal microvascular abnormalities. *J Diabetes Investig.* 2017;8:134-148.
11. Stehouwer CDA. Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle With Widespread Consequences. *Diabetes.* 2018;67:1729-1741.
12. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams DE and Geiss L. Changes in diabetes-related complications in the United States, 1990-2010. *N Engl J Med.* 2014;370:1514-23.
13. Xu WL, Qiu CX, Wahlin A, Winblad B and Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. *Neurology.* 2004;63:1181-6.
14. Yu M, Zhang X, Lu F and Fang L. Depression and Risk for Diabetes: A Meta-Analysis. *Can J Diabetes.* 2015;39:266-72.
15. Gregg EW, Cheng YJ, Saydah S, Cowie C, Garfield S, Geiss L and Barker L. Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey. *Diabetes Care.* 2012;35:1252-7.
16. Imano H, Kitamura A, Sato S, Kiyama M, Ohira T, Yamagishi K, Noda H, Tanigawa T, Iso H and Shimamoto T. Trends for blood pressure and its contribution to stroke incidence in the middle-aged Japanese population: the Circulatory Risk in Communities Study (CIRCS). *Stroke.* 2009;40:1571-7.
17. Verdecchia P, Reboldi GP, Angeli F, Schillaci G, Schwartz JE, Pickering TG, Imai Y, Ohkubo T and Kario K. Short- and long-term incidence of stroke in white-coat hypertension. *Hypertension.* 2005;45:203-208.

18. Li G, Rhew IC, Shofer JB, Kukull WA, Breitner JC, Peskind E, Bowen JD, McCormick W, Teri L, Crane PK and Larson EB. Age-varying association between blood pressure and risk of dementia in those aged 65 and older: a community-based prospective cohort study. *J Am Geriatr Soc.* 2007;55:1161-7.
19. Sharp SI, Aarsland D, Day S, Sonnesyn H, Ballard C and Syst AsSVD. Hypertension is a potential risk factor for vascular dementia: systematic review. *Int J Geriatr Psychiatry.* 2011;26:661-669.
20. Barengo NC, Antikainen R, Kastarinen M, Laatikainen T and Tuomilehto J. The effects of control of systolic and diastolic hypertension on cardiovascular and all-cause mortality in a community-based population cohort. *J Hum Hypertens.* 2013;27:693-7.
21. Georgakis MK, Dimitriou NG, Karalexi MA, Mihas C, Nasothimiou EG, Tousoulis D, Tsivgoulis G and Petridou ET. Albuminuria in Association with Cognitive Function and Dementia: A Systematic Review and Meta-Analysis. *J Am Geriatr Soc.* 2017;65:1190-1198.
22. Heringa SM, van den Berg E, Reijmer YD, Nijpels G, Stehouwer CD, Schalkwijk CG, Teerlink T, Scheffer PG, van den Hurk K, Kappelle LJ, Dekker JM and Biessels GJ. Markers of low-grade inflammation and endothelial dysfunction are related to reduced information processing speed and executive functioning in an older population - the Hoorn Study. *Psychoneuroendocrinology.* 2014;40:108-18.
23. Huang CW, Tsai MH, Chen NC, Chen WH, Lu YT, Lui CC, Chang YT, Chang WN, Chang AY and Chang CC. Clinical significance of circulating vascular cell adhesion molecule-1 to white matter disintegrity in Alzheimer's dementia. *Thromb Haemost.* 2015;114:1230-40.
24. Rafnsson SB, Deary IJ, Smith FB, Whiteman MC, Rumley A, Lowe GD and Fowkes FG. Cognitive decline and markers of inflammation and hemostasis: the Edinburgh Artery Study. *J Am Geriatr Soc.* 2007;55:700-7.
25. Yoon CY, Steffen LM, Gross MD, Launer LJ, Odegaard A, Reiner A, Sanchez O, Yaffe K, Sidney S and Jacobs DR, Jr. Circulating Cellular Adhesion Molecules and Cognitive Function: The Coronary Artery Risk Development in Young Adults Study. *Front Cardiovasc Med.* 2017;4:37.
26. Huijts M, Duits A, van Oostenbrugge RJ, Kroon AA, de Leeuw PW and Staals J. Accumulation of MRI Markers of Cerebral Small Vessel Disease is Associated with Decreased Cognitive Function. A Study in First-Ever Lacunar Stroke and Hypertensive Patients. *Front Aging Neurosci.* 2013;5:72.
27. Fazekas F, Kleinert R, Offenbacher H, Payer F, Schmidt R, Kleinert G, Radner H and Lechner H. The morphologic correlate of incidental punctate white matter hyperintensities on MR images. *AJNR Am J Neuroradiol.* 1991;12:915-21.
28. Saji N, Toba K and Sakurai T. Cerebral Small Vessel Disease and Arterial Stiffness: Tsunami Effect in the Brain? *Pulse (Basel).* 2016;3:182-9.
29. Forbes JM and Cooper ME. Mechanisms of diabetic complications. *Physiol Rev.* 2013;93:137-88.
30. Taniguchi Y, Fujiwara Y, Nofuji Y, Nishi M, Murayama H, Seino S, Tajima R, Matsuyama Y and Shinkai S. Prospective Study of Arterial Stiffness and Subsequent Cognitive Decline Among Community-Dwelling Older Japanese. *J Epidemiol.* 2015;25:592-9.
31. Hajjar I, Goldstein FC, Martin GS and Quyyumi AA. Roles of Arterial Stiffness and Blood Pressure in Hypertension-Associated Cognitive Decline in Healthy Adults. *Hypertension.* 2016;67:171-5.
32. Tsao CW, Himali JJ, Beiser AS, Larson MG, DeCarli C, Vasan RS, Mitchell GF and Seshadri S. Association of arterial stiffness with progression of subclinical brain and cognitive disease. *Neurology.* 2016;86:619-26.

33. Meyer ML, Palta P, Tanaka H, Deal JA, Wright J, Knopman DS, Griswold ME, Mosley TH and Heiss G. Association of Central Arterial Stiffness and Pressure Pulsatility with Mild Cognitive Impairment and Dementia: The Atherosclerosis Risk in Communities Study-Neurocognitive Study (ARIC-NCS). *J Alzheimers Dis.* 2017;57:195-204.
34. Muela HCS, Costa-Hong VA, Yassuda MS, Moraes NC, Memoria CM, Machado MF, Bor-Seng-Shu E, Nogueira RC, Mansur AJ, Massaro AR, Nitrini R, Macedo TA and Bortolotto LA. Higher arterial stiffness is associated with lower cognitive performance in patients with hypertension. *J Clin Hypertens (Greenwich).* 2018;20:22-30.
35. Rouch L, Cestac P, Sallerin B, Andrieu S, Bailly H, Beunardeau M, Cohen A, Dubail D, Hernandorena I, Seux ML, Vidal JS and Hanon O. Pulse Wave Velocity Is Associated With Greater Risk of Dementia in Mild Cognitive Impairment Patients. *Hypertension.* 2018;72:1109-1116.
36. Palta P, Sharrett AR, Wei J, Meyer ML, Kucharska-Newton A, Power MC, Deal JA, Jack CR, Knopman D, Wright J, Griswold M, Tanaka H, Mosley TH and Heiss G. Central Arterial Stiffness Is Associated With Structural Brain Damage and Poorer Cognitive Performance: The ARIC Study. *J Am Heart Assoc.* 2019;8:e011045.
37. Pase MP, Beiser A, Himali JJ, Tsao C, Satizabal CL, Vasan RS, Seshadri S and Mitchell GF. Aortic Stiffness and the Risk of Incident Mild Cognitive Impairment and Dementia. *Stroke.* 2016;47:2256-61.
38. Huck DM, Hanna DB, Rubin LH, Maki P, Valcour V, Springer G, Xue X, Lazar J, Hodis HN, Anastos K, Kaplan RC and Kizer JR. Carotid Artery Stiffness and Cognitive Decline Among Women With or at Risk for HIV Infection. *J Acquir Immune Defic Syndr.* 2018;78:338-347.
39. DuBose LE, Voss MW, Weng TB, Kent JD, Dubishar KM, Lane-Cordova A, Sigurdsson G, Schmid P, Barlow PB and Pierce GL. Carotid beta-stiffness index is associated with slower processing speed but not working memory or white matter integrity in healthy middle-aged/older adults. *J Appl Physiol (1985).* 2017;122:868-876.
40. Lim SL, Gao Q, Nyunt MS, Gong L, Lunaria JB, Lim ML, Ling A, Lam CS, Richards AM, Ling LH and Ng TP. Vascular Health Indices and Cognitive Domain Function: Singapore Longitudinal Ageing Studies. *J Alzheimers Dis.* 2016;50:27-40.
41. Poels MM, van Oijen M, Mattace-Raso FU, Hofman A, Koudstaal PJ, Witteman JC and Breteler MM. Arterial stiffness, cognitive decline, and risk of dementia: the Rotterdam study. *Stroke.* 2007;38:888-92.
42. Tarumi T, Gonzales MM, Fallow B, Nualnim N, Pyron M, Tanaka H and Haley AP. Central artery stiffness, neuropsychological function, and cerebral perfusion in sedentary and endurance-trained middle-aged adults. *J Hypertens.* 2013;31:2400-9.
43. Geijselaers SL, Sep SJ, Schram MT, van Boxtel MP, van Sloten TT, Henry RM, Reesink KD, Kroon AA, Koster A, Schaper NC, Dagnelie PC, van der Kallen CJ, Biessels GJ and Stehouwer CD. Carotid stiffness is associated with impairment of cognitive performance in individuals with and without type 2 diabetes. The Maastricht Study. *Atherosclerosis.* 2016;253:186-193.
44. Koivisto T, Virtanen M, Hutri-Kahonen N, Lehtimäki T, Jula A, Juonala M, Moilanen L, Aatola H, Hyttinen J, Viikari JS, Raitakari OT and Kahonen M. Arterial pulse wave velocity in relation to carotid intima-media thickness, brachial flow-mediated dilation and carotid artery distensibility: the Cardiovascular Risk in Young Finns Study and the Health 2000 Survey. *Atherosclerosis.* 2012;220:387-93.

45. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H and European Network for Non-invasive Investigation of Large A. Expert consensus document on arterial stiffness: methodological issues and clinical applications. *Eur Heart J*. 2006;27:2588-605.
46. Geijselaers SLC, Sep SJS, Stehouwer CDA and Biessels GJ. Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic review. *Lancet Diabetes Endocrinol*. 2015;3:75-89.
47. Badescu SV, Tataru C, Kobylinska L, Georgescu EL, Zahiu DM, Zagrean AM and Zagrean L. The association between Diabetes mellitus and Depression. *J Med Life*. 2016;9:120-5.
48. Hughes TM, Wagenknecht LE, Craft S, Mintz A, Heiss G, Palta P, Wong D, Zhou Y, Knopman D, Mosley TH and Gottesman RF. Arterial stiffness and dementia pathology: Atherosclerosis Risk in Communities (ARIC)-PET Study. *Neurology*. 2018;90:e1248-e1256.
49. Tomlinson DR and Gardiner NJ. Glucose neurotoxicity. *Nat Rev Neurosci*. 2008;9:36-45.
50. Mitchell GF. Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. *J Appl Physiol (1985)*. 2008;105:1652-60.
51. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. *Lancet*. 2010;375:938-48.
52. Zhou TL, Kroon AA, Reesink KD, Schram MT, Koster A, Schaper NC, Dagnelie PC, van der Kallen CJH, Sep SJS, Stehouwer CDA and Henry RMA. Blood pressure variability in individuals with and without (pre)diabetes: The Maastricht Study. *J Hypertens*. 2018;36:259-267.
53. Parati G, Ochoa JE, Lombardi C and Bilo G. Assessment and management of blood-pressure variability. *Nat Rev Cardiol*. 2013;10:143-55.
54. Hall J.E. *Guyton and Hall textbook of medical physiology*. 13th ed. Philadelphia, PA: Elsevier; 206.
55. De Silva TM and Faraci FM. Microvascular Dysfunction and Cognitive Impairment. *Cell Mol Neurobiol*. 2016;36:241-58.
56. Skelly AC, Dettori JR and Brodt ED. Assessing bias: the importance of considering confounding. *Evid Based Spine Care J*. 2012;3:9-12.
57. Sorensen BM, Houben AJ, Berendschot TT, Schouten JS, Kroon AA, van der Kallen CJ, Henry RM, Koster A, Sep SJ, Dagnelie PC, Schaper NC, Schram MT and Stehouwer CD. Prediabetes and Type 2 Diabetes Are Associated With Generalized Microvascular Dysfunction: The Maastricht Study. *Circulation*. 2016;134:1339-1352.
58. Schisterman EF, Cole SR and Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. *Epidemiology*. 2009;20:488-95.
59. Yarmolinsky J, Wade KH, Richmond RC, Langdon RJ, Bull CJ, Tilling KM, Relton CL, Lewis SJ, Davey Smith G and Martin RM. Causal Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization? *Cancer Epidemiol Biomarkers Prev*. 2018;27:995-1010.
60. Aldrich J. Correlations genuine and spurious in Pearson and Yule. *Statistical Science*. 1995;10:364-376.
61. Song MK, Lin FC, Ward SE and Fine JP. Composite variables: when and how. *Nurs Res*. 2013;62:45-9.
62. van Sloten TT, Schram MT, Adriaanse MC, Dekker JM, Nijpels G, Teerlink T, Scheffer PG, Pouwer F, Schalkwijk CG, Stehouwer CD and Henry RM. Endothelial dysfunction is associated with a greater depressive symptom score in a general elderly population: the Hoorn Study. *Psychol Med*. 2014;44:1403-16.
63. Martens RJ, Henry RM, Houben AJ, van der Kallen CJ, Kroon AA, Schalkwijk CG, Schram MT, Sep SJ, Schaper NC, Dagnelie PC, Muris DM, Gronenschild EH, van der Sande FM, Leunissen KM, Kooman JP and Stehouwer CD. Capillary Rarefaction Associates with Albuminuria: The Maastricht Study. *J Am Soc Nephrol*. 2016;27:3748-3757.

64. Van der Elst W, van Boxtel MP, van Breukelen GJ and Jolles J. Rey's verbal learning test: normative data for 1855 healthy participants aged 24-81 years and the influence of age, sex, education, and mode of presentation. *J Int Neuropsychol Soc.* 2005;11:290-302.
65. Van der Elst W, Van Boxtel MP, Van Breukelen GJ and Jolles J. The Stroop color-word test: influence of age, sex, and education; and normative data for a large sample across the adult age range. *Assessment.* 2006;13:62-79.
66. Van der Elst W, Van Boxtel MP, Van Breukelen GJ and Jolles J. The Concept Shifting Test: adult normative data. *Psychol Assess.* 2006;18:424-32.
67. van der Elst W, van Boxtel MP, van Breukelen GJ and Jolles J. The Letter Digit Substitution Test: normative data for 1,858 healthy participants aged 24-81 from the Maastricht Aging Study (MAAS): influence of age, education, and sex. *J Clin Exp Neuropsychol.* 2006;28:998-1009.
68. Batzias K, Antonopoulos AS, Oikonomou E, Siasos G, Bletsas E, Stampoulouglou PK, Mistakidi CV, Noutsou M, Katsiki N, Karopoulos P, Charalambous G, Thanopoulou A, Tentolouris N and Tousoulis D. Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis. *J Diabetes Res.* 2018;2018:1232583.
69. Ling MC, Ruddy TD, deKemp RA, Ukkonen H, Duchesne L, Higginson L, Williams KA, McPherson R and Beanlands R. Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease. *Am Heart J.* 2005;149:1137.
70. Dufouil C, Chalmers J, Coskun O, Besancon V, Bousser MG, Guillon P, MacMahon S, Mazoyer B, Neal B, Woodward M, Tzourio-Mazoyer N, Tzourio C and Investigators PMS. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. *Circulation.* 2005;112:1644-50.
71. Arima H and Chalmers J. PROGRESS: Prevention of Recurrent Stroke. *J Clin Hypertens (Greenwich).* 2011;13:693-702.
72. Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, Sullivan M, Horowitz KR, Ding J, Marcovina S, Lovato LC, Lovato J, Margolis KL, O'Connor P, Lipkin EW, Hirsch J, Coker L, Maldjian J, Sunshine JL, Truwit C, Davatzikos C, Bryan RN and investigators AM. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. *Lancet Neurol.* 2011;10:969-77.
73. Williamson JD, Launer LJ, Bryan RN, Coker LH, Lazar RM, Gerstein HC, Murray AM, Sullivan MD, Horowitz KR, Ding J, Marcovina S, Lovato L, Lovato J, Margolis KL, Davatzikos C, Barzilay J, Ginsberg HN, Linz PE, Miller ME and Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes I. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. *JAMA Intern Med.* 2014;174:324-33.

Nederlandse samenvatting

Ouderdomsgerelateerde hersens ziekten zoals dementie en beroertes, maar ook depressie, maken de laatste jaren een sterke opmars als veroorzakers van sterfte en ziektelast. Eén van de veroorzakers van deze ziekten kan schade aan de kleinste bloedvaatjes van het lichaam, de haarvaatjes, zijn. De haarvaatjes, ook wel de microcirculatie genoemd, vervullen een belangrijke rol in het gezond houden van het lichaam, door een veelvoud aan taken zoals het leveren van voedingsstoffen aan, en het weghalen van afvalstoffen uit de organen. Daarbij vervullen ze (onder andere) een belangrijke rol in het reguleren van de bloeddruk. Schade aan de haarvaten (microvasculaire dysfunctie), kan ertoe leiden dat deze processen verstoord raken. Dit is vooral het geval in organen die sterk afhankelijk zijn van een goede bloedvoorziening, zoals de hersenen. Daarom wordt microvasculaire dysfunctie genoemd als een mogelijke oorzaak van hersenproblematiek zoals dementie, depressie en beroertes. Nu de bevolking steeds ouder wordt, zijn er steeds meer mensen die lijden onder een ongunstig vasculair risicoprofiel met 'klassieke' cardiometabole risicofactoren zoals overgewicht, hoge bloeddruk (hypertensie) en suikerziekte (type 2 diabetes). Het is belangrijk om te onderzoeken hoe deze risicofactoren bijdragen aan microvasculaire dysfunctie en daardoor hersenproblematiek. Er zijn al meerdere risicofactoren voor microvasculaire dysfunctie geïdentificeerd, zoals stijfheid van de grote slagaderen (arteriën) van het lichaam (vaatstijfheid), type 2 diabetes, hypertensie, leeftijd en overgewicht. We weten momenteel niet welke andere factoren ook bijdragen aan microvasculaire dysfunctie, en het mechanisme waardoor deze risicofactoren en microvasculaire dysfunctie leiden tot hersenproblematiek is nog onduidelijk.

Dit proefschrift richt zich op het evalueren van de oorzaken van microvasculaire dysfunctie en de effecten ervan op hersenproblematiek (i.e. dementie, depressie en beroertes). Daarbovenop onderzoekt dit proefschrift of microvasculaire dysfunctie een spil is in de reeds bekende associatie tussen cardiometabole risicofactoren en hersenproblematiek. De hoofdbevindingen in deze thesis zijn:

1. Microvasculaire dysfunctie is geassocieerd met dementie, depressie, beroerte en mortaliteit;
2. Hoe meer verschillende vormen van microvasculaire dysfunctie in de hersenen aanwezig zijn, des te hoger het risico op een beroerte;
3. Microvasculaire dysfunctie kan de relatie tussen vaatstijfheid en hersenproblematiek, en type 2 diabetes en hersenproblematiek deels verklaren;
4. Grotere fluctuaties in bloeddruk zijn geassocieerd met albuminurie, een maat van microvasculaire dysfunctie.

Aan het eind van deze samenvatting wordt er een pathofysiologisch model beschreven dat de relatie tussen bovenstaande bevindingen beschrijft. Tot slot worden de gevolgen van deze bevindingen voor de dagelijkse praktijk besproken, alsmede de aard van de studies die verricht dienen te worden om de kennis verder uit te breiden.

Hoofdbevindingen

Microvasculaire dysfunctie is geassocieerd met dementie, depressie, beroerte en mortaliteit

In het tweede hoofdstuk van deze thesis hebben we de hypothese getest dat microvasculaire dysfunctie in de hersenen gerelateerd is aan het krijgen van hersenproblematiek. Om dit uit te zoeken, hebben wij een grote literatuurstudie uitgevoerd, waarin we systematisch alle artikelen over dit onderwerp hebben bekeken. Vervolgens hebben wij de vergelijkbare data ervan hebben samengevat middels een test, waarmee op statistische wijze wordt vastgesteld of deze associatie bestaat. Hiertoe hebben we gekeken naar alle studies die een relatie hebben onderzocht tussen bepaalde kenmerken van microvasculaire dysfunctie in de hersenen, *cerebral small vessel disease* genoemd, en het krijgen van dementie, depressie, en beroerte, of het optreden van sterfte. We vonden een sterke en ook consistente associatie tussen verschillende van deze kenmerken van cerebral small vessel disease, en het optreden van bovenstaande uitkomsten. Om een idee te geven van de relevantie van cerebral small vessel disease; als er cerebral small vessel disease aantoonbaar is, dan is iemands risico op het krijgen van dementie, depressie, en beroerte hetzelfde als bij aanwezigheid van type 2 diabetes¹⁻⁴ of hypertensie.⁵⁻⁹ Hieruit kunnen we opmaken dat de microcirculatie in de hersenen belangrijk is voor optimale hersenfunctie. Als de gemeten microvasculaire functie in de hersenen een weerspiegeling is van de rest van het lichaam, betekent dit dat de microcirculatie belangrijk is voor optimale orgaanfunctie. Een belangrijk gegeven voor de interpretatie van deze data is dat de geïnccludeerde onderzoeken in deze literatuurstudie van *longitudinale* aard zijn, dat wil zeggen, iedere deelnemer is voor een lange periode gevolgd nadat cerebral small vessel disease is gemeten. Hierdoor weet je vrij zeker dat er éérs microvasculaire dysfunctie in de hersenen moet optreden, voordat de klinische uitkomstmaten meetbaar zijn, in plaats van andersom.

Microvasculaire dysfunctie in andere organen dan de hersenen zouden de mate van cerebral small vessel disease kunnen weerspiegelen, en daarom dus ook geassocieerd kunnen zijn met hersenproblematiek. Andere studies hebben al aangetoond dat bepaalde tekenen van microvasculaire dysfunctie, zoals albumineverlies via de urine,¹⁰ en verhoogde bloed biomarkers van microvasculaire dysfunctie, aanwezig zijn bij mensen met verslechterde geheugenfunctie. Om dit principe verder te onderzoeken, hebben we in hoofdstuk vier gekeken of een composietscore, een soort optelsom van verschillende maten van microvasculaire dysfunctie, weerspiegelt of iemand een slechtere geheugenfunctie heeft. Hiervoor hebben we verschillende maten voor microvasculaire dysfunctie samengevat in een score, namelijk: maten van cerebral small vessel disease, vaatreactiviteit van netvliesvaten op lichtflitsen, albumineverlies in de urine, bloed biomarkers van microvasculaire dysfunctie en vaatreactiviteit van de huid op warmtestimulatie. We concludeerden dat deze composietscore inderdaad verhoogd (i.e. ongunstiger) is bij mensen met een slechtere geheugenfunctie, en dat deze associatie aanwezig bleef wanneer we cerebral small vessel disease uit de score haalden. Dit betekent dat ook microvasculaire dysfunctie in andere organen dan de hersenen geassocieerd is met een slechtere geheugenfunctie. Deze studie is dus een onderbouwing voor de hypothese dat microvasculaire dysfunctie in het hele lichaam de (dys)functie van de

microcirculatie in de hersenen weerspiegelt, en dus ook een rol zou kunnen spelen bij het pathofysiologische proces dat leidt tot hersenproblematiek.

Hoe meer verschillende vormen van microvasculaire dysfunctie in de hersenen aanwezig zijn, des te hoger het risico op een beroerte

In hoofdstuk twee toonden we aan dat de aanwezigheid van twee maten van cerebral small vessel disease sterker geassocieerd is met het optreden van een beroerte dan alleen enkelvoudig aanwezige maten. Deze bevinding impliceert dat er een dosis-respons relatie zou kunnen zijn tussen de mate van cerebral small vessel disease en de mate van hersenproblematiek die daarbij optreedt. Dit is een relevante bevinding voor klinici, omdat het kan leiden tot een betere voorspelling voor patiënten die een risico lopen op bijvoorbeeld dementie of beroerte. Een speciale schaal om de mate van cerebral small vessel disease te scoren zou dan nog een risicopredictie kunnen geven bovenop reeds bekende risicofactoren.

Microvasculaire dysfunctie kan de relatie tussen vaatstijfheid en type 2 diabetes, en hersenproblematiek (deels) verklaren

Zoals boven al aangegeven, zijn meerdere cardiovasculaire risicofactoren geassocieerd met hersenproblematiek, en zou deze associatie veroorzaakt (ook wel gemedieerd genoemd) kunnen worden door microvasculaire dysfunctie.¹¹⁻¹⁴ Het doel van hoofdstuk drie en vijf was om te onderzoeken of microvasculaire dysfunctie inderdaad een mediërende rol heeft in de associatie tussen zowel vaatstijfheid en hersenproblematiek, als type 2 diabetes en hersenproblematiek.

De aanvoerende slagaderen in het lichaam, de arteriën, werken als een buffer voor de bloeddrukgolven vanuit het hart, door middel van hun meeverende elastische wand. Stijvere arteriën, bijvoorbeeld door aderverkalking, leiden tot een ongunstig bloeddrukpatroon, waardoor schade kan ontstaan.^{11, 12} Voorgaande studies¹⁵⁻¹⁶⁻²⁹ toonden al aan dat er een associatie bestaat tussen arteriële stijfheid en de aanwezigheid van dementie, of het optreden van cognitieve achteruitgang. In hoofdstuk vijf hebben we deze associatie opnieuw onderzocht, door te kijken of twee verschillende maten van vaatstijfheid, namelijk buikslagaderstijfheid (aortastijfheid) en halsslagaderstijfheid (carotisstijfheid), een associatie vertonen met een slechtere geheugenfunctie. Het bleek dat aortastijfheid geassocieerd is met een slechtere geheugenfunctie. Vervolgens hebben we met een statistische analyse aangetoond dat deze associatie deel verklaard kon worden door microvasculaire dysfunctie. We vonden in onze studie geen associatie tussen carotisstijfheid en geheugenfunctie, dit kan komen doordat de meting voor aortastijfheid betrouwbaarder is dan de meting voor carotisstijfheid,^{30,31} waardoor eventuele associaties eerder kunnen worden aangetoond met aortastijfheid dan met carotisstijfheid.

Type 2 diabetes kan, net als vaatstijfheid, leiden tot microvasculaire dysfunctie. Het wordt verondersteld dat in patiënten met type 2 diabetes, het hebben van o.a. hoge bloedsuikers, verminderde insulineafhankelijke vaatfunctie, aantasting van eiwitten en cellen door reactie met glucose (glycolysering) en zuurstofradicalen (oxidatieve stress), kan leiden tot deze schade aan de microcirculatie.^{13, 14, 32} De aanwezigheid van type 2 diabetes bleek eerder al geassocieerd met het optreden van depressieve klachten, hetgeen dus

mogelijk veroorzaakt wordt door microvasculaire dysfunctie. In hoofdstuk drie hebben we bevestigd dat type 2 diabetes geassocieerd is met een toename van depressieve klachten over de tijd. Tevens hebben we aangetoond dat deze associatie deels verklaard wordt door microvasculaire dysfunctie in de hersenen.

De bevinding dat microvasculaire dysfunctie de associatie tussen 'klassieke' cardiovasculaire risicofactoren en hersenproblematiek medieert is belangrijk, omdat microvasculaire dysfunctie daarmee een doel kan worden voor het behandelen en voorkomen van hersenziekten bij mensen met deze cardiovasculaire risicofactoren. Het is echter wel belangrijk vast te stellen dat een aanzienlijk deel van de gevonden associaties tussen cardiovasculaire risicofactoren en hersenproblematiek niet (statistisch) gemedieerd werd door microvasculaire dysfunctie in onze studies. Dit 'niet-verklaarde deel' kan bestaan uit een effect van microvasculaire dysfunctie dat niet goed geobjectiveerd kan worden met onze gemeten maten van microvasculaire dysfunctie. Wij hebben bijvoorbeeld geen onderzoek gedaan naar functionele uitkomstmaten voor microvasculaire dysfunctie, zoals het adaptatievermogen van de microcirculatie in de hersenen op bepaalde stimuli (cerebrale autoregulatie genoemd). Dit adaptatievermogen kan echter wel een belangrijke weerspiegeling zijn van microvasculaire dysfunctie, en eerder afwijkingen vertonen dan structurele metingen van de hersenen, zoals het geval is bij cerebral small vessel disease.³³ Het is ook mogelijk dat slechts een deel van de mensen met vaatstijfheid of type 2 diabetes hersenproblematiek krijgt die direct gerelateerd is aan microvasculaire dysfunctie. Zo kan slechtere cognitie bij vaatstijfheid of type 2 diabetes ook een gevolg zijn van macrovasculaire schade, of de ziekte van Alzheimer.³⁴ Daarnaast kunnen depressieve symptomen in type 2 diabetes ook veroorzaakt worden door aan diabetes gerelateerde risicofactoren, zoals psychosociale factoren,³⁵ comorbiditeit³⁵ en directe zenuwschade door hoge bloedsuikers.³⁶

Grotere fluctuaties in bloeddruk zijn geassocieerd met albuminurie, een maat van microvasculaire dysfunctie

Naast 'klassieke' risicofactoren voor microvasculaire dysfunctie, worden er ook nieuwe risicofactoren beschreven. Een mogelijke risicofactor voor microvasculaire dysfunctie is het hebben van fluctuaties in de bloeddruk. Fluctuaties in de bloeddruk zijn normaal, maar wanneer dit te veel wordt (wanneer het lichaam het verschil in bloeddrukken minder goed kan opvangen), kan het leiden tot microvasculaire dysfunctie.^{37, 38} Om deze hypothese te testen, hebben we in hoofdstuk 6 bekeken of grote fluctuaties in de bloeddruk leiden tot microvasculaire dysfunctie. We hadden hierbij de verwachting dat organen die bloeddruk (fluctuaties) makkelijk doorlaten, namelijk de nieren en hersenen, meer schade zouden ondervinden dan andere organen. We vonden dat een grotere bloeddrukvariabiliteit alleen was geassocieerd met microvasculaire dysfunctie in de nieren, maar niet in de hersenen of andere organen. Mogelijk komt dit omdat de nieren van alle organen de grootste bloedtoevoer hebben, waardoor zij meer blootgesteld worden aan bloeddrukfluctuaties dan andere organen.³⁹

Conclusie

Dit proefschrift laat zien dat microvasculaire dysfunctie een centrale rol speelt in de relatie tussen cardiometabole risicofactoren en het krijgen van hersenproblematiek, zoals dementie, depressie en beroertes. In onderstaande figuur zijn de belangrijkste bevindingen van dit proefschrift schematisch weergegeven. Wij hopen dat deze thesis aanknopingspunten geeft voor vervolgonderzoek dat kan helpen het risico op hersenziektes te verminderen.

Figuur. Potentiele mechanismen voor de oorzaken en gevolgen van microvasculaire dysfunctie

1. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams DE and Geiss L. Changes in diabetes-related complications in the United States, 1990-2010. *N Engl J Med*. 2014;370:1514-23.
2. Xu WL, Qiu CX, Wahlin A, Winblad B and Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. *Neurology*. 2004;63:1181-6.
3. Yu M, Zhang X, Lu F and Fang L. Depression and Risk for Diabetes: A Meta-Analysis. *Can J Diabetes*. 2015;39:266-72.
4. Gregg EW, Cheng YJ, Saydah S, Cowie C, Garfield S, Geiss L and Barker L. Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey. *Diabetes Care*. 2012;35:1252-7.
5. Imano H, Kitamura A, Sato S, Kiyama M, Ohira T, Yamagishi K, Noda H, Tanigawa T, Iso H and Shimamoto T. Trends for blood pressure and its contribution to stroke incidence in the middle-aged Japanese population: the Circulatory Risk in Communities Study (CIRCS). *Stroke*. 2009;40:1571-7.
6. Verdecchia P, Reboldi GP, Angeli F, Schillaci G, Schwartz JE, Pickering TG, Imai Y, Ohkubo T and Kario K. Short- and long-term incidence of stroke in white-coat hypertension. *Hypertension*. 2005;45:203-208.
7. Li G, Rhew IC, Shofer JB, Kukull WA, Breitner JC, Peskind E, Bowen JD, McCormick W, Teri L, Crane PK and Larson EB. Age-varying association between blood pressure and risk of dementia in those aged 65 and older: a community-based prospective cohort study. *J Am Geriatr Soc*. 2007;55:1161-7.
8. Sharp SI, Aarsland D, Day S, Sonnesyn H, Ballard C and Syst AsSVD. Hypertension is a potential risk factor for vascular dementia: systematic review. *Int J Geriatr Psychiatry*. 2011;26:661-669.
9. Barengo NC, Antikainen R, Kastarinen M, Laatikainen T and Tuomilehto J. The effects of control of systolic and diastolic hypertension on cardiovascular and all-cause mortality in a community-based population cohort. *J Hum Hypertens*. 2013;27:693-7.
10. Georgakakis MK, Dimitriou NG, Karalexi MA, Mihos C, Nasothimiou EG, Tousoulis D, Tsigoulis G and Petridou ET. Albuminuria in Association with Cognitive Function and Dementia: A Systematic Review and Meta-Analysis. *J Am Geriatr Soc*. 2017;65:1190-1198.
11. Fazekas F, Kleinert R, Offenbacher H, Payer F, Schmidt R, Kleinert G, Radner H and Lechner H. The morphologic correlate of incidental punctate white matter hyperintensities on MR images. *AJNR Am J Neuroradiol*. 1991;12:915-21.
12. Saji N, Toba K and Sakurai T. Cerebral Small Vessel Disease and Arterial Stiffness: Tsunami Effect in the Brain? *Pulse (Basel)*. 2016;3:182-9.
13. Forbes JM and Cooper ME. Mechanisms of diabetic complications. *Physiol Rev*. 2013;93:137-88.
14. Stehouwer CDA. Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle With Widespread Consequences. *Diabetes*. 2018;67:1729-1741.
15. van Sloten TT, Protogerou AD, Henry RM, Schram MT, Launer LJ and Stehouwer CD. Association between arterial stiffness, cerebral small vessel disease and cognitive impairment: A systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2015;53:121-30.
16. Taniguchi Y, Fujiwara Y, Nofuji Y, Nishi M, Murayama H, Seino S, Tajima R, Matsuyama Y and Shinkai S. Prospective Study of Arterial Stiffness and Subsequent Cognitive Decline Among Community-Dwelling Older Japanese. *J Epidemiol*. 2015;25:592-9.
17. Hajjar I, Goldstein FC, Martin GS and Quyyumi AA. Roles of Arterial Stiffness and Blood Pressure in Hypertension-Associated Cognitive Decline in Healthy Adults. *Hypertension*. 2016;67:171-5.

18. Tsao CW, Himali JJ, Beiser AS, Larson MG, DeCarli C, Vasan RS, Mitchell GF and Seshadri S. Association of arterial stiffness with progression of subclinical brain and cognitive disease. *Neurology*. 2016;86:619-26.
19. Meyer ML, Palta P, Tanaka H, Deal JA, Wright J, Knopman DS, Griswold ME, Mosley TH and Heiss G. Association of Central Arterial Stiffness and Pressure Pulsatility with Mild Cognitive Impairment and Dementia: The Atherosclerosis Risk in Communities Study-Neurocognitive Study (ARIC-NCS). *J Alzheimers Dis*. 2017;57:195-204.
20. Muela HCS, Costa-Hong VA, Yassuda MS, Moraes NC, Memoria CM, Machado MF, Bor-Seng-Shu E, Nogueira RC, Mansur AJ, Massaro AR, Nitrini R, Macedo TA and Bortolotto LA. Higher arterial stiffness is associated with lower cognitive performance in patients with hypertension. *J Clin Hypertens (Greenwich)*. 2018;20:22-30.
21. Rouch L, Cestac P, Sallerin B, Andrieu S, Bailly H, Beunardeau M, Cohen A, Dubail D, Hernandorena I, Seux ML, Vidal JS and Hanon O. Pulse Wave Velocity Is Associated With Greater Risk of Dementia in Mild Cognitive Impairment Patients. *Hypertension*. 2018;72:1109-1116.
22. Palta P, Sharrett AR, Wei J, Meyer ML, Kucharska-Newton A, Power MC, Deal JA, Jack CR, Knopman D, Wright J, Griswold M, Tanaka H, Mosley TH and Heiss G. Central Arterial Stiffness Is Associated With Structural Brain Damage and Poorer Cognitive Performance: The ARIC Study. *J Am Heart Assoc*. 2019;8:e011045.
23. Pase MP, Beiser A, Himali JJ, Tsao C, Satizabal CL, Vasan RS, Seshadri S and Mitchell GF. Aortic Stiffness and the Risk of Incident Mild Cognitive Impairment and Dementia. *Stroke*. 2016;47:2256-61.
24. Huck DM, Hanna DB, Rubin LH, Maki P, Valcour V, Springer G, Xue X, Lazar J, Hodis HN, Anastos K, Kaplan RC and Kizer JR. Carotid Artery Stiffness and Cognitive Decline Among Women With or at Risk for HIV Infection. *J Acquir Immune Defic Syndr*. 2018;78:338-347.
25. DuBose LE, Voss MW, Weng TB, Kent JD, Dubishar KM, Lane-Cordova A, Sigurdsson G, Schmid P, Barlow PB and Pierce GL. Carotid beta-stiffness index is associated with slower processing speed but not working memory or white matter integrity in healthy middle-aged/older adults. *J Appl Physiol (1985)*. 2017;122:868-876.
26. Lim SL, Gao Q, Nyunt MS, Gong L, Lunaria JB, Lim ML, Ling A, Lam CS, Richards AM, Ling LH and Ng TP. Vascular Health Indices and Cognitive Domain Function: Singapore Longitudinal Ageing Studies. *J Alzheimers Dis*. 2016;50:27-40.
27. Poels MM, van Oijen M, Mattace-Raso FU, Hofman A, Koudstaal PJ, Witteman JC and Breteler MM. Arterial stiffness, cognitive decline, and risk of dementia: the Rotterdam study. *Stroke*. 2007;38:888-92.
28. Tarumi T, Gonzales MM, Fallow B, Nualnim N, Pyron M, Tanaka H and Haley AP. Central artery stiffness, neuropsychological function, and cerebral perfusion in sedentary and endurance-trained middle-aged adults. *J Hypertens*. 2013;31:2400-9.
29. Geijselaers SL, Sep SJ, Schram MT, van Boxtel MP, van Sloten TT, Henry RM, Reesink KD, Kroon AA, Koster A, Schaper NC, Dagnelie PC, van der Kallen CJ, Biessels GJ and Stehouwer CD. Carotid stiffness is associated with impairment of cognitive performance in individuals with and without type 2 diabetes. The Maastricht Study. *Atherosclerosis*. 2016;253:186-193.
30. Koivisto T, Virtanen M, Hutri-Kahonen N, Lehtimäki T, Jula A, Juonala M, Moilanen L, Aatola H, Hyttinen J, Viikari JS, Raitakari OT and Kahonen M. Arterial pulse wave velocity in relation to carotid intima-media thickness, brachial flow-mediated dilation and carotid artery distensibility: the Cardiovascular Risk in Young Finns Study and the Health 2000 Survey. *Atherosclerosis*. 2012;220:387-93.

31. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H and European Network for Non-invasive Investigation of Large A. Expert consensus document on arterial stiffness: methodological issues and clinical applications. *Eur Heart J*. 2006;27:2588-605.
32. Geijselaers SLC, Sep SJS, Stehouwer CDA and Biessels GJ. Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic review. *Lancet Diabetes Endocrinol*. 2015;3:75-89.
33. Purkayastha S, Fadar O, Mehregan A, Salat DH, Moscufo N, Meier DS, Guttman CR, Fisher ND, Lipsitz LA and Sorond FA. Impaired cerebrovascular hemodynamics are associated with cerebral white matter damage. *J Cereb Blood Flow Metab*. 2014;34:228-34.
34. Hughes TM, Wagenknecht LE, Craft S, Mintz A, Heiss G, Palta P, Wong D, Zhou Y, Knopman D, Mosley TH and Gottesman RF. Arterial stiffness and dementia pathology: Atherosclerosis Risk in Communities (ARIC)-PET Study. *Neurology*. 2018;90:e1248-e1256.
35. Badescu SV, Tataru C, Kobylinska L, Georgescu EL, Zahiu DM, Zagrean AM and Zagrean L. The association between Diabetes mellitus and Depression. *J Med Life*. 2016;9:120-5.
36. Tomlinson DR and Gardiner NJ. Glucose neurotoxicity. *Nat Rev Neurosci*. 2008;9:36-45.
37. Mitchell GF. Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. *J Appl Physiol (1985)*. 2008;105:1652-60.
38. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. *Lancet*. 2010;375:938-48.
39. Hall J.E. *Guyton and Hall textbook of medical physiology*. 13th ed. Philadelphia, PA: Elsevier; 2006.

Valorisation addendum

The goal of scientific research is to establish new facts and to reach new conclusions, but without any impact to society, these new conclusions would have little consequences. The goal of this chapter is to discuss the impact on society of the conclusions reached in this thesis, and to discuss any recommendations for further research on this topic in order to maximize this impact.

Relevance of this research

In the Netherlands and most other parts of the world, life expectancy has been increasing for the last couple of decades and will continue to do so for some more decades to come. With the increasing age of the population, the amount of individuals with a high burden of cardiovascular risk factors increases. More importantly, so does the number of individuals with age-related brain diseases such as dementia, late-life depression and stroke. The findings in this thesis suggest that deterioration of the microvasculature, i.e. the vascular meshwork comprised of arterioles, capillaries and venules, is an important contributor to the development of these age-related brain diseases. In addition, this thesis suggests that microvascular deterioration, also called microvascular dysfunction, mediates the association between cardiovascular risk factors and age-related brain diseases.

The conclusions in this thesis provide an important contribution to our current understanding of the pathophysiology of age-related brain diseases and indicate that prevention and/or treatment of microvascular dysfunction may be an important clinical goal. In practice, to prevent or slow down progression of age-related brain diseases in individuals with microvascular dysfunction, early and adequate cardiometabolic health must be pursued. Moreover, interventions aiming to favourably influence microvascular function on top of cardiometabolic management may provide additional prevention of age-related brain diseases.

Future research

Before studies on prevention of and intervention for microvascular dysfunction can be conducted, further longitudinal observational studies are needed to confirm the causal relationship between cardiovascular risk factors, microvascular dysfunction, and age-related brain diseases. Although the results in this thesis are consistent across all chapters, only chapter 2 and chapter 3 describe longitudinal relationships from which temporal associations, and thus causality, may be implied. Furthermore, in the present thesis, microvascular dysfunction was defined as a higher composite score of several measures of microvascular dysfunction, and sometimes specifically by measures of cerebral small vessel disease, instead of clinically relevant microvascular disease. There is currently no scale to define clinically relevant microvascular dysfunction based on the measures of microvascular dysfunction used in this thesis. Future studies are therefore needed to evaluate at what point microvascular dysfunction becomes clinically relevant, and whether the observed associations with microvascular dysfunction and age-related brain diseases are also present at this point. This thesis already demonstrated that the combination of two cerebral small vessel disease features is most strongly associated with incident stroke. This suggests that scales that incorporate the effect of multiple measures of microvascular

function are most suitable to assess microvascular dysfunction, and most likely to enable improved risk prediction of clinical outcomes beyond established risk factors.

In addition to observational studies, randomized controlled trials are needed to evaluate the possible effectiveness of interventions for microvascular dysfunction. Currently, evidence for improved outcome with treatment programs aimed at strict cardiovascular risk management in patients with microvascular dysfunction is lacking. It has been suggested however, that statins, ACE inhibitors and aspirin improve microvascular function by mechanisms beyond their respective lipid-lowering, blood pressure-lowering and anticoagulant effects; the so-called pleiotropic effect.

Clinical recommendations

As stated above, there are currently no comprehensive guidelines available for the diagnosis and treatment of microvascular disease. In 2013, the STRIVE neuroimaging standards to aid in the standardized assessment of microvascular disease in the brain were published. However, it is not advisable for a clinician to actively screen for microvascular dysfunction using neuroimaging or other techniques, given the current lack of guidelines for intervention. However, features of microvascular dysfunction are often found as incidental findings on scans with other primary indications. A clinician should, upon diagnosing a patient with microvascular dysfunction, be prompted to perform adequate cardiovascular risk assessment. The risk factors that are associated to macrovascular disease appear to be similarly associated with microvascular dysfunction; e.g. smoking, type 2 diabetes, obesity, hypertension and hyperlipidaemia. As such, treatment aimed at cardiovascular risk factor management, including lifestyle counselling regarding smoking cessation, nutrition and physical activity is warranted.

Conclusion

The findings in this thesis suggest that identification and treatment of microvascular dysfunction can be helpful in prevention of age-related brain disease.

Dankwoord

Dit proefschrift is het resultaat van 4 jaar intensieve, inspirerende, humoristische en prijzenswaardige samenwerking met vele collega's, familieleden en vrienden. Ik had mij geen fijnere start van mijn werkend leven kunnen wensen dan als onderdeel van het team van promovendi bij De Maastricht Studie. Ik ben iedereen met wie ik de afgelopen 4 jaar heb samengewerkt erg dankbaar voor hun prettige omgang en wil een aantal mensen graag in het bijzonder bedanken.

Mijn promotor, prof. dr. C.D.A. Stehouwer.

Beste Coen, ik ben heel dankbaar dat ik jou als promotor heb mogen hebben voor dit proefschrift. Iedere hypothese, onderzoeksmethode en conclusie werd minutieus door je uitgeplozen en verbeterd, maar ook bij een spel- of taalfout kon ik op een uitgebreide uitleg rekenen. Ik heb ontzettend veel van je geleerd en ben hierdoor een scherpzinniger onderzoeker en persoon geworden.

Mijn copromotor, dr. T.T van Sloten.

Beste Thomas, als het gaat om mensen met kwaliteiten zoals het minutieus overwegen van iedere aspect van het verrichten van onderzoek, sta jij ook bovenaan. Ik ben je ontzettend dankbaar voor de zeer prettige, rustige en behulpzame begeleiding in de afgelopen jaren. Zonder jouw bijdrage zou dit werk niet half zo mooi en leeswaardig zijn geweest. Het was soms frustrerend te noemen hoe we ellenlange discussies konden hebben over iets, waarbij jij uiteindelijk toch weer gelijk bleek te hebben. Ik bewonder je doelmatige en overzichtelijke manier van het benaderen van problemen.

De leden van de beoordelingscommissie.

Graag wil ik Prof. dr. H.J.G.M. Crijns, Prof. dr. D.E.J. Linden, Prof. dr. F.E. de Leeuw, Prof. dr. M. Muller en Prof. dr. P.W. de Leeuw bedanken voor het beoordelen van mijn proefschrift. Geachte Dr. V.P.M. van Empel, hartelijk dank voor het deelnemen aan de corona en het voorzitten van de promotiezitting.

Alle collega's bij De Maastricht Studie en Interne Geneeskunde.

Mijn kamergenoten Tan Lai en Yuri. Ik weet niet of ik meer hulp of oponthoud heb ondervonden aan de samenwerking met jullie, maar een ding is zeker, zonder de slechte (woord)grappen en bijzondere verhalen die wij samen vertelden zou ik met veel minder plezier mijn promotie-traject hebben afgerond. Beste Tan Lai, wij kennen elkaar al sinds het eerste jaar van onze studie en werken nog steeds in het zelfde gebied. Je bent stevast een goede vriend en collega geweest met bijzonder veel kennis van zaken en altijd hulpvaardig. Ik hoop dat deze samenwerking nog lang zal blijven! Beste Yuri, al snel bleek dat er achter het masker van een zeer welbespraakt en net gekleed onderzoeker een flauwe humor verscholen zat die gelukkig vooral binnen de vier muren van onze kamer

bleef (helaas niet altijd, vanwege de dunne wandjes). Naast je humoristische bijdrage heb ik ook inhoudelijk zeer veel hulp van je gehad, op taalkundig en wetenschappelijk gebied.

Carla, Yvette, Nadine en Miranda: bedankt voor de uitstekende, zowel inspirerende als laagdrempelige supervisie. Mede-promovendi Rianneke, Niki, Frank, April, Anouk, Cindy, Laura, Wenjie en Jeremy, bedankt voor de gezellige samenwerking en de uitputtende pingpong- en squashsessies. Marnix, Ben, Ellis, Marja, Charlotte, Peggy, Remy, Yannick en Veronica, bedankt voor de hulp aan een goede start van mijn promotie-traject. Mijn zeer gewaardeerde collega's met wie ik meerdere jaren lang intensief heb samengewerkt bij en rondom de metingen: Jos, Jeroen, Marion, Michiel, Anouk, Ingeborg, Sara, Lina, Lisanne, Ramona, Michiel, Marleen, Anke, Brigitte, Josephine, Manuela, Ank, Carine, Chantalle, Daniel, Else, Robin, Roel, Hannah, Demi, Ineke, Kayleigh, Laura, Simone, Myrthe en Paula.

Graag wil ik de co-auteurs die geholpen hebben bij het schrijven van de artikelen bedanken voor hun uitgebreide feedback en fijne samenwerking.

Dr. L. Launer, dear Lenore, thank you for the extensive help in writing our paper using data from the AGES-Reykjavic study.

Dr. A. Houben, beste Boy, bedankt voor de interessante gesprekken over de pathofysiologie van microvasculaire dysfunctie. Die hebben ervoor gezorgd dat ik ook op een meer basaal-geneeskundige wijze ben na gaan denken over de associaties die wij vonden in onze artikelen.

Dr. S. Köhler, beste Seb, bedankt voor je hulp bij de soms zeer ingewikkelde statische vraagstukken, waarbij je altijd tijd vrij maakte om dit zeer rustig uit te leggen.

Prof. Dr. P. Dagnelie, Beste Pieter, ook van jou heb ik ontzettend veel hulp ervaren bij het uitvogelen van statische probleemstukken, bedankt voor je hulp!

Prof. Dr. A. Kroon, Dr. R. Henry, Beste Bram, Ronald, bedankt dat jullie mij, Tan Lai en Frank zo goed geholpen hebt bij het schrijven van een stuk met zijn drieën.

Dr. K. Reesink, beste Koen, bedankt voor de interessante discussies over wetenschap en wetenschapsfilosofie. Dankzij jouw rustige uitleg en brede kennis heb ik veel geleerd.

Graag wil ik alle overige co-auteurs bedanken voor hun uitgebreide feedback en fijne samenwerking bij het tot stand komen van de artikelen:

Dr. M. van Boxtel, Dr. T. Berendschot, Dr. J. Jansen, Prof. Dr. F. Verhey, Prof. Dr. A. Kroon, Dr. A. Koster, Prof. Dr. W. Backes, Prof. Dr. N. Schaper, Prof. Dr. G. Dinant, Prof. Dr. C. Schalkwijk, Else M.L. Wolfs, Mike J.A. van Heumen, Dr. M. van Dongen, Dr. S. Eussen, Prof. Dr. J.H.A. Bosma, Dr. J. Schouten, Dr. M. van Dongen en Prof. Dr. C. Webers.

I would like to thank all other co-authors from foreign collaborations: Dr. J. Ding, Dr. S. Sigurdsson and Dr. V. Gudnason.

De overige collega's van de onderzoeksgroep Interne Geneeskunde, bedankt voor de interessante discussies tijdens de Journal Club.

Aan mijn studievriendengroep; Giel, Robin, Mark, Marisya en Kim, bedankt voor de gezellige avonden, spelletjes en bijeenkomsten.

Aan al mijn vrienden van de Maastrichtse Studenten Alpen Club (MaasSAC), bedankt voor de leuke afleiding gedurende de weekenden en avonden middels klimuitjes. Een weekend naar de rotsen in België of Luxemburg voelt altijd aan als een kleine vakantie.

Aan alle vrienden uit mijn studentenhuys; Timo, Guus, Stefan, Alicia, Mohamed, Veerle, Lise, Jennie, Bernard en Lobke, jullie hebben er mede voor gezorgd dat ik succesvol door de studie ben heen gekomen, dankzij het gezellige gezamenlijke koken, en de vele activiteiten die wij nog steeds met enige regelmaat ondernemen, zelfs al wonen we al vele jaren niet meer in hetzelfde studentenhuys.

Aan mijn collega's van het Zuyderland MC, mijn promotie-traject was natuurlijk erg leuk, maar ik ben ook erg blij met hoe ik inmiddels driekwart jaar met jullie heb kunnen samenwerken!

Aan Birgit, bedankt dat je deze mooie kافت van mijn boekje hebt willen ontwerpen!

Lieve papa en mama, bedankt voor jullie steun en hulp de afgelopen jaren. Ik heb een fantastisch voorbeeld aan jullie. Lieve Hanneke, Pauline en Leonie, gelukkig krijgen wij het voor elkaar om, ondanks dat we allemaal artsen zijn geworden, we het aan de eettafel nog over andere zaken kunnen laten gaan dan patiëntenzorg. Bedankt voor jullie steun!

Liefste Nienke, bedankt dat je altijd klaarstaat om me te helpen, of het nu om hulp bij moeilijke wetenschappelijke vragen gaat, of om het maken van een lekkere koffie. Ik ben heel blij met jou in mijn leven!

Curriculum Vitae

Sytze Rensma was born on May 7, 1991 in Nieuwegein, the Netherlands. He graduated from secondary school in 2009 (Gymnasium [VWO], Mill-Hillcollege, Goirle). In that year, he started his medical education at Maastricht University and in Augustus 2015 he obtained his medical degree. During his study, he conducted research as a student assistant at the Division of Clinical and Experimental Immunology of the Department of Internal Medicine. In October 2015, he started his PhD research under supervision of Prof. Dr. Coen Stehouwer at the Department of Internal Medicine of Maastricht University Medical Centre, within the CARIM School for Cardiovascular Disease. As of Januari 2020, he has worked as a resident Internal Medicine at Zuyderland Medical Centre.